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ABSTRACT
Ovine pulmonary adenocarcinoma (OPA) is a contagious lung cancer of sheep. OPA
is found in over 20 countries on the continents of Europe, Africa, America and Asia,
and in a wide variety of breeds. The tumour also has been diagnosed sporadically in
goats and wild moufflon. OPA is caused by an exogenous beta-retrovirus, jaagsiekte
sheep retrovirus (JSRV), which is different from the transcriptionally active
endogenous retroviral sequences present in the ovine genome. A unique feature of
OPA is the absence of a specific humoral immune response to JSRV, despite the
highly productive infection in the lungs and the disseminated lymphoid infection.
The absence of detectable antibodies has hampered the diagnosis and control of the
disease before the development of clinical signs. The disease can be reproduced
consistently in neonatal lambs by intra-tracheal injection of inocula containing
JSRV, but this experimental model was unsuitable for various purposes, such as the
assessment of potential vaccine preparations. In the present study, the clinical
disease was reproduced, pathologically confirmed as OPA, in a high proportion of
lambs inoculated intra-tracheally with infectious lung fluid at either one, three or six
months of age. The incubation periods, however, were found to be longer in the
older age groups than in one week old lambs. During the course of the experiment,
viraemia was detected consistently by PCR (JSRV U3 PCR). The persistent viraemia
and the delayed development of OPA in the older lambs paralleled epidemiological
observations in naturally affected flocks. The optimisation of the JSRV U3 PCR
represented an important breakthroughs for studies on the pathogenesis of this
infection and for the diagnosis and control of the disease. JSRV U3 PCR was
employed for the first longitudinal survey for detecting JSRV infection in a flock
with natural history of OPA. Ewes and offspring were followed for a period of two
and half years and the JSRV U3 PCR test was repeated every 3-4 months. It was
shown that the flock was heavily infected with JSRV. The lambs from both negative
and positive mothers became JSRV positive as early as 20-30 days after birth. The
rate of infection of the ewes and of the lambs increased significantly after the first
test. JSRV incidence in the ewe population was higher in the period prior to lambing.
The results suggested that Texel breedline had a higher susceptibility to JSRV
infection and a higher probability of remaining positive.
New envelope and capsid recombinant proteins were produced not only for
immunological assays but also for preliminary immunisation trials in sheep. The
present experiments have been able to overcome previous difficulties regarding
JSRV Env protein production.
In the present study IHC gave new insight about histogenesis and viral pathogenesis
of OPA. In fact SU Env protein was found widespread on the surface of tumour
cells. This finding proved that envelope protein is consistently produced suggesting
again a role in cell proliferation. These epidemiological and experimental
transmission data point to JSRV as a non-acute transforming retrovirus and raise





1.1 Introduction and history of ovine pulmonary adenocarcinoma (OPA)
Ovine pulmonary adenocarcinoma (OPA) is a contagious disease characterised by a
tumour in the lungs of sheep (Sharp, 1987). OPA is also known as jaagsiekte, sheep
pulmonary adenomatosis or ovine pulmonary carcinoma. OPA is caused by an
exogenous retrovirus called jaagsiekte sheep retrovirus (JSRV).
The disease was first recognised in South Africa in the 19th century as a cause of
respiratory distress in sheep. The Afrikaans name "jaagsiekte" derived from
"driving" (jaag) and "sickness" (ziekte), reflected the tendency of diseased sheep to
lag behind the flock during herding (Tustin, 1969).
Since then, OPA has been identified in a wide variety of breeds in over 20 countries
on the continents of Europe, Africa, America and Asia, with the notable exceptions
of Australia and New Zealand (Eber, 1899; Aynaud, 1926; Sigurdsson et al., 1954;
Shirlaw, 1959; Ceretto F. et al. 1967; Al-Zubaidy et al., 1979; Tontis et al., 1979;
Stevenson et al. 1980; Verwoed et al., 1985; Toumazos, 1989; Sharp & De las
Heras, 2000). The disease does not appear to affect Australia and New Zealand,
apart from two isolated reports (Dalefield & Aleey, 1988; Hooper & Ellard, 1995).
Iceland is now free from OPA but after a lot of effort and paying high economic
costs for the eradication programme. OPA was introduced in Iceland in 1933 along
with scrapie, maedi-visna and paratubercolosis by a small number of sheep imported
from Germany (Sigurdsson et al. 1954). A year after the introduction of those
animals, the first cases of OPA appeared in 1-3 year old sheep. During the next 2-3
years, about 60% of the breeding stock in affected flocks died of OPA. In the
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following 3 years the mortality decreased to under 10% and at this time another
respiratory disease called maedi-visna appeared. It was later determined that this
disease was caused by a lentivirus called maedi-visna virus (MVV) (Sigurdsson,
1958).
Sigurdsson in 1954 used the adjective "slow" to describe the peculiar clinical
evolution of this group of diseases. He had studied the three imported diseases of
sheep peculiar to Iceland, maedi, visna, and rida. In 1954 he proposed that 'A
number of [slow] infections exist and the following criteria could be tentatively
suggested: (1) A very long period of latency lasting from several months to several
years. (2) A protracted course after clinical signs have appeared usually ending in
serious disease or death. (3) Limitation of the infection to a single host species and
anatomical lesions in only a single organ or tissue system. These last statements may
have to be modified as knowledge increases.'
OPA is a tumour. Tumours are generally uncommon in domestic livestock, but in
sheep, two neoplastic diseases are recognised, OPA and enzootic intranasal
adenocarcinoma (Duncan et al., 1967; Charray et al., 1985; De las Heras et al.,
1991; Gazquez et al., 1992; Vitellozzi et al., 1993; De las Heras et al., 1995;
DeMartini & York, 1997). Both types of tumour arise from secretory epithelial cells
that retain their secretory function after transformation (Nisbet et al., 1971). Each
disease is associated exclusively with betaretroviruses that are highly related but
distinct (Sharp, 1987; DeMartini & York, 1997; Ortin et al., 2003).
Many scientists have noticed similarities between OPA and human
bronchioloalveolar carcinoma (Bonne, 1939; Perk & Hod, 1982; Rosenberg, 2001).
Understanding the mechanisms of tumourigenesis in OPA may offer insights into
some forms of human adenocarcinoma (Palmarini & Fan, 2001).
1.1.1 Clinical Signs and Epidemiological Features in OPA.
The incubation period in naturally infected sheep appears to be long, so that the
disease is not usually seen until sheep are about 2-4 years old (Hunter & Munro,
1983). However, tumours have been seen exceptionally in lambs as young as 2
months old and sheep 11 years of age (Sharp & Angus, 1987).
Clinical signs are those of an afebrile progressive respiratory illness associated with
loss of weight. The severity of the tachypnoea and dyspnoea, often associated with
noticeable movement of the abdominal wall, depends on the extent of the tumour
and loss of normal functional lung. A pathognomonic feature of OPA is the
accumulation of lung fluid within the respiratory tract; in advanced cases "bubbling"
sounds may be heard when the chest is auscultated. In addition, a very helpful test
for this disease, is to lower the head of the sheep below the chest, when fluid may
run from the nostrils ("wheel-barrow test") (Sharp & Angus, 1990) (Fig. 1.1).
Sometimes quite copious amounts of mucoid fluid, up to 300 ml, can be collected
(Fig. 1.2). Appetite is maintained, though loss of weight is obvious. OPA affected
sheep show signs which continue over several weeks. Death is often due to inter
current bacterial infection by Mannhaemia haemolytica. In some countries, another
form of the tumour, described as atypical OPA, has been reported. This form is not
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Fig. 1.1. OPA clinical signs.
Frothy seromucous seromucous fluid is discharged from the
nostrils when OPA-affected sheep hindquarters are raised and
the head lowered.
Fig.1.2. OPA clinical signs: fluid collection.
The amount of fluid that can be collected from an affected animal
varies from 50-60ml to as much as 300 ml.
associated with excess accumulation of fluid in the lung and, therefore, generally
presents as an incidental finding at necropsy or in the abattoir (Garcia-Goti et al.,
2000). Due to the lack of ante-mortem diagnostic tests the control of OPA is
hindered severely.
Most information on the prevalence of OPA has been based on clinical observations
and histopathological diagnosis. Information of the true prevalence of JSRV
infection in OPA-affected flocks has been a major gap in our knowledge.
The prevalence of OPA appears to vary between countries. For example OPA is
endemic in Peru, Scotland and South Africa. In these countries it can cause between
2 and 10% annual mortality in adult sheep in the affected flocks (Sharp &
DeMartini, 2003).
Annual losses from OPA in affected flocks have been put from 1-2% up to 6%
(Sharp & Angus, 1985; Verwoerd et al., 1985; Sharp & De las Heras, 2000). Losses
in infected flocks in Scotland are generally between 2% and 10% annually (Sharp,
1991). Hunter and Munro (1983) found an average annual mortality rate of 3 % in
three affected flocks in Scotland. In a flock in East Anglia with concurrent maedi-
visna infection and OPA, there was an increase to about 20% in the number of ewes
culled prematurely for loss of condition (Pritchard & Done, 1990).
A longitudinal survey lasting five years based on histopathological studies in two
OPA affected flocks in Scotland revealed that about 30% of the sheep had
histologically confirmed lesions in their lungs and between 12% and 21% of the
sheep had subclinical tumours (Sharp, 1981).
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In contrast, OPA is infrequently diagnosed in the USA or Canada, where only few
cases have been reported (Stevenson et al., 1980). These differences in prevalence
and incidence of OPA may reflect variations in viral strains, host susceptibility, or
may reflect the result of different management systems.
The detection of JSRV in the peripheral blood of experimentally infected lambs,
before the development of tumour or onset of clinical disease, therefore, was an
important finding that offered a means to investigate the extent of JSRV infection in
OPA-affected flocks (Holland et al., 1999).
These findings have been extended in studies involving sheep from OPA-affected
commercial flocks in Spain (Garcia-Goti, 1999). Peripheral blood leukocytes (PBLs)
and tissue samples from sheep were examined for JSRV by PCR. Overall, JSRV was
detected in all OPA sheep, with either the classical or atypical form of OPA, as well
as in 80% of OPA in-contact sheep. None of 71 samples from the control sheep was
positive. Although an earlier report had indicated that as few as 1/250,000 PBLs
might be positive for JSRV (Holland et al., 1999), in this study, JSRV was detected
in the PBLs of all classical OPA sheep, 83% of the sheep with atypical OPA, as well
as 40% of lesion-free in-contact sheep. These results clearly demonstrated that JSRV
could be detected in naturally infected live sheep before the onset of clinical OPA
and even in the absence of discernible lung tumours. Although only a small number
of in-contact sheep were examined, it seems clear that subclinical JSRV infection
can reach a high prevalence in OPA-affected flocks.
To provide further information of the dynamics of JSRV infection in OPA-affected
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flocks, Garcia-Goti et al. in 2000 conducted a small prospective longitudinal survey
in an OPA-affected flock. JSRV was detected by PCR in PBLs from 28% of the
flock. Fifteen positive sheep and five negative were selected and PBLs examined by
JSRV PCR at monthly intervals for the next four months. JSRV was detected in only
nine of the original 15 positive sheep during this period and in four of those that
were negative. These results demonstrated the fluctuation in detection of JSRV in
blood and, more importantly, confirmed the high prevalence of JSRV infection in
OPA-affected flocks.
1.1.2 Pathology of OPA
1.1.2.1 Gross pathology
At post-mortem examination, lungs affected with OPA are 2-4 times heavier than
normal and they fail to collapse when the thorax is open (Fig. 1.3). Frequently, in the
cranioventral region of the lungs there is a firm, grey-purple neoplastic mass which
is often surrounded by small satellite tumour nodules (Dungal et al., 1938; Cuba-
Caparo et al., 1961; Dualde-Perez, 1966; Wandera, 1970; Gonzalez, 1990; Sharp &
Angus, 1990), (Fig. 1.4). The cut surface of the neoplastic tissue is generally moist
and frothy fluid may pour from the bronchioles of the affected area. In most cases,
this fluid accumulates in the airways and is discharged from the nostrils (Fig. 1.5).
Lung adenocarcinoma can give metastases, mainly affecting regional lymph nodes,
although some reports found metastases in extrathoracic tissue (Cuba-Caparo et al.,
1961; Cutlip &Young, 1982; Snyder et al., 1983; DeMartini et al., 1988). In the
Awassi sheep of Israel, metastases have been observed in 50% of cases (Nobel et al.,
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Fig.1.3. Classical OPA: macroscopic pathology.
Gross lesion are generally confined to the lungs. The lungs appear
considerably enlarged and they do not collapse when the chest is opened.
The normal weight can be increased three or more times, depending on the
extent of the tumour. The neoplastic areas vary from small discrete nodules
(0.5 - 2 cm) to extensive tumours involving the entire ventral half of the
diaphragmatic and other lobes.
Fig. 1.4. Classical OPA: macroscopic pathology of the lung.
Tumours appear as purple coloured areas in the cranioventral part of the
lung. The surface is moist and frothy fluid pours from the trachea.
Fig. 1.5. Typical OPA: section of the diaphragmatic lobe of the
lung showing tumour.
Affected areas with meaty aspect and frothy fluid pouring from the
bronchioles.
1969).
In some cases, an "atypical OPA" has been observed. In contrast to "classical
OPA", in "atypical OPA" solitary or coalesced nodules are hard, pearly white and
with a dry cut surface (Fig. 1.6). The tumoral nodules are clearly demarcated from
the sorrounding parenchyma, either underneath the pleura or deep in the lung tissue;
fluid is absent in the bronchi (Fig. 1.7 & 1.8).
The features of atypical OPA are responsible for a subclinical course of the disease.
Infact this condition is commonly found only in abattoir studies (De la Heras et al.,
1992), or at necropsy of sheep dying from other unrelated causes (Gonzalez, 1990).
In contrast to the classical form ofOPA, there are few reports of atypical OPA in the
literature. In Spain, De las Fleras et al. (1992) and Dualde-Perez (1966) described
these lesions in the course of abattoir studies, and Gonzalez (1990) did so in the
course of a clinico-pathological survey of ovine chronic pneumonias. Similar lesions
were also identified in Peru by Cupa-Caparo et al. (1961). In both Spain and Peru,
classical OPA is also commonly recognised and, in some reports, specific reference
is made to the fact that both forms of OPA may appear in the same flock (Gonzalez,
1990). However, in other countries in which classical OPA is well recognised, such
as Scotland, South Africa and Israel, there appear to be no specific references to the
atypical form of the disease (Nobel, 1958; Tustin, 1969; Hunter & Munro, 1983;
Sharp & Angus, 1990).
Secondary bacterial infections, such as pneumonic pasteurellosis and
mycoplasmosis, are common, leading to pleurisy and abscessation and they may
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Fig.1.6. Atypical OPA.
Well demarcated white, solitary tumour nodule in the dorsocaudal area of
the right lung.
Fig.1.7. Atypical OPA: section of a lung.
Severe case of atypical OPA with disseminated, numerous, dry confluent
nodules.
explain the eventual appearance of inflammatory infiltrates in the stroma of the
tumour (Cutlip & Young, 1982).
1.1.2.2 Histopathology and Electron Microscopy
OPA is a tumour arising from alveolar type II pneumocytes and the non-ciliated
bronchiolar (Clara) cells. Histologically neoplastic masses are composed of cuboidal
to columnar epithelial cells that line the alveolar and bronchiolar air spaces
exhibiting a papillary or an acinar pattern (Fig. 1.9); sometimes the tumour cells form
papilliform growths that project into the alveoli and bronchiolar spaces. Neoplastic
areas present a thin stromal tissue in which mononuclear inflammatory cells and
connective tissue fibres are usually present in small numbers. The non transformed
alveoli contiguous to the neoplastic foci are usually compressed and are
characteristically filled with enlarged macrophages with a foamy cytoplasm (para-
adenomatous lesion) (Garcia-Goti et al., 2000).
Histological observation of lung sections from natural cases of OPA shows the
presence of several foci of epithelial neoplastic proliferation in alveolar and
bronchiolar regions. These proliferations can have a papillary or an acinary
appearance. The alveolar neoplastic nodules compress the neighbouring alveoli
causing atelactasis and/or coalescence. Cuboidal or columnar cells replace the
normal flat type I pneumocytes. The nuclei of the transformed cells are located in the
basal region of the cells. The cytoplasm of these cells can be homogeneously
eosinophilic, clear and vacuolated and frequently it stains positively for glycogen
deposits (Wandera, 1970; Gonzalez, 1990; Sharp & Angus, 1990). The stroma of the
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Fig 1.8. Atypical OPA: section of a solitary demarcated atypical OPA
nodule.
The atypical nodules are pearly white in colour, very well demarcated
from the sorrounding parenchima, very hard in consistency and
sometimes look like scars.
Fig.1.9. Histopathology of experimental OPA.
Neoplastic lesions in the lung of a lamb inoculated with JSRV
at 1 month of age. (a) Co-existence of papillary (t) and
acinary (t) forms of the tumour and presence of desquamated
alveolar macrophages. H-E, bar = 400/vm. (b) Papillary
neoplastic proliferations involve alveoli and bronchioles, which
also show hyperplasia of associated lymphoid tissue. Para-
adenomatous change is also conspicuous. H-E, bar = 200>t/m.
tumour is generally thin but may be infiltrated by variable amounts of lymphocytes,
plasma cells and connective tissue fibres (De las Heras et al., 1995). However, in
more advanced tumours and particularly in their central areas, fibrosis of the stroma
can be prominent (Gonzalez, 1990; Sharp & Angus, 1990).
Macrophages with vacuolated cytoplasm are consistently found surrounding
neoplastic alveoli and filling the lumena of the normal ones; they are called para-
adenomatous areas because they look like a delimiting barrier of the tumour nodules
(Gonzalez, 1990; Sharp & Angus, 1990; De las Heras et al., 1995). Another
histopathological feature of OPA, usually seen concurrently with alveolar lesions,
occurs in the terminal bronchioles, in which multiple polypoid ingrowths arise from
the bronchiolar epithelium. In some cases, masses of myxomatous tissue, probably
ofmesodermal origin, are found in association with the epithelial neoplastic growths
(Cutlip & Young, 1982; Sharp & Angus, 1990; Garcia-Goti et al., 2000).
According to De la Heras et al., (1992) the histopathological expression of atypical
tumours is essentially the same as that of the classical ones, but in the "atypical
OPA" the stroma of the tumour is heavily infiltrated by mononuclear inflammatory
cells, mostly lymphocytes and plasma cells, and connective tissue fibres; lymphoid
proliferations are also consistently seen around the bronchioles of neoplastic areas
(Garcia-Goti et al., 2000).
The reactive changes in the stroma of atypical OPA may be due to a host immune
response. In the tumour stroma there is presence of lymphocytes, macrophages and
connective tissue. The fibrocellular infiltrates are essentially the same in classical
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and atypical OPA and the main difference between the two patterns is only
quantitative (Dualde-Perez, 1966; Hod et al., 1977; Payne & Verwoerd, 1984; De las
Heras et al., 1992).
Regional lymph nodes of OPA affected lungs may show either depletion of cortical
follicles and moderate plamacytosis in the medullary area (De las Heras et al., 1995),
hyperplastic reactive cortices, or no specific changes (Sharp & Angus, 1990). Lymph
node metastases when present, consist of epithelial neoplastic cells arranged in a
similar acinar or papillary pattern as in the lung tumour, but scirrous and mixed
epithelial/scirrous proliferations have also been described (Nobel et al., 1969). The
scirrous proliferation in the metastases very much resembles the myxomatous
proliferation in the lung (Nobel et al., 1969). Metastases in regional lymph nodes
seem to be less frequent in atypical OPA than in classical OPA (Garcia-Goti et al.,
2000).
The major capsid protein of JSRV (JSRV CA) can be detected in OPA tumours by
immunohistochemical (IHC) techniques (Palmarini et al., 1995). This viral protein is
located in the cytoplasm of transformed alveolar and bronchioalveolar cells, and can
be shown both in classical and atypical OPA cases (Fig. 1.10). Positive labelling can
also be found in a few mononuclear cells with lymphocyte morphology in the
paracortical areas of the regional lymph nodes. Within a tumour nodule individual
cells or group of cells may stain intensely for JSRV CA while other cells within the
same tumour nodule may not stain at all (Palmarini et al., 1995; Piatt et al., 2002).
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Fig. 1.10. Immunohistochemistry for JSRV-CA protein.
Immunolabelling is associated with the cytoplasm of neoplastic alveolar
cells. Immuno-histochemistry and counterstaining, x25.
JSRV-positive cells in the atypical tumours than in the classical ones. This finding
agrees with the results obtained from the detection of JSRV proviral DNA when a
smaller number of positive replicates was obtained from atypical tumours, which
would indicate a lower number of target proviral DNA copies than in classical
tumours. In addition, viral dissemination in the host appeared to be less pronounced
in atypical OPA, as demonstrated by the lower numbers of positive samples and
positive replicates in PCR on blood than in the cases of classical OPA.
Thus, JSRV-exogenous specific U3 long terminal repeat (LTR) sequence and JSRV
capsid protein (CA) were detected in lungs from animals with classical OPA and
from those with atypical OPA. The LTR is the region that presents most variations in
different retroviruses, such as JSRV, sheep endogenous retroviruses and ovine
enzootic nasal tumour virus; even sequencing did not make possible to distinguish
atypical from classical samples (Garcia-Goti et al., 2000).
More extensive studies are needed to confirm this apparent common aetiology, as
differences in other regions of the JSRV genome may exist and account for the
different lesions in classical and atypical OPA.
Based on electron microscopy (EM), the alveolar type II cells and the non ciliated
bronchiolar Clara cells are the predominant neoplastic cell phenotypes in naturally
occurring OPA and in experimentally induced OPA (Nisbet et al., 1971; Perk et al.,
1971; Hod et al., 1977; Sharp, 1987; Piatt et al., 2002). Transformed cells maintain
the appearance of the cells from which they originated. Type II pneumocytes and
Clara cells are both secretory epithelial cells. In type II pneumocytes there is
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synthesis, storage and secretion of the alveolar surfactant (Voelker & Manson, 1989;
Mason & Shannon, 1997). Clara cells are involved in the synthesis, storage and
secretion of protein components of the extracellular lining layer of bronchioles
(Massaro, 1989; Plopper et al., 1997). Ultrastructurally, tumour cells of type -II cell
origin are usually well differentiated, with microvilli, desmosomes, and intracellular
lamellar bodies; tumour cells of Clara-cell origin contain cytoplasmic dense bodies
instead of lamellar bodies (Nisbet et al., 1971; Perk et al., 1971; Payne & Verwoerd,
1984; Cutlip & Young, 1982; Herring et al., 1983; DeMartini et al., 1987). By IHC
studies, both cell types are occasionally found in the same tumour but they are
involved in different percentages. To further characterise the neoplastic cell
population, Piatt et al., 2002 immunostained sections of tumours with antibodies to
surfactant protein A (a phenotypic marker for ATII pneumocytes and Clara cells),
surfactant protein C (specific marker for ATII cells) and Clara cell 10-Kd protein.
Overall surfactant Proteins A and C were expressed in 70% and 80% of tumour cell,
respectively, whereas Clara cell 10-Kd protein was expressed in 17% of tumour
cells.
JSRV CA was detected in 71% of tumour cells and macrophages (5/12 tumours
examined) and in non neoplastic and bronchiolar cells (6/14 tumours) (Piatt et al.,
2002).
1.1.2.3 OPA in other species
There are few descriptions of natural OPA in goats. In the pathology reports from
India the features of the tumours are very similar to those for sheep (Rajya et al.,
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1964; Sharma et al., 1975). OPA has been experimentally reproduced in goats after
intracheal inoculation of very young goat kids with concentrated lung fluid of sheep
origin (Sharma et al., 1975; Tustin et al., 1977; Sharp et al., 1986).
In the mid-1980s, a severe outbreak of a disease resembling OPA was described in
captive Sardinian moufflon (Ovis musimon). Moufflon are wild sheep
phylogenetically related to the domestic sheep, Ovis aries (Hiendleder et al., 1998).
A flock of over 60 mufflon was kept on a game farm in Sassari (Sardinia, Italy) with
the aim of producing animals to be released later into their natural habitats. The
moufflon and a flock of sheep in which OPA was endemic had repeated contacts
(Ceretto & Deiana, 1967). Studies on DNA from archival materials concluded that
JSRV was the cause of OPA in the moufflon (Sanna et al., 2001).
Bronchiolo-alveolar carcinoma has been described in human beings and in several
animal species such as, cattle, horses, pigs, cats, dogs, chinchilla, Virginia opossum
(Didelphis Virginiana)and mice but the investigations on the moufflon resulted in
the first report that positively associated JSRV with bronchiolo-alveolar carcinoma
in an animal species other than the domestic sheep and goats (Tyzzer, 1907; Theiler,
1918; Grumbach, 1926; Monlux et al., 1953, 1955; Liebow, 1960; Sherwood et al.,
1969; Perk & Hod, 1982; Sriraman et al., 1982; Maruo et al., 1995; Hahn et al.,
1996; Okada et al., 1998; Kim et al., 2002; Grossman et al., 2002 a & b).
1.1.3 Viruses associated with OPA
From the beginning of the century OPA has been associated with different organisms
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such as the sheep lung worm Muellerius capillaris, Mycoplasma and Chlamydia but
none of them was demonstrated to be the etiological agent of OPA (McFadyean,
1894 and 1920; Mackay, 1969a and b; Tustin, 1969).
An interesting finding was the isolation ofherpesviruses from lungs ofOPA sheep in
geographically distinct locations such as Scotland, ex-Yugoslavia, Kenya and South
Africa (Mackay 1969a and 1969b; Nevjestic et al., 1971; Malmquist et al., 1972; De
Villiers et al., 1975; Martin et al., 1976 and 1979). The different herpesvirus isolates
were all antigenically related and could be differentiated by restriction endonuclease
analysis (Scott et al., 1984). This herpesvirus was initially classified as caprine
herpesvirus-1 (CHV-1) and later as ovine herpesvirus-1 (OHV-1) (Roizman et al.,
1992). Although ovine herpesvirus 1 (OHV-1) had been isolated exclusively from
OPA tumours, epidemiological studies and experimental infections provided no
evidence for a role in the aetiology of OPA (De Villiers et al., 1975, Martin et al.,
1976 & 1979; Scott et al., 1984). Ovine herpesvirus 2 (OHV-2) is the sheep-
associated malignant catarrhal fever herpesvirus and has never been linked to OPA
(Baxter etal., 1993; Bridgen & Reid, 1991).
It is an interesting possibility that retroviral information may be transmitted by
herpesvirus and that herpesvirus expression can be modulated by retroviral elements.
Retroviruses and herpesviruses are naturally occurring pathogens of humans and
animals. Co-infection of the same host with both these viruses is common. It has
been reported that a retrovirus can integrate directly into a herpesvirus genome.
Specifically, insertion of a non acute retrovirus, reticuloendotheliosis virus (REV),
into a herpesvirus, Marek disease virus (MDV) has been demonstrated. Both viruses
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are capable of inducing T lymphomas in chickens and often coexist in the same
animal. REV DNA integration into MDV occurred in a recently attenuated strain of
MDV and in a short-term coinfection experiment in vitro. There is also provide
suggestive evidence that REV has inserted into pathogenic strains of MDV in the
past. Sequences homologous to the REV long terminal repeat are found in oncogenic
MDV but not in non oncogenic strains (Isfort et al., 1992). Recombination after
integration of retrotransposons or retroviruses into the genome of another large
dsDNA virus i.e. baculovirus has been documented (Malik et al., 2000; Pearson &
Rohrmann, 2002).
The association of retroviruses with OPA has been recognised for several years.
The earliest electron microscopy studies in OPA tumour cells were consistent with
findings of A and B type retroviruses particles. However there were also reports of
isolation from OPA tumours of type C retroviral particles (Malmquist et al., 1972;
Irving et al., 1984; Perk et al., 1985; Payne et al., 1986). The nucleotide sequence of
one of the South African isolates [South African ovine maedi-visna virus (SA-
OMVV)] confirmed that the virus was related to the icelandic maedi-visna virus
strain 1514 (Querat et al., 1987). Experimental infection of sheep with this lentivirus
caused mild immunosuppression, but no tumours were ever produced (Myer et al.,
1988). This situation could be explained by the fact that concurrent "maedi" and
OPA infection have been recognised frequently in several countries. Many authors
have proposed a synergism between these two retroviruses (Al-Zubaidy & Sokkar,
1979; Cutilip & Young, 1982; Markson et al., 1983; Snyder et al., 1983; Rosadio et
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al., 1988; Gonzalez et al., 1993).
Different hypothesis could be formulated about a possible pathogenetic mechanism
arising from a double infection maedi-visna/OPA or OHV-1/OPA.
Synergism between maedi-visna and OPA could arise from the presence of an
abundant population of macrophages in OPA lesion representing an abundant
substrate of target cells for MVV (Payne et al., 1986; Demartini et al., 1987; Dawson
et al., 1990). Nevertheless, recent investigation on atypical OPA cases indicated that
the inflammatory changes in the tumour stroma were not connected with concurrent
maedi-visna infection in the non neoplastic areas of the lung (Garcia-Goti et al.,
2000). A further possibility is that OHV-1 plays a role in the reactive changes in
atypical OPA. This theory is supported by the fact that infection of young lambs
with OHV-1 results in interstitial pneumonia (Scott et al., 1984) although OHV-1
has been isolated on a number of occasions from lungs with lesions of classical
OPA, without significant interstitial inflammation (Sharp & Angus, 1990).
1.1.4 General features of the Family Retroviridae
Retroviruses comprise a large and diverse family of enveloped, RNA viruses
(Coffin, 1992a and 1992b; Coffin et al., 1997). The virions are 80-100 nm in
diameter (Fig. 1.11). The virion RNA is 7-12 kb in size, and it is linear, single-
stranded, diploid, non-segmented, and of positive polarity. The retroviral replicative
strategy includes as essential steps reverse transcription of the virion RNA into linear
double-stranded DNA by a virus-coded polymerase called reverse transcriptase







Fig. 1.11. Schematic representation of a retroviral particle.
The viral envelope is formed by a cell-derived lipid bilayer into which
proteins encoded by the env region of the viral genome are inserted.
These consist of the transmembrane (TM) and the surface (SU)
components linked together by disulfide bonds. Internal nonglycosylated
structural proteins are encoded by the gag region of the viral genome.
They are the matrix (MA) protein, capsid (CA) protein, and nucleocapsid
(NC) protein. Major products of the pol-coding region are reverse
transcriptase (RT) and integrase (IN). The protease (PR) is derived from
the pro gene between gag and pol (Coffin et al., 1997J.
From this reverse flow of genetic information originates the terms "retroviruses" and
"reverse transcriptase."
The family Retroviridcie is divided into seven genuses (Van Regenmortel, 2000) and
the nucleocapsid is concentric for Alpharetrovirus, Gammaretrovirus,
Deltaretrovirus and Spumavirus, and rod or truncated coneshaped, for Lentivirus and
Betaretrovirus (Table 1.1). The Epsilonretrovirus is a recently discovered group that
is not well understood, although it appears to group with the mammalian type C
retroviruses. The form of assembly was used as means of classification, where
Betavretrovirus assembled A-type particles (immature capsid) in the cytoplasm and
budded as a B-type (MMTV, Mouse mammary tumour virus) or as a D-type (M-
PMV). Alpharetrovirus and Gammaretrovirus that assemble their capsids on the
plasmamembrane, were classified morphologically as C-type viruses.
The early classification had three subfamilies, Oncovirinae, Lentivirinae and
Spumavirinae, having three different outcomes of infection; leukaemia and sarcomas
from the oncoviruses, immunodeficiencies and neurological disorders from
lentiviruses and spumaviruses that are not presently associated with any known
disease in vivo. Retroviruses are widely distributed as exogenous infectious agents of
vertebra above or as endogenous proviruses that have resulted at some time from
infection of germline cells and that are inherited as Mendelian genes. Endogenous
retrovirus (ERV) families are derived from their exogenous counterparts by means
of a process of germ-line infection and proliferation within the host genome. Several
families in the human and mouse genomes now consist of many hundreds of
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ALV (Avian leukosis virus,)
MMTV (Mouse mammary tumor virus)
MLV(Murine leukemia virus)
BLV (Bovine leukemia virus)
HTLV (Human T-cell leukemia virus)
WDSV (Walleye dermal sarcoma virus)
HIV (Human immunodeficiency virus)
MW (Maedi visna virus)
HFV (Human foamy virus)
elements (Belshaw et al., 2004).
Retroviruses are associated with a variety of diseases. These comprise malignancies,
including certain leukemias, lymphomas, sarcomas; mammary carcinomas and
carcinomas of lung, liver and kidney; immunodeficiencies (such as AIDS);
autoimmune diseases; lower moton neuron diseases; and several acute diseases
involving tissue damage. Some retroviruses are non pathogenetic. In general
transmission of retroviruses is horizontal via a number of routes, including blood,
saliva, sexual contact, etc., and vertical via direct infection of the developing
embryo, or via milk or perinatal routes. Endogenous retroviruses are transmitted by
inheritance of proviruses (van Regenmortel et al., 2000).
1.1.4.1 Genome organization
All retroviruses contain three major genes with information for virion proteins: gag,
synthesis internal virion proteins that form the matrix, the capsid, and the
nucleoprotein structures; pol contains the information for the reverse transcriptase
and integrase enzymes; env contains the information for the surface and
transmembrane components of the viral envelope protein. An additional, smaller,
coding gene present in all retroviruses is pro, which encodes the virion protease.
Simple retroviruses usually carry only these four genes, whereas complex
retroviruses have additional genes (accessory genes) that code for additional
regulatory non virion proteins. Retroviruses can be divided into two categories:
simple and complex distinguishable by the organisation of their genomes (Fig. 1.12)
(Coffin, 1992a; Murphy et al., 1994). Five of the seven genera include retroviruses
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with oncogenic potential (also referred to as oncoviruses), and the other two groups
are the lentiviruses and the spumaviruses. All oncogenic members except the human
T-cell leukemia virus, bovine leukemia virus (HTLV-BLV) genus are simple
retroviruses. HTLV-BLV and the lentiviruses and spumaviruses are complex . A fish
virus genus (Epsilonretrovirus) also contains "accessory" genes. Accessory genes
regulate and coordinate viral gene expression. These genes are located between pol
and env, just downstream from env including the U3 region of the LTR, or
overlapping portions of env and each other. Lentiviruses demonstrate a genomic
complexity far greater than that of a prototypic retrovirus, possessing as many as six
additional genes, which are involved in regulatory processes.
All known lentiviruses encode an apparent transactivating protein (herein referred to
as Tat) and a Rev protein that are both essential for virus replication (Cullen, 1998;
Emerman & Malim, 1998). In addition to tat and rev, HIV-1 contains four additional
regulatory genes: nef vif, vpr, and vpu, encoding the so-called accessory proteins. It
is noted that whereas HIV-2 and SIV genomes lack the vpu gene, they contain
another gene, vpx. Some of the accessory proteins are not absolutely required for
viral replication in all in vitro systems but represent critical virulence factors in vivo.
Nef is expressed from a multiply splicedmRNA and is therefore Rev independent. In
contrast, Vif, Vpr, and Vpu are the products of incompletely spliced mRNA and thus
are expressed only during the late, Rev-dependent phase of infection from singly
spliced mRNAs.
Most of the small accessory proteins of HIV have multiple functions manifested at
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Fig. 1.12. Retroviral genome.
(A) A simple retroviral genome. The genetic map of an ALV contains
four major coding regions, gag, pro, pol, and env and pro gene.The
terminal noncoding sequences include two direct repeats (R), a U5 (5'
unique), and a U3 (3' unique) sequence. (S) A complex retroviral
genome. The genetic map of HTLV contains, besides the major coding
domains, information for two regulatory proteins, Tax and Rex, encoded
in regions (boxes) joined by RNA splicing.
l
different stages of virus replication (Miller et al., 2000).
1.1.4.2 Replication
Retroviruses enter the host cell through the attachment of their surface glycoproteins
to specific plasma membrane receptors, which leads to fusion of virus and cell
membranes. The interaction of virus and cell surfaces is highly specific; it
constitutes the main determinant of viral host range, defining susceptible animal
species and target cells within the host. After penetration into the cell, the RNA
genome, still contained in a core complex of non-glycosylated proteins and
associated with the virion reverse transcriptase (RT), is transcribed into a double-
stranded DNA. Transcription into DNA involves two jumps of the reverse
transcriptase from the 5' terminus to the 3' terminus of the template molecule. These
sequences then occur fused in tandem on both ends of the viral DNA, forming the
long terminal repeats (LTRs) (Fig. 1.13). The LTR regions regulate viral gene
expression and therefore replication and pathogenesis.
Reverse transcription takes place in the cytoplasm; the viral DNA is translocated into
the nucleus where the linear copy of the retroviral genome is inserted into
chromosomal DNA with the aid of the virion integrase to form a stable provirus.
Integration does not change the linear order of the proviral sequences, LTR-gag-pol-
ewv-LTR. The number of possible sites of integration into the cellular genome is
very large and very widely distributed. With integration, the provirus achieves the
status of a cellular gene and is expressed by the cellular RNA polymerase II and


















Fig. 1.13. Comparison of the RNA and the DNA forms of the
viral genome.
Reverse transcription of the RNA genome generates identical
structures referred to as long terminal repeats (LTRs) found at both
ends of the DNA provirus. Transcription of the provirus between the
upstream U3 and downstream U5 regions generates RNA with the
same terminal organization as in the parental virus. (R) Terminal
direct repeat RNA; (U5) unique regulatory sequences at the 5' end;
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Fig. 1.14. Retroviral life cycle.
The life cycle of retroviruses is defined by the binding of virion to the
host cell receptor, cell entry, followed by reverse transcription and
subsequent integration into the host genome. Full length viral
transcripts and individual viral mRNAs are synthesized in the
nucleus, which subsequently encode both structural and regulatory
proteins, permitting viral assembly and eventual budding of new
virions.
1
the non coding sequences of the viral LTR. Transcription of the provirus generates
spliced and unspliced mRNAs and full-length progeny RNA genomes. In infection
with simple retroviruses, control of transcription is mediated by interaction of
cellular factors with the DNA of the LTR. Complex viruses, in contrast, take a more
active role, encoding traws-activating factors that affect the levels of transcripts and
the relative amounts of the products of the various genes.
Viral messages are translated on cellular ribosomes. The translation products,
together with progeny RNA, are assembled at the cell periphery into viral particles
that are released from the cell by budding of the plasma membrane. Budding of
viruses is followed by proteolytic cleavage of virion polyproteins by a viral protease
and by cellular proteases (Fig. 1.14). Productive retroviral infection is not of
necessity cytopathic; infected cell cultures often show no visible effects of viral
production. In some congenital infections in animals, virus can be produced by most
cells in most tissues without deleterious effect on the development and function of
the organism (Rubin et al., 1961 and 1962).
1.1.4.3 Provirus and interaction with cellular genome
A provirus, once integrated into the cellular genome, has the genetic stability of a
cellular gene. Reverse transcription and integration make retroviral infection
permanent, as integrated proviruses are only rarely lost from the cellular genome: "A
retrovirus is forever."
Retroviruses have developed mechanisms of pathogenicity involving the transfer or
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transcriptional activation of specific cellular genes. These mechanisms are based on
genetic recombination between virus and cell and between viral genomes. Retroviral
particles contain two copies of their genome linked by regions near the 5' termini
(Billiter et al., 1974; Kung et al., 1975; Beemon et al., 1976). A direct consequence
ofdiploidy is the formation of heterozygote virions in cells that are infected with two
or more genetically distinct but related retroviruses. Such heterozygotes give rise, in
the next cycle of infection, to stable genetic recombinants that are formed during the
process of reverse transcription of the two parental genomes from the same viral
particle. Rates of recombination between related retroviruses are high (Temin, 1964;
Coffin, 1979; Linial & Blair, 1982).
A plausible hypothesis for this acquisition of cellular genetic material postulates that
a provirus integrates upstream of a cellular gene and leads to the production of
chimeric virus-cell transcripts. In the next round of replication, non homologous
recombination between virus and cell sequences leads to the incorporation of the
cellular gene into the retroviral genome, so that it is now transported by the virus
from cell to cell and expressed under control of the viral LTR (Goldfarb &
Weinberg, 1981; Swannstrom et al., 1983; Raines et al., 1988; Felder et al., 1991,
1993; Coffin, 1992b; Swain & Coffin, 1992). The usual product of this transduction
process has acquired the host sequence at the cost of one or more viral genes. Such
viruses are therefore generally defective for replication, requiring the presence of a
replication-competent provirus in the same cell to provide viral proteins for
replication. The transduction of cellular genes has been found only with simple
retroviruses and not with complex retroviruses. The reasons for this difference are
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not clear, but they may have to do with the mechanism by which retroviruses acquire
cellular sequences or with viral genome organisation that must incorporate foreign
inserts (Coffin et al., 1997).
The modified cellular genes carried by retroviruses convey a high degree of
tumorigenicity to the virus. These viral or \-onc genes are usually mutated growth-
regulatory genes. Their cellular progenitors are referred to as protooncogenes or c-
onc genes (Bishop, 1983; Varmus, 1984). Overexpression or inappropriate
expression, often combined with mutation of an oncogene that has become part of a
viral genome, results in a gain of function of a positive growth signal and in
tumourogenesis.
Retroviruses with oncogenes in their genomes are particularly fast-acting
carcinogens and in most cases also transform cells in culture.
Retroviruses lacking an oncogene do not transform cultured cells, but some can
induce tumours in animals. This process is characterized by a long latent period. In
this case, it is a cellular homolog that is activated through the insertion of a provirus.
The viral LTR, through its promoter and enhancer sequences, alters expression of the
neighbouring cellular oncogene (Lazo & Tsichlis, 1990; van Lohuizen & Berns,
1990; Kung & Vogt, 1991). Transduction and insertional activation of cellular
oncogenes are the two main mechanisms by which most retroviruses induce
tumours.
For other retroviruses the mechanisms of oncogenesis are not clear. One example is
by Human T-cell leukemia virus type-I (HTLV-1) is the first discovered human
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retroviral pathogen (Poiesz et al., 1980). It has been implicated with the etiology of
an aggressive malignancy known as adult T-cell leukemia (ATL) and of a
neurological progressive inflammatory syndrome called tropical spastic paresis or
HTLV-1 associated myelopathy (TSP-HAM) (Barmak et al., 2003; Jeang et al.,
2004) HTLV-1 is a complex retrovirus that, in addition to the two long terminal
repeats (LTRs) and the gag, protease, pol and env genes, which are typical to most
other retroviruses, its genome contains an additional region called pX, which resides
between the env gene and the 3'-LTR. This region includes four partially
overlapping reading frames (ORFs), of which the most investigated ones are ORFs
III (Silverman et al., 2004) and IV that encode for the viral regulatory Rex and Tax
proteins respectively. This virus neither carries a transduced oncogene in its genome
nor activates a resident oncogene by insertion; it may cause tumours through one of
its regulatory proteins, possibly by changing the expression levels of cellular genes
(Feuer & Chen, 1992; Azran et al., 2004).
A unique model of tumor induction is also seen with a form of the Friend murine
leukemia virus. In the past two decades, several oncogenes and tumour suppressor
genes, which play critical roles in the induction and progression of Friend
erythroleukemia, have been identified. Retroviral insertional activation of Fli-1 and
Spi-l/PU.l, as well as loss of tumour suppressor genes such as p53 or p45 NFE2
have been shown to be critical for the induction and progression of Friend virus-
induced erythroleukemias (Lee et al., 2003). It produces a modified Env protein that
appears to mimic a component of the erythropoietin signalling pathway (Li et al.,
1990; D'Andrea et al., 1992; Johnson & Benchimol, 1992). In Table 1.2 genomic
-27-
























































































organization of some retroviruses and some primate and non -primate lentiviruses
are correlated with their pathogenetic features.
1.1.5 Retroviruses and cancer
Oncogenic retroviruses occur in all classes of vertebrates. Tumour-inducing retroviruses
have been isolated from rodents, cats, cows, primates and other animals (Gross, 1970).
Some of the more studied are Rous sarcoma virus (RSV), a highly pathogenic agent
inducing connective tissue tumors in chickens (Rous, 1911); mouse mammary tumor and
murine leukemia viruses (MMTV and MLV); and more recently HTLV. A representative
example is human immunodeficiency virus (HIV), the causative agent of acquired
immunodeficiency syndrome (AIDS).
With regard to the incubation time of the tumour to appear and from a clinical point of
view retroviruses can be divided in two classes (Rosenberg & Jolicoeur, 1997):
1) acutely transforming retroviruses;
2) non- acutely transforming retroviruses.
The acutely transforming retroviruses cause tumours rapidly (1 week to a few weeks) and
are able to transform cells in culture, whereas the non acute retroviruses induce disease
slowly (months to years) and cannot transform target cell in vitro.
1.1.5.1 Acutely transforming retroviruses
Retroviruses that carry v-onc genes (sometimes called transforming viruses) induce a
wide range of malignancies including sarcomas and hematopoietic cell tumours.
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Their ability to induce tumours rapidly and to transform cells in vitro has made them
powerful tools for studies addressing the ways in which oncogenes alter cell growth
The acutely transforming retroviruses possess a cellular oncogene (known as proto-
oncogene or c-onc) in their genome often altering its structure (deletions, point
mutations, etc.) and (Duesberg & Vogt, 1970; Stehelin et al., 1976; Bishop et al.,
1984; Rasheed, 1995/ Cellular proto-oncogenes are usually conserved over long
evolutionary distances, suggesting that they are indispensable for fundamental
cellular functions (Benjamin & Vogt, 1990/ Viral oncogenes work through the
synthesis ofproteins (oncoproteins) that have the potential to transform a normal cell
into a neoplastic one. Most retroviral oncogenes have homology with cellular genes
(proto-oncogenes), a hallmark of an oncogene. For example, the avian
erythroblastosis virus strain H carries the erbB oncogene that has close homology to
the chicken epidermal growth factor receptor (Downward et al., 1984). v-onc are
usually classified in families based on the function of the protein encoded by their
protooncogene parent. Most classes of proteins involved in growth stimulation are
represented by growth factors, growth factor receptors, non receptor protein tyrosine
kinases, G proteins, serine/threonine kinases, and transcription factors (Blackwood et
al, 1992a and 1992b).
As a result of the transduction of the oncogene, the acutely transforming retroviruses
typically lack portions of their structural genes and are replication defective. Acutely
transforming retroviruses are thus propagated in conjunction with a replication-
competent virus called "helper" that encodes all of the viral structural and enzymatic
proteins {Fung et al., 1983; Green et al., 1987). Viruses containing oncogenes are
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relatively rare in naturally occurring retrovirus-induced tumors for several reasons:
1) Oncogene capture is an unlikely event, 2) the rapid and lethal course of the
induced disease could limit the spread of the infection, and 3) there is probably no
evolutionary-positive selection of replication-defective oncogene-containing
retroviruses (Palmarini & Fan, 2001).
1.1.5.2 Non- Acute transforming retroviruses
The majority of oncogenic retroviruses do not carry an oncogene in their genome
(Teich et al., 1984; Benjamin & Vogt, 1990; Rosenberg & Jolicoeur, 1997). Such
viruses are called "non acute retroviruses" because the incubation period of the
resulting neoplasia is usually several months or more. Non acute retroviruses are
replication competent. Tumour induction appears to occur through multiple steps,
many with similarities to non-virus-induced cancer. The best understood mechanism
of nonacute retroviral carcinogenesis is LTR activation of proto-oncogenes, also
known as insertional activation, creactivation, or insertional mutagenesis. In these
tumors, a provirus is integrated in the vicinity of a cellular proto-oncogene, resulting
in overexpression of the proto-oncogene by one of several mechanisms. Retroviruses
that act by insertional activation generally induce tumors with a long incubation
period because retroviral insertion near oncogenes occur by chance (Steffen &
Weinberg, 1978; Brown, 1997). Thus, multiple rounds of infection are typically
necessary before integration near (e.g., few to a hundred kilobases) a proto-oncogene
occurs in one cell. Under the influence of the viral LTR, the transcription of the
proto-oncogene is elevated in that cell and triggers transformation (Hayward et al.,
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1981; Nusse & Varmus, 1982; Fung et al., 1983; Cuypers et al., 1984; Dickson et
al., 1984).
Insertional inactivation of tumor suppressor genes in retrovirus-induced tumors is
very rare because, unlike proto-oncogenes, the loss of function of a tumor suppressor
gene requires that both copies of the gene be damaged or lost. However, the
insertional inactivation of one allele could potentiate spontaneous mutations
occurring in the other allele, leading to transformation. For instance, the insertional
inactivation of p53 has been observed in a proportion of non-B-, non-T-cell
lymphomas induced by the Cas-Br-E virus (Bergeron et al., 1993; Palmarini & Fan,
2001).
1.1.6 Endogenous retroviruses (ERVs)
The genomes of all vertebrates, humans included, have been colonized during
evolution processes by retroviruses via integration of their genomes into the germ
line and subsequent fixation in the gene pool of the host population (Vogt, 1997).
These viruses are called endogenous retroviruses (ERV), are inherited by the host
vertically, according to the mendelian principles. In contrast, exogenous retroviruses
are horizontally transmitted and they do not efficiently infect the germ line (Boeke &
Stoye, 1997; Patience et al., 1997; Lower, 1999). Like other transposable elements,
ERV are thought to have played an important role in the evolution of mammalian
genomes and the human genome sequence has already been used in phylogenetic
studies.
Most ERVs have retained some similarity to their exogenous counterparts but they
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have lost replication competence as a result of the accumulation of deletions and
mutations acquired over the course of evolutionary time so that most of them are
now defective and incapable of producing protein. ERVs have been suggested to
play important roles in a number ofphysiological and pathological processes.
ERVs have the potential to interfere with the exogenous counterparts and with the
host immune system. For example Human endogenous retrovirus W (E1ERV-W) is
specifically expressed in the syncytiotrophoblast of the human placenta. It is possible
that EIERV-W envelope protein induces formation of syncytia, thereby sustaining
the hypothesis that HERV-W is involved in human placental morphogenesis (Mi et
al., 2000; Frendo et al., 2003). Another human endogenous retrovirus, ERV-3, is
conserved throughout primate evolution and ERV-3 is highly expressed in the
trophoblast of the normal placenta; the similarity between a portion of the
transmembrane (TM) glycoprotein of ERV and a putatitve immunosuppressive
region of gammaretroviruses, pl5E, led to the speculation that ERV-3 may protect
the implantation of the foetus protecting it from a maternal adverse immunological
reaction (Boyd et al., 1993; Venables et al., 1995; Medzhitov & Janeway Jr., 2002).
ERVs may also protect the host against infection by related exogenous retroviruses.
For example, ERV loci of chickens express envelope proteins that confer resistance
to Rous sarcoma virus subgroup E infection through receptor interference (Payne &
Pani, 1971). A similar situation has been described in mice in which the receptor for
Murine Leukaemia virus (MLV) is blocked by an endogenous synthesis of Gag gp
70 (Kozak et al., 1984).
Endogenous interference through the immune system is well established in Mouse
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mammary tumour virus (MMTV) model through the expression of a superantigen
(sag). Expression during ontogeny of of the endogenous sag sequences in the
developing immune system ofmouse strains induces clonal deletion of the reactive T
cell required, thus preventing infection of activated leukocytes (the intermediate
carriers ofMMTV) with related exogenous strains (Golovkina et al., 1992; Held et
al., 1993; Karapetian et al., 1994).
In terms of negative effects, the generation of pathogenic retroviruses can result
from reactivation and/or recombination among different endogenous loci or by
recombination with related exogenous viruses (van Nie & Verstraeten, 1975; Hartley
et al., 1977; van Nie et al., 1977; Verstraeten & van Nie, 1978 Imai et al., 1983;
Stoye & Coffin, 1987; Neil et al., 1991; Stoye et al., 1991; Golovkina et al., 1994;
Golovkina et al., 1996; Benson et al., 1998; Golovkina et al., 1997; Ruis et al.,
1999).
In mice, chickens and cats, endogenous retroviruses have been demonstrated to be
involved in recombination events leading to the generation of oncogenic retroviruses
or virus with a broader host range (Stoye & Coffin, 1987; Fan, 1994; Golovkina et
al., 1994; McDougall et al., 1994; Bai et al., 1995).
Infection of both mice and cats may lead to the emergence of new retroviruses
through recombination between the incoming exogenous viruses and endogenous
viral sequences (Kim et al., 2004). The mouse mink cell focus-forming (MCF)
viruses, also designated polytropic MLV, were the first retroviruses identified as
resulting from such de novo recombinations following MLV infection (Fischinger et
-33 -
al., 1975; Hartley & Rowe, 1976). Subsequent to infection by an ecotropic MLV,
acquired mcf env sequences broaden the cellular tropism of the parental ecotropic
MLV through the acquisition of heterologous receptor-binding determinants in the
env SU (Fan, 1997). Generation of new e/zv-recombinant viruses also occurs upon
infection of cats with feline leukemia viruses (FeLV). Thus, infection with the
FeLV-A subtype can result in the generation of FeLV-B subtypes with markedly
modified tropism (Stewart et al., 1986).
Infection of T lymphocytes by the cytopathic retrovirus feline leukemia virus
subgroup T (FeLV-T) requires FeLIX, a cellular coreceptor that is encoded by an
endogenous provirus and closely resembles the receptor-binding domain (RBD) of
feline leukemia virus subgroup B (FeLV-B) (Barnett et al. 2003).
The acquisition of heterologous viral sequences, however, is not limited to env, and
it is important to note that recombination among or with mcf sequences involves
other regions of the MLV genome as well (Evans & Cloyd, 1985). Irrespective of the
region of the viral genome, it is generally accepted that recombination between
endogenous mcf and exogenous MLV sequences occurs after coencapsidation of
heterologous genomic RNA into virus particles (Katz & Skalka, 1990). The
production and characteristics of the resulting recombinant viruses depend upon the
subspecies or strain of mouse and the type of exogenous infectious virus inoculated
(Chesebro et al., 1983; Lavignon et al., 1997). It is also noteworthy that the initial
dissemination of these recombinant viruses depends largely on pseudotyping with
env from the infecting, exogenous MLV (Sitbon et al., 1985).
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HERVs have frequently been proposed as etiological cofactors in chronic diseases
such as cancer, autoimmunity and neurological diseases (Lower, 1999).
In human, for example, HERV-W has been widely investigated following the
isolation of an HERV-W- related retrovirus (multiple sclerosis-associated retrovirus,
MSRV) from retroviral particles produced in cell cultures from patients with
multiple sclerosis (Perron et al, 1997). HERV-W are under investigation as potential
causative agents of various human diseases including cancers following several
findings suggesting that HERV-W elements are actively expressed in human tissues
and cancer cells (Yi et al., 2004; Yi et al., 2002).
Another human endogenous retrovirus family (HTDV/HERV-K family) has links
with testicular tumours. This family is interesting because it has retained coding
capacity in all viral genes. In patients with testicular tumours, an immune response is
induced against the Gag and Env proteins and it declines after tumour removal
(Gotzinger et al., 1996; Tonjes et al., 1996).
Most studies on the pathological potential of HERVs have looked for expression of
HERV RNA or protein, on the assumption that disease symptoms result from
inflammatory or autoimmune reactions to HERV proteins. The effect of HERVs in
disease may be at the level of cellular gene transcription, however, since it is well
known that enhancer and promoter elements in retroviral LTRs can influence the
transcription of neighbouring genes. This can result in transcriptional activation or
gene silencing and in changes in tissue specificity of expression (Ting et al., 1992;
Schulte et al., 1996). Data mining of the human genome sequence has already been
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used to identify two HERV-E LTRs that act as alternative promoters for cellular
genes (Kowalski et al., 1999).
1.1.7 JSRV
The genome of JSRV is 7,462 nucleotides with the typical organization of type B
and D retroviruses with the overlapping gag, pro and pol reading frames except for
an additional open reading frame (orf-x) of 683 bp overlaps pol. Orf-x has a codon
usage different from that of other genes within JSRV, and a very hydrophobic
predicted amino-acid sequence (Bai et al., 1999; Rosati et al. 2000). The role of this
open reading frame is unknown but orf-x region of endogenous and exogenous JSRV
isolates collected from UK, Italy, Spain and South Africa are highly conserved
(Rosati et al., 2000). Orf-x does not seem to be required for JSRV replication in vitro
(Palmarini, M. & Fan, H., unpublished results) or for cell transformation in vitro
(Maeda et al., 2001). The long terminal repeat of JSRV provirus is 397 bases in
length. The U3 region contains regulatory signals for viral transcription (York et al.,
1992) (Fig. 1.15).
So far, three strains of JSRV have been completely sequenced: the original South-
African strain (JSRV-SA) (York et al., 1991, 1992), JSRV21 (Palmarini et al.,
1999a) and JSRVJS7 (DeMartini et al., 2001). Partial sequences of JSRV isolates
have been obtained from different strains from various geographical locations (Bai et
al., 1996; 1999; Hecht et al., 1994; Palmarini et al., 1996a and 1996b; Rosati et al.,
2000). The sequence of JSRV21 confirmed the genomic structure published for
JSRV-SA by York et al., 1991 and 1992.
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1.1.7.1 JSRV mRNA Splicing Pattern
Retroviral proviruses contain a single transcriptional unit that is transcribed in the
nucleus in full-length genomic RNA. The viral RNA is then transported to the
cytoplasm with and without RNA splicing. All retroviruses use full-length genomic
RNA as mRNA for the Gag, Pro and Pol products. A single spliced mRNA
consisting of the 3' end of the genome of the env gene is used for translation of the
envelope proteins (Coffin et al., 1997). Simple retroviruses usually use only this two
form of RNAs. In contrast complex retroviruses encode additional subgenomic
single or double spliced mRNAs for the synthesis of regulatory proteins (Rabson &
Graves, 1997). The full-length viral mRNA is translated on polyribosomes free in
the cytoplasm; the subgenomic mRNAs and env mRNA are translated on
polyribosomes associated with the rough endoplasmic reticulum. The cleavage of
Env polyprotein happens in the Golgi apparatus producing the SU and TM proteins;
SU and TM remain associated with each other on the surface of virions.
Palmarini et al., (2002) characterized the virus-specific RNAs in 293T cells
transiently transfected with a human cytomegalovirus promoter-driven JSRV
expression plasmid, in productively infected OHH1.LU deer lung cells, and in OPA
tumors from field isolates. Typical unspliced (7.5kb) (for gag, pro, and pol) and
singly spliced (2.4kb) env mRNAs were detected. In addition, six other virus-
specific RNAs were detected that resulted from the use of alternate splice acceptor
sites and two premature polyadenylation sites (located in gag and in env). The orf-x
gene of the virus appeared to be expressed from two singly spliced subgenomic
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Fig. 1.15. Schematic representation of the genome of jaagsiekte
sheep retrovirus (JSRV).
The JSRV genome contains the retroviral gag, pro, pol, and env genes as
well as an additional open reading frame (o/f-x) that overlaps pol and
whose function is unknown. LTR = long terminal repeat.
acids.
1.1.7.2 JSRV proteins
The Gag precursor polyprotein is a 612-amino-acid polypeptide with a calculated
molecular weight of 68 kDa. Alignment of the predicted JSRV Gag polyprotein with
those ofMPMV, squirrel monkey retrovirus (SMRV), and MMTV shows that there
is a strong sequence conservation corresponding to the capsid proteins (CA) of the 3
viruses (York et al., 1992). From the analysis of the genome sequence Pro, the
protease is probably expressed as a fused Gag-Pro polypeptide as for MMTV (Jacks
et al., 1987). Pro (326 residues; calculated molecular weight 35kDa) consists of two
parts: a pseudoprotease or protease-like (PrL) and an active protease (PR) which
exhibits the core amino acid sequence of cellular aspartyl protease. Alignment of the
JSRV PrL and PR domains against some lentiviruses shows that the PrL polypeptide
is even more conserved than the protease. Pol is likely to be translated as a fused
Gag-Pro-Pol polypeptide (York et al., 1992).
Orf-x has a very unusual location and a codon usage; its predicted amino acid
sequence is very hydrophobic and it doesn't show any similarities with other known
proteins, with the exception of a low homology to a G-protein-coupled receptor (Bai
et al., 1999; Rosati et al., 2000). The role of orf-x is unknown but it is conserved
among various endogenous and exogenous JSRV isolates collected from different
geographical locations (Rosati et al., 2000).
Env ORF encodes the precursor of the viral envelope protein. Env is composed by
two parts the outer membrane and surface protein (SU) and the cell membrane
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spanning domain of the transmembrane protein (TM). The calculated molecular
weight of the non glycosylated Env precursor is 69 kDa. The calculated molecular
weight ofmature SU protein is 47 kDa and that ofTM is 33 kDa.
The complete genome sequence of JSRV enabled the expression of viral proteins in
vitro and to overcome the inability of the virus to grow on cell culture.
Palmarini et al., in 1999 established a convenient method to prepare infectious JSRV
in vitro. This involved transfection of human 293T cells with a plasmid DNA
containing the JSRV21 provirus that had been modified by replacement of the U3
sequences in the upstream long terminal repeat (LTR) with the human
cytomegalovirus immediate-early promoter (pCMV2JS2i). The in vitro-synthesised
virus particles were called JSRV21.
Proteins in JSRV21 virions were labelled by incubation of transfected 293T cells for
24 h with [35S]methionine. Labelled supernatant from transfected 293T cells was
banded in an isopycnic sucrose gradient, and fractions corresponding to 1.14 to 1.16
g/ml were pooled and subjected to SDS-PAGE and autoradiography.
Several prominent labelled proteins were detected, while supernatant from mock-
transfected and labelled 293T cells yielded no detectable radioactivity in material
banding at 1.14 to 1.16 g/ml. By analogy to the sizes of other type D and type B
retroviral proteins, it seemed possible that the 53- and 37-kDa proteins were
envelope proteins and their diffuse migration in SDS-PAGE could be consistentwith
glycosylation (Dion et al, 1977; Li, 1987). Similarly, some of the lower-molecular-
mass proteins (26, 23, 17, and 14 kDa) were detected and considered as mature Gag
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proteins or proteins encoded by other viral genes (Bradac & Hunter, 1984; Hizi et
al., 1987; Hizi et ah, 1989). The 26-kDa protein had the same mobility as the 26-
kDa CA protein present in lung fluid from SPA-affected sheep that is detectable by
Western blots (Fig. 1.16).
1.1.7.3 Homologies between JSRV and other retroviruses.
JSRV protein sequences were aligned to those of other beta retroviruses and scored
for the percentage of amino acid identity.
There is more than 50% amino acid identity between JSRV, MPMV and SIV-1 Gag,
Pro and Pol proteins but there is not reliable alignment of their envelope precursor
proteins.
On the other hand , Env proteins of JSRV and MMTV are homologous, although
there is less than 38% amino acid identity between their Gag proteins (Doolittle et
al., 1989; York, et al., 1992).
The viral JSRV envelope is more similar to MMTV than MPMV exhibiting
prominent surface spikes and an eccentric core. The MPMV-type morphology has
less dense surface spikes and a cylindrical core. Phylogenetic analysis of the RT
subdomain suggests that JSRV evolved from the type A (hamster intracisternal type
A particles), B and retroviruses D and diverged between the B prototype MMTV and
the D prototype MPMV (Chiu, et al., 1985; McClure, et al., 1988; York et al.,
1992).
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Fig.1.16. Major proteins encoded within the retroviral genome.
Gag: is processed to matrix and other core proteins that determine
retroviral core.
Pol: is processed to reverse transcriptase, Rnase H and integrase
functions.













Fig1.17. Expression of proteins in JSRV2i virions.
Palmarini et at., in 1999 labeled JSRV21 prepared from transfected 293T cells that had been
treated with [35S]methionine 24 h prior to supernatant harvest. Viral particles were purified by
isopynic centrifugation, and the fractions corresponding to 1.14 to 1.16 g/ml were pooled and
analyzed by SDS-PAGE on 8.7 and 15% polyacrylamide gels followed by autoradiography
(JSRV21). 293T cells that were mock-transfected were labeled and processed in parallel (M).
No radioactivity banded at 1.14 to 1.16 g/ml from tissue culture supernatant from the mock-
transfected culture. JSRV21 virions contained major bands of 53, 37, 26, and 23 kDa visible
in the 8.7% polyacrylamide gel (left). An additional band migrated at the bottom of the 8.7%
polyacrylamide gel that resolved into three bands of 15, 10, and 5 kDa in the 14%
polyacrylamide gel. The sizes of the radioactive proteins were calculated from the mobilities
of protein size markers.
exogenous, vertically transmitted (milk), and endogenous viruses of mice, as well as
exogenous, horizontally transmitted and endogenous viruses ofNew and Old World
primates. Murine viruses are associated with mammary carcinoma and T-cell
lymphomas, while the exogenous primate viruses are associated with
immunodeficiency diseases (Table 1.3). No oncogene-containing member is known.
Table 1.3. Viruses included in the Genus Betaretrovirus.
Genus Betaretrovirus
Type species Mouse mammary tumor virus (MMTV)
Species in the Genus
Langur virus (LNGV)
Mason-Pizermonkey virus (MPMV)
Simian retrovirus 1 (SRV-1)
Simian retrovirus 2 (SRV-2)
Mouse mammary tumor virus (MMTV)
Ovine pulmonary adenocarcinoma virus
(Jaagsiekte sheep retrovirus) (JSRV)
Squirrel monkey retrovirus (SMRV)
1.1.7.4 Experimental transmission of OPA
The transmissibility of OPA to in-contact sheep was first demonstrated by de Kock
in 1929; Dungal in 1946 proved that OPA could be transmitted by aereosol: affected
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sheep were made to breath through a 20% solution of glycerine in normal saline for
30 minutes and this solution was used to inoculate intratracheally 3 lambs. Two of
the lambs developed OPA four months after the experimental infection. The
experiment was positively repeated after filtering the glycerol-saline solution
through a gradacol membrane (pores 0.9pm in diameter). Several other authors
reproduced the disease by aerosol spray or by intratracheal or intrapulmonary
inoculation of lung tumour homogenates or lung fluid (Sigurdsson, 1958; Cuba-
Caparo et al., 1961; Wandera, 1968; Tustin, 1969).
When OPA lung fluid from field isolates concentrated by ultracentrifugation and
injected intratracheally in new-born lambs, disease occurs extremely rapidly. In fact
animals developed clinical signs ofOPA between 3 and 6 weeks post-inoculation but
some developed OPA within 4-10 days (Verwoerd et al., 1980; Sharp et al., 1983).
Early experiment involving infection of mature sheep resulted in increased
incubation time of OPA, more than 12 months, and in very small resulting lesions
(Dungal, 1949; Wandera, 1968). Several authors demonstrated the experimental
transmission ofOPA to goats (Tustin et al., 1977; Sharp et al., 1986).
The virus cannot be cultivated on cell culture and transmission ofOPA to laboratory
animals failed with the exception of transplantation studies of OPA tumour cells into
nude mice (Verwoerd et al, 1977; Zimber et al., 1984; Jassim, 1987).
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1.1.7.5 Involvement of JSRV with OPA
In the 1970s retroviral A-particles were observed in OPA tumour cells (Hod et al.,
1971, Perk et al., 1971; Bucciarelli, 1973). The first report on the transmission of
OPA with particles containing reverse transcriptase activity was by Martin et al.,
1976. Verwoerd et al., (1980) succeeded in transmitting the disease with the
cytoplasmic fraction of tumour cells that had a buoyant density in sucrose gradient
of around 1.175 g/ml and which contained reverse transcriptase particles that
resembled those of a retrovirus. The same group in 1981 showed that during
experimental transmission there was an inverse dose relationship between the
reverse transcriptase (RT) activity in the inoculum and the incubation time between
inoculation and appearance of OPA symptoms (Verwoerd et al., 1980). In 1983
Sharp et al., confirmed that lung fluid from clinically OPA affected sheep contained
both the virus and the viral particles carried RT activity. In the same year and from
the Scottish group came the report of an immunological cross-reaction between the
27000 mol.wt. core protein of Mason-Pfizer monkey virus, mouse mammary
tumour virus, and a 25000 mol wt. Protein in OPA tumours and lung fluid by
Western blotting technique (Sharp & Herring, 1983).
In 1992 York et al., released the complete genomic sequence of JSRV.
The JSRV genome was cloned from viral particles secreted in lung fluid of affected
animals (York et al., 1991 and 1992). The virus was produced in new born lambs by
injecting Freon-extracted virus intratracheally. The inoculum was previously
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obtained by lung lavages and then purified (Herring et al., 1983; Verwoerd et al.,
1983). Polyadenylated RNA was isolated from isopynic-gradient-purified virus
(York et al., 1991); cDNA was synthesised with oligo (dT) as primer, and then
cloned in appropriate vectors. Recombinant clones were selected by using either
labelled random primed cDNA from JSRV polyadenylated RNA or JSRV specific
clones as probes. Clones were ordered relative to each other by restriction mapping
and by nucleotide sequencing of the extremities and alignment of the predicted
translational products against MPMV and MMTV protein sequences.
The availability of a genomic sequence for JSRV facilitated the development of
recombinant JSRV capsid antigens (CA). These were used to develop specific
antisera and a blocking-ELISA to detect JSRV and to determine the anatomic
distribution of JSRV in sheep. JSRV was detected only in lung fluid and tumours
from affected animals and not in any other tissue from affected or unaffected sheep
(Palmarini et al., 1995). Immunohistochemical examination of the same tissues,
using the same antiserum to JSRV-CA, detected JSRV protein in the cytoplasm of
the transformed epithelial cells in the pulmonary alveoli of both naturally and
experimentally OPA-affected sheep. Although JSRV-CA was observed in all OPA
tumours, not all tumour cells were positive, even in the same nodule. There was no
staining of non-transformed epithelial cells nor of the stromal cells and specific
staining was observed only rarely in the extracellular alveolar spaces. Specific
staining was not demonstrated in any other tissue, with the exception of a few large
lymphoblastoid cells in the paracortical zones and medullary sinuses of the
tracheobronchial and mediastinal lymph nodes and some macrophages within the
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pulmonary alveoli. These observations demonstrated that JSRV appears to replicate
principally in the transformed epithelial cells in OPA tumours as well as a minor
subset of lymphoid cells (Palmarini et al., 1995).
1.1.7.6 JSRV and its endogenous counterpart
However, confirmation of the pathogenic role of JSRV in OPA was complicated by
the presence of 15-20 copies per sheep genome of JSRV-related endogenous
sequences (York et al., 1992).
To investigate this point York et al., (1992) analysed genomic digests of an OPA
derived tumour cell line, primary foetal fibroblastic type cells from sheep and goats
and primary culture of choroid plexus. All the samples contained JSRV-like
sequences as integrated proviral DNA without any detectable linear or circular
unintegrated proviruses. Several sheep breeds in different places such as Kenya,
Peru, Europe and north America were tested, indicating that all sheep populations
contain these sheep endogenous retrovirus sequences (Hecht, et al., 1994). Sheep
harbour in their genome about 20 copies of endogenous betaretroviruses (York et al.,
1992; Hecht et al., 1994 and 1996; DeMartini et al., 2003).
These results did not rule out the possibility that JSRV might be acting as a helper
virus for some other replication defective, acutely transforming retrovirus or
represent an endogenous virus, reactivated as a consequence of neoplasia or, indeed,
result from recombination with endogenous sequences as has been reported in other
species. The identification of reagents and techniques to distinguish exogenous and
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endogenous ovine retroviruses, therefore, was a critical development.
To investigate this relationship further, the distribution of JSRV transcripts by RT-
PCR was examined in various tissues (lung, lymphoreticular tissues) from OPA-
affected and unaffected animals (Palmarini et al., 1996a). Clear evidence enJSRV
transcripts in tissues of affected and unaffected animals was shown.
Differentiation between exogenous and endogenous RNA was evaluated by
sequencing and/or restriction enzyme digestion of PCR products obtained from viral
pellets and tumour of OPA sheep and tissues of unaffected sheep. DNA was
collected from the same OPA animals and from control animals and tissues. The
comparison of sequences derived from the RT-PCR products revealed a Sea I site in
the gag region that was present only in lung fluid, tumours and viral pellets and
mediastinal lymph nodes of affected sheep (Palmarini et al., 1996a). The same result
was obtained after analysis ofDNA provirus in affected and not affected animals. So
the Sea I site was correlated with the exogenous virus. The absence of the Sea I site
was confirmed in a separate molecular characterisation of endogenous sheep
retrovirus (Bai et al., 1996).
The molecular characterisation of a number of endogenous sheep retrovirus loci
(Bai et al., 1996) and the identification of the major differences in the U3 region of
the LTR of exogenous JSRV allowed the development of an hemi-nested PCR
specific for the exogenous JSRV proviral DNA (Palmarini et al., 1996b). Using this
new assay the tissue distribution of JSRV in sheep with natural and experimentally
induced SPA was analysed. Proviral DNA and JSRV transcripts were found in all
-46-
tumours and lung secretions of SPA-affected sheep (n = 22) and in several lymphoid
tissues. The mediastinal lymph nodes draining the lungs were consistently
demonstrated to be infected by JSRV (10/10). JSRV transcripts were also detected in
spleen (7/9), thymus (2/4), bone marrow (4/8) and peripheral blood mononuclear
cells (3/7). Proviral DNA was also detected in these tissues although in a much
lower proportion of cases. JSRV was not detected in samples from unaffected
control animals (Palmarini et al., 1996b).
To rule out the possibility that the exogenous form of JSRV may have represented
enJSRV that normally were transcriptionally silent but reactivated as a downstream
event of neoplasia, it was necessary to demonstrate exogenous JSRV proviral DNA
only in OPA-affected sheep and not unaffected animals.
1.1.7,7 Definitive proof that JSRV was the etiological agent of OPA
The identification of exogenous JSRV-specific restriction endonuclease
polymorphisms (Bai et al., 1996; Palmarini et al, 1996a) and the development of a
diagnostic PCR specific for the exogenous JSRV DNA (Palmarini et al., 1996b)
opened the way for finally obtaining an infectious molecular clone of JSRV. A
lambda phage library was constructed from a natural case of OPA (Palmarini et al.,
1999a). The tumour library was screened by sib-selection followed by plaque
hybridization using JSRV DNA probe and specific PCR for the exogenous virus. A
full length exogenous JSRV proviral clone was obtained (A.JSRV21). The insert from
this clone was subcloned in to a plasmid to give pJSRV21. Sequence analysis
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confirmed that JSRV21 was indeed the integrated provirus, that it was full length
and with expected open reading frames (ORFs). Recently another JSRV proviral
clone has been isolated from an OPA lung tumour- derived cell line (JS7) that was
originated from an OPA clinical case ofUK origin (Jassim et al., 1987; DeMartini et
al, 2001).
The U3 region of the upstream LTR in pJSRV21 was replaced with the human
cytomegalovirus (CMV) immediate early enhancer/promoter. This plasmid, called
pCMV2JS21, was successfully used to transfect 293T cells that released substantial
amounts of JSRV21 virus (Palmarini et al., 1999a). Four newborn lambs were
inoculated with JSRV21 particles produced in this manner, and two of them showed
the classical signs of SPA 4 months postinfection. The resulting tumours were
positive for JSRV DNA and protein. Thus, JSRV21 was recognized as an infectious
and pathogenic molecular clone, necessary and sufficient to induce sheep pulmonary
adenomatosis (Palmarini et al., 1999a).
1.1.8 Features of Endogenous JSRV (enJSRV)
Endogenous betaretroviruses of sheep are highly related to the exogenous and
pathogenetic JSRV (York et al., 1992; De las Heras et al., 1993; DeMartini & York,
1997; Palmarini et al., 1999b). Two approaches have been undertaken to identify
and characterise the nucleotide sequence and genomic organization of enJSRV in the
sheep genome: PCR amplification and molecular cloning of proviruses isolated from
sheep lambda libraries (Bai et al., 1996; Palmarini et al., 1996b).
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Recently three enJSRV proviruses have been molecularly cloned, sequenced and
functionally characterized (Palmarini et al., 2000a). The genome of the enJSRVs
loci is highly related to exogenous JSRV with 90-98% identity at the amino acid
level in most parts of the genome ( Bai et al., 1996, 1999; Palmarini et al., 1996a,
2000b; Rosati et al., 2000). One of the endogenous proviruses was full length and
maintained open reading frames in all its structural genes but could not assemble
viral particles when highly expressed in human 293T cells; by making chimeras
between this provirus and JSRV 21 the defect for viral assembly was detected in the
first two-thirds of the gag gene (Palmarini et al., 1996a, 2000b).
Two short regions (VR1 and VR2) were identified to contain major differences
between ovine endogenous and exogenous betaretroviruses. Besides VR1 and VR2,
a third region (VR3) located in the carboxy-terminal portion of the transmembrane
(TM) protein of the viral envelope is divergent between the exogenous JSRV and
enJSRV sequences (Palmarini et al., 2000a).
By PCR enJSRV RNA has been detected in many sheep tissues examined, including
lungs, kidney, thymus, bone marrow, spleen, mediastinal lymph nodes, leukocytes
and reproductive tract (Palmarini et al., 1996a). However, in situ hybridisation
indicates that enJSRV expression is mostly limited to the reproductive tract.
High levels of enJSRV expression are detectable in the endometrial luminal and
glandular epithelium of the uterus and in the epithelia of the oviducts and in the
cervix (Spencer et al., 1999; Palmarini et al., 2000b).
In situ hybridisation detected en JSRV RNAs in lymphoid cells associated with the
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lamina propria of the small intestine and in the thymuses of sheep foetuses. Low
level expression of enJSRV also have been found in the lung (Spencer et al., 2002).
EnJSRV expression is not limited to RNA, in fact the epithelia of the lumen and
glands of the endometrium of the uterus were positive by for enJSRV proteins by
immunofluorescence when antiserum to the highly related exogenous JSRV CA and
SU were used (Palmarini et al., 2001b).
enJSRV RNAs are highly expressed in the epithelium of the uterus, while the
exogenous JSRV appears to have a strict tropism for secretory cells of respiratory
tract (De las Heras et al., 1991; Palmarini et al., 1995; Spencer et al., 1999;
Palmarini et al., 2000a; Palmarini et al., 2000b).
To further investigate the role of enJSRVs in sheep reproductive biology, studies
were conducted to determine effects of neonatal age, estrus cycle, early pregnancy
and progesterone on expression of enJSRVs in the ovine uterus.
By in situ hybridisation enJSRV expression has been studied in uteri of neonatal
ewe lambs between postnatal (PND) day land 56 when the uterine gland
morphogenesis occurs and no positive result was obtained at PND 1 while it was
detected between day 7 and day 56 PND. In pregnant ewes expression of enJSRV
RNAs was detected in endometrial lumenal epithelia and glandular epithelia of all
regions of the uterus in the ampulla and isthmus regions of the oviduct, as well as in
the cervix (Palmarini et al., 2001b).
The oestrus cycle and pregnancy also influence the levels of enJSRV expression in
the uterus. In cyclic ewes, endometrial enJSRV RNA is increased 12-fold between
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days 1 and 13 and then decreased to day 15. The initial increase of enJSRV RNAs
between days 1 and 13 of the oestrus cycle correlates with the formation of the
corpus luteum after ovulation and consequent increase of progesterone in the blood
(Palmarini et al., 2001).
The high level and specificity of expression of enJSRVs in the endometrium of the
ovine uterus might suggest physiological functions of this sequences in regulation of
conceptus-endometrium interaction, as well as placental morphogenesis, during the
peri-implantation period (Palmarini et al., 2001b).
In OPA-infected sheep or OPA clinical cases there is not detectable antibody
response toward JSRV (Sharp & Herring, 1983; Ortin et al., 1998; Verwoerd et al.,
1980), consequently, it is conceivable that enJSRVs expression during foetal
ontogeny leads to the tolerance of sheep towards the pathogenic JSRV.
EnJSRVs may interact and or interfere at different levels both with the host and with
their exogenous and pathogenic counterparts (Spencer et al., 2003; Palmarini et al.,
2004).
1.1.9 Molecular basis for the lung tropism of JSRV
JSRV appears to be unique among retroviruses in inducing transformation of the
differentiated epithelial cells of the lungs (Rosenberg & Jolicoeur, 1997). The only
sites where JSRV is highly expressed in vivo are the transformed epithelial cells of
the lung (Palmarini et al., 1995). Although it is also possible to detect JSRV DNA
and RNA by sensitive PCR assays in a variety of lymphoid tissues of SPA-affected
sheep (Palmarini et al., 1996b; Holland et al., 1999). Proviral DNA has been found
in adherent cells (macrophages), B lymphocytes, and CD4+ and CD8+ T lymphocytes
of the mediastinal lymph nodes of SPA-affected animals (Holland et al., 1999).
Therefore, although JSRV is highly expressed only in the epithelial tumour cells of
the lungs in vitro experiment JSRV infects several different sheep cell lines of
various tissue origins (Palmarini et al., 1999). In vitro observations suggested that the
cellular receptor for JSRV is common to a variety ofcell types; this data suggest that
the restriction of viral expression to epithelial tumor cells in the lungs is likely not
due to the presence ofthe JSRV receptor only on these cells and it could reside in the
LTR region.
Palmarini et al., (2000a) investigated whether JSRV-specific expression in the
differentiated epithelial cells of the lung was due to lung epithelial cell-specific
activation of the viral LTR. Reporter assays were performed with several cell lines
originating from different cell types with a construct (pJS21-luc) in which the
luciferase gene is under the transcriptional control of the JSRV LTR. JSRV LTR
function was then studied by assaying the transcriptional activity of LTR deletion
mutants and cotransfections with potentially activating transcription factors. By
transient-transfection assays of 23 different cell lines with a reporter plasmid driven
by the JSRV long terminal repeat (LTR), pJS21-luc, we found that the JSRV LTR is
preferentially active in cell lines derived from type II pneumocytes and Clara cells
(MLE-15 and mtCCl-2 mouse cell lines). Reporter assays using progressive 5'
deletions of pJS21-luc allowed us to establish that the JSRV enhancers are able to
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activate the JSRV proximal promoter in MLE-15 and mtCCl-2 cells, but they have
very low activity in mouse cells of other lineages (e.g., NIH 3T3). The JSRV
enhancers were able to activate heterologous promoters in both MLE-15 and 3T3
cells, although optimal activity was achieved in MLE-15 cells only with the
homologous JSRV promoter. Thus, JSRV cell-specific LTR activity appeared to
result from an interaction between the enhancer elements and the JSRV proximal
promoter elements. After analysis of the U3 sequences in JSRV LTR for potential
binding sites 2 putative enhancer binding motifs for transcription factors such as
hepatocyte nuclear factor 3 (HNF-3) were found. HNF-3 is an important factor in
lung-specific SP gene expression. Co-transfection experiments demonstrated that
exogenous HNF-3 was able to enhance the expression of pJS21-luc in NIH 3T3
cells, which normally showed minimal enhancer activity for the JSRV LTR
(Palmarini et al., 2000a). Further studies, using a mouse cell line derived from typell
pneumocytes, indicated that JSRV LTR interacts with the hepatocyte nuclear
transcription factor called HNF-3P (McGee-Estrada et al., 2002). HNF-3P and its
isoform, a, are highly expressed in hepatic and lung tissues (Costa et al., 2001);
HNF-3 isoforms are highly expressed in both type II pneumocytes and Clara cells
and they regulate the transcription of several lung-specific genes, including
surfactant protein B and CC10, a protein anchored on the surface of mature Clara
cells (Clevidence et al., 1994; Costa et al., 2001).
Recently, the cellular receptor for JSRV has been identified as a hyaluronidase-2
(HYAL-2), a glycosylphosphatidylinositol-linked cell-surface protein (Rai et al.,
2001).
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HYAL2 is a member of a protein family that includes the hyaluronidase present on
the sperm surface (SPAM1, also called PH-20) that enables sperm to penetrate the
hyaluronic acid-rich cumulus cells surrounding the oocyte, and a hyaluronidase
found in lysosomes and serum, called HYAL1 (Lepperdinger, et al., 1998); HYAL2
is widely expressed in most tissues, with the notable exception of brain (Csoka et al.,
1999). Therefore the distribution ofHYAL2 does not drive the tissue tropism.
1.1.10 Mechanisms of oncogenesis in OPA
The mechanism by which JSRV transforms the target type II epithelial pneumocyte is not
clear. In the following two paragraphs the hypothesis of JSRV as an acutely transforming
retrovirus or as slow transforming retrovirus will be explored and supported by the data
obtained by in vitro transformation of cell cultures and the features of the pathogenesis of
the disease in vivo. So is JSRV:
a) an acute-transforming retrovirus
or
b) a slowly transforming retrovirus?
a) Is JSRV an acute transforming retrovirus?
JSRV can induce lung cancer in sheep quite rapidly, 4 months with the cloned virus
and 3 to 4 weeks with the uncloned virus; moreover the pattern of tumour cells is
close with multifocal disease (Verwoerd et al., 1980; Sharp et al., 1983).
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This pattern of disease is almost always characteristic of retroviruses that carry
oncogenes, viral versions of highly conserved cellular genes that play key roles in
growth and development (Rosenberg & Jolicoeur, 1997), however, JSRV lacks an
oncogene (Palmarini et al., 1999).
One of the characteristics of acute transforming retroviruses is that they can
morphologically transform cells in culture (Coffin et al., 1997).
Maeda et al., (2001) used the pCMVJS21 plasmid (in which the JSRV genome is
driven by the human CMV immediate early promoter/enhancer (to assess the
hypothesis that JSRV could transform NIH3T3 murine cell line). Many scientists
have used these cells to test the presence of viral oncogenes or activated cellular
proto-oncogenes (Shih & Weinberg, 1982). When pCMVJS21was transfected into
NIH3T3 fibroblasts, foci of transformed cells were obtained; in contrast transfection
with a control plasmid lacking JSRV sequences did not produced foci of
transformation. Cells from the foci were analysed and JSRV DNA could be detected
in all the transformants and also showed the capacity to grow in soft agar sospension
(Maeda et al., 2001). Similar results were obtained transfecting rat fibroblast cell
line 208F (Rai et al., 2001) and Rat6 (Maeda et al., 2001).
At this point of the studies it was very interesting to understand which gene
implicated in the transformation. The potential transformation power of orf-x region
was checked using the plasmid pCMVJS21 in which to termination codons were
inserted into the orf-x reading frame in positions where the amino acids of the
overlapping integrase protein would not be affected; this plasmid was called
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pCMVJS21AorfX and it was used to transfect NIH3T3 cells (Maeda et al., 2001).
pCMVJS21AorfX did not induce any decrease in the number of foci compared to the
original plasmid pCMVJS21. Thus it could be deduced that Orf-x is not essential for
transformation. Maeda et al., (2001) then tested the possibility of that the env gene
could be implicated in transformation. So it was generated a plasmid,
pCMVJS21AGP, in which the coding sequences for gag and pol were eliminated,
but the splice donor and acceptor sites for the envelope gene were maintained; it
efficiently induced transformed foci. This result showed that JSRV envelope gene
was responsible for the transformation of cell culture. Two additional plasmids for
the expression of the truncated envelope protein were prepared for investigating
which part of env was responsible for transformation. The results indicated that the
truncated forms of env were not sufficient for transformation and that probably full-
length envelope protein is required for transformation (Maeda et al., 2001). The
transformation of JSRV envelope protein has also been demonstrated using avian
DF-1 cells (Allen et al., 2002). This experiment used avian sarcoma virus (ASLV)
derived vectors (pRCAS) and the avian fibroblast cell line, DF-1 (Federspiel &
Hughes, 1997; Himly et al., 1998; Schaefer-klein, et al., 1998).
The pRCAS vectors were constructed by removing the src gene from the virus
genome and replacing it with a cloning site (Federspiel & Hughes, 1997). JSRV gag,
pro, pro, pol, orf-x, env, where cloned separately into the vector and their effects
after transfection were monitored. Only cells transfected with the vector containing
the JSRV env gene transformed. Cells transfected with PRCAS containing the JSRV
env gene were inoculated into nude mice and they were tumorigenic (Allen et al.,
-56-
2002).
Palmarini et al., (2001b) mapped the determinants of cell transformation of the
JSRV envelope. A series of chimeric construct between the envelope of infectious
molecular clone JSRV 21 and two JSRV-related endogenous retroviruses of sheep
(enJS56Al and en JS5F16) were constructed and used to transform NIH 3T3 cells.
The VR3 region includes the putative membrane-spanning region and cytoplasmatic
tail of JSRV TM glycoprotein; this suggested that the cytoplasmatic tail of JSRV
ENV mediates transformation. Mutation ofY590 and M593 in the cytoplasmatic tail
of the JSRV envelope were sufficient to inhibit the transforming abilities of these
constructs. Y590 and M593 are part of a Y-X-X-M motif that is recognised by the
phosphatidylinositol 3-kinase (PI-3K). PI-3K initiates a cell signalling pathway that
inhibits apoptosis and is required for a number ofmitogens during the Gl-to-S-phase
transition of the cell cycle (Palmarini et al., 2001b). These data indicated that the
cytoplasmatic tail of JSRV TM was necessary for cell transformation of rodent
fibroblast. Further experiments (Maeda et al., 2003; Liu et al., 2003) showed that
PI3K was not necessary for establishment of JSRV envelope-induced
transformation, despite the requirements of the YXXM motif and that interestingly
as already highlighted by Palmarini et al., (2001b) the downstream AKT kinase is
phoshorylated in JSRV transformed cells. The PI3K/Akt pathway has been
implicated in several cancers and oncogenic systems. Avian and murine acute
transforming retroviruses have transduced bot Akt (v-Akt in the AKT8 murine
lymphoma virus) and the pi 10 of PI3K (v-P3k in avian S-7 virus) (Bellacosa et al.,
1991; Chang et al., 1997). Amplification and/or overexpression of the Akt gene has
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also been reported in a variety of human cancers (Vivanco & Sawyers, 2002).
The finding that JSRV envelope is able to transform cells opens further investigation
for possible mechanisms for JSRV envelope induced oncogenesis.
JSRV envelope SU binds to its receptor Hyal-2 that could start a signal transduction
cascade towards other regulatory mechanism. For example HIV-1 infects target cells
that present CD4 surface molecules as receptor as well as another co-receptor. In the
case of macrophage tropic HIVs, the coreceptor is the CCR5 chemokine molecule
(Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Dragic et al., 1996). The
interaction of macrophages tropic HIV-1 with CCR5 leads to an intracellular
signalling event involving calcium release (Weissman et al., 1997). An argument
against this theory is the fact that although rodent cells lack the JSRV receptor, they
can be transformed by JSRV. Infact rodent cells show low levels of infectability by
JSRV pseudotypes of retroviral vectors (Rai et al., 2000).
JSRV envelope SU protein binds to a cell surface protein that is different from Hyal-
2, and it stimulates cell growth through this other receptor. SU envelope proteins of
MMTV and MuLV bind to the Toll-like receptor (TLR) 4 cell surface protein (Rassa
et al., 2002). TLR4 is present on the surface of B Lymphocytes, and its normal
function is to mitotically activate them.
JSRV TM protein binds a cytoplasmic tail leading to a cascade signalling for cell
growth. It is possible that a cellular protein could interact with the TM cytoplasmic
tail. For example SIV and in particular the strain SIV macPBJ14 has a TM domain
that can interact with cellular factors involved in the signalling for cell death (Fultz
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etal., 1989).
b) Is JSRV a slowly transforming retrovirus?
However, JSRV lacks an oncogene, containing only gag, pol, and env, the three
genes typically found in simple, replicating retroviruses. Non-acute transforming
retroviruses are typically associated with tumours that arise after a long latent period.
Invariably, such tumours contain an integrated provirus that alters the expression of
cellular proto-oncogenes (Rosenberg et al., 1997). The JS7 tumour cell line contains
one integrated JSRV provirus (DeMartini et al., 2001). The provirus from JS7 cells
was molecularly cloned and was found in the surfactant protein A gene. The analysis
of the JSRV insertion sites was greatly complicated by the presence in sheep genome
of approximately 20 copies of enJSRV (DeMartini et al., 2003; Palmarini et al.,
2004). Recently 70 JSRV integration sites from 23 sheep and also the integration site
from the JS7 OPA tumour cell line were cloned (Cousens et al., 2004). The
chromosomal location of the integration sites was determined by PCR, using as a
template DNA isolated from a panel of sheep-hamster somatic hybrid cells, each
containing 1 or few of the 28 sheep chromosomes. After sequence aligning and
Southern blotting techniques, the final data from this study suggested that there is a
common integration site for JSRV on chromosome 16 in tumour DNA extracted
from two sheep with OPA, neither of the insertion sites was found to be clonal
(Cousens et al., 2004). These data could support a role for insertional mutagenesis
even if further evidence of integration sites in this region is required. The fact that
none of the integration site was found to be clonal cannot exclude insertional
mutagenesis infact multiclonality has been reported for tumours induced by MMTV
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(Sarkar, 1995). The host background could play a strong effect on the frequency
with which a particular gene is insertionally activated. In MMTV for instance, in
CH3 mice wnt-1 is activated in 75% of tumours while in other mouse strains is
activated only in 25-59% of the cases (Marchetti et al., 1991). OPA affects an
outbred sheep population, therefore analysis of a greater numbers of tumours is
required to identify additional preferred sites (Cousens et al., 2004).
How to link the insertional mutagenesis mechanism with the role of the recent
identified JSRV receptor (HYAL-2) is still in the land of hypothesis (Rai et al.,
2000).
HYAL2 was previously described as a lysosomal hyaluronidase, but Rai et al.,
(2000) showed that HYAL-2 is a glycosylphosphatidylinositol (GPI)-anchored cell-
surface protein. Furthermore, the hyaluronidase activity associated with or secreted
by cells expressing HYAL-2 could not be detected, whereas such activity could be
detected from cells expressing the related serum hyaluronidase HYAL-1 (Rai et al.,
2000). Although the function ofHYAL-2 is currently unknown, other GPI-anchored
proteins are involved in signal transduction, and some mediate mitogenic responses,
suggesting a potential role of HYAL-2 in JSRV oncogenesis (Low, 1989; Lublin,
1992). Another interesting finding about this receptor is that the Hyal-2 gene resides
in the 3p21.3 region (Rai et al., 2000). The human chromosome 3p21.3 region has
been studied in correlation with tumour suppressor gene loss in human tumours;
infact one common method to scan tumour cells for tumour suppressor loss is to
examine them cytologically and/or molecularly for chromosomal loss of
heterozygosity (LOH), a prominent common site of LOH in lung cancers is on
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human chromosome 3p21.3 (Sekido et al., 1996). The HYAL-2 gene thus has been
considered a candidate tumour suppressor gene for lung tumours (Rai et al., 2000).
As has been shown for other retrovirus-induced tumours ( Li et al., 1990; Ruscetti et
al., 1990), OPA is likely to be a multistep process resulting from an accumulation of
events. The recent data on the transforming activity of the transmembrane envelope
protein in vitro suggest an important but not necessary exclusive role for the acute
transformation by JSRV (Palmarini et al., 2001a; Rai et al., 2001; Alberti et al.,
2002; Allen et al., 2002; Chow et al., 2003; Danilkovitch-Miagkova et al., 2003; Liu
et al., 2003; Zavala et al., 2003). In particular, an acute transformation mechanism
does not fit with the long incubation periods between infection and OPA clinical
signs seen in natural OPA.
At this stage insertional mutagenesis cannot be excluded. It has been shown that for
certain acute transforming retroviruses, insertional activation of proto-oncogenes
occurs as well. In particular Abelson murine leukemia virus, which carries the v-abl
oncogene also requires insertional activation of proto-oncogenes for efficient
tumorigenesis (Poirer & Jolicoeur, 1989).
1.1.11 OPA and bronchioloalveolar carcinoma in human
The histology and the ultrastructure of human bronchioloalveolar carcinoma (BAC)
closely resembles OPA: similarities between OPA and BAC have been noticed for
more than half a century (Bonne, 1939; Nobel & Perk, 1978; Perk & Hod, 1982;
Gazdar & Linnoila, 1988). BAC is a subset of pulmonary adenocarcinoma arising
from type II pneumocytes or Clara cells. BAC is now defined as a type of
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adenocarcinoma with a pure bronchioloalveolar carcinoma growth pattern and no
evidence of stromal, vascular, or pleural invasion; the neoplastic cells grow as a
single layer along the walls of the terminal airways and alveoli (Liebow, 1960;
Edwards, 1984; Travis et al., 1999). Bronchioloalveolar carcinoma can be divided
into non mucinous and mucinous adenocarcinomas.
In the non mucinous adenocarcinoma, the Clara cells and/or type II pneumocytes
grow along the alveolar walls and there is no stromal invasion. The mucinous
adenocarcinoma is composed of tall columnar cells with cytoplasmic mucin, which
displace the nucleus to the base of the cell, growing along alveolar walls and without
stromal invasion.
The existence of bronchioloalveolar adenocarcinoma as a distinct clinical and
pathological type of adenocarcinoma has been somewhat controversial, mainly
because of the difficulty in differentiating bronchioloalveolar carcinoma from other
adenocarcinomas (Schraufnagel et al., 1982; Sorensen et al., 1993; Saleh et al.,
1998).
Lung cancer is the most common cause of cancer deaths: every year more than a
million of people dye from lung cancer world-wide (Parkin, 1998; Greenlee et al.,
2000).
The majority of lung cancers are associated with cigarette smoking; however, about
10% of lung cancers in men and 20-25% in women are not associated with smoking
(Shopland, 1995). Adenocarcinoma is increasing in frequency and accounts for
almost half of lung cancers in some countries, and it is associated less strongly with
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cigarette smoking (Greco et al., 1986; Geddes, 1987; Morabia & Wynder, 1992).
Renewed speculation regarding the involvement of a retrovirus in BAC has been
supported by the association of retroviruses with several diseases of humans, such as
seminoma, undifferentiated germ cell tumours, multiple sclerosis, acute-onset type I
diabetes and Sjogren's syndrome (Cremer & Gruber, 1992; Sauter et al., 1995;
Herbst et al., 1996; Conrad et al., 1997; Griffiths et a/., 1997; Perron et al., 1997).
Recently the evidence for a protein related immunologically to JSRV in some human
lung tumour suggested a positive correlation between BAC and an endogenous
retrovirus (De las Heras et al., 2000). 274 samples from patients with BAC, other
pulmonary malignancies, non malignant pulmonary lesions and normal lung were
examined by immunohistochemistry using a rabbit antiserum toward the major
capsid protein of JSRV The tumours included 129 bronchioloalveolar carcinomas,
65 adenocarcinomas, and 41 squamous cell carcinomas. Positive samples included
39 (30.2%) of 129 broncioloalveolar carcinoma and 17 (26.2%) of 65
adenocarcinomas.
No positive staining was observed in non tumour lesions or normal lung tissues.
The positive reaction was confined to the epithelial tumour cells and showed the
same characteristics as that obtained with OPA tumours. These results support the
view that the antigen in the human tumours may be a retrovirus protein although no
other virologic or molecular data was obtained for supporting this observation
(Yousem et al., 2001).
The antigenic positivity observed might reflect cross reaction with the JSRV
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antiserum of a protein whose expression is increased in the transformed cells or
another hypothesis might be that a human endogenous retrovirus (HERV) is over
expressed in the neoplastic cells. Recently JSRV endogenous related sequences
have been obtained from human blood collected in Africa and Europe (Morozov et
al., 2004). The expression of some HERVs in human malignancies has been
observed, but it is not clear if this expression is correlated with the etiology of the
tumour (Lower et ah, 1996; Tonjes et al., 1996).
1.1.12 Immuno and inflammatory responses to JSRV in OPA-affected
and unaffected sheep
A peculiar feature of OPA is the absence of a specific antibody response to JSRV,
despite the highly productive infection in the lungs and disseminated lymphoid
infection. The reactivity to recombinant JSRV CA in sera from affected sheep,
described in some works (Kwang et al., 1995), was shown not to be specific and
reflected the presence of antibodies to the GST fusion partner of the recombinant
antigen used in the assays (Ortin et al., 1998).
However, serum antibodies can be induced readily in sheep by immunisation with
recombinant JSRV CA protein in adjuvant (Sharp et al., unpublished data).
These results indicate that sheep are not inherently unresponsive to JSRV antigens. It
is possible that the expression of endogenous JSRV during ontogeny or in neonatal
life may interfere with the exogenous JSRV infection and disease outcome via the
induction of immune tolerance. To date, specific cellular immune responses have not
been demonstrated.
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Another prominent feature of naturally OPA-affected sheep is the marked peripheral
neutrophilia and lymphopaenia, particularly affecting CD4+ T lymphocytes as other
subsets remained unaffected (Rosadio & Sharp, 1992; Holland et al, 1999).
The persistent and disseminated infection of the lymphoreticular system by JSRV
and dysregulation of the immune and inflammatory responses of infected sheep
suggest that JSRV may interfere with the host immune responses (Palmarini et al.,
1996a). This notion is supported by studies demonstrating JSRV infection of a wide
range of lymphoid cells. Holland et al., (1999) showed that in naturally infected
sheep, JSRV proviral burden was greatest in the macrophage/monocyte cell
population [1/2500 cells], followed by B cells [1/3800 cells], CD4+ T lymphocytes
[1/6800 cells] and CD8+ T lymphocytes [1/16700 cells]. Furthermore, dissemination
of JSRV was an early event following experimental infection of young lambs. The
virus was present in CD4+ and CD8+ T lymphocytes, B lymphocytes and adherent
mononuclear cells in the pulmonary lymph nodes as early as 7 days post-inoculation,
and was detected in peripheral blood leukocytes (PBLs) by 14 days post-inoculation.
These observations are particularly significant as they indicate that dissemination of
JSRV precedes transformation and, for the first time, that infected animals might be
detected in OPA-affected flocks before the appearance of clinical signs.
In contrast to the changes in phenotypic frequencies observed in naturally-occurring
OPA, no significant alterations were identified at any time during the first 20 weeks
after inoculation in the blood of young lambs experimentally inoculated with JSRV,
compared to age- and breed-matched controls. These observations indicate that the
alterations in peripheral blood lymphoid cell subsets are not an early event and,
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probably, do not occur in direct response to JSRV infection, but are a consequence
of the superimposed bacterial infections that are common in natural cases of OPA.
Functional defects were also demonstrated in the immune responses of JSRV
infected sheep. Lymphocytes from both natural cases of OPA and lambs inoculated
experimentally with JSRV showed a significantly reduced proliferative response to
concanavalina-A, a cell mitogen substance. The reduced response was detected in
the lambs as early as eight weeks after inoculation and prior to clinical disease, when
the response was only 33% that of the control lambs (Summers et al, 2002). These
observations have provided the first indications that JSRV may alter the functional
activity of immune cells in infected animals, although the virus apparently does not
alter the phenotypic profile of the peripheral blood.
1.1.13 Diagnosis and Control of OPA
OPA has been recognised by EU (Directive 91/68: Intra-community trade in ovine
and caprine animals) as an important infectious disease of sheep because of its high
prevalence in several member states. This disease results in large economic losses
arising from its direct effects, as well as a loss of trade in live sheep.
Most information on the prevalence of OPA is based on clinical observations and
histopathological diagnosis. Information of the true prevalence of JSRV infection in
OPA-affected flocks has been a major gap in our knowledge. The detection of JSRV
in the peripheral blood of experimentally infected lambs, before the development of
tumour or onset of clinical disease, therefore, was an important finding that offered a
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means to investigate the extent of JSRV infection in OPA-affected flocks (Gonzalez
et al., 2001).
These findings have been extended in studies involving sheep from OPA-affected
commercial flocks in Spain (Garcia-Goti, 1999). Peripheral blood leukocytes (PBLs)
and tissue samples from sheep were examined for JSRV by PCR. Overall, JSRV was
detected in all OPA sheep, with either the classical or atypical form of OPA, as well
as in 80% of OPA in-contact sheep. None of 71 samples from the control sheep was
positive. Although an earlier report had indicated that as few as 1/250,000 PBLs
might be positive for JSRV, in this study JSRV was detected in the PBLs of all
classical OPA sheep, 83% of the sheep with atypical OPA, as well as 40% of lesion-
free in-contact sheep. These results clearly demonstrated, for the first time, that
JSRV can be detected in naturally infected live sheep before the onset of clinical
OPA and even in the absence of discernible lung tumours. Although only a small
number of in-contact sheep were examined, it seems clear that subclinical JSRV
infection can reach a high prevalence in OPA-affected flocks.
To provide further information of the dynamics of JSRV infection in OPA-affected
flocks, Garcia-Goti et al., in 2000 conducted a small prospective longitudinal survey
in an OPA-affected flock. JSRV was detected by PCR in PBLs from 28% of the
flock. Fifteen positive sheep and five negative were selected and PBLs examined by
JSRV PCR at monthly intervals for the next four months. JSRV was detected in only
nine of the original 15 positive sheep during this period and in four of those that
were negative. These results demonstrated the fluctuation in detection of JSRV in
blood and, more importantly, confirmed the high prevalence of JSRV infection in
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OPA-affected flocks.
At present, the only means of control is regular inspection of adult sheep in affected
flocks. Prompt culling of any suspicious animal is advisable, as well as the offspring
of affected ewes, which frequently develop OPA. These methods have not been
shown to eradicate OPA from a flock in which the disease is endemic, but a
reduction in the prevalence of infection may be obtained. PCR techniques able to
detect JSRV in the blood before the onset of clinical signs offer new opportunities
that may lead to effective control. Currently, a large EU collaboration involving
Scotland, Spain and Italy is undertaking research to improve diagnostics tests to
detect JSRV during the preclinical stages of infection. New diagnostic procedures
will change the overall approach to this disease. The epidemiological studies that are
currently in progress in Scotland and Spain will report the rate of prevalence of
JSRV infection in flocks with history ofOPA.
Further aims of these studies are to understand what proportion of infected sheep
will develop OPA, when the infection acquired and what are the routes of
transmission (vertical transmission, in utero, milk). There is some preliminary
evidence for the presence of JSRV in foetuses by PCR techniques (de las Heras et
al., 2000). This finding apparently conflicts with one study showing that embryo
transfer can be used to obtain animals free of OPA. In this experiment 215 embryos
recovered from 76 donor ewes from flocks with endemic OPA and mated with rams
that did not have any sign of OPA were transferred to 131 recipients. 38 of 51
progeny from OPA positive donors and 55 of 74 progeny from donors in which no
lesions ofOPA were detected survived for at least five years. There was no evidence
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of OPA in the recipients or their progeny on the basis of clinical and pathological
criteria (Parker et a!., 1998). Further investigations are necessary to clarify possible
vertical transmission of the infection.
1.1.14 Aims of the project
OPA is an economically important infectious disease, endemic in several countries.
OPA cannot be controlled because it is recognised only when the disease is obvious.
The present project has as a main goal the development of strategies for the control
of the disease.
The base for OPA control programme will be epidemiology studies. The hypothesis
is that improved understanding of routes of transmission will allow new approaches
to management ofOPA. Recent demonstration of JSRV in blood of sheep during the
preclinical phase has created opportunities for prospective studies to describe the
epidemiology of the infection (Gonzalez et al., 2001).
The epidemiology project will consist of two steps:
first a high throughout robust and sensitive PCRs will be developed to detect JSRV
in the blood of clinical and pre-clinical animals (Chapter 3); and then for the first
time JSRV infection will be studied in longitudinal surveys in flocks with history of
OPA (Chapter 4). Improved understanding of risk factors for transmission and
maintenance of OPA will improve management control strategies to reduce the
impact factor of the disease.
-69-
The other part of the project will create the basis for a vaccination strategy to control
OPA. The first objectives for the long term JSRV vaccine development are:
to develop an experimental model for OPA in older lambs, so that the protective
effect of vaccines can be evaluated (Chapter 3); this experiment has as a background
the fact that OPA can be induced reliably in a high proportion of neonatal lambs by
intratracheal inoculation of concentrated lung fluid (Sharp, 1983). Although this
model has been critical to explain the role of JSRV and its pathogenesis, because of
the age of the lambs, it clearly, is not suitable for assessment of potential vaccines.
During this experiment the preclinical JSRV PCR will be used for monitoring the
viraemia of experimentally infected lambs.
Part of the work has the aim to generate new forms of JSRV recombinant proteins to
use in immunological techniques and immunisation trials (Chapter 2). Particular
emphasis will be addressed to the production of the JSRV envelope protein.
The possibility to overcome the apparent tolerance to JSRV will be explored through
the vaccination of JSRV viraemic and non viraemic animals with appropriate
recombinant proteins (Chapter 2).
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Chapter 2
Studying the pathogenesis of JSRV: synthesis of
recombinant proteins and immunisation trials
-71 -
2.1 Introduction
This chapter describes the development ofnew JSRV recombinant proteins to use for
raising antibodies in rabbits and in sheep.
Research on the pathogenesis of OPA has been hampered for years by the lack of an
in vitro system for the propagation of the virus and by the lack of appropriate
immunological reagents for the detection of the virus.
The complete sequencing of JSRV (York et al., 1992) offered new possibilities for
the development of new JSRV antigens.
The first production of JSRV capsid recombinant proteins represented a crucial first
step towards studying the distribution and site of replication of JSRV in OPA
affected sheep (Palmarini et al., 1995).
To date OPA tumours have been studied using polyclonal antibodies against JSRV
capsid recombinant proteins; no study has been done using JSRV recombinant
envelope proteins.
The aim of this part of the work was to produce new envelope and capsid
recombinant proteins not only for immunological assays but also for preliminary
immunisation trials in sheep. Essential features of the recombinant proteins for
reaching these aims are solubility and high yield. According to these necessities, new
protein production methods were attempted.
In OPA-affected animals there is no evidence of circulating JSRV-specific antibodies
and the reduced response to ConA indicated an alteration in systemic immunity
(Ortin et al., 1998; Summers et al., 2002). In this chapter it was investigated whether
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sheep infected with JSRV can develop antibodies against JSRV capsid (CA) and
envelope protein (SU) after immunisation with fusion proteins.
The lack of immune responses has been explained with two different hypotheses:
the virus could have a direct immunosuppressive activity on the immune system;
previous work has shown that during JSRV infection the cellular immune-response
can be compromised; in fact reduced responses to concanavalin A stimulation were
demonstrated in the JSRV-inoculated lambs, prior to the onset of clinical disease, and
also in the terminally ill adult sheep (Summers et al., 2002);
Sheep may be tolerant to JSRV as a consequence of expression of related endogenous
viruses in the foetus (Spencer et al., 2003).
However, antibodies can be raised in sheep by immunisation with different forms of
recombinant JSRV CA protein in Freund's complete adjuvant (Sharp & Dewar,
unpublished results). This result was achieved in several sheep breeds.
Since it has been shown that uninfected sheep do respond to immunisation with CA in
FCA, the ability of JSRV infected sheep to develop an immune response against
JSRV CA was investigated. If antibodies to JSRV CA are produced in infected sheep
this would indicate that JSRV infection does not directly render the immune system
non-responsive to JSRV antigens.
If antibodies to JSRV-CA are not produced in infected sheep this would be consistent
with the hypothesis that JSRV infection does have some immuno-inhibitory activity.
Since an antibody response to JSRV proteins in sheep has only been successfully
raised when FCA has been used as an adjuvant, FCA was used in this experiment
(section 2.4.1). However, given the welfare concerns regarding the use of this
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reagent, the effect of another adjuvant, Quil-A also was measured and the antibody
response compared with that obtained with FCA (Kensil et al., 2004; Yu et al., 2004).
In the following experiment (section 2.5) sheep were immunised with JSRV SU
recombinant proteins. No sheep immunisation trial with JSRV SU recombinant
protein has been attempted before. It was possible only to immunise OPA negative
sheep with JSRV SU recombinant proteins; budgetary and time constraints precluded
studies with viraemic animals.
The results provided information about immune responses to JSRV. Such information
is a necessary starting point for future rational design of vaccination protocols.
The aim of this chapter was to generate new JSRV capsid and envelope recombinant
proteins to use in immunisation experiments with viraemic and non viraemic sheep
for testing the hypothesis that JSRV viraemic sheep are immunocompromised.
In this chapter the following experiments were carried out:
-production of JSRV recombinant proteins;
-immunisation of rabbit with JSRV SU protein for obtaining an immune serum to use
in immunohistochemistry studies;
-immunisation of OPA viraemic and non viraemic sheep with recombinant JSRV CA
protein (paragraph 2.4);
-immunisation ofnon viraemic sheep with JSRV SU recombinant proteins (paragraph
2.5).
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2.2 Production of JSRV recombinant proteins
2.2.1 Approach to the expression of JSRV recombinant proteins
Previous experiences ofproduction of JSRV recombinant proteins had encountered
solubility and concentration problems.
Recombinant JSRV antigens have been expressed previously in E.coli as (3-
galactosidase (Pgal-gag) and glutathione-S-transferase (GST-gag) fusion proteins and
used to generate specific antisera in rabbits and a new blocking-ELISA (Palmarini et
al. 1995). Using these reagents, tissues from naturally and experimentally OPA-
affected sheep, as well as age and breed-matched controls, were examined to
determine the anatomic distribution of JSRV (Palmarini et al., 1995). The specific
antisera for recombinant JSRV CAs were used also in IHC studies: JSRV protein was
detected only in the cytoplasm ofneoplastic epithelial cells in the pulmonary alveoli
ofOPA affected sheep (Palmarini et al., 1995, 1996a; Holland et al., 1999; Piatt et
al., 2002).
Currently, three strategies are used for protein production: chemical synthesis, in vivo
expression, and cell-free protein synthesis. The first two methods have severe
limitations. Chemical synthesis is not practical for the synthesis of long peptides
(Blaschke et al., 2000), and in vivo expression can produce only those proteins that do
not affect the physiology of the host cell (Henrich et al., 1982: Goff& Goldberg,
1987; Chrunyk et al., 1993). These methods require transformation, cell maintenance,
expression and optimisation procedures that can be both time-consuming and
technically challenging. Due to fast growth, easy handling and low cost, Escherichia
coli is the principal expression system of choice (Baneyx, 1999). However,
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production of recombinant proteins with E. coli has many limitations: many of these
proteins are insoluble, biologically inactive and in aggregated forms or inclusion
bodies and do not undergo post-translational modifications, for example
glycosylation. Other disadvantages are that the polypeptide product that may be
unstable in a given cell, and in some cases the product is toxic to the cell. Traditional
protein expression systems involve expressing recombinant proteins in intact
eukaryotic or prokaryotic cells.
Wheat germ embryos store all the components of translation in a dried state, in high
content, and are ready for protein synthesis after germination in response to
transcription ofmRNAs triggered by an environmental signal (Roberts & Paterson,
1973). The lack of a physical barrier, the cell wall, makes the reaction environment
accessible to manipulation in the cell free system. The reaction conditions can also be
varied over a wider range because living cells are not required (Alimov et al., 2000).
These cell-free translation systems can synthesize proteins with high speed and
accuracy, approaching in vivo rates (Kurland, 1982; Pavlov & Ehrenberg, 1996), and
they can express proteins that would interfere with cell physiology (Roberts &
Paterson, 1973). Cell-free systems have great potential for large-scale protein
synthesis and many efforts have been made to increase their efficiency. Spirin et al.,
(1988) proposed a continuous flow cell-free (CFCF) system, in which a solution
containing amino acids and energy sources is supplied to the reaction chamber
through a filtration membrane. The CFCF system uses a continuous flow of the
feeding buffer [including amino acids, adenosine triphosphate (ATP), and guanosine
triphosphate (GTP) ] through the reaction mixture and a continuous removal of





Fig. 2.1. Rapid translation system (RTS) technology (Roche).
On the left the RTS reaction device. Principle of Continous Exchange
Cell-free protein synthesis (CECF) as invented by Spirin etal., 1988.
The RTS device is formed by a reaction compartment where
transcription and translation occur and the protein product is retained
and a feeding compartment into which inhibitory reaction by-products
diffuse from which reaction substrates and energy components are
continuously supplied for sustained synthesis. Once the RTS device
has been filled with the appropriate solutions it can be inserted in the
RTS 500 instrument (Roche).
hundreds ofmicrograms permilliliter reaction volume ( Spirin et al., 1988; Baranov
et al., 1989; Kigawa &Yokoyama, 1991; Endo et al., 1992). Recently, several
modified versions of the Spirin system have been reported (Endo et al., 1992;
Kawarasaki et al., 1995; Kim et al., 1996; Kigawa et al., 1999). Cell-free translation
systems can be generated from both prokaryotic and eukaryotic cells.
Although JSRV-CA has been expressed successfully in E. coli and it was used to
raise antibodies, problems of solubility remained and no success had been obtained
with the expression of JSRV-SU in E. coli (Dewar et al., unpublished data) or in yeast
systems (Pichia pastoris) (Philbey et al., unpublished data). The availability of the
new cell-free systems offered a different approach for the production of JSRV-CA
and SU that may overcome the previous problems.
Therefore, this chapter reports results obtained with a commercial cell-free system,
the Rapid translation System-500 (RTS-500) produced by Roche.
2.2.2 Materials and Methods.
2.2.2.1 Introduction to the RTS-500
The rapid translation system (RTS) E. coli circular template Kit (Roche Applied
Science) was used to express recombinant CA and SU. It consists of the digitally
controlled RTS 500 instrument, which ensures optimal expression conditions
(Fig.2.1), and a reagent kit that utilizes coupled in vitro transcription/ translation for
the expression of up to 5 mg ofprotein/ml reaction in 20-24 hours (Cho et al., 2001;
Murayama et al., 2001; Fukushima & Kawaguchi, 2001; Betton, 2000).
-77-
The disposable RTS-500 reaction device has three components (Fig.2.1): the upper 1
ml reaction compartment, the semi-permeable membrane and the lower 10 ml feeding
compartment. Transcription and translation take place simultaneously in the reaction
compartment.
Substrates and energy needed for a sustained reaction are continuously supplied
through the semi-permeable membrane. During coupled transcription and translation
energy components, nucleotides and aminoacids are consumed, whereas waste
products like inorganic pyrophosphate, phosphate, nucleotide mono- and
diphosphates, and other degradation products are formed. The accumulation of
inhibitory waste components and the depletion of substrates would quickly result in
the stopping of the reaction. This is prevented by a continuous removal ofwaste and
supply with substrate components by diffusion through a semipermeable dialysis
membrane, which separates the upper reaction compartment from the lower feeding
compartment (Spirin et al., 1988).
2.2.2.2 Cloning of JSRVCA
The 660bp region of gag encoding the CA protein was amplified by PCR
from pJSRV21 using primers p26CA-for
(CGGAGCTCCCTGTTTTTGAAAATAA) and p26CA-rev
(GCGAATTCAAGCAATACCTTGCATA). Primers lie between position 1029 and
position 1689 of the JSRV genome. The forward primer contains a SacI site
(GAGCT v C). This site was important to keep the frame in the correct position with
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the upstream His-tag in the chosen final vector pIVEX 2.4a (Roche). The reverse
primer contains a stoop codon (TCA).
PCR cycles employed were 94°C for 1 min and 35 cycles of 94°C for 45 s, 57°C for 1
min, and 72°C for 1 min, with a final extension of 72°C for 2 min in a Perkin-Elmer
GenAmp 2400 thermal cycler.
The PCR product was cloned into pT7blue-2 vector (Novagen) according to the
manufacturer's instructions.
The CA gene was excised from pT7Blue-2 vector by restriction endonuclease
digestion (Smal/Sacl, Roche). The relevant 660 bp CA band was visualised after gel
electrophoresis (1% agarose gel), by UV and then excised. The CA DNA was
extracted from the gel using QIagen gel extraction kit (Roche)(Appendix II.3). Then
CA DNA was inserted in pIVEX2.4 (Fig.2.2), previously cut with restriction
endonucleases Sacl (Roche) and Smal (Roche).
The insert (CA DNA) was added to the vector at approximate molar ratio of 3:1, 6:1,
9:1. One /xl 2x ligase buffer and 1 /xl of ligase were added, the final volume was made
up to 20/xl with distilled water (Rapid DNA Ligation Kit, Roche). The ligation
reaction was incubated at + 4°C overnight before being used to transform competent
E.coli JM109 (Promega). Transformants were selected by plating on to LB/Amp agar
incubated overnight at 37°C. Single colonies were picked and grown overnight in 10
ml LB/Amp broth at 37°C with shaking. Plasmid DNA was extracted using QIaprep
mini prep kit (QIagen), (Appendix II.4). The presence of the inserted CA DNA in







Fig 2.2. Map of plVEX2.4a vector (Roche).
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The plVEX2.4a vector was used for subctoning and expression of JSRV
CA and SU DNA. The coding sequence is cloned downstream from a
hexa-His tag into a multiple cloning site. T7-P:phage T7 promoter; RBS:
ribosomal binding site; Histag: tag sequence for purification;
Xa: factor Xa restriction protease cleavage site; MCS: multiple cloning
site; T7T: phage T7 polymerase terminator sequence.
The correct DNA sequence for CA was confirmed by automated sequencing using an
ABI 700 (Applied Biosystem, MRI Functional Genomics Unit),(Sanger et al., 1977).
Glycerol stocks ofpIVEX2.4a-CA were frozen at -70°C.
2.2.2.3 Cell free production of JSRV CA
The plasmid pIVEX2.4a-CA was expressed using the RTS 500 circular template kit
(Roche) according to the product instructions (Appendix VIII).
In the first attempt with the RTS system, 15jag of pIVEX2.4a-CA was introduced in
the reaction and the instrument was set at 30°C for 24 h at 120 rpm. These parameters
had been commonly used for the expression of other proteins using the RTS system
according to the manufacturer's protocol. The expression of JSRV capsid protein by
the RTS system (JSRV RTS CA) was ascertained after purification (2.2.2.4) by SDS-
PAGE stained with Coomassie and confirmed by Western-blot.
Thereafter JSRV RTS CA production was optimised. Different combinations of
quantity ofplasmid DNA (5-20pg) and reaction temperature (25°C and 30°C) were
varied to determine the conditions that would result in the highest expression levels.
The chosen time ofprotein expression was 24 h (Table 2.1) (Martin et al., 2001).
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The RTS instrument was set at a stirring speed of 120 rpm (Fig. 2.3).
The recombinant JSRV protein obtained with the RTS system was referred to as
JSRV RTS CA.
2.2.2.4 JSRV RTS CA purification
The plasmid pIVEX2.4a-CA creates a his tagged protein, which allows easier
detection and purification of the expressed protein because the his tag has a specific
affinity for metal ions, such as nickel. A striking feature of the his tag system is that
binding of the his-tagged protein to the solid phase metal is not affected by strong
denaturants, allowing the protein to be soluble and purified in such i.e. agents as 8 M
urea or 6 M guanidinium. Rapid and mild elution of the his-tagged protein is another
key asset of the system because the bound protein can be displaced using basic or
















Fig. 2.3. Illustration of RTS protein expression system.
On the left a diagram of the 1 ml RTS vial; on the right a diagram of the reaction that
happens in the upper compartment of the RTS device.Transcription and translation take
place simultaneously in the 1 ml reaction compartment of the reaction device.
Substrates and energy components essential for a sustained reaction are continously
supplied via a semipermeable membrane.
First JSRV CA and SU were cloned in the template vector plVEX2.4a and added to the
reaction compartment. Then in a coupled in vitro reaction DNA is first transcribed from
the template vector into mRNA by T7 polymerase, followed by translation by the
ribosomal machinery present in the E.coli lysate. Expressed protein accumulates in the
reaction compartment and is harvested after 24 hours run.
(Diagram adapted from Roche www.proteinexpression.com).
(Invitrogen) was used for the purification of recombinant RTS JSRV CA and SU. The
kit utilizes nickel-chelating resin that is supplied with native and denaturing buffers
for efficient purification of recombinant proteins under different conditions. The RTS
system facilitates the purification because there is no bacterial cell lysis step and the 1
ml reaction fluid can be used straight away in the purification steps.
RTS- JSRV CA recombinant protein was purified following the "ProBond
Purification System" (Invitrogen). JSRV RTS CA was purified using either
a) denaturing conditions or
b) native conditions.
The purification method under native conditions has the advantage to keep intact the
functionality of the protein. When the protein has solubility problems, it is necessary
to introduce denaturing agent (i.e. urea) in the purification steps (Basharov, 2003).
a) Denaturing method for the purification ofRTS-JSRV CA
In general JSRV RTS CA was bound to nickel resin (Invitrogen) in 8 M Urea, 20 mM
phosphate buffer, 500mM NaCl (pH 7.8 ). Other host cell proteins that have some
affinity for the beads under these conditions can be removed by washing protein-
bound beads with the same buffer but with a lower pH buffer (e.g. pH 6.0). The RTS-
JSRV CA was eluted from the beads by washing with the buffer at pH 4.00 under
denaturing conditions (see Appendix V.l).
The total 1ml content of the reaction compartment of the RTS device was collected
and equal 500pl aliquots placed in two Eppendorf tubes and kept at 4°C until
purification. Each aliquot was purified separately. One ml of nickel beads slurry
(nickel beads in 50% ethanol, Invitrogen) was centrifuged at 800g for 2 minutes to
remove the ethanol and then a further three times in 500pl of denaturing binding
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buffer pH7.8. The supernatant was discarded after centrifugation to remove any
possible trace of ethanol.
Then a 500pl aliquot of the RTS reaction was added to the Eppendorf tube containing
the beads and 500pl of denaturing binding buffer pH 7.8.
The effect of incubation time was determined by incubation of the beads with the
RTS reaction product in denaturing binding buffer pH 7.8 for 1 hour, 2 hours, 12
hours on a rocker at ambient temperature.
Then the beads were spun down as described previously and the supernatant was kept
as "post-beads lysate". The beads were washed twice with denaturing binding buffer
pH 7.8 by re-suspending the beads in 1ml of buffer, mixing well, spinning down the
beads and discarding the supernatant. To wash, the beads were resuspended with 0.5
ml of denaturing binding buffer pH 7.8, centrifuged at 800g for 2 minutes and then
the supernatant was discarded. The beads were washed twice with denaturing buffer
pH 6.0 and twice with denaturing buffer pH5.3 and each time they were spun down
by centrifugation to remove as much buffer as possible. The beads were re-suspended
in 500pl of denaturing elution buffer pH 4.00 and mixed gently on a rocker at room
temperature. (Ausubel et al., 1994). The sample was spun down and the supernatant
collected as "first eluate".
The effect of different incubation times was evaluated testing different incubation
times (30 minutes, 1,2, 12 hours) ofbuffer pH 4.00 with the beads.
The elution was repeated two more times with 500pl of denaturing elution buffer pH
4.00 to collect second and third eluates after mixing for 30 minutes on a rocker. A
sample of the beads was kept to check how much of the protein remained bound to
the beads. Elution samples were stored at -20°C.
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b) Purification ofRTS-JSRV CA under native conditions
Another approach for the purification ofRTS-JSRV CA undertaken was the elution
ofRTS-JSRV CA under native conditions.
Nickel beads were used as previously described for the denaturing conditions
protocol. The purification steps under native conditions were essentially the same
described for the purification under denaturing conditions. The native purification
buffers were:
native binding buffer pH 7.2-7.6,
native wash buffer pH 5.5,
native elution buffer pH 4.0 (see Appendix V.2 for the preparations of the native
purification buffers).
Only 2 washing steps were performed after the incubation of the RTS reaction with
the nickel beads and before the elution step.
Imidazole was included in the native wash and elution buffers (final concentration
3M) to minimise the binding of untagged contaminating proteins and increase the
purity of the target protein with fewer wash steps.
As already described the total 1ml content of the reaction compartment of the RTS
device was collected and equal 500pl aliquots placed in two Eppendorf tubes and
kept at 4°C until purification. One ml of nickel beads slurry (nickel beads in 50%
ethanol, Invitrogen) were carefully washed with native binding buffer pH 7.2-7.6 as
described during the denaturing method to remove any possible trace of ethanol.
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Then a 500pl aliquot of the RTS reaction was added to the Eppendorf tube containing
the beads and 500pl of denaturing binding buffer pH 7.8.
The effect of incubation time was determined by incubation of the beads with the
RTS reaction product in native binding buffer pH 7.2-7.6 for 1 hour, 2 hours, 12
hours on a rocker at ambient temperature.
Then the beads were spun down as described previously and the supernatant was kept
as "post-beads lysate". The beads were washed twice with native binding buffer pH
7.2-7.6 by re-suspending the beads in 1ml ofbuffer, mixing well, spinning down the
beads and discarding the supernatant. To wash, the beads were suspended with 0.5
ml ofnative binding buffer pH 7.2-7.6, centrifuged at 800g for 2 minutes and then the
supernatant was discarded. The beads were washed twice with native wash buffer
pH 5.5. The beads were re-suspended in 500pl of native elution buffer pH 4.00 and
mixed gently on a rocker at room temperature. (Ausubel et al., 1994). The sample
was spun down and the supernatant collected as "first eluate".
The effect of different incubation times was evaluated testing different incubation
times (30 minutes, 1,2, 12 hours) ofbuffer pH 4.00 with the beads.
The elution was repeated two more times with 500pi of denaturing elution buffer pH
4.00 to collect second and third eluates aftermixing for 30 minutes on a rocker. A
sample of the beads was kept to check how much of the protein remained bound to
the beads. Elution samples were stored at -20°C.
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2.2.2.5 Analysis of JSRV RTS CA
The reaction product was analysed for the presence of recombinant CA by SDS-
PAGE gel stained with Coomassie blue and by immunoblot (Appendix IV).
The protein yield was evaluated in the first eluate using Coomassie, SDS-PAGE gel
and the BCA method.
An E.coli expressed his- tag CA was used as a positive control [gift ofVan der
Molen], (Summers et al., 2002). The Western-Blot was performed using a previously
produced anti-rabbit immune serum (Palmarini et al., 1995).
2.2.2.6 Cloning of JSRV SU
DNA encoding the JSRV SU was amplified by PCR from an infectious molecular
clone of JSRV (pJSRV2i), from nucleotide 5557 to nucleotide 6483 (York et al.
1992).
The primers sequences were as follows:
-forward primer: 5'- TACCATGGAAAATGGGGCAGCTG -3'.
-reverse primer: 5'- ATCTGCAGCTGAGCCGTATTAA. -3'. In the forward primer
the CCATGG Ncol site was designed to keep JSRV SU coding sequence (which
starts with ATG) in frame with the His-tag. In the reverse primer the CTGCAG PstI
site was designed to keep JSRV SU in frame with the Stop codon encoded by the
vector pIVEX2.4.
The PCR reaction was carried out in 2.5mM MgCl2, lOmM Tris (pH 9.2)50mM KC1,
20mM (NH4)2S04, lOmM dNTPs (Roche), lOmM forward and reverse primers and 5
units ofTaq polymerase (Promega) made up to 45pi with distilled water for each
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tube. 5ng of the DNA template pJSRV2i was used. A HyBaid gradient block was
programmed to provide amplification cycles that consisted of 94°C for 1 min
(lcycle), 94°C for 30 s, 67°C for 30s, 72°C for 45 s (30 cycles), and a 5 minute final
extension at 72°C (1 cycle).
Ten pi of each PCR reaction was analysed by electrophoresis through a 2% agarose
gel in IX tris-borate-EDTA buffer in the presence of 0.5 pi g of ethidium bromide per
ml. The length of the amplification product was of 826 bp. The remaining
amplification product was loaded on a 2% agarose gel and electrophoresis was
performed: the 826bp band was excised and DNA extracted with the QIAquick gel
extraction kit (Roche). DNA concentrations were estimated by the use of a
spectrophotometer. The SU PCR product was then inserted in pGEM-T Easy
(Promega) vector to facilitate PCR cloning. Ligation reactions were set up at a molar
ratios of approximately 3:1, 6:1, 9:1, of insert: vector. 50ng ofpGEM-T Easy was
used for each reaction. Ligation reactions were set up in a total reaction volume of
lOpl. 5 pi of 2X rapid ligation buffer (Promega) and lpl ofT4 DNA Ligase (3 Weiss
units/ pi, Promega) were added for each reaction. Half of each ligation was used to
transform competent E.coli JM109 (Promega). Transformants were selected by
plating onto LB agar containing Ampicillin (50pg/ml), X-Gal, and IPTG. Colonies
were picked and inoculated onto a fresh LB agar plate containing Ampicillin and into
Universals containing 5ml LB/50pg/ml Amp and incubated overnight at 37°C.
Plasmid mini-preps were prepared with QIAprep Miniprep kit (Qiagen). The presence
of the insert of the right size was confirmed.
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The insert SU fragment was excised from pGEM-T Easy using Ncol IPst I (Promega)
and it was subcloned into pIVEX2.4a cut with Ncol/Pstl (Promega) restriction
enzymes (Roche). The ligation was performed with the rapid DNA ligation kit
(Roche) at +4°C overnight. Half of each ligation was used to transform competent
E.coli JM109 (Promega). Transformants were selected by plating onto LB agar
containing Ampicillin (150pg/ml). Colonies were picked and inoculated onto a fresh
Amp plate and into Universals containing 5ml LB/50pg/ml Amp and incubated
overnight at 37°C. Plasmid mini-preps were prepared with QIAprep Miniprep kit and
checked for the presence of the insert (Qiagen). The correct DNA sequence for SU
was confirmed by sequencing the SU insert still present in the plasmid using an
automated sequencer (MRI, Functional Genomics Unit).
2.2.2.7 Cell-free production of JSRV-SU.
The expression of JSRV SU in the RTS system followed the same production and
optimisation scheme adopted for JSRV CA. During this work, the manufacturer of the
RTS system produced a new system for higher yield ofprotein. This new system
called RTS-500-HY (Roche) was also investigated.
2.2.2.8 JSRV RTS SU purification
RTS-JSRV SU was purified using Pro-bond nickel beads essentially as described for
CA (section 2.2.2.4) using native and denaturing methods.
The RTS reaction optimisation for SU took advantage of the optimisation results
already achieved for CA.
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The samples kept from the different steps of the purification were analysed by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), stained with Coomassie blue and
by Western-blotting.
The band of about 40 kDa that was assumed to be JSRV RTS SU and an upper band
of around 50 kDa also present in the first eluate were excised from a SDS-PAGE and
analysed by MALDI-TOF (Matrix assisted Laser Desorption Ionisation Time Of
Flight) and submitted to database searches (MS-Fit Search). MALDI-TOF mass
spectrometry is a highly sensitive technique (femtamole level) that can provide
information on the molecular weight, structure, N and C terminal sequence and post-
translational modifications of proteins.
2.2.2.9 Analysis of JSRV RTS SU
The 1ml reaction product was analysed for the presence of recombinant SU by SDS-
PAGE gel stained with Coomassie blue and by immunoblot (Appendix IV). The
concentrations of the proteins in the first eluate were measured by the BCA protein
quantification method (Pierce method, see Appendix IX).
The Western-Blot was performed using a rabbit anti JSRV SU immune serum JS107
(Dewar et al., unpublished data) and 3 different rabbit polyclonal anti JSRV SU
immune sera obtained using synthetic peptides as immunogens (gift from Massimo
Palmarini).
The JS107 serum was prepared in rabbits by inoculation of recombinant GST-SU and
P-Gal-SU embedded in SDS-PAGE gel (Dewar & Sharp, unpublished data).
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These proteins were totally insoluble and not quantified before producing the immune
serum. Before use JS107 immune sera was absorbed over night with a lysate ofE.coli
JM109 cells that were previously transformed using the plasmid DNA ofpIVEX2.4
without the SU DNA insert.
At the time this work was done no recombinant JSRV SU protein was available to use
as a positive control in the Coomassie or in the Western blot.
2.2.3 Results
2.2.3.1 Production of JSRV RTS CA
PCR resulted in the production of a DNA fragment of the predictable size of 660 bp.
The amplified JSRV CA DNA fragment was cloned into plasmid pT7blue. A clone
was selected and the presence of the 660 bp insert was visualised after restriction
endonuclease digestion on 1% agarose gel by electrophoresis.
The JSRV CA DNA fragment was then subcloned in pIVEX2.4a.
The presence of inserted CA-DNA in pIVEX2.4a after digestion with Sacl/Smal was
checked by gel electrophoresis. 24 colonies were picked and checked by gel
electrophoresis, 8 colonies that were picked had an insert of the predicted size
(Fig.2.4). One clone was selected for further studies. The nucleotide sequence for CA
inserted in pIVEX2.4a confirmed that CA was in the right frame, orientation and
corresponded to the expected sequence. Initially it was checked if it was possible to
obtain RTS JSRV CA following the manufacturer's recommended protocol for the
native method. The instrument was set at 30° for 24 h at 120 rpm and the 1ml
reaction product was purified following the denaturing and native methods. A band of
the expected size of 30 kDa was observed.
-90-
Very little JSRV RTS CA protein was observed in the first and second elutions
following the native purification (Fig 2.5). The observation of the Coomassie stained
SDS-PAGE gel(Fig. 2.5) revealed that JSRV RTS CA was not eluted from the beads.
Infact lanes 5 and 6, first and second elution respectively, did not contain the CA 30
KDa band. Only a very weak line of 30 kDa in lane 7 could be observed. Analysis of
the nickel beads at the end of native method purification, showed a thick 30 kDa band
indicating that the protein was still bound to the beads. The presence of the 30kDa
band in lane 2 showed that after one hour of incubation of the RTS reaction with the
beads, protein is still free in the supernatant.
After purification ofRTS JSRV CA with the denaturing method and staining of the
SDS-PAGE gel with Coomassie, a clear band of 30 kDa was detected in lanes 5 and
6, related to the first and second elution (Fig. 2.6). A weak 30kDa line was observed
in lane 7. In lane 8, the presence of the weaker 30 kDa band showed that still a small
amount of JSRV RTS CA was bound to the beads even after the third elution. The
presence of JSRV RTS CA in the different fractions was confirmed by Western blot
using rabbit polyclonal anti CA antibodies (Fig 2.7).
Following these preliminary results it was decided to investigate whether the yield of
JSRV RTS CA could be increased by altering the incubation times (30 minutes, 1, 2,
12 hours) of the beads with buffer pH 4.00 during the first elution step. The first eluate
obtained from the 30 min , 1, 2 and 12 hours incubation time was analysed using SDS-
PAGE gel (Fig 2.8). The bands related to JSRV RTS CA were evaluated after staining
the gel with Coomassie Blue. One, 2 and 12 hours of incubation time (lanes 4,5,6,
respectively) produced similar band densities. The band obtained after 30 minutes
(lane 7) of incubation time was slightly less dense (Fig 2.8). The band that represented
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the second elution after incubation for one hour (lane 3) was quite clean indicating
that most of the JSRV RTS CA was collected in the first elution. These results were
confirmed by Western blot, using rabbit polyclonal antibodies.
In all subsequent experiments the elution time was fixed at 1 hour. One hour
incubation time allowed similar recovery of the protein to the longer incubation (2
and 12 hours) times and higher presence of the protein than lower incubation time (30
min.); in addition this incubation time allows to protein purification and
quantification to be performed in one.
The optimisation ofRTS JSRV CA yield proceeded according to the different
parameters shown in Table 2.1. These results are summarised in Table 2.2 and in
Figures 2.9a and 2.9b. The higher JSRV RTS CA yield was obtained using 15pg of
DNA and setting the instrument at 30°C for 24 hours.
Table 2.2. JSRV RTS CA yield obtained using different RTS reaction
conditions.
DNA temperature time protein yield (mg/ml)
5 fig 25°C 24h 0.2
30°C 24h 0.4
15pg 25°C 24h 0.8
30°C 24h 2.0
-92-
Fig. 2.4. Cloning JSRV CA
Single colonies of E.coli JM109 transformed with plVEX2.4a in which
JSRV-CA was inserted.These were picked and grown in liquid broth
overnight at 37°C; DNA was extracted and digested with Xhol and
Smalto check the presence of the insert by gel electrophoresis. The
figure shows 8 colonies (c1 to c8) that contain an insert of the
predicted size. M1= Hyperladder 1, range 200-10.OOObp 1 (Bioline);








Fig 2.5. Purification of RTS-JSRV CA by native method.
Samples from different steps of the purification were analysed by SDS-PAGE gel
stained with Coomassie blue.
M: molecular weight standard, low range (Biorad)
1: RTS reaction fluid before purification
2: analysis of supernatant after 1 hour incubation of the RTS reaction with the nickel
resin (pH 7.6).
3: analysis of the nickel resin after 1 hour incubation of the RTS reaction with the
nickel resin
4: analysis of the first wash collected after washing the nickel resin with native buffer
pH 7.6
5: first eluate (elution buffer pH 4.00; elution time 1 hour)
6: second eluate (elution buffer pH 4.00; elution time 30 min.)
7: third eluate (elution buffer pH 4.00; elution time 30 min.)
8: analysis of nickel resin after the third elution
9: pBad-HisCA (+ve control)








Fig 2.6. Purification of RTS-JSRV CA by denaturing method.
Samples from different steps of the purification were analysed by SDS-PAGE
gel stained with Coomassie blue.
M: molecular weight standard, low range (Biorad)
1: RTS reaction fluid before purification
2: analysis of supernatant after 1 hour incubation of the RTS reaction with the
nickel resin (pH 7.8).
3: analysis of the nickel resin after 1 hour incubation of the RTS reaction with
the nickel resin
4: analysis of the first wash collected after washing the nickel resin with buffer
pH 7.8.
5: first eluate (elution time, 1 hour)
6: second eluate (elution time, 30min.)
7: third eluate (elution time, 30min.)
8: analysis of nickel resin after the third elution
9: pBad-HisCA (+ve control)






Fig. 2.7. Western blot of CA purified by " Pro-Bond denaturing
method". The presence of JSRV RTS CA in the different phases of
the purification was confirmed by Western-blot using rabbit
polyclonal anti-CA antibodies
M: molecular weight standard, low range (Biorad)
1: RTS reaction fluid before purification
2: analysis of supernatant after 1hour incubation of the RTS
reaction with the nickel resin (pH 7.8).
3: analysis of the nickel resin after 1hour incubation of the RTS
reaction with the nickel resin
4: analysis of the first wash collected after washing the nickel resin
with buffer p'H 7.8.
5: first eluate (elution time: 1 hour)
6: second eluate (elution time: 30 min.)
7: third eluate (elution time: 30 min.)
8: analysis of nickel resin after the third elution
9: pBad-HisCA (+ve control)






Fig 2.8. Optimisation of the denaturing method for the
purification of RTS JSRV CA.
The first elution step was optimised using different incubation times of the elution
buffer pH 4.00 with the nickel beads. The first elution from each incubation time was
analysed by SDS-PAGE gel stained with Coomassie.
M: Pre-stained Protein standard (Invitrogen)
4,5,6,7: first eluate after incubation of the elution buffer ph 4.00 with the beads, for
12 h, 2 h, 1 h and 30 min respectively.
3: second elution from the sample that was incubated for one hour
2: nickel beads after 1 hour incubation of the RTS reaction with the nickel resin
1: supernatant after 1 hour incubation of the RTS reaction with the nickel resin (pH
7.8).
M 1 7 3 4 5 6 7 8 9
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Pig. 2.9a. Optimisation ot UA UNA amount and temperature in
the RTS reaction.
5pl of DNA was included in the reaction and JSRV RTS CA
protein was purified by denaturing method. This amount of DNA
was used for two different RTS reactions: in the first one the
temperature was 25°C and in the second one was 30°C.
The first eluate from each reaction was analysed by SDS-PAGE
gel stained with Coomassie
M: molecular weight standard, low range (Biorad)
1: RTS reaction fluid before purification (5|nl of DNA, 30°C)
2: supernatant after 1 hour incubation of the RTS reaction with the
nickel resin (pH 7.8), (5pl of DNA, 30°C)
3: nickel resin after 1 hour incubation of the RTS reaction with the
nickel resin (5jul of DNA, 30°C)
4,5,6: first, second and third eluate JSRV RTS CA (5p! of DNA,
30°C)
7,8: first and second eluate JSRV RTS CA (5pl of DNA, 25°C)
9: pBad-HisCA (+ve control)
The estimated total amount ofCA protein in the first elution was about 2mg/ml
(BCA, Pierce method).
2.2.3.2 Production of JSRVRTSSU
The JSRV SU DNA excised from pGEM-T Easy using Ncol /Pst I (Promega) was
successfully subcloned into pIVEX2.4a cut with NcoI/PstI (Promega) restriction
enzymes (Fig. 2.10 and 2.11).
The nucleotide sequence for SU inserted in pIVEX2.4a confirmed that SU was in the
right frame, orientation and corresponded to the expected sequence.
pIVEX2.4a-SU DNA was then ready to be included in the RTS reaction.
According to the results from the optimisation of the production ofCA, 15pg of
pIVEX 2.4a-SU DNA was used, the reaction time was 24 hours and the temperature
employed was 30°C. The 1 ml reaction collected after 24 hours was cloudy and flake
shaped whitish formations were sticking to the semi-permeable membrane. It was not
possible to recover any protein from this 1 ml reaction. It was attempted to open the
RTS device and gently recover the flakes. This operation was hampered by the
impossibility of opening the device without breaking the semi-permeable membrane.
Decreasing the reaction temperature to 28°C, as suggested in the manufacturer's
protocol in case of insoluble proteins, avoided the formation of the flakey material;
this temperature was employed for subsequent experiments to express JSRV-SU.








Fig 2.10. Cloning JSRV SU. Analysis by gel electrophoresis of
SU DNA previously excised from pGEM-T Easy (Ncol/Pstl) (lane
1, SU is 826 bp) and then inserted in the plasmid
plVEX2.4a(A/co//Psf/) .In lane 2 the DNA band is referred to
plVEX2.4a ready for the ligation reaction with SU DNA. M1=1Kb
DNA ladder (bp range: 250-10.000)(Promega).
Fig. 2.11. Cloning JSRV SU. Gel electrophoresis of
plVEX2.4a (Pstl/Ncol) DNA. JSRV DNA insert was excised
from pGEM-T Easy and inserted in plVEX2.4a
M1: 1Kb DNA ladder (bp range: 250-10.000)(Promega).
1-5 : plVEX2.4a (Pstl/Ncol) that contains SU insert DNA (826
bp band)
7: pGEM-T Easy (Ncol/Pstl).
The different steps of the purification were analysed by SDS-PAGE stained with
Coomassie and by Western Blot. The predicted size of JSRV RTS SU was 43.4 kDa
but no bands of this size were obtained using the native method.
By the denaturing method ofpurification, a band of the expected size was observed
(Fig. 2.12); and its identity was confirmed by Western Blot using JS107 serum (Fig.
2.13). The band containing the supposed JSRV RTS SU protein was excised from a
SDS-PAGE gel, digested with proteolytic enzymes and then analysed by MAFDI-
TOF at the Moredun Functional Genomics Unit.
The MAFDI-TOF application, followed by database search, confirmed that the 43
kDa band fitted the predicted sequence of JSRV SU protein (Appendix XII, Fig.XII.l
A & B).
The first eluate of RTS JSRV SU analysed by Coomassie (fig. 2.12, lane 5) contained
not only the band related to JSRV RTS SU but another main band of about 56 kDa.
ByMAFDI-TOF analysis the 56 kDa band was shown to be E.coli elongation factor
TU (EF-TU).
The final SU concentration for 1ml RTS-500 reaction in the first eluate was about
O.lmg/ml. SU was produced with an advanced cell-free system called RTS-500-HY
(Roche) and the final concentration measured with BCA method was 0.18mg/ml.
2.2.4 Discussion
CA was previously produced as GST-CA and P-gal-CA (Palmarini et al., 1995) and
His-CA (Summers et al.,2002). The final concentration of P-gal-CA was about








Fig 2.12. Purification of RTS-JSRV SU by denaturing
method.
Samples from different steps of the purification were analysed by SDS-PAGE
gel stained with Coomassie blue.
M: molecular weight standard (Invitrogen)
1: RTS reaction fluid before purification.
2: supernatant after 1 hour incubation of the RTS reaction with the nickel resin
(PH 7.8).
3: nickel resin after 1 hour incubation of the RTS reaction with the nickel resin
4: first wash collected after washing the nickel resin with buffer pH 7.8.
5: first eluate. 6: second eluate .
7: third eluate.
8: analysis of nickel resin after the third elution.
Ml 2 3 4 5 6
SOkDci
40kDa
Fig. 2.13. Western blot of JSRV RTS SU purified by "
Pro-Bond denaturing method".
After SDS-PAGE gel (Fig 2.12) and electronic transfer to a
membrane. RTS JSRV SU was detected using polyclonal
anti-SU antibodies (JS107 immune serum).
M: molecular weight standard (Invitrogen).
1: RTS reaction fluid before purification.
2: analysis of supernatant after 1hour incubation of the
RTS reaction with the nickel resin (pH 7.8).
3: first eluate. JSRV RTS SU has an estimated molecular




6: analysis of nickel resin after the third elution.
and P-gal-CA was prolonged and the final product was heavily contaminated by other
E. coli proteins and the protein yield was variable. In contrast the JSRV RTS CA
appeared much purer than these other recombinant proteins [Fig. 2.6, lane 6 (JSRV
RTS CA) and lane 9 (pBad-HisCa)].
Considering that the RTS reaction takes 24 hours and that the denaturing method for
protein purification takes no more than one working day, the RTS system represents a
convenient method in terms of time and protein yield.
Previous attempts to express JSRV SU as P-gal or GST JSRV SU in E. coli resulted
in production of insoluble protein which could not be purified (P.Dewar & J.M.
Sharp, personal communications). Moreover the E. coli system did not give a
constant protein yield.
Also attempts to express JSRV SU in the yeast Pichia pastoris (A. Philbey,
unpublished data) were unsuccessful. The yeast Pichia pastoris was selected as a
eukaryotic expression system to facilitate post-translational modifications including
glycosylation and thus enhance antigenicity (Stubbs et al., 2001).
The present experiments have been able to overcome the previously difficulties,
although with low yields.
The RTS JSRV SU yield (0.18 mg/ml) was much lower than the yield obtained for
RTS JSRV CA (2 mg/ml). This may be explained by the fact that SU has a
hydrophobic nature (York et al., 1992) or by the size of the protein which can
influence the performance of the RTS system (Endo & Sawasaki, 2003).
JSRV SU RTS (43kDa) is bigger than JSRV CA (30kDa). In fact high productivity
with the RTS system can be expected with fairly small proteins such as Ras protein
(21 kDa) or chloramphenicol acetyltransferase (26 kDa). The problem with larger
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proteins is that with the increasing molecular weight of the mRNAs, their degradation
by endogenous E. coli ribonuclease(s) also increases (Endo & Sawasaki, 2003).
For future vaccination plans it would be worth investigating the possibility of
expressing SU protein in vectors that can overcome some of these problems, e.g.
poxvirus vectors.
A number of features make poxvirus recombinants suitable as vaccines: (i) the
stability of ffeeze-dried vaccine, low cost, ease ofmanufacture and administration
(Pastoret & Vanderplasschen, 2003). (ii) the vaccine can be administrated by several
routes (Gherardi & Esteban, 1999). In the case of vaccinia virus it has even been
shown that the virus can be administrated per os, this feature has been used for
vaccination ofwild fox and racoons (Pastoret & Brochier, 1996). (iii) The ability to
induce both antibody and cytotoxic T cell responses against foreign antigen with long
lasting immunity after a single inoculation (Smith et al., 1983a; Smith et al., 1983b).
(iv) The packing flexibility of the genome, which allows large amounts of the genome
to be lost or deleted and foreign DNA to be inserted (at least 25 kb), thus enabling
multivalent vaccines to be created (Perkus et al., 1985 ). Poxvirus vectors, such as
avipoxviruses, have proved to be extremely safe and efficacious non replicating
vectors when used in non avian species (Lee et al., 2004; Wright et al., 2004).
Recombinant canarypox vaccines expressing the entire envelope proteins ofFeLV
and HIV have been successfully used for vaccination trials (Cox et al., 1993;
Tartaglia et al., 1993).
More expensive, transgenic animal technology appears to be a good alternative for
producing complex glycosylated proteins (Loftus & Rogers, 1997).
-96-
Rabbit can be used to produce proteins and vaccines. Rabbit mammary gland has the
ability to make the post-translational modifications necessary for the functionality of
human proteins. The rabbit is therefore suitable for the production of complex
glycosylated proteins. Transgenic rabbits can be generated by micro-injection
method, where the expression vector (gene constructs allowing the expression of the
protein of interest under the control of a milk protein promoter) is directly injected
into the pronucleus of a single-cell fertilized ovocyte. The transgenic embryos are
then transferred to recipient female rabbits (Gibbs et al., 1979). Several species of
transgenic animals such as sheep, goat and cattle have been produced for production
ofphysiologically active proteins in milk. This system is expensive but it could be
approachable when high yield ofprotein is necessary and in the case of extensive
vaccination plans.
At the moment cultivated mammalian cells are the dominant system for the
production of recombinant proteins for clinical applications because of their capacity
for proper protein folding, assembly and post-translational modification. Thus, the
quality and efficacy of a protein can be superior when expressed in mammalian cells
versus other hosts such as bacteria, plants and yeast. Recently, the productivity of
mammalian cells cultivated in bioreactors has reached the gram per liter range in a
number of cases, a more than 100-fold yield improvement over titers seen for similar
processes in the mid-1980s (Wurm, 2004).
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2.3 Production of SU immune serum in rabbit
2.3.1 Materials and methods
A specific JSRV-SU antiserum was prepared by immunising two rabbits with 500p.g
JSRV RTS SU combined with Freund's incomplete adjuvant. After 15 days, the
rabbit was boosted with 500pg ofGST-SU bound to the glutathione-sepharose beads
( gift from P. Dewar, Moredun Research Institute).
A third injection of JSRV RTS SU was given after 4 weeks and the rabbit was bled
15 days after this last injection. The sera reactivity was tested by Western Blot
against GST-SU blotted on a nitrocellulose membrane. Antiserum against GST-SU
(JS107)(P. Dewar, unpublished data) was used as a positive control.
2.3.2 Results
The serum from one of the 2 immunised rabbits recognised the recombinant protein
GST-SU (55 kDa) in Western blot analysis as shown in lane 2 (Fig. 2.14, Western
Blot b). The immuneserum JS107 against JSRV SU used as a positive control
produced a strong band (Fig. 2.14, Western Blot b. lane 1). The other rabbit serum
was tested but no reactivity could be demonstrated.
The anti JSRV SU immune serum produced using JSRV RTS SU was used for the




















Fig. 2.14. Reactivity of antisera to RTS JSRV produced in sheep
(a) and rabbit (b).
Western Blot a : Antibodies production in sheep was checked testing
the sheep sera against GST-SU (55kDa) blotted on a nitrocellulose
membrane. After blotting the nitrocellulose membrane was inserted in
a multi-chamber apparatus in which it is possible to use different
antibodies for different lanes of the same blot.
Lane 1(+ve control): GST-SU was revealed using JS107 serum as
primary antibody and goat anti-rabbit IgG serum conjugated with
horseradish peroxidase as secondary antibody (Sigma).
Lane 2: the serum from one of the two sheep was tested against GST-
SU. Donkey anti-sheep IgG serum conjugated with horseradish
peroxidase was used as secondary antibody (Sigma).
Western Blot b : Antibodies production in rabbit was checked testing
the rabbit sera against GST-SU blotted on a nitrocellulose membrane.
Lane 1: GST-SU was revealed using JS107 serum (+ve control)
Lane 2: the serum from one of the two rabbit was tested against GST-
SU
2.4 Immunisation of viraemic and non viraemic animals with JSRV CA
recombinant proteins
2.4.1 Rationale of the experiment
In OPA-affected animals there is no evidence of circulating JSRV specific antibodies
and the reduced response to ConA stimulation indicates an alteration in systemic
immunity. However, antibodies against JSRV can be raised by immunisation of sheep
from flocks with no history ofOPA with recombinant JSRV CA; indicating that
sheep are not inherently incapable of recognising JSRV antigens and mounting an
immune response. Therefore, the failure to respond to JSRV infection may be the
result from infection by JSRV.
To test this hypothesis, JSRV infected sheep and JSRV non infected sheep were
immunised with JSRV CA to determine if JSRV infected sheep were able to produce
antibodies to recombinant JSRV proteins.
2.4.2 Materials and methods
2.4.2.1 JSRV recombinant proteins
The JSRV CA proteins used in this study were: P-Gal CA, GST-CA and RTS- JSRV
CA. P-Gal CA and GST-CA were prepared and purified as described in Appendix VI.
RTS JSRV CA was prepared and purified as previously described (section 2.2.2).
For each different recombinant protein a total of 15 mg ofprotein was prepared.
Each protein production batch was checked by Coomassie and Western blot.
P-Gal CA and GST-CA were inoculated into the sheep bound to the beads as
described previously (Palmarini et ai, 1995).
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2.4.2.2 Experimental plan
The JSRV status of the sheep in each group was confirmed by at least 3 blood tests at
3 month intervals. The test used was the JSRV U3-PCR test for detecting JSRV
provirus in genomic DNA.
The JSRV positive animals were obtained from a flock with history of OPA in which
the longitudinal epidemiological survey for JSRV infection (described in Chapter 4)
was carried out. They were randomly selected from a group of approximately 60
sheep which were JSRV positive but clinically normal (i.e. had no signs of OPA and
were not pregnant) (Table 2.3). The five sheep were brought to Moredun Research
Institute animal facilities from the farm, at least one week before the start of the
experiment to allow acclimatisation. In this JSRV viraemic group, three animals were
3 years old and British milksheep x Suffolk cross-breed; one animal was 4 years old
and Milksheep x Texel cross-breed; the other was 3 years old and Suffolk x Texel
cross-breed.
The JSRV negative sheep in groups 2 and 3 (group 2, n=5; group 3, n=5) were from
the Moredun flock and were negative by JSRV U3 PCR test. The non viraemic
animals were all one year old and Blackface breed.
The experimental design and immunisation regimes are summarised in Table 2.3.
Each group of sheep was subject to the same immunisation regime with recombinant
CA (GST:CA fusion protein, BgakCA fusion protein or RTS JSRV CA) and
ovalbumin (Sigma). Each sheep was immunised subcutaneously in areas of loose skin
with 1 mg of each protein antigen and 100/xg of ovalbumin.
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For groups 1 and 2, the first inoculation was in 25% FCA formulated in a double
emulsion with Tween 80. Subsequent inoculations used incomplete Freund's
adjuvant. The immunisation regime took advantage of the different forms ofCA so
that responses were boosted to CA and not to the fusion partner of the recombinant
proteins.
Sheep in group 3 were immunised using Quil-A adjuvant (5mg/ml) in order to
compare the response with that of the animals in group 2.
The animals were inoculated once a month for 3 months with each different fusion
protein in the following order: P-Gal CA, GST-CA, RTS JSRV CA.
The group of viraemic animals were kept separated from the two groups of non
viraemic animals until the end of the experiment.
Blood was collected into EDTA vacutainers for JSRV U3 PCR tests from group 1, 2
and 3 sheep before starting the experiment as described and then once a month after
each immunisation.
All of the animals were bled before and after each immunisation. The sera were
examined by Western Blot for the presence of antibodies to JSRV CA and to
ovalbumin. At the end of the experiment, each animal was bled.
Necropsy and histopathological investigation were carried out following standard
techniques. Pieces of lung tissue were frozen in liquid nitrogen and then kept at -
70°C for further PCR analysis.
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Table 2.3. Immunisation of JSRV positive and negative sheep:
experimental design.
GROUP Treatment Frequency of
treatment












2.4.2.3 Analysis of sheep serum
The Western blot method was used to analyse the humoral response to the fusion
proteins. It was performed using the purified histidine tagged CA protein ( Appendix
IV). Briefly histidine tagged CA protein samples were transferred from SDS page
gels on to nitrocellulose membranes (Bio-Rad) by electroblotting in Tris/glycine blot
buffer, at a constant 100 V for 1 h. After staining with Ponceau red to confirm
transfer of the separated proteins, the membrane was inserted in a multi-blotting
apparatus (Bio-Rad). This apparatus creates compartments in the nitrocellulose
membrane so that through different holes that are on the top lid, different sera can be
tested. The sheep sera to test were diluted 1:50 in washing fluid B (WFB, 20 mM
- 102 -
NaCl, 20 raM Tris pH 7.5, 0.1 mM EDTA) and incubated for 1 hour at room
temperature. After washing three times, rabbit anti-sheep horse radish peroxidase
conjugate diluted 1: 1000 in WFB was added and incubated for a further hour at
room temperature. After further washings, the reaction was visualised with
diaminobenzidine (DAB, Sigma).
2.4.3 Results
One sheep in the viraemic group died after 2 weeks from the first protein inoculation
due to causes unrelated to OPA.
In sera from all the groups analysed by Western Blot 30 days after the first
inoculation, no antibodies to JSRV CA were detected. However, antibodies to JSRV
CA were detected in sera analysed 30 days after the second and the third protein
inoculation for all the animals included in the experiment (lanes 2 and 3, Fig 2.15).
Antibodies to ovalbulmin were produced in all group of animals.
The JSRV negative animals remained PCR negative until the end of the experiment.
The viraemic animals remained constantly JSRV U3 PCR positive during the whole
experiment. At necropsy none of the viraemic animals nor the non viraemic animals
had gross or microscopic evidence of OPA. Fung tissues from the viraemic animals
were negative by PCR.
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Fig 2.15. JSRV viraemic sheep can produce antibodies to
JSRV capsid protein.
Antibody production in viraemic and non viraemic sheep was analysed by
western blot, 30 days after the third immunisation with CA fusion proteins:
Histidine tagged CA protein samples were transferred from SDS page gels
on to nitrocellulose membranes.
In lane 1. the serum from a sheep previously immunised by Dewar et ai,
(unpublished data) with GST-CA and p-gal-CA was tested (positive control);
in lane 2 serum from a JSRV viraemic sheep was tested; in lane 3 and 4
sera were obtained from 2 different non JSRV viraemic animals. The non
viraemic animal in lane 3 was immunised using as adjuvant CFA; the non
viraemic animal in lane 4 was immunised using Quil-A. Rabbit anti-sheep
horseradish peroxidase conjugate was used as secondary antibody.
2.5 Immunisation of OPA non viraemic sheep with recombinant
JSRV SU protein
2.5.1 Rationale of the experiment
JSRV-SU interacts with the cellular receptor. JSRV envelope has been identified as a
primary determinant of viral-induced transformation in vitro (Maeda et al., 2001; Rai
et al., 2001, Hofacre & Fan, 2004). To further investigate the role of JSRV SU in
OPA pathogenesis and the possibility of the tolerance, JSRV infected sheep were
immunised with JSRV SU recombinant.
2.5.2 Materials and methods
2.5.2.1 JSRV SU recombinant proteins
The SU recombinant proteins used in this experiment were: the RTS JSRV SU
produced as previously described and GST SU produced according to a previous
protocol (Dewar & Sharp, unpublished data see Appendix VI.2).
GST-SU could not be eluted with free glutathione from the sepharose beads and
therefore rabbits were immunised with the GST-SU coupled to the beads. GST-SU
estimated concentration was O.lmg/ml using the Pierce method.
2.5.2.2 Experimental plan
Before starting the immunisation with JSRV SU fusion protein, 2 JSRV negative
sheep were selected according to the results obtained by JSRV U3 PCR test for the
blood.
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The JSRV status of the sheep in each group was confirmed in advance of this
experiment by at least 3 blood tests at 3 month intervals. The two animals were from
the Moredun flock, they were both Black-face breed and one year old. The sheep
were immunised 3 times at one month intervals.
For the first inoculation 500pg of JSRV RTS SU per sheep was used; the second and
third immunisation was with GST- SU and JSRV RTS SU respectively, following the
same regime. Before inoculation the fusion proteins were combined with Freund's
incomplete adjuvant. Blood was collected into EDTA tubes before starting the
experiment as described and then once per month after each immunisation for JSRV
U3 PCR tests. Clotted blood was taken from each sheep before and after each
immunisation and examined for the presence of antibodies to JSRV SU by Western-
blot. At the end of the fourth month all the animals were euthanased. Necropsy and
histopathological investigation were carried out following standard techniques.
2.5.2.3 Analysis of sheep serum
Western blot was used to analyse the antibody response to the JSRV SU fusion
proteins. It was performed on GST- SU protein (Appendix IV). Briefly GST- SU
samples were transferred from SDS PAGE gels onto nitrocellulose membranes and
Western Blot was performed following the same protocol described in section 2.3.
The sheep sera to test were diluted 1:50 in WFB (WFB, 20 mM NaCl, 20 mM Tris
pH 7.5,0.1 mM EDTA).
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2.5.3 Results
The 2 animals remained JSRV negative by PCR throughout the experiment.
No antibodies to JSRV SU production were detected in the sera collected at different
times (Fig. 2.14). After necropsy the animal appeared perfectly normal.
2.6 Discussion
CA antibodies were produced in all of the JSRV viraemic and non-viraemic animals.
The result in non viraemic sheep confirms the data obtained 10 years ago by Sharp &
Dewar (unpublished data). In fact CA antibodies were obtained in non- viraemic and
in different age- breed groups of sheep.
It is well established that sheep infected by JSRV do not develop detectable immune
responses to this virus (Ortin et al., 1998; .Summers et al., 2002). This maybe a
consequence of central tolerance or may be due to peripheral tolerance.
Central tolerance concerns immature T or B cells as they differentiate in the primary
lymphoid organs, the thymus or bone marrow (Ohashi, 2003; Venanzi et al., 2004).
Relevant antigens, then, would be those synthesized by nurturing stromal cells,
circulating hematopoietic cells, or, ubiquitously, by all cells. The major mechanisms
that come into play during central tolerance appear to be clonal deletion or
inactivation of self-reactive lymphocytes, in particular the former. Peripheral
tolerance (Walker & Abbas, 2002) on the other hand, relates to mature T or B cells
after they have exited the primary lymphoid organs and are circulating through the
blood, lymph, and secondary lymphoid organs or have accessed the parenchymal
tissues in response to some stimulus. Antigens of concern would primarily be those
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expressed in the tissues and not in the thymus or bone marrow. Clonal deletion and
anergy are tolerance mechanisms also employed in the periphery, but a variety of
other means are also exploited, including clonal ignorance, deviation, helplessness,
and suppression (Mathis & Benoist, 2004).
It has been proposed that the failure to induce specific immunity during OPA is a
consequence of the expression of endogenous retroviral sequences, closely related to
JSRV, which can be expressed in utero (Palmarini & Fan, 2001b; Palmarini et al.,
2004), and may lead to central tolerance. Similarly, no JSRV-specific T cell
responses in the blood have been found, although a reduced response to the mitogen
Concanavalin A been observed in JSRV-inoculated lambs, prior to the onset of
clinical disease, and in terminally ill sheep (Summers et al. 2002). Peripheral
tolerance in OPA, perhaps could be induced by direct immunosuppressive effects of
JSRV infection. Retroviruses may inhibit local immune responses through
immunosuppressive domains contained within the Env proteins (Cianciolo et al.,
1980, 1985). Alternatively, the inability to detect systemic responses to JSRV may
simply reflect the level of sensitivity of the JSRV-specific immunological assays that
are currently available.
In this chapter anti JSRV CA antibodies could be induced in viraemic animals. This
result would indicate that the ovine immune system is capable of recognising and
responding to at least one of the JSRV proteins and specifically that the capacity of B
cells to generate antibody responses to the virus is not impaired by infection with
JSRV. On the other hand the findings do not permit a conclusion to be made about
the responsiveness of virus-specific T cells, since help for antibody production could
have been provided by T cells responding to the non-viral part of the fusion protein
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Further studies using viral polypeptides on their own as immunogens are necessary to
investigate the possible role of T cell tolerance.
The immune system in previous studies was approached by studying naturally
infected adult sheep in the terminal stages ofOPA and lambs infected with
concentrated lung fluid so that the changes noted have been due to secondary
infections, known to be common in OPA cases (Cutlip & Young , 1982; Garcia-Goti
et al., 2000) or to the high dose of the inoculum. In order to minimise any
immunological effects caused by concurrent infections a recent study (Summers et
al., 2002 and 2004 submitted) used only lambs born and reared under SPF conditions,
experimentally infected with JSRV. Summers et al., (2004 unpublished results)
found strong evidence for a local immune response during OPA mediated
predominantly by infiltrating macrophages that produced high levels of IFN-y. No
significant lymphocyte influx was detected in the lungs of the experimentally infected
lambs, as might be expected during viral infection or oncogenesis. The most striking
observation was the presence of strongly positive MHC Class II cells, which were
found within the tumours as well as in the alveolar spaces located within close
proximity to the tumour nodules. On morphology alone, the MHC Class II-positive
cells at these two locations appeared to be different and it was suggested that they
were primarily fibroblasts, with a minority being macrophages. Based on these
findings the authors suggest that a peripheral tolerance rather than a central tolerance
should be considered as a mechanism contributing to the apparent lack of an immune
response during JSRV infection and in animals with OPA.
It is not known what is the consequence of JSRV provirus in the lymphoid cells and
mononuclear phagocytes. In previous studies it has been shown that in experimentally
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infected lambs, JSRV proviral DNA can be detected in lymphoid cells as early as 7
days post infection when no histological signs of OPA are present (Holland et al.,
1999). This would indicate that infection of lymphoid cells precedes the neoplastic
transformation. This conclusion has been supported by findings in naturally infected
flocks that indicate that proviral DNA can be detected in the blood before the onset of
the clinical signs (see chapter 4). The lack of antibody production after immunisation
with recombinant JSRV SU protein could be due to the amount of protein that was
injected (500pg each inoculum) or to tolerance.
The lack of antibody production after immunisation of JSRV non-infected sheep with
recombinant JSRV SU proteins requires further studies. The lack of immune response
could be due to the amount of protein that was injected (500pg each inoculum).
Moreover, for supporting the tolerance theory it would be useful to repeat the
immunisation in viraemic animals.
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Chapter 3
Induction of ovine pulmonary adenocarcinoma (OPA) in




Natural OPA has a long incubation period with most clinical cases occurring in 2-4
year old animals. However, in experimentally inoculated new born lambs, JSRV
induces multifocal tumours in a few weeks (De las Heras et al., 2003). Early
transmission studies using tumour extracts were performed in sheep older than one
year by several routes ofparenteral inoculation or aerosol exposure, (Dungal, 1946;
Wandera, 1968). In these experiments, clinical disease was seldom achieved, with
incubation periods usually longer than one year and pathological changes consisting
of confined small tumour nodules. In contrast, later experiments demonstrated that
OPA could be induced much more rapidly and efficiently by intra-tracheal
inoculation ofnewborn lambs with concentrated lung fluid or less efficiently with
tumour extracts from OPA affected sheep (Verwoerd et al., 1980; Sharp et al., 1983;
DeMartini et al., 1987). Newborn lambs inoculated with lung fluid developed
clinical signs characteristic of OPA in 3-6 weeks post infection (p.i.) or even earlier
and histopathological confirmation was achieved in 70-100% of inoculated lambs.
However, when a similar intra-tracheal challenge was conducted in 10 week-old
lambs with tumour extract, only 25% of them developed scattered neoplastic nodules
and none showed clinical disease after 8 months, suggesting a possible age effect.
(Rosadio et al., 1988). The neonatal lamb model has been very useful in determining
the aetiological role of JSRV in OPA and some aspects of its pathogenesis. However,
due to the very young age of the lambs, it is unsuitable to evaluate the efficacy of
potential vaccine preparations and to study pathogenic mechanisms of JSRV
infections occurring later in life. For example the long incubation period in natural
OPA points to insertional activation of cellular proto-oncogenes as a mechanism of
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oncogenesis (Rosenberg & Jolicoeur, 1997); on the other hand the rapid induction of
the disease in experimentally inoculated neonatal lambs suggests that JSRV is an
acutely transforming retrovirus (Sharp & DeMartini, 2003). The study of the
pathogenic mechanisms of JSRV also has been hampered by the absence of
detectable antibodies to JSRV in affected animals (Palmarini et al., 1996b; Ortin et
al., 1998), a feature ofOPA that also has compromised the pre-clinical diagnosis of
the infection and the undertaking of epidemiological studies. More recently, JSRV-
specific polymerase chain reaction (PCR) techniques have been used to identify
infected sheep during clinical and subclinical stages of both natural and experimental
OPA (Garcfa-Goti et al., 2000; Gonzalez et al., 2001).
The main aims of this work therefore were:
1) to investigate whether JSRV infection, OPA lesions and clinical disease could be
induced in older lambs (Age experiment, paragraph 3.3);
2) to determine the dynamics of the infection by PCR testing of peripheral blood
samples. During this experiment DNA extraction from blood and high throughput
PCRs assays were optimised. The techniques developed in this chapter (blood
collection, DNA extraction, PCR tests, paragraph 3.2) will be used to study JSRV
infection in natural OPA affected flocks. For this reason high throughput assays of
clinical samples were needed to support the extensive molecular epidemiological
survey that will be described in chapter 4.
3) a secondary aim was to determine the expression of JSRV SU in the lungs of
inoculated lambs to better understand the interaction of JSRV with pulmonary
epithelial cells in the neoplastic process ( Age experiment, paragraph 3.3). In vitro
studies recently demonstrated that envelope (Env) proteins of JSRV can transform
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rodent and chicken fibroblasts in culture, suggesting a role for Env proteins in
oncogenesis (Maeda et al., 2001, Rai et al., 2001; Allen et al., 2002). From these
studies a new mechanism of transformation for JSRV has been postulated, so that
functional Env proteins can serve as oncogenes in addition to their primary function
ofmediating viral entry into cells (Alian et al., 2000; Alberti et al., 2002; Dirks et
al., 2002). Examination of JSRV genome revealed no apparent oncogene (York et
al., 1992), although orf-x had been suspected but later excluded (Palmarini et al.,
2001a).
The prelude to the experiments using animals was the development ofmethods to
obtain DNA from ovine blood and to optimise the detection of JSRV in these
samples by PCR (Section 3.2: description ofBlood collection, DNA extraction and
PCRs test).
The optimised procedures where then used as part of the subsequent experiment to
investigate the the susceptibility to JSRV in animals infected at different ages
(Section 3.3: induction ofOPA in older lambs).
3.2 Blood collection, DNA extraction, PCR tests
3.2.1 Material and methods
3.2.1.1 Blood collection and DNA extraction
Blood collection and DNA extraction were first optimised on blood samples from the
Moredun flock (Blackface sheep) and then applied to the samples from the
experimental animals.
Two different approaches were considered for extracting DNA from the blood:
3.2.1.1a) extraction ofDNA from the whole blood;
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3.2.1.1b) extraction ofDNA from PBLs ("peripheral blood leukocytes).
3.2.1.1a) Extraction ofDNA from the whole blood:
Ten ml blood samples were taken from 15 different animals in EDTA
vacutainers. From each different animal blood sample, DNA was extracted by six
different commercial kits following the manufacturer's protocols; l)Flexigene
(Qiagen), 2)Puregene (Gentra system,MN), 3)Genisol (ABgene), 4)DNAzol
(BD), 5)Dneasy tissue kit for whole blood samples (QIAgen) and 6)Ultraclean
(Flowgen) as shown in Table 3.1. Aliquots of fresh blood were taken from the 10
ml tubes and DNA was extracted on the same day. The rest of the blood was
stored at -20°C for one week and then DNA was extracted (Steinberg et al.,
1997). Each DNA extraction kit was run sequentially.
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Table 3.1. Different methods for extracting DNA were applied to individual





Flexigene 1ml 15 (fresh blood)
15 (frozen blood)
Puregene 600 pi 15 (fresh blood)
15 (frozen blood)
Genisol 1ml 15 (fresh blood)
15 (frozen blood)
Dnazol 0.5 ml 15 (fresh blood)
15 (frozen blood)
DNeasy 100 pi 15 (fresh blood)
15 (frozen blood)
Ultraclean 200 pi 15 (fresh blood)
15 (frozen blood)
The different protocols for DNA extraction are briefly reported in this chapter; more
details are described in Appendix XI.
1) FlexiGene DNA Kits provide a method for purification ofDNA from human
whole blood (1 ml starting material, 30-35ng/pl expected DNA concentration,
processing time 30 minutes). The procedure can be scaled up or down, allowing
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purification from variable amounts of starting material. Purification is performed in a
single tube, to minimise the risk of sample mix-up and to reduce waste. Lysis buffer
is added to the sample. Cell nuclei and mitochondria are pelleted by centrifugation.
The pellet is resuspended and incubated in denaturation buffer, which contains a
chaotropic salt, and protease. This step should efficiently remove contaminants such
as proteins. DNA is precipitated by addition of isopropanol, recovered by
centrifugation, washed in 70% ethanol, dried, and resuspended in hydration buffer.
2) Using the Puregene kit the average DNA yield expected is 200 ng/pl and the
processing time is 25 minutes. First, 600 ju.1 whole blood are aliquoted into 2.0 ml
microfuge tubes containing 900 jUl Red blood cell lysis solution. The next steps are
summarised in the diagram below:
RBC Lysis: lyse red blood cells
A








3) The Genisol kit is designed for the rapid isolation of high molecular weight DNA
from a variety ofmammalian sample types without the use of phenol or chloroform
(typical expected yield up to 40ng per pi ofblood, execution time ~20min).
No specialised plastic consumables or columns are required and all centrifugation
steps can be performed in a low-speed centrifuge. The protocol is based on salting-
out ofprotein contaminants using the Miller technique (1998). This method does not
require chaotropic reagents (guanidine, urea, etc.)
The components of the kit are: Lysis Buffer, Digestion Buffer, RnaseA, Precipitation
Buffer, DNA Buffer. All reagents were stable at room temperature and the quantity
of the different solutions can be scaled up or down according to the amount of
starting material. It was decided to start with 1 ml ofwhole blood. The method could
not be carried out in microcentrifuge tubes.
4) DNAzol is a reagent specifically formulated for the isolation of genomic DNA
from whole blood. The DNAzol procedure is based on the use of a guanidine-
detergent lysing solution (DNAzol) which hydrolyzes RNA and allows the selective
precipitation ofDNA from the lysate. Blood samples are mixed with DNAzol and
DNA is precipitated from the resulting lysate with isopropanol. The DNA pellet is
washed successively with DNAzol BD and ethanol, and solubilized. The entire
procedure can be completed in 30 minutes and the estimated DNA yield was 10-20
ng/pl. The protocol includes the following steps:
1. LYSIS: 1 ml DNAzol BD + 0.5 ml ofwhole blood.
2. DNA PRECIPITATION: lysate + 0.4 ml isopropanol at 6,000 g x 6 min.
3. DNA WASH: 0.5 ml DNAzol BD at 6,000 g x 5 min.; 1 ml 75% ethanol at 6,000
g x 5 min.
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4. DNA SOLUBILISATION: 8 mM NaOH or water.
5) Dneasv tissue kit method for the whole blood This method can be used for whole
blood, PBLs, fresh or frozen tissues.
DNeasy Tissue Kits are based on a silica-gel-membrane technology for purification
of total cellular DNA without organic extraction or ethanol precipitation. The buffer
system is optimised to allow direct cell lysis followed by selective binding ofDNA
to the DNeasy membrane. After lysis, the DNeasy procedure can be completed in
about 20 minutes. By centrifugation, contaminants and enzyme inhibitors such as
proteins and divalent cations are removed. Samples are first lysed using proteinase
K. Buffering conditions are adjusted to provide optimal DNA-binding conditions and
the lysate is loaded onto the DNeasyMini spin column. During a brief centrifugation,
DNA is selectively bound to the DNeasy membrane and contaminants pass through.
Remaining contaminants and enzyme inhibitors are removed in two efficient wash
steps and DNA is then eluted in water or buffer, ready for use.
This protocol is essentially the same for the different sources ofDNA (cultured cells,
tissues, whole blood), only the first steps differ according to the material from which
DNA needs to be extracted.
6) Ultraclean: This kit has been conceived for isolating DNA from 200pl ofwhole
blood using a spin filter method, with similar steps to the Dneasy Tissue kit (see
appendix for details).
In general DNA was eluted or resuspended in 150pl of the appropriate solution.
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3.2.1.1b) Extraction ofDNA from PBLs.
In previous work, lymphocytes were obtained using Lymphoprep TM (Axis-
Shield,PoC.As, Oslo) following the manufacturer's instructions (Palmarini et al.,
1996b). This method is labour intensive and requires multiple tube transfers that
increase the risk of loss ofDNA and unwanted contaminants ofDNA material. It
therefore is not practical for use in large scale experiments and/or epidemiological
studies (Miller et al., 1973; Gross-Bellard et al., 1994; Hawkins et al., 1994). In this
study a method based on PBLs lysis was performed. The interval between blood
collection and PBLs separation was 24 hours maximum during which the tubes were
stored at ambient temperature. No reduction in DNA yields, as a result of keeping
samples at ambient temperature for up to 3 days have been reported (Madisen et al.,
1987; Polakova et al., 1989; Schunemann et al., 2000).
Blood samples were obtained in EDTA vacutainers from the same 15 animals
used for the previous study; from each animal 2 EDTA tubes were taken. Each
vacutainer tube contained 10 ml of blood.
Blood tubes were centrifuged at 800g for 15 minutes. The buffy coat layer was
removed with a 1ml Gilson pipette and transferred into a 1.7 ml Eppendorf tube
containing 700pl ofNH4CI solution (RBC Lysis Solution, Puregene, Gentra
Systems, MN, USA), at room temperature for at least 5 minutes. The tubes were
centrifuged for 1 minute and the pellet suspended in 1 ml PBS. The wash with PBS
was repeated twice. The pellet obtained from each blood tube was divided in two:
one sample was used fresh for extracting DNA and the other one was stored at -20°C
for one week before DNA extraction. This buffy coat extraction method was
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followed by DNA extraction using QIAgen Dneasy tissue kit (method for cultured
animal cells). DNA was eluted in 150pl of the appropriate solution.
3.2.1.2 DNA concentration and DNA quality
DNA concentration was measured for all the samples obtained from the whole blood
and from the PBLs extraction (details ofmethods in appendix III). All the DNA
samples were stored at -20°C until further use. The quality of the DNA was tested
with GAP-DH PGR (for method see appendix X). Each sample was tested in
triplicate and was considered positive when at least one of the replicates was
positive.
3.2.1.3 JSRV U3 PCR
A single-round PCR for JSRV detection was developed based on the primers PI and
PHI used for the hemi-nested protocol reported previously (Palmarini et al., 1996a,
b). The new PCR was developed using as positive control the OPA cell line JS7
(Jassim et al., 1987), which contains a single copy of JSRV provirus per cell (Bai et
al., 1999; Holland et al., 1999; DeMartini et al., 2001); DNA from Icelandic sheep
PBLs was used as negative control.
Assuming that each JS7 cell contains one copy of JSRV provirus and that 100 ng of
DNA correspond to about 14,000 cells, the sensitivity of JSRV U3 PCR was
estimated using serial dilutions (10,000- 0.1 copies) of JS7 DNA in a background of
800 ng ofDNA from Icelandic sheep.The optimised PCR conditions were as follows:
5 pi of 10X PCR Buffer (Qiagen), 200pM dNTPs (Roche Diagnostics Ltd, East
Sussex, UK), 200 nM of each primer (MWG, Milton Keynes, UK) and 1.25 U ofHot
- 120-
Start Taq polymerase (Qiagen) were added to ultra-pure water (Sigma, Surrey,UK) to
a final 50pl volume. To this pre-mix, 800 ng of test DNA were added and incubated
at 94°C for 16 minutes, followed by 35 cycles at 94°C/30 seconds, 59°C/30 seconds
and 72°C/30 seconds, with a final extension step of 5 minutes at 72°C. PCR products
were visualized following electrophoresis in a 2% agarose gel containing 100pg-ml
ethidium bromide. The test samples were analysed in triplicate and considered
positive if one or more of the replicates gave a band of the correct molecular weight.
To confirm the integrity of the DNA, samples that were negative in the JSRV-U3-
PCR were tested for the house-keeping gene GAPDH transcripts (Palmarini et al.,
1996b).
The efficiency of JSRV-U3-PCR was first tested on blood from sheep with clinical
evidence OPA, submitted to Moredun from Scottish farms (n=18), on blood samples
from New Zealand (n=8) and from Iceland (n=50). DNA from Icelandic sheep was
used as negative control in each batch of PCR reactions. The New Zealand sheep
were recently imported to Great Britain. The Icelandic samples were shipped at
different times by express courier. The minimum amount ofDNA, from OPA
clinical cases, to give a visible amplification product on 2% agarose gel was
determined by testing 3 different concentration of DNA, lOOOng, 500ng and 300ng
from five different OPA clinical cases confirmed positive after necropsy.
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3.2.2 Results
3.2.2.1 Blood collection and DNA extraction
The six different commercial kits for extracting DNA from the whole blood were in
general very easy to use. Microcentrifuge tubes could be used for all the kits with the
exception of the Genisol kit.
When DNA extraction was performed using whole blood as starting material the best
DNA yield was obtained using DNeasy and Ultraclean kits (Table 3.2).
The GAP-DH results from the same samples are summarised in Table 3.2. The
higher number of positive samples were obtained with Puregene and DNeasy kits
(7/15 and 8/15 respectively). Genisol method gave only one positive result out of 15,
Dnazol gave 2 positive out of 15, Flexigen and Ultraclean 4 out of 15.
The GAP-DH results from frozen samples are summarised in Table 3.2. All the
DNA samples obtained by Genisol gave negative results. 3 positive samples out of
15 were obtained with Puregene and Dnazol, respectively. Ultraclean gave 4
positive out of 15, Flexigene and Dneasy 5 out of 15.
DNA extraction from fresh and frozen PBLs with the Dneasy tissue kit gave a mean
DNA yield of 133 and 155 ng/pl respectively. GAP-DH was positive in all the 15
fresh and frozen tested samples. The DNA samples extracted from PBMC with
Dneasy tissue kit gave the highest number ofpositive replicates by GAP-DH PCR
without any difference between fresh and frozen samples (15/15) (Table 3.2). Due to
the consistency of results this extraction method from WBC was used for the
remainder of the experiments.
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Table 3.2 (a & b): Evalution of different methods for extracting DNA
from fresh and frozen blood. DNA yield (ng/pl) in the final DNA solution, per
ml of initial whole blood, was expressed as mean of 15 samples and the standard
deviation (SD) and the standard error (SE) were calculated. DNeasy method was
used to extract DNA from PBMC derived from 1 ml of blood, which contains
approximately 7.8x105 of PBMC. Data from frozen and fresh blood samples are
compared using an unpaired t-test, assuming unequal variances. The results are
summarised in the following tables:













Flexigene 12.2 2 4/15 16 4.7 5/15
Puregene 37.1 3 7/15 38.6 3.3 3/15
Genisol 11.7 1.9 1/15 14.9 3.9 0/15
Dnazol 44.6 3.6 2/15 44.8 3.6 3/15
DNeasy 171 19 8/15 223 29 5/15
Ultraclean 100 15.5 4/15 136 10 4/15






Flexigene 3.8 1.3 2.88 0.01
Puregene 1.5 1.2 1.30 0.21
Genisol
3.2 1.1 2.86 0.01
Dnazol
0.2 1.3 0.15 0.88
DNeasy 52 9.0 5.81 <0.001
Ultraclean
36 4.8 7.56 <0.001
DNeasy 22 12.5 1.76 0.10
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3.2.2.2 JSRV U3 PCR
From the JSRV U3 PCR a product of 176 bp was expected. This JSRV U3 PCR
successfully amplified between 5-10 copies of JSRV template integrated in genomic
DNA from JS7 cells (Fig. 3.1). All 18 OPA clinical cases gave positive results when
their blood was examined with this test. Negative results were obtained with the
blood from the 8 New Zealand and 50 Icelandic sheep (Fig. 3.2). Three different
amounts ofDNA, 800, 500 and 300ng from five different OPA animals were tested
in triplicate by the JSRV U3. The 300ng DNA concentration gave negative results in
all the samples tested. The minimum amount ofDNA necessary for giving the
expected amplified product was 500 ng; 800ng of total DNA did not inhibit the PCR
reaction on the contrary the amplified 176bp band appeared stronger in 2% agarose
gel (Fig 3.3).
3.2.3 Conclusion
The kits for DNA extraction from the whole blood offered a number of advantages.
The kits for extracting DNA from the whole blood required at least 30 minutes less
than the method in which isolation of PBMC was performed. The use of
microcentrifuge tubes in the whole blood kits (with the exception of the Genisol Kit)
allows decreasing time of centrifugation and easier storage of the obtained DNA.
However, each kit had a major disadvantage that made them unsuitable for the
proposed application: the poor quality of the DNA. The low number ofpositive
samples by GAP-DH highlights the presence of inhibitors in the DNA. The quality of
DNA was a crucial factor for choosing the DNA extraction method that had to be
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Fig 3.1. Sensitivity of the JSRV U3-PCR.
The sensitivity of JSRV U3 PCR was performed using serial dilutions
(10,000- <5 copies) of JS7 DNA in a background of 800 ng ofDNA
from Icelandic sheep.
1-3: 10,000 copies of JSRV template; 4-6: 1,000 copies of JSRV
template; 7-9: 100 copies of JSRV template; 10-12: 10 copies of JSRV
template; 13-15: 5 copies of JSRV template; 16-18: less than 5 copies of
JSRV template; 19-21: icelandic blood sample; 22-23: water. Lane M:
contains molecular mass DNA marker IV(Bioline).
176bp
176hp
Fig 3.2. Detection of JSRV provirus in sheep blood by
JSRV U3-PCR.
M: molecular marker (Hyperladder IV Bioline). Each blood
sample was tested in triplicate. 3,4: samples sheep imported
from New Zealand; 1, 2,5,9,10,11,12,13, 14: samples from
OPA clinical animals; 6,7,8: samples from Icelandic sheep; 15:
water; 16: DNA from JS7 cells (1000 copies of JSRV template).
The positive samples show an amplified product of 176bp.
Fig 3.3. Titration of the DNA necessary for the JSRV U3 PCR.
M=molecular marker (Hyperladder IV Bioline). 1= Icelandic blood;
8=water. 9= DNA from JS7 cells (1000 copies of JSRV template).
The positive samples show an amplified product of 176bp.
5,6,7: blood DNA from one OPA clinical case; in the triplicates
panel 5 the amount of DNA for each replicate was 300 ng, in
panel 6 was 500ng and in 7 was 800ng.
Each of the replicates 2, 3 and 4 contains DNA from three OPA
clinical cases animals; for each of the replicates 2, 3 and 4 a total
DNA amount of 800ng was used.
include only three replicates. These limitations were due to concerns regarding the
available budget and the management of a consistent number of samples to test.
After DNA extraction from the PBMC with Dneasy tissue kit a good DNA yield and
a significant improvement in terms ofDNA quality were achieved. DNA extraction
from PBMC gave 100% percentage of positive samples by GAP-DH PCR.
The storage ofPBMC at -20°C did not influence the quality of the DNA and the
DNA yield (Table 3.2).
The previous heminested PCR protocol for detecting the provirus from the blood
used a minimum amount 500 ng ofDNA per PCR reaction (Palmarini et al., 1996b;
Gonzalez et al., 2001). Each sample has to be repeated in triplicate in the GAP-DH
and U3 JSRV PCRs. After these considerations the highest DNA yield and the best
DNA quality were obtained with DNA extraction of the PBMCs with Dneasy tissue
kit. The amount of time necessary for PBMC isolation from the whole blood was
kept to a minimum by devising a method to perform the red cell lysis in a
microcentrifuge tube. PBMC DNA extraction using the Dneasy tissue kit allowed a
high degree of confidence, based on the DNA yield and DNA quality, for applying
this method to the experimental samples and samples from the epidemiological
survey.
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3.3 Induction of OPA in older lambs
3.3.1 Materials and methods
3.3.1.1 Experimental infection
Four groups of Scottish Blackface lambs of different ages were inoculated with
JSRV-containing lung fluid, as confirmed by western-blot and reverse transcriptase
PCR (Palmarini et al., 1995). The ages at inoculation were: one week (n=5), one
month (n=10), 3 months (n=T0) and 6 months (n=10). All the animals were from an
OPA-free flock at Moredun Research Institute (Edinburgh, UK). Six lambs from the
same source were used as unchallenged controls.
Lung fluid (LF) collected from sheep naturally affected with OPA was first filtered
through a double layer of sterile gauze and clarified by centrifugation at 11,000 X g
for 60 minutes at 4°C and stored at -70°C. In order to remove variation in JSRV
titres between batches of LF and ensure that each lamb received the same inoculum,
several batches of LF from different sheep were thawed, pooled together, aliquoted
and stored at -70°C. Immediately before inoculation of the lambs, the appropriate
number of aliquots were thawed and concentrated by centrifugation at 100,000 X g
on a glycerol cushion, and the resulting pellet suspended in TNE (0.01M Tris pH7.5,
0.1M NaCl, ImM EDTA) buffer to give a 12.5 fold concentrate of the original
volume (Sharp et al. 1983). Each lamb in each age group received 5 ml of this
concentrated lung fluid pool by the intra-tracheal route, as previously described
(Sharp et al., 1983).
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3.3.1.2 Blood collection and DNA extraction in the experimental
animals
Peripheral blood samples were collected immediately prior to experimental JSRV
challenge and at intervals until necropsy. From each animal, a final blood sample
was taken immediately before necropsy. Ten ml ofblood was collected by
venipuncture into individual EDTA vacutainers (BD) (Wang et al., 1992; Holodniy
et al., 1991; Lam et al., 2004).
3.3.1.3 Clinical examination, culling and post mortem
examinations
After experimental infection, animals were monitored regularly for clinical signs of
respiratory disease suggestive ofOPA including tachypnoea, dsypnoea, noticeable
movement of the abdominal wall (abdominal lift), moist rales and nasal discharge of
pulmonary fluid. According to their nature and severity, the clinical signs were
described as highly suggestive or compatible with OPA. As soon as these signs were
identified, lambs were euthanased by an intravenous overdose ofpentobarbitone.
Lambs not showing any clinical signs were kept for a maximum of six or seven
months p.i. and then culled. The unchallenged control animals were retained until the
end of the experiment and culled at the same time as the last inoculated lambs.
At necropsy, visual examination of the lungs was performed to identify any gross
lesions suggestive of OPA. Neoplastic-like areas or, in their absence, a range of sites
from all pulmonary lobes were taken for microscopic examination. Samples were
fixed in 10% neutral buffered formalin, routinely processed, sectioned at 5 pm, and
stained with hematoxylin and eosin (HE). Sections from selected lung samples were
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subjected to immunohistochemical examination for JSRV capsid protein (JSRV-CA)
as described by Palmarini et al., 1995, and for JSRV surface glycoprotein (JSRV-
SU) using a newly developed antiserum (Chapter 2).
Incubation period (days from experimental infection to post-mortem) ofOPA in four
groups of sheep challenged at different ages, all ofwhich showed clinical signs of the
disease and histopathological confirmation ofpulmonary neoplasia was further
anlysed using a statistical method (Fig.3.4). The comparison of incubations periods
between groups was done using the "unpaired test". The following comparison were
carried out:
1.- 1 week versus 1 month-old lambs: the non-parametric, unpaired t test (Mann-
Whitney test) was used; this is because there were only four sheep in the 1 week-old
group and this figure was too low to tell if the incubation periods were arranged in a
normal (Gaussian) distribution.
2.- 1 month versus 3 month-old lambs: the unpaired t test with Welch correction was
used; this was because the two groups had significantly different standard deviations.
3.-3 month versus 6 month-old lams: the unpaired t test was used; this time the
normal t test was included because the data followed a Gaussian distribution and the
two groups had similar standard deviations.
3.3.1.4 Immunohistochemistry (IHC)
Tissue samples were fixed in 10% neutral buffered formalin, processed routinely in
an automatic tissue processor, embedded in paraffin wax and sectioned at 4-6pm.
Lung tissue sections were microwaved at 800 w for 10 min. in citrate buffer pH 6.0
and endogenous peroxidase was inhibited by immersion in 1% vol (v/v) hydrogen
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peroxide in methanol for 25 min. The sections were then incubated overnight at 4°C
with either anti-JSRV-SU or anti-JSRV-CA polyclonal antibodies, both at 1/1000
optimised dilution. As a additional control, slide sections were incubated with the
relevant rabbit pre-immunisation serum. Section were then washed 3X10 minutes
with TBS/Tween (TBS, 0,5% [v/v]Tween) and incubated with a biotinylated goat
anti rabbit immunoglobulin (1: 100; Vector Laboratories). After 3X10 min washings
with TBS/Tween, the ABC Vectastatin complexTM (Vector-elite ABC kit; Vector
Laboratories, Peterborough) containing avidin and biotinylated horse radish
peroxidase was added to the sections and incubated for one hour at room
temperature. Washing were then performed as above and the reaction was developed
after incubation with DAB substrate solution (0.05 DAB[w/v] in TBS, activated with
0.15, v/v H2O2). After one minute, the reaction was stopped with tap water
At the end, sections were counterstained with Carazzi's haematoxylin. Sections from
natural OPA cases were used as positive controls.
3.3.2 Results
3.3.2.1 Situation in the different age groups
Unchallenged controls
None of the uninoculated control lambs developed clinical signs of respiratory
disease and their PBMCs were negative by JSRV-U3-PCR throughout the
experiment. These lambs were kept until 14 months old and neither histopathological
lesions of typical OPA nor proviral DNA were detected in lung samples or
mediastinal lymph nodes taken at necropsy.
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One week old lambs
Severe clinical signs highly suggestive ofOPA were observed in four lambs of this
group, and two of them showed nasal discharge of lung fluid. They were killed
between 70 and 74 days p.i. (Fig.3.4). One lamb (1W1, Fig. 3.5) died 28 days after
experimental challenge of an unrelated illness without obvious OPA clinical signs.
All five lambs showed gross lesions highly suggestive ofOPA, which were
confirmed by microscopic examination (Fig. 3.5). All lambs were PCR negative at
the time of infection but their PBMC were consistently positive from there onwards
(Fig. 3.2), including the lamb that died from an unrelated cause.
One month old lambs
Nine out of ten lambs in this group showed clinical signs highly suggestive or
compatible with OPA, with incubation periods ranging from 92 to 209 days (average
152, Fig. 3.4). The remaining lamb (1M10, Fig. 3.5) was asymptomatic when culled
at almost seven months p.i. All ten lambs had macroscopic pulmonary lesions
histologically confirmed as OPA (Fig. 3.5). The PBMC of all lambs also were JSRV-
U3-PCR positive throughout the experiment with the exception of one (1M7, Fig.
3.5). This lamb was positive only in the sample taken immediately before necropsy,
even though it had developed clinical signs ofOPA with lung fluid production.
Three month old lambs
Nine of 10 lambs challenged at 3 months of age developed clinical signs highly
suggestive or compatible with OPA, with incubation periods ranging from 159 to 192
days (average 185, Fig. 3.4). The other animal (3M10, Fig. 3.5) remained
asymptomatic until it was culled at 192 days p.i. Macroscopic lung lesions were
confirmed histologically as OPA in all 10 lambs. PBMC from all 10 also were JSRV-
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U3-PCR positive at some point during the experiment. While JSRV viraemia was
consistently detected in six of them, including the one that remained asymptomatic,
the other four (3M2, 3M3, 3M5 and 3M8 in Fig. 3.4) gave some PCR negative
results.
Six month old lambs
Five of the 10 animals in this group developed clinical signs of respiratory disease
mainly manifested as tachypnoea and dyspnoea after exercise and never with
production of lung fluid. The incubation period ranged from 164 to 169 days
(average 182, Fig. 3.4). Amongst the five other sheep, two (6M1 and 6M2 in Fig.3.5)
were culled and died respectively from OPA-unrelated conditions at 104 and 145
days p.i. The other three (6M8, 6M9 and 6M10) were asymptomatic when culled at
190-192 days p.i. All five sheep with clinical signs ofOPA showed characteristic
gross lesions confirmed by histopathological examination. Neither macroscopic nor
microscopic lesions ofOPA were found in the two sheep that died from unrelated
conditions and in one of the three asymptomatic sheep (3M10, Fig. 3.5). The other
two asymptomatic sheep showed pathological evidence of neoplasia although in one
of them (6M9, Fig.3.5) only microscopic lesions were detected. Within this 6 month-
old group, PBMC from all animals were JSRV-U3-PCR negative at 3 weeks p.i., but,
with the exception of a single sheep (6M9 in Fig. 3.5) they were consistently positive
thereafter.
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Fig.3.5. Evolution of JSRV viraemia as detected by U3 PCR (0 , negative; ® , positive)
during the course of the experimental infection and at culling of sheep showing clinical
signs of OPA ( m ) or not showing such signs ( [-] ), and in which gross and/or
histopathological lesions ofOPA were confirmed (£) or absent (<^>).
3.3.2.2 Histopathoiogical and IHC observations and PCR
examination of tissue samples
In all sheep with histologically confirmed OPA, regardless of their age at challenge,
the tumour was predominantly a papillary adenocarcinoma of the alveoli even if in
some cases an acinary pattern was also present (Fig.3.6a). Papillary neoplastic
growths into the lumena of bronchioles and alveolar nodules of acinary and
bronchioloalveolar appearance were found inconsistently and were unrelated to the
age at infection. Fibrosis of the stroma of the neoplastic nodules and presence of
spiral shaped myxoid tissue were rare. Infiltration of the tumour stroma by
mononuclear cells was relatively frequent, though mild, in the lambs challenged at
one and six months of age, but inconspicuous in the other two groups, particularly in
the one week old lambs. Also in the animals inoculated at one month, hyperplasia of
the bronchiole associated lymphoid tissue was common and prominent in half of
them (Fig. 3.6b). Desquamation of enlarged alveolar macrophages in para-neoplastic
alveoli was a common finding in all sheep groups, while suppurative exudates in
tumour and non-tumour areas were very variable between individuals within the
same age group.
IHC examinations showed JSRV-CA protein in the cytoplasm of a proportion of
ATII neoplastic cells and nodules as already described in previous studies (Palmarini
et al., 1995; Piatt et a!., 2002). As expected JSRV CA was identified mainly in
tumour cells (Fig 3.7a and Fig 3.8a). In some tumour nodules individual cells or
group of cells stained intensely yet were adjacent to cells that did not stain at all.
There was no staining of non transformed epithelial cells nor of the stromal cells.
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Fig.3.6. Histopathological lesions in JSRV experimentally
inoculated lambs.
a) Co-existence of papillary (arrow) and acinary (triangle) forms of the
tumour in the lung of a lamb inoculated at three months of age. H-E
x4. b) Papillary neoplastic proliferations involve alveoli and
bronchioles, which also show hyperplasia of associated lymphoid
tissue. Para-adenomatous change is also evident. Lamb challenged
at 3 months of age. H-E x8.
Fig 3.7. IHC of experimental OPA.
Papillary alveolar tumour showing:
a)strong immunoreactivity for viral capsid protein in the
cytoplasm of the transformed cells. The arrow in fig 3.9a
indicates the presence of desquamated alveolar macrophages in
the alveoli
b) strong immunoreactivity for viral surface protein mainly in the
apical border of transformed ATII cells (magnification 400x).
Fig 3.8. IHC of experimental OPA.
Proliferating cells in a bronchiole showing a) staining confined to the cytoplasm
using anti JSRV CA immune serum; b) immunoreactivity for JSRV-SU protein,
which is most evident in the apical cytoplasm, while non-transformed cells are
negative (a,b). The arrows in fig 3.8a&b indicate the presence of desquamated
alveolar macrophages in the alveoli. Magnification 400x.
Detection of IHC reactivity to JSRV-SU was consistent in epithelial cells lining
neoplastic alveoli (Fig. 3.7b) and in cells lining neoplastic polypoid structures in the
bronchioles (Fig. 3.8b). In both cases, immunolabelling was localised in the
cytoplasm but was most intense at the apical surface of the tumoral cells. On some
occasions, isolated cells with morphology ofATII cells also showed cytoplasmic
immunolabelling. While normal epithelial cells of the alveoli and bronchioles were
not labelled, a few interstitial cells (macrophages-like) within the bronchiole-
associated lymphoid tissue or in the stroma of the alveolar tumours were JSRV-SU
positive.
The same pattern of JSRV SU and JSRV CA staining was observed in tumours with
papilliform and/or acinary formations. IHC results did not show any difference
between natural and experimentally infected animals.
Proviral JSRV DNA was detected by U3-PCR in all mediastinal lymph node and
lung tissue samples collected from the 35 challenged sheep.
3.3.3 Discussion
The present study has demonstrated clearly that JSRV infection can be induced in
100% of lambs aged one to six months at the time of inoculation and that a high
proportion of these animals develop clinical signs (62-90%) and lesions (87-100%)
of OPA (Fig.3.9). These findings are in contrast with a much smaller-scale previous
study that employed tumour extract as inoculum, in which only 25% of older lambs
developed neoplastic lesions (Rosadio et al., 1988). One explanation for the success
of the current experiment would be a large amount of JSRV in the inoculum, as it has
been demonstrated that LF contains more JSRV than tumour extracts (Herring et al.,
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Fig3.9.Experimentalinf ctionofdi fer ntagegrouplambswithLF. Summaryoffinicalandpathologicalresultsithediff r ntgegro psnima s.
O)






2345678£101234790 14262 283 323 3 1weekmonth3mont s6onths
1983) and that there is an inverse relationship between incubation period and amount
of JSRV in the inoculum (Verwoerd et al., 1980). Nevertheless some features of the
present study support the notion of an age-related resistance to OPA.
First, within those animals that developed clinical signs ofOPA, the incubation
period was significantly shorter (p<0.001) in the lambs inoculated at one week of age
than in the older lambs (Fig.3.4). It also was significantly shorter (p=0.03) in the
animals challenged at one month than in those inoculated at 3 months.
However it is possible to argue that the age effect was so remarkable because the
dose was not adjusted to weight size of the animals. It would have been interesting
to have had time to investigate a possible dose effect. An important prelude to such
studies would be the development of a quantification system for JSRV in the LF and
the dose-effect experiment could be carried out challenging lambs that are 3 months
old with 3 or 4 different concentrations of JSRV virions.
In the family Retroviridae, other examples of age-related susceptibility can be found.
The two factors that determine whether a cat exposed to FeLV will become viraemic
or recover are the age at which the cat becomes infected (Hoover et al., 1976; Flynn
et al., 2000) and the dose of virus to which it is exposed. Kittens that lack protective
maternal antibodies and that are infected within the first 4-5 months of life have a
high risk ofbecoming permanently infected. After this period, resistance to infection
develops rapidly so that by the time cats are 6 months of age only about 15% develop
persistent viraemia following exposure to high doses of virus. The effect of dose is
seen dramatically in the contrast between the prevalence of infection in multicat
households in which the virus is enzootic and in free ranging cats, generally from
single-cat households. In multicat households, the dose of virus to which the cats are
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exposed is high due to continuous contact with viraemic cats, so in this population of
cats there is a high prevalence of viraemic cats (30-40%) which have a high risk of
developing FeLV-associated disease. By contrast, animals from single-cat
households have a prevalence of only around 1% and the incidence of FeLV-related
disease is very low (Jarrett, 2001).
Certain avian leukosis viruses are able to induce rapid lymphomas after inoculation
of 9 to 13 day-old chickens, while neoplasia in mature chickens takes longer to
develop (Pizer et al., 1992; Stedman et al., 2001). Another example is provided by
Maedi-visna virus (MVV) infection, which usually leads to long incubation periods
and low rate of lesions and disease in adult animals. Experimental infection of young
lambs, however, can result in acute disease with very high mortality (Lairmore et al.,
1986; Andresson et al., 1993). These observations could be explained by differences
in the ability of neonates and older animals to mount an immune response against
MVV, as some authors found that the appearance of circulating anti-MVV antibodies
was correlated with a decrease in viraemia titres (Flaase et al., 1977). This
explanation, however, would not seem likely for JSRV infection, in view of the lack
of a specific humoral immune response (Ortin et al., 1998; Sharp & Herring, 1983),
perhaps due to the early expression of closely related JSRV-endogenous retroviruses
(Palmarini et al., 2004).
A more plausible explanation for the age effect in OPA would be that the target cells
for primary JSRV infection and oncogenesis are present in higher numbers in
newborn lambs than in older animals. The major target cells for JSRV replication in
the lung are the ATII and Clara cells of the bronchioles (Palmarini et al., 1995) in
which the active LTR causes the enhanced JSRV gene expression (Palmarini et al.,
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2000b). In rodents and ruminants the proportion ofATII cells changes with age. At
birth, the ratio of type I pneumocytes to ATII cells is around 1:2, and ATII
pneumocytes account for approximately 60% of alveolar cells (Kahwa et al., 1997;
Otto, 1997; Weibel & Taylor, 1996). During the first month of life, the number of
ATII cells declines progressively and dramatically, so that they represent only 6% of
alveolar cells at 7 days, 1% at 3 weeks, and 0.2% at one month, with no further
significant changes occurring later (Wright & Alison, 1984). Similarly, Clara cells
retain foetal characteristics in calves and goat kids that are up to 30 days old, but lose
them and become fully differentiated after this time (Castleman & Lay, 1990; Kahwa
et al., 2000).
The hypothesis proposed is that following intra-tracheal inoculation of JSRV,
primary viral replication would occur in the ATII pneumocytes and Clara cells and
that the magnitude of such replication would depend on the availability of those
target cells. Thus, a higher viral production could be expected in newborn lambs,
leading to earlier detection of viraemia and development of neoplastic lesions (and
hence shorter incubation period). As the number of available target cells decreases,
initial viral replication would occur at a lower rate resulting in delayed viraemia and
development of lesions (and hence longer incubation period). This age effect would
be particularly noticeable during the first month of life and, as far as viraemia is
concerned, needs to be confirmed by new experiments involving more exhaustive
PCR testing of blood samples.
The persistent viraemia and the delayed development ofOPA in older lambs parallel
epidemiological observations from naturally affected flocks where JSRV could be
detected in the blood before the onset of clinical OPA and even in absence of
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discernible lung tumours (Garcia-Goti, et al., 2000; Gonzalez et al., 2001). It is also
noticeable that in flocks with endemic OPA only a proportion of sheep (up to 30%,
but usually less) develop neoplastic lesions (Sharp & DeMartini, 2003), which may
or may not lead to overt clinical disease, while JSRV infection appears much more
widely disseminated (around 75%, as judged by PCR; Garcia-Goti, 1999). These
observations on the natural disease would suggest that JSRV is a slow-transforming
retrovirus, raising questions about the in vivo role of JSRV env gene in
transformation (Fan et al., 2003), even though recent in vitro studies have indicated
that JSRV Env protein is capable of transforming rodent and avian cells (Maeda, et
al., 2001; Zavala, et al., 2003). However, our finding of consistent expression of SU
protein in tumour cells is consistent with a role in proliferation of these cell. This
hypothesis is reinforced by the fact that positive IHC results have been obtained
using the anti JSRV-SU polyclonal rabbit serum on nasal gland tissues obtained from
animal with natural ENA (de las Heras et al., 2003). The mechanisms of in vivo
oncogenesis in OPA appear therefore to be more complex than those of cell
transformation in vitro, with several steps being probably necessary to achieve viral-
induced cell transformation.
In conclusion a new experimental model to induce JSRV infection and OPA in aged
lambs has been developed. Infection also can be monitored by an efficient PCR
technique using blood samples. Apart from providing new insights into the
pathogenesis of the disease, confirming an effect of the age in the time scale ofOPA-
related events, the model will be useful to test the efficacy of potential vaccines.
Finally, our PCR results reinforce previous studies on detection of JSRV infection in
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Epidemiological and transmission studies in sheep
naturally infected by JSRV
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4.1 Introduction
Currently there is no treatment or pre-clinical diagnosis for OPA and it is invariably
fatal. OPA has a widespread prevalence throughout the world (Sharp & DeMartini,
2003). Economic losses due to OPA can vary. For example in Scotland some farms
report losing 5 - 10% of sheep per year to this disease (Sharp & De Las Heras,
2000). However all available data on the prevalence and distribution of OPA are
based on retrospective histopathological reports. Information of the true prevalence
of JSRV infection is a major gap in the knowledge of the disease.
In UK most of the data are limited to reports on cases submitted to Veterinary
Investigation centres. For example, of 653 lung samples submitted to the MAFF
veterinary laboratory in Lasswade, Midlothian during 1975-1979, 191 presented
lesions of OPA (Hunter & Monroe, 1983), (Table 4.1). In this study and that of
Harbour & Jamieson, (1946), the OPA cases came particularly from the East of
Scotland and the Borders. Recent reports of OPA in the Borders, Dumfries,
Caithness and Orkney suggest a wider distribution across Scotland (SAC veterinary
services monthly reports Jan02-July03). Farming groups, veterinarians and
regulatory authorities all recognise OPA as an important target for control or
eradication. Currently farmers attempt to control OPA by managerial measures such
as reductions in animal density or culling of animals showing signs consistent with
the disease. However, much of the information required to develop and implement a
rational control or eradication strategy is lacking.
The detection of JSRV in the peripheral blood of experimentally infected lambs,
before the onset of clinical disease (Holland et al., 1999) was an important finding
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Table 4.1. Occurrence and Distribution of OPA in
Scotland based on histopathological diagnosis (Hunter
& Munro, 1983).
year Lung samples No. ofOPA No. of
examined positive affected farms
1975 100 24 unknown
1976 95 24 unknown
1977 128 46 34
1978 178 45 33
1979 152 52 41
1980/81 526 99 63
that offered a means to investigate the extent of JSRV infection in OPA affected
flocks. These findings were extended in studies involving sheep from OPA-affected
commercial flocks (Gonzalez et al., 2001). Peripheral blood leukocytes (PBLs) and
tissue samples from 36 sheep were examined for JSRV by hemi-nested PCR.
Animals were classified according to the status of OPA which was confirmed by
pathological examination, as follows: (i) sheep with classical OPA (cOPA, n=10),
(ii) sheep with atypical SPA (aOPA, n=6), (iii) non-affected sheep from OPA-
affected flocks (in-contact, n=10) and (iv) non-affected sheep from OPA-free flocks
(control, n=10). JSRV proviral DNA was detected in the PBLs of 10/10 cOPA, 5/6
aOPA, 4/10 in-contact and 0/10 control sheep. The number of positive PCR results
was greater for sheep in the cOPA group than for those in the aOPA and in-contact
groups. These results showed that JSRV can be detected in naturally infected sheep
before the onset of clinical disease and even before the development of discernible
tumours.
Further information of the dynamics of JSRV infection in OPA-affected flocks were
provided by a small prospective survey in an OPA-affected flock (Garcia Goti.,
1999). JSRV was detected by hemi-nested PCR in PBLs from 28% of the flock.
Fifteen positive sheep and five negative sheep were selected and PBLs were
examined by JSRV PCR at monthly intervals for the next 4 months. JSRV was
detected in only 9 of the original 15 positive sheep during this period and in 4 of
those that were negative (Table 4.2).
The development during this study of a one step PCR test (JSRV U3 PCR) for JSRV
infection (Chapter 3) gave the possibility to start the first prospective and
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Table 4.2. Longitudinal survey of JSRV infection in a small OPA
affected commercial flock. (Garcia-Goti, 1999).
Fifteen positive sheep and five negative sheep were selected and
PBLs were examined by hemi-nested PCR at monthly interval for 4
months.
JSRV No. of JSRV positivitv Necropsy Total
status sheep during time (months)
a 1 n i A
\J X ^ ~T
PCR(+ve) 15 15 9 5 1 4 6 11
PCR(-ve) 5 5 2 3 1 1 2 4
comprehensive study of JSRV infection following JSRV incidence within a single
flock with previous history of OPA cases.
The longitudinal survey of JSRV infection that is presented in this study lasted two
and half years. Ewes of different ages were bled at 3-4 months intervals. Lambs from
selected JSRV positive and negative ewes also were tested at same time.
The overall aim of the work was to characterise the epidemiological features of
JSRV infection, particularly its routes of transmission in OPA affected flocks, which
can be used to identify the risk factors for transmission and maintenance of OPA in
flocks. In particular the aims of the study were i) to determine the ranges of
prevalence and preliminary indications of the influence of the breed and the
management system, ii) determine the times and ages at which infection first occurs,
iii) to evaluate JSRV infection in sheep of different ages, iv) determine the
proportion of JSRV viraemic sheep that eventually develop OPA i.e. the prognostic
significance of viraemia, v) determine the presence of a familial trend that could
predispose descendants of infected sheep. The analyses presented in this chapter will
form the basis for a larger epidemiology survey aimed at control and eradication of
OPA.
The longitudinal study of the offspring of JSRV viraemic and non-viraemic ewes
was planned to provide preliminary indications of the occurrence or absence of JSRV
transmission from dam to lamb. If maternal transmission is epidemiologically
relevant, the control strategies will be designed taking this into consideration.
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Maternal transmission was further investigated studying the presence of JSRV in
foetuses from OPA clinically ill sheep that did not belong to the flock under
epidemiological survey.
All the samples from the epidemiological studies were tested using the JSRV U3
PCR developed in Chapter 3, although a real-time PCR approach was evaluated and
developed during the survey. Real-time PCR will represent the next step forward for
testing large numbers of blood samples and possibly milk samples for a future OPA
control and eradication programme.
4.2 Materials and Methods
4.2.1 Experimental plan
A farm with a history of OPA over many years was recruited. The commercial flock
was located in England, and the productive attitude was for meat. A schematic of the
experimental design is presented in Fig. 4.1.
Samples were taken from an initial number of 194 ewes; the following test was
repeated in the same group of animals 3 months after, in February 2003. An initial
selection of the dams was made on the basis ofPCR results obtained in the pre-
lambing period (December 2002 and February 2003) in May 2003.
Each single ewe was considered negative when the PCR result was negative in both
pre-lambing bleed and was considered positive when it was JSRV positive in one of
the two bleeds. The positive and negative group of dams included different age
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Fig. 4.1. Design of the JSRV longitudinal survey.
The selection of the study groups was made after lambing, to account for the sex and
viability of the offspring, as only those dams whose progeny were kept for
replacement were eligible.
The initial group ofpositive animals included 50 JSRV positive ewes and the
negative group included 49 JSRV negative ewes. In total 117 lambs were selected for
the prospective survey. It was not possible to include equal number of dams from
the different age groups.
All ewes and lambs, both the negative and positive animals, were part of the same
flock and they were managed together. There was no introduction of new animals
within the flock during the experiment. After May 2003 it was necessary to
reintroduce in the study ewes that were negative or positive in December 2002 and
February 2003 to balance the age and breed composition of the ewes.
The darmoffspring ratio was set in most of the cases at 1, only in few cases more
than one lambs from multiple births were included.
In the lambing period ofMay 2003, blood samples were tested from 24 rams that
generated the offspring obtained in May 2003. At that time the animals were two
years old and they were Suffolk or Texel pure breed.
The tissues from those animals that died during the survey were collected and
subjected to histopathological studies. The survey lasted until May 2004, the ewes
and the lambs were bled every 3-4 months until May 2004.
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4.2.2 Sample handling and JSRV U3 PCR test
Blood was collected, DNA was extracted from fresh PBLs with the Dneasy tissue kit
(Qiagen)) and PCR tests were performed as described in Chapter 3. The performance
of the PCR test was first evaluated in a group of 18 OPA clinical diseased animals, a
group of 50 animals from Iceland and 8 animals from New Zealand (section 3.2.2.2).
The provirus could be detected in all diseased animals. The result obtained was
always negative for the 58 animals from Countries without history ofOPA.
The JSRV U3 PCR test was evaluated under experimental conditions in a total
number of 35 lambs of different ages that had been inoculated i.t. with infectious
lung fluid (Fig.3.7). During the course of the experiment, viraemia was detected
consistently by the PCR test. Viraemia could already be detected at one month after
infection, with the exception of the 6 months old group, in which a delay was
registered for all the lambs in the group. The prognostic value of the test in the
experiment was considerable; in fact viraemia could be detected in all the infected
animals before the onset of the clinical signs.
The aim of the JSRV U3 PCR test in the epidemiological survey was to detect the
viraemia in a flock that had a previous history of OPA, but with no clinical cases at
the time at which the survey started.
The number of blood samples collected for each bleed was considerable and had to
be done in such a way that created minimal disruption to the management of the
flock. For this reason the adopted strategy was to bleed all the animals in one day and
to dedicate the day after the bleed to extract the white cells from all the blood
samples, storing them at -20°C and then during the following days proceed with
DNA extraction. The samples therefore were processed in random order regarding
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breed, age or previous OPA test result. A positive result was assigned where one or
more of the triplicate PCR reactions produced a visible product upon agarose gel
electrophoresis.
4.2.3 Data exploration
4.2.3.1 Collection of the PCR test results
The results for each single test of the ewes and the lambs are summarised in tables
(from Table 4.3 to 4.15) in which the number ofpositive animals related to age and
breed are highlighted.
4.2.3.2 Statistical analysis of the data
A further statistical analysis was necessary to understand which factors could have
influenced the PCR test results. This statistical analysis took into consideration the
data collected for each single bleed and the whole data set. For this purpose the
results from each single test were summarised in Excel format. The data were
analysed with the statistical support from BioSS, UK. The final Excel format
required some manipulation prior to analysis. For example lambs that did not have
any ewe associated with them were removed from the analysis. In addition the data
were checked for missing values, and the column names were standardised. An
example of the working data is shown in Appendix XIII, Table XIII. 1.
First it was calculated for each single bleed of ewes and lambs the number ofnew
JSRV positive animals (JSRV incidence).
The second approach undertaken for the evaluation of the PCR test result aimed to
connect the PCR results over time. In other words it was evaluated which factors
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would influence the fact that an animal in a given time could become positive when
in previous tests it was negative or alternatively in which an animal can become
JSRV negative although in previous tests it was JSRV positive. This kind of
evaluation is called JSRV conditional incidence. This approach took into account the
fact that animals could give fluctuant results during the survey. In statistical terms
JSRV conditional incidence uses the concept of "conditional probability".
Conditional probability calculates the probability of an event occurring given that
another has already occurred (Papoulis, 1984).
The statistical calculation of JSRV incidence included all the sheep being present at
all sampling times; it was relevant that a number of animals were removed from the
sampling group during the study when JSRV incidence was calculated. Summaries
for the calculation of JSRV incidence therefore were restricted to animals which had
a complete set of observations over the study. This was done for removing some
sources of errors in the elaboration of the data.
In contrast a higher number of sheep could be used in the conditional incidence
approach. In fact animals with no missing values plus animals with missing values
that were subsequent to a positive observation where included. Hence when a
missing observation was followed by a subsequent negative it was not assumed that
the missing value was negative; however, where the missing values were after a
positive detection of the virus, the missing value was filled in as positive.
The data were analysed using Generalised Linear Mixed Models (GLMMs) (Brown
& Prescott, 1999). Subsets of data also were analysed using Fisher Exact Test. These
statistical calculations were carried out by Dr I. McKendrick (Bioss) using Genstat
for Windows Version 7.1 (Payne, 2000). Confidence intervals for binomial
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proportions were calculated using the exact procedure defined by Armitage & Berry
(1987).
4.2.4 Collection of fetuses and DNA extraction from foetal tissues
The tissues of 22 fetuses from OPA clinical ewes, that were pregnant at the time of
necropsy, were collected and stored at -70°C. The foetuses were first carefully
removed from the uterus to avoid contamination by maternal blood. Foetal lungs,
thymus and kidney were collected. The ewes were not part of the flock used in the
epidemiological survey, but they were kindly donated by the farmers to the Moredun
Research Institute. DNA was prepared from the collected tissues using Dneasy tissue
kit (Qiagen) and analysed by JSRV U3-PCR as described in Chapter 3.
4.3 Results
4.3.1 JSRV infection in the ewe and lamb groups for each single bleed
The following data consider the population of animals analysed for each single test.
At the beginning of the survey (December 2002) 194 animals were included. The
flock was composed as follows: 96 animals were Milksheep x Suffolk cross breed,
50 animals were Milksheep x Texel cross breed, 48 were Suffolk x Texel cross
breed. 96 animals were 2 years old, 67 were 3 years old, 23 were 4 years old and 8
were 5-7 years old. Sixty of the 194 animals (31%) were positive in the first
sampling (Table 4.3). In February 2003, only 187 ewes could be bled; 80 of thel87
(43%) ewes were JSRV positive (Table 4.3). The increase in positivity occurred in 2
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Table 4.3. Detection of JSRV positive and negative animals in
December 2002 and February 2003.
Bleeds Tot. no. of animals JSRV+ animals JSRV- animals
Dec 2002 194 60(31%) 134(69%)
Feb 2003 187 80(43%) 107(57%)
Table 4.4. Age distribution of JSRV infection at the two sampling
times December 2002 and February 2003.
2 years 3 years 4 years 5-7 years
Dec 02 23/96 14/67 18/23 5/8
(24%) (21%) (78%) (63%)
Feb 03 31/92 27/65 17/22 5/8
(34%) (42%) (77%) (63%)
and 3 years old sheep (Table 4.4). In fact increases ofpositivity of 10% and 21%
were registered in the 2 years and 3 years old group of animals respectively.
In December 2002, 51 out of 98 (52%) animals with Texel genes were JSRV
positive, whereas only 9 of 96 (9%) ewes that did not have Texel genes were
positive.
In February 2003, 48 animals were JSRV positive on a total of 95 (51%) ewes with
Texel genes; 32 of 92 (35%) ewes without Texel genes were JSRV positive (Table
4.5).
Of the 185 sheep that were tested twice, in December 2002 and February 2003, 100
were negative and 50 were positive at both samplings and 35 were positive at only
one of the two (Table 4.6). Seven animals that were positive at the first test were
negative at the second test (Table 4.6).
After the first two bleeds (December 2002 and February 2003) a positive and a
negative group of ewes were selected to proceed with the epidemiological survey
over the following year of the ewes and their female lambs. Female lambs were
selected to enable a long-term study, whereas the male lambs were not retained.
The positive ewes were selected from the animals that were JSRV-positive at least
once in December 2002 and February 2003 tests. The negative ewes were animals
constantly negative in the December 2002 and February 2003 tests. Following this
criterion, in May 2003, 50 positive ewes and their 65 offspring, were bled together
with 49 negatives ewes and their 52 offspring.
When blood was collected in May 2003 the lambs were between 20 -30 days old. At
the May 2003 test the 50 positive ewes remained positive; 14 of their 65 lambs
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Table 4.5. Cross breed distribution of JSRV positive ewes in
December 2002 and February 2003.
Dec 2002 Feb 2003
Crossbreed JSRV+/JSRV-sheep(%) JSRV+/JSRV-sheep(%)
Milksheep x Suffolk 9/96 (9%) 32/92 (35%)
Milksheep x Texel 32/50 (64%) 28/45 (62%)
Suffolk x Texel 19/48 (40%) 20/50 (40%)
Table 4.6. Comparison of results for individual animals over the
December 2002 and February 2003 bleeds.
Dec 2002 Feb 2003 No. animals %
- - 100 54%
+ + 50 27%
+ - 7 4%
- + 28 15%
(22%) were positive; 4 ewes in the negative groups converted to positive (Table
4.7c); 9 of the 52 lambs (17%), were positive (Table 4.7a & b).
Tables 4.7. Summary of the results obtained in the selected positive
and negative cohorts of ewes and their respective offspring in the May
2003 JSRV U3 PCR test.
Table 4.7.a. In May 2003, 50 positive ewes and 65 lambs were bled. Positive results
were confirmed in all the ewes; the presence of positive lambs related to the age and
cross breed status of the mother it is shown between brackets.
AGE
Cross breed 2 years 3 years 4 years 6 years
Milksheep
x
11 ewes 8 ewes
(2+ve lambs) (1+ve lambs)
Suffolk
Milksheep
x 2 ewes 5 ewes 14 ewes 2 ewes








Table 4.7.b. In May 2003, 49 negative ewes and 52 lambs were bled. Between
brackets it is shown the presence ofpositive lambs related to the age and cross breed
status of the mother. Four ewes that were negative in the December 2002 and
February 2003 test resulted positive the May 2003 sampling (Table 4.7.c).
AGE






















Table 4.7.C, Four ewes that were included in the negative cohorts (Table 4.7.b) of the
dams became positive after the May 2003 test. Two lambs, offspring of these ewes
were JSRV U3 PCR positive.
Ewe No. Cross breed Age +ve lambs
12 Milksheep x Suffolk 2 1+ve lambs
24 Milksheep x Suffolk 2
26 Milksheep x Suffolk 3 1+ve lambs
50 Milksheep x Suffolk 2
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A total number of 24, 2 years old rams which were the fathers of the May 2003
offspring were tested in May 2003. Eight out of the 24 rams were JSRV positive.
Five of the 8 positive were pure Suffolk breed and other 3 were pure Texel Breed.
After May 2003, the positive and negative cohorts of dams and their offspring were
tested in September 2003, January 2004 and May 2004.
In September 2003 it was necessary to add other 39 ewes to the survey. The 39 ewes
were already tested in December 2002 and February 2003. This was necessary to
keep the different age and cross-breed groups of ewes balanced enough to carry out
statistical calculation.
In September 2003, 78 of 138 (57%) ewes were JSRV positive. 32 of the 71 (45%)
ewes with non Texel genes were JSRV positive; 46 animals of the 67 (68%) ewes
with Texel genes were JSRV positive (Table 4.8). 33 of the 67 (49%) 2 years old
animals were JSRV positive, 26 of the 50 (52%) 3 years old animals were positive;
19 of the 21 (90%) >4 years old animal were JSRV positive (Table 4.9).
Table 4.8. JSRV positive ewes in the September 2003 test.
The number of positive ewes is given for each different cross-breed group.
September 2003








Table 4.9. JSRV positive ewes arranged by age and cross-breed
according to the September 2003 test results.
The number of JSRVpositive animals is indicated over the total number of ewes for
each age and breed class of ewes.
AGE
2 years 3 years 4 years > 5 years
Cross-breed
Milksheep x 17/37 15/33 0/1
Suffolk
Milksheep x 5/6 7/12 13/14 5/5
Texel
Suffolks x 11/24 4/5 1/1
Texel
In January 2004, 69 of 124 (56%) ewes were JSRV positive. 27 of the 69 (39%)
Milksheep/Suffolk cross-breed ewes were JSRV positive; 42 of the 55 (76%) ewes
with Texel gene were JSRV positive (Table 4.10). 22 of the 58 (38%) 2 years old
animals were JSRV positive; 30 of the 48 (63%) 3 years old ewes were JSRV
positive and 17 of the 18 (94%) >4 years old animals were JSRV positive (Table
4.11).
Table 4.10. JSRV positive ewes in the January 2004 test.
The number of positive ewes is given for each different cross-breed group.
January 04 test
Cross-breed JSRV+/ total No. of ewes
Milksheep x Suffolk 27/69
Milksheep x Texel 33/33
Suffolk x Texel 9/22
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Table 4.11. JSRV positive ewes arranged by age and cross-breed
according to the January 2004 results.
The number of JSRVpositive animals is indicated over the total number of ewes for
each age and breed class of ewes.
AGE
2 years 3 years 4 years > 5 years
Cross-breed
Milksheep x 12/36 15/32 0/1
Suffolk
Milks xTexel 6/6 11/11 14/14 2/2
Suffolks x 4/16 4/5 1/1
Texel
In May 2004, 106 ewes were bled; 47 (44%) were JSRV positive (Table 4.12).
12 of the 53 (23%) Milksheep x Suffolk cross-breed were JSRV positive. 35 of the
53 (66%) ewes with Texel genes were JSRV positive (Table 4.12). For one of the
milksheep x Suffolk cross breed the age could not be identified. In May 2004 only
49 of the initially 2 years old ewes could be bled, 19 of which were JSRV positive,
corresponding to 39%; 15 of the 43 (35%) 3 years old ewes were JSRV positive;
only 13 animals that at the beginnning of the survey were >4 years old could be
tested, all of them were JSRV positive (Table 4.13).
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Table 4.12. JSRV positive ewes in the May 2004 test.
The number of positive ewes is given for each different cross-breed group.
May 04 test
Cross breed JSRV+/ total No. of ewes
milksheep x Suffolk 12/53
milksheep x texel 24/29
Suffolk x texel 11/24
Table 4.13. JSRV positive ewes arranged by age and cross-breed
according to the January 2004 results.
The number of JSRVpositive animals is indicated over the total number of ewes for
each age and breed class of ewes.
Cross breed
AGE
2 years 3 years 4 years > 5 years
Milksheep x 7/23 5/29 0/0
Suffolk
Milksheep x 2/5 9/11 9/9 4/4
Texel
Suffolks x 10/21 1/3 0/0
Texel
In summary the ewe population after May 2003 had a percentage ofpositive animals
of 57% and 56% in September 2003 and January 2004 respectively; in May 2004 the
percentage ofpositive animals decreased to 44% (Table 4.14).
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Table 4.14. Percentage of JSRV infected ewes examined at 3-5 months
intervals, until May 2004.






September 2003 138 78 57%
January 2004 124 69 56%
May 2004 106 47 44%
In May 2003 a group of 117 lambs was chosen for the longitudinal survey. 23 of 117
(20%) lambs were JSRV positive. In September 2003, 54 of 114 (47%) lambs were
positive. In January 2004, 110 lambs of the original group could be tested and the
number of JSRV positive lambs increased to 65 (59%). In the following May 2004
test, 42 of the 100 lambs were tested JSRV positive. In May 2004 the percentage of
positivity dropped to 42% (Table 4.15). The lambs results were subjected to further
statistical analysis. The aims were to explore:
- if the positivity of the mother could influence the positivity of the lambs;
- if there were any other factors such as age and breed of the mother that could have
influenced the test results in the lambs.
During the statistical survey period clinical OPA was not detected in the ewes or in
the lambs.
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Table 4.15. Percentage of JSRV infected lambs examined at 3-4 months
intervals, from May 2003 until May 2004.






May 2003 117 23 20%
September 2003 114 54 47%
January 2004 110 65 59%
May 2004 100 42 42%
4.3.2 Statistical analysis of the ewes and lambs data
The data from ewes and lambs were collected in a working dataset as shown in
Appendix XIII (Table XIII. 1).
JSRV incidence was calculated for the lambs and the ewes that were present at all
sampling times.
JSRV conditional incidence was calculated for the lambs and the ewes including
either animals with a complete record or animals with a missing test result, where the
missing test result was subsequent to a positive observation.
4.3.2.1 JSRV incidence in the ewe population
Fifty- five ewes had a record with no missing tests. Confidence intervals were
calculated using the exact formula for the binomial confidence interval (CI). In
December 2002, 23 of 55 ewes with a complete record were tested positive; in
February 2003 the number of JSRV positive animals increased to 32. In May and
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September 2003, 35 animals were JSRV positive by PCR. In January 2004, 42 ewes
were JSRV positive. In May 2004, 30 animals were JSRV positive.
JSRV fractional prevalence (n. of JSRV positive animals/ total n. of animals, for
each test date) and the associated 95% confidence intervals were calculated (Table
4.16) and the results are represented in Fig. 4.2. From December 2002 to January
2004 a gradual increase in the number ofpositive animals was noticed; in the May
2004 test a decrease of the number of JSRV positive animals was observed.
4.3.2.2 JSRV conditional incidence in the ewe population
In the list of animals for the calculations of JSRV conditional incidence 83 ewes
were included. These animals had a result record either with no missing values or
with missing values that were subsequent to a positive observation (Table 4.17). In
this calculation a greater number of ewes could be included for each single test. The
fractional prevalence of JSRV positive animals was calculated for each single bleed
These prevalences, and the associated 95% confidence intervals, are presented in the
Fig. 4.3.
The data expressed in Table 4.17 can be analysed further to give an idea of the
population of ewes at risk ofbecoming JSRV positive after each sampling (Table
4.18). The animals at-risk were defined as those animals not observed as positive up
to and including the previous sampling occasion; then it was considered JSRV
incidence rate at the sampling occasion, this was given by the number ofnew JSRV
positive animals. In these data the first month of the study (December 2002) was not
included because it was not possible to estimate the at-risk population.
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Table 4.16. JSRV incidence in the ewe population that had a complete sampling
record.
The incidence of JSRV infection was calculated taking in account 55 ewes that were present
at all the sampling times. The number of JSRV positive ewes for each test, the fractional
prevalence and the corresponding confidence intervals were calculated. Analysis of the
pattern of incidence was done using a generalised linear model, with a binomial response











Dec-02 55 23 0.31
Feb-03 55 32 0.45
May-03 55 35 0.51
Sep-03 55 35 0.51
Jan-04 55 42 0.62
May-04 55 30 0.47
Fig. 4.2. JSRV infection in the ewe population that had a complete sampling record at
different times.
JSRV incidence in each bleed was expressed as fractional prevalence. Fractional prevalence
was expressed in the graph associated with 95% confidence intervals (CI).
Table 4.17. JSRV cumulative incidence in the ewe population that had either a
complete sampling record or missing values subsequent to a positive observation.
83 animals included ewes with either no missing values or with missing value where missing
values were subsequent to a positive observation. After each test the number of JSRV
positive animals was recorded. Confidence intervals (CI) were calculated using the formula









Dec-02 83 31 0.37
Feb-03 83 52 0.63
May-03
83 56 0.67
Sep-03 83 60 0.72
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Month of sample
Fig 4.3. JSRV conditional prevalence in the ewe population that had either a complete
sampling record or missing values subsequent to a positive observation.
83 animals included ewes with no missing values and ewes with missing value where
missing values were subsequent to a positive observation. After each test the number of
JSRV positive animals was recorded. Confidence intervals (CI) were calculated using the
formula for the binomial CI.
Table 4.18. Incidence rates of new JSRV positive ewes after the first test (December
2002).
The animals at-risk were defined as those animals not observed as positive up to and
including the previous sampling occasion; the JSRV incidence rate at the sampling occasion
was given by the number of new JSRV positive animals in the following test. Data from
December 2002 were excluded because was not possible to have an estimate of the at-risk
animals.
Date At-Risk Animals







Fig. 4.4. Estimated JSRV incidence rate in the ewe population in
February 2003 and in the later periods.
The incidence rates of new JSRV positive animals in February 2003 and in
the later months were estimated and the 95% confidence intervals were
generated.
In February 2003 the estimated incidence rate for the previous period
corresponded to an incidence of 0.26 new observed JSRV positive animals
per susceptible animal. In the later months, the estimated incidence rate
corresponded to an incidence of 0.05 new observed JSRV positive animals









Feb-03 May-03 Aug-03 Nov-03
Month of Sample
Feb-04 May-04
Fig 4.5. Estimation of the mean probability of observing JSRV positive
cases related to the lambing period.
The results obtained from the May 2003 and 2004 bleeds were considered
as belonging to the post-lambing period. The January, February and
September observations were considered as pre-lambing period. The data
collected in the pre-lambing and post-lambing periods were subjected to
"generalised linear mixed model" analysis.
There was statistically significant evidence that the incidence rate of positive
observations was significantly higher among the ewes immediately prior to
lambing relative to the rates seen at other times (p=0.04).
The incidence rates for every month after the February 2003 were statistically
significantly lower than that for February 2003 (t=5.1, p<0.001). However there was
no evidence of any significant differences between the incidence rates observed in
the subsequent months. In February 2003, the estimated incidence rate for the
previous period corresponded to an incidence of 0.26 new observed JSRV positive
animals per susceptible animal. In the later months, the estimated incidence rate
corresponded to an incidence of 0.05 new observed JSRV positive animals per
susceptible animal per month (Fig 4.4).
It was then explored the possibility to associate the analysis of the incidence rates of
JSRV positive animals with particular physiological state of the ewe; the more
obvious situation to consider was the lambing period. Hence, the May 2003 and
2004 observations were considered as belonging to the post-lambing period, and the
January, February and September observations were considered as pre-lambing
period. There was statistically significant evidence that the incidence rate ofpositive
observations was significantly higher among the ewes immediately prior to lambing
relative to the rates seen at other times (p=0.04) (Fig.4.5).
The consecutive set of results in the ewe population were evaluated to investigate the
incidence of a positive observation conditional on the previous month having given
rise to a negative observation.
The data across all the subsequent months were analysed together, and for each
observation in the data set was also recorded whether any of the previous
observations had been positive, for each ewe was taken in account the age and the
cross-breed. The incidence of JSRV positive animals conditional on the previous
month having given rise to a negative observation was not dependent on the effect of
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the breedline, age or negative result in the previous test. These factors were not
statistically significant.
Then it was investigated the incidence of observing a PCR negative result
conditional on the previous month having given rise to a positive observation. As in
the previous analysis all the subsequent months were analysed together and for each
ewe the age and the cross-breed were considered. It was noticed that only the group
of ewes which were aged 4/Texel breedline/non-Suffolk breedlines exhibited a
higher mean probability (p<0.001) of remaining positive on consecutive samples.
4.3.2.3 JSRV incidence in the lamb population
JSRV incidence was calculated taking into account 72 lambs that registered a
complete record over the study. The confidence intervals were calculated using the
exact formula for the binomial CI. In May 2003, when the lambs were 20-30 days
old, 21 animals out of 72 gave JSRV positive results. The number of positive lambs
increased in September 2003 when 41 animals were JSRV positive. In January 2004,
44 out of the 72 lambs were JSRV positive. In May 2004, the number of JSRV
positive lambs dropped to 31 out of 72 (Table 4.19). Confidence intervals were
calculated using the exact formula for the binomial CI. The prevalences for each
sampling date and the associated 95% confidence intervals were represented in Fig.
4.6. In Sep-03 there was a statistically significant increase of JSRV positive animals
compared to May-03 (p<0.01). In May-04 the number of JSRV positive animals was
statistically significantly lower than that for the Sep-03 period (t=2.1, p=0.03).
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Table 4.19. JSRV incidence in the lamb population that had a complete
sampling record.
72 lambs were present at all sampling times. The number of JSRV positive
lambs for each test, the fractional JSRV prevalence and the corresponding
confidence intervals were calculated. In Sep-03 there was a statistically
significant increase of JSRV positive animals compared to May-03 (p<0.01). In
May-04 the number of JSRV positive animals was statistically significantly lower
than that for the Sep-03 period (t=2.1, p=0.03).
Test Date N. of lambs with a JSRV positive JSRV fractional prevalence
complete record lambs
May- 03 72 21 0.29
Sep-03 72 41 0.57
Jan-4 72 44 0.61




















Fig 4.6. JSRV infection in the lamb population at different sampling times.
JSRV incidence for each test was expressed as JSRV fractional prevalence.
The JSRV fractional prevalence was expressed in the graph associated with
95% confidence intervals.
4.3.2.4 JSRV conditional incidence in the lamb population
The lamb population was further analysed for the evaluation of JSRV conditional
incidence. Eighty-two lambs had a sufficient record to be included in the analysis.
The number of JSRV positive animals was registered for each sampling time (Table
4.20) and the associated 95% confidence intervals were calculated. The JSRV
fractional prevalence for each single test and the associated 95% CI were represented
in Fig. 4.7.
The data in Table 4.20 were analysed and converted to provide a table of population
at-risk (lambs not observed as positive up to and including the previous sampling
occasion) and the incidence of new JSRV positive cases observed at the sampling
occasion (Table 4.21). The estimates of new JSRV positive cases for each month
were reviewed; the incidence rates for month May 2004 were statistically
significantly lower than that for the initial months (p=0.04) (Fig.4.8). However,
there was no evidence of any significant differences between the incidence rates
observed in the first two months.
These estimates of new JSRV cases in the earlier months and in May 2004 were
converted to incidence rates and 95% confidence intervals were generated (Fig. 4.8).
In September 2003/January 2004, the estimated incidence rate corresponded to an
incidence of 0.18 new observed infections per susceptible animal per month. In May
2004, the estimated incidence rate corresponded to an incidence of 0.04 new
observed infections per susceptible animal per month.
The presence of a mother with Texel breedline was associated with a marginally
higher chance of the lamb being observed to convert to positive but this effect was
not close to statistical significance. The positivity of the mother was associated with
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Table 4.20. JSRV cumulative incidence in the lamb population that had
either a complete sampling record or missing values subsequent to a
positive observation.
82 lambs had either a complete record or a missing value subsequent to a
positive observation. The number of JSRV positive cases was reported for each










prevalence 95% Confidence Interval
May-03 82 26 0.32 0.218652842 0.429156
Sep-03 82 55 0.67 0.558141419 0.770579
Jan-04 82 68 0.83 0.730163982 0.903395
May-04 82 70 0.85 0.758320584 0.922032
Table 4.21. Incidence rates of new JSRV positive lambs after the first test
(May 2003).
The animals at-risk were defined as those lambs not observed as positive up to
and including the previous sampling occasion; the JSRV incidence rate at the
sampling occasion was given by the number of new JSRV positive animals in
the following test. Data from May 2003 were excluded because was not
possible to have an estimate of the at-risk animals.
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Fig 4.7. JSRV conditional incidence in the lamb population that had either
a complete sampling record or missing values subsequent to a positive
observation.
82 lambs were included. The 82 lambs had either a complete record or a
missing values subsequent to a positive observation. The number of JSRV
positive cases was reported for each sampling time; JSRV fractional prevalence













Fig. 4.8. Estimated JSRV incidence rate in the lambs population in earlier
month and in the last sampling time (May 2004).
The incidence rates of new JSRV positive lambs in the earlier months
(September 2003 and January 2004) and in the later month (May 2004) were
estimated and the 95% confidence intervals were generated.
The incidence rates for May 2004 are statistically significantly lower than that
for the initial months (p=0.04).
a higher risk of the lamb converting to positive, but none of these effects was
statistically significant (p= 0.7-0.8). The results were consistent with the hypothesis
that animals with Texel mothers became positive earlier in time, more quickly, than
those born to non-Texel line ewes, but this result was not formally statistically
significant (p=0.28).
The lamb data were elaborated analysing the incidence of negative observations
conditional on previous observations being positive. There was no evidence that
factors which influenced the mothers affected the lambs in the same way.
It was significant that a prior observation of a positive sample in the lamb made it
more likely that subsequent samples were positive (p=0.005).
The estimates for the probabilities of remaining positive were consistently lower in
the lambs than in the ewes, for each of the sampling months.
Statistically significant differences in the incidence probabilities were registered in
different months (p=0.003): there was clear evidence of a down wards trend in the
probability, similar to that seen in the ewes.
The positive JSRV status of the mother considered over the whole study was
associated with a higher probability of the lamb remaining positive, but did not give
a statistically significant value.
4.3.3 PCR analysis of the foetal tissues from OPA diseased sheep:
results
In total 14 foetuses were collected (Table 4.22) from 8 ewes (A-H). It was not
possible to collect blood samples from ewes A, D and H. Foetal lung tissue was
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tested for all the 14 collected foetuses. From some of the fetuses (Al, El, E2, Fl,
G1,H1 and H2) kidney and/or thymus tissues were collected.
The lungs from six fetuses were positive by PCR. In lambs Gl, HI and H2 when the
lung tissue was positive the kidney or thymus tissues also were positive (Table 4.22).
Table 4.22. JSRV U3 PCR analysis of foetal tissues collected from OPA
diseased ewes.
A,B,C,D,E,F,G,H indicates the mothers of the collected fetuses. All the ewes except E ewe
were positive for OPA after clinical and histopathology examinations. Ewes B,C,E,F,G were
positive for JSRV provirus by PCR from the blood. Lung tissue could be analysed for all the
14 fetuses. Thymus and kidney could be collected only from 4 and 2 fetuses, respectively.
ND=not done. Fetuses were collected approximately between the second months and the














































+ + F1 neg ND neg
+ + G1 pos ND pos
+ ND H1 pos pos ND
H2 pos pos ND
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4.4 Discussion
This longitudinal survey represents the first example of a longitudinal molecular
epidemiology survey for JSRV, in a flock of about 200 ewes and related offspring
over 2 years of study.
Using the JSRV U3 PCR on blood, the flock tested for JSRV infection showed a
high proportion of infected animals in Dec 2002. In fact at this time 60 (31%) of the
194 ewes were positive. Three months later the percentage of positive animals
increased by 12% (Table 4.3). After the second test (February 2003), 80 of 187
(43%) tested ewes were positive. The high incidence of the initial December 2002
sample represents a long-term build-up of infection over the lifetime of the animals.
The flock had a long history ofOPA clinical cases although during the survey
clinical OPA cases were not observed. The owner adopted the policy to promptly
cull animals that had OPA signs. In the two years prior to the beginning of the
survey, animals with OPA clinical signs were not noticed. It can be challenging
doing ante mortem diagnosis ofOPA if the tumour is not in an advanced state of
development. Disease signs may be influenced by concurrent infections which may
vary with different geographic areas and management practices. Longitudinal small
studies in flocks with endemic OPA have shown that losses due to OPA can vary
between 2% and 10% annually and at necropsy the tumour can be demonstrated in
approximately 30% of the breeding sheep (Martin, unpublished data; Sharp & De las
Heras, 2000). The flock under study had 60 of 194 and 80 of 187 infected ewes in
December and February respectively without showing clinical signs. This situation
shows that despite the high rate of infection in the flock the disease develops slowly.
The fact that a high percentage of ewes and lambs in the study are JSRV viraemic
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without clinical disease support the hypothesis that JSRV is a slow transforming
retrovirus. The development of the clinical signs could be due to other factors such as
co-infections, management practices, genetic factors and viral load such as for other
small ruminant lentivirus infections (Peterhans et al., 2004).
At the end of the experiment presented in this thesis, the animals will be culled. The
necropsy of the ewes and of the lambs represents a crucial moment for evaluating the
prognostic value of the JSRV U3 PCR in the field.
The JSRV U3 PCR showed its reliability during the survey. In fact from the results
of the December 2002 and February 2003 tests, 50 animals of the ewe population had
their JSRV positivity confirmed, 28 animals became JSRV positive, 100 animals
stayed negative in both sampling time; seven animals were positive in December
2002 and tested negative in February 2003 (Table 4.6). The switching from positive
to negative of the seven animals could be due to a variable amount of virus in the
blood; the fluctuating positivity has been observed already in other studies (Garcia-
Goti, 1999; Gonzalez et al., 2001) and it can be due to a low viral load.
The trend of JSRV infection in the ewes showed an increase in the number of
positive ewes until the May 2004 test (Table 4.14). The results collected in February
2003 showed a higher level of incidence (p=0.04) that can be interpreted as a residual
effect arising from the use of a PCR test with less than 100% sensitivity on a
population with well established infection. When this test was applied in the field
situation and the target was not OPA diseased animals but JSRV infected sheep, the
sensitivity and specificity can be considered below 100%. In the experimental
infection of lambs of different ages the test was able consistently to detect viraemia
before the onset of the clinical signs. This may be due to the high infectious dose
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used in the experimental infection described in Chapter 3. The low viral load in
blood is a major challenge for small ruminant lentiviruses detection. In addition, as
shown in goats experimentally infected with CAEV and in sheep infected with
MVV, the viral load may fluctuate over time and may differ between individual
animals (Juste et al., 1998; Greco et al., 2002; Peterhans et al., 2004).
A further step in the pathogenesis of OPA would be the investigation of viral load
during natural and experimental JSRV infection. JSRV DNA and JSRV RNA in the
lymphoid tissue and in the PBMC can be quantified by Real-time PCR (Niesters,
2002). Qualitative PCR provides no useful quantitative assessment of the infection
level or disease progression and does not indicate pathogen replication. The ability to
quantify using PCR can offer insights into the molecular pathogenesis of an
infection. Quantification using Real-time PCR is rapid, accurate, with smaller risk of
contaminations, and can provide an absolute determination of the number or copies
of the targeted DNA. A reliable method for PCR quantification is by competitive
PCR (Stocher & Berg, 2002). This technique utilises a known amount of engineered
internal standard which has the same primer binding sites as the target DNA or RNA.
The internal standard is differentiated from the target on the bases of size by
inclusion of a small deletion, or by including a single base mutation that allows
separation after restriction enzyme digestion. Since the target DNA and internal
standard are virtually identical, the efficiency of amplification should be equivalent,
leading to a fair competition when co-amplified and an accurate measurement of the
relative concentrations (Heid et al., 1996; Gerard et al., 1998). This eliminate tube-
to-tube and template variability.
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JSRV was detected more frequently in the animals that were 4 -7 years old (Tables
4.4, 4.9, 4.11; 4.13). In the 4-7 age group the percentage of JSRV positive ewes was
74% in December 2002 when the survey started and reached 100% in May 2004. The
4-7 year old ewes were consistently JSRV positive during the survey. This indicates
that 4-7 year old animals had already established a detectable and constant level of
viraemia when the survey started. For this group of animals the viral load remained
over the detectable limit by PCR during the six JSRV PCR test. Natural disease has
been usually observed in animals that are around 4 years of age; probably certain
level of viraemia is a requisite for developing disease. For example a high HTLV-I
proviral load is also associated with an increased risk of progression to disease
(Barmak et al., 2003).
In the 2 and 3 year old ewes the percentage of JSRV positive animal increased
progressively until January 2004. In December 2002, 24% of the 2 years old 21% of
the 3 years old were JSRV positive. In the second test (February 2003) the
percentage of JSRV positive animals increased by 10% and 21% in the 2 and 3 years
old group of animals respectively; in the following tests the increase of JSRV
positivity was between 10 and 15%. In January 2004 only in the 2 years old group of
ewes there was a 9% decrease of JSRV positive animals. The increased JSRV
positivity from December 2003 and excluding May 2004 describe a built up of
infection in the 2 and 3 years old of animals (Table 4.14). Negative and positive
animals were managed together during period of this study, so it is possible that more
animals were becoming JSRV positive because of an intra-flock transmission of the
infection. Sheep of all ages could have acquired infection from direct and indirect
contact with aerosols and lung secretions containing the virus. For example
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horizontal transmission of MVV between adult sheep can be efficient (Berriatua,
2003).
In May 2004 the percentage of positive animals in the 3 years old group diminished
by 28%. The same downwards trend regarding the percentage of JSRV positive
animals could be observed in the lamb population (Table 4.15). The decreased JSRV
positivity in the 2 and 3 years old ewe groups can be explained by the fact that the
number of animals of these age groups included in the survey diminished especially
in May 2004. In fact 96 of the 2 years old animals and 67 of the 3 years old animals
were present in December 2002 test. In May 2004 the group of the 2 years old ewes
was composed of 49 animals, and the group of 3 years old ewes was composed of 67
animals. Because the number of JSRV positive ewes and lambs in May 2004
decreased, other possible factors could have influenced the diagnostic test were
investigated. After careful analysis, no difference could be found between the
procedures adopted in May 2004 and those adopted in the previous tests.
JSRV was detected more frequently in animals with Texel genes. The percentage of
JSRV positive animals was always higher in the animals with Texel genes than in the
animals with non-Texel gene after each single test. The possibility of a Texel breed
susceptibility was further analysed by statistical methods. Indeed the analysis of
December 2002 and February 2003 highlights that the Texel breedline was
associated with statistically significantly higher prevalences (p<0.001) over years 2
and 3, and a further statistically significant increase in year 4 and 5-7. It was
noticeable that the statistical analysis of the consecutive test results showed that
animals which were aged 4, Texel breedline, non Suffolk breedline exhibited a
higher mean probability (p<0.001) of remaining positive on consecutive samples. In
- 168-
animals of other ages and without Texel genes, the prior observation of a positive
result made the animal more likely to be positive in the subsequent samples
(p<0.001). Lambs with Texel breedline had a higher incidence of JSRV positive
cases although it was not statistically significant (p=0.67). One explanation for the
lack of statistical significance after the first two PCR tests was that the number of
animals with Texel breedline was too low in the following tests.
The presence of Texel genes in the mothers influenced to a certain extent the JSRV
positivity in the lambs. In fact, in May 2003 lambs with mothers that at the beginning
of the survey were aged 4 -7 with Texel breedline had a higher JSRV prevalence
although this result was not statistically significant (p=0.65). The lambs with mothers
with Suffolk breedline had a lower prevalence (p=0.56). Lambs with Texel mothers
were detected as JSRV positive earlier than those born from ewes without Texel
genes. It is important to underline that the studied samples of each breedline are
small and therefore may be influenced by the particular susceptibility to the disease
of a certain family within the breed.
The possible involvement of a genetic factor that could influence the extent of
infection and the outcome of the disease is an important finding of this study and it
will deserve further future investigations. Susceptibility to infectious diseases and
retroviral infections is influenced by the genetic background of the host. For example
in scrapie, the fact that a genetic predisposition for this disease exists in sheep
suggested that genetic selection could be helpful in the control and eradication of
clinical disease within flocks (Hunter et al., 1997; Baylis et al.,2004). The
devastating visna maedi epidemic in Iceland reflected differences in the
susceptibilities of Icelandic sheep and European breeds (Petursson, 1994).
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Differences in breed susceptibility to MVV have been reported (Houwers et al.,
1989). Iceland breeds appear to be more susceptible than British breeds and Texels
and Border Leicester are more susceptible to disease than Columbia sheep (Cutlip et
al., 1986; Joag et al., 1996). Snowder et al., (1990) determined significant
differences in the seroprevalence of MVV between 6 breeds comprising a flock of
2,976 sheep. Nevertheless, complete breed-associated resistance has not been
demonstrated and some authors suggest that apparent susceptibility may also depend
on the viral strain (Houwers et al., 1989).
Molecular biology genotyping techniques have become an every-day tool to solve a
number of issues in the fields of detection and diagnosis of human and animal
diseases (Rappuoli, 2004). Recent progress in cancer genetics has identified specific
loci that are involved in cancer progression, many of which have key roles in DNA
repair, cell-cycle control and cell-death pathways. Recent genetic studies and
quantitative population-genetic analyses provide a framework for understanding the
frequency of inherited mutations and the consequences of these mutations for
increased predisposition to cancer (Frank, 2004). A larger epidemiological survey
will be necessary to investigate a possible genetic predisposition to OPA. The survey
should include a significant number of flocks of different breeds distributed in
representative areas.
Another important finding regarding the features of JSRV infection was the
statistically significant evidence that the incidence rate of JSRV positive ewes was
higher among the ewes immediately prior to lambing relative to the rates seen at
other times (Fig. 4.5). The immune system can play a role in the fluctuation of
positive results investigated in the ewe population.
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Pregnancy influences the cytokine balance even in the case of infectious diseases in
the maternal periphery (Entrican, 2002a & b). For example experimental infection of
pregnant mice with the protozoan parasite Leishmania major does not result in
placental invasion by the parasite, the infection stays in the peripheral blood.
However, the pregnancy influences the quality of maternal immune response and in
this particular case affects the outcome of the pregnancy. In non pregnant mice the
host is able to generate a Th-1 type inflammatory response mediated by IFN-y.
Pregnant mice infected with Leishmania major differ from non-pregnant controls in
developing larger cutaneous lesions and harbouring more parasites. They also show
an increased production of IL-4, IL-5 and IL-10 and a reduced production of IFN-y
when compared with infected non-pregnant controls (Krishnan et al, 1996).
This study for the first time proved that JSRV infection happens very early in life. In
fact PCR results on blood samples from 117 lambs that were 20-30 days old (in May
2003) showed that 23 animals (20%) were JSRV positive. Nine of the 23 positive
lambs were the offspring of the JSRV negative group of ewes; the remaining 14
positive lambs were the offspring of the JSRV positive group of ewes (Table 4.7a &
4.7b). Because lambs were found infected so early in their life it is possible to
presume the vertical route plays an important role in the transmission of the
infection. During this study 6 of the 14 analysed fetuses were JSRV positive by PCR.
These data suggest that the fetuses can be exposed to JSRV infection. This is
evidence in favour of intrauterine/transplacental route of transmission.
The outcome of the statistical analysis on these data supported horizontal
transmission as a route of infection. Firstly, having a positive mother was not a
statistically significant factor for a lamb to be positive. Secondly, the increase in
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JSRV positive samples in the second test in both the lamb and ewe populations, is
probably due to horizontal transmission. The fact that the positive ewes were
managed together with negative could have represented a risk factor for the newborn
lambs.
Horizontal transmission for OPA has been demonstrated by many studies. OPA was
transmitted by cohabitation of healthy with diseased sheep already in 1929 by de
Kock, 1929. This was repeated by Dungal (1946) in Iceland, who housed non
diseased sheep with diseased sheep. Dungal also proved that exhaled respiratory air
of an affected sheep contained the infectious agent. In one experiment a diseased
sheep was made to breathe through a 20% solution of glycerine in normal saline for
30 minutes. The injection of this mixture by intra tracheal and intrapulmonary routes
in lambs caused the development of the disease (Dungal, 1946).
The separation of the JSRV positive ewes from the JSRV negative ewes and the
complete separated management of the two groups and their respective offspring
could help to clarify if the infection of lambs from negative ewes is due to co¬
habitation with JSRV infected ewes.
It was investigated, taking in account the overall results, whether a ewe's current and
cumulative positive JSRV infection status were associated with a higher risk of the
lamb converting to positive. It was found that a lamb had a higher risk of converting
to positive and staying positive if the mother was JSRV infected, but it was not
statistically significant (p in the range 0.7-0.8).
The finding of JSRV positive fetuses in this study were consistent with a previous
study by De las Heras et al. (2000) in which tissues and blood were collected from
five fetuses from 2 Spanish ewes and 4 fetuses from 2 Scottish ewes. The ewes had
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OPA confirmed by histopathology. PBLs and lung tissues from the fetuses were
analysed. JSRV was detected by PCR in the lungs of 4/5 foetuses from one Spanish
ewe and in PBMCs from two foetuses from one of the Scottish ewe.
Previous experiments showed that OPA transmission could be prevented by embrio-
transfer (Parker et al., 1998). Two-hundred-and-fifteen embryos recovered from 76
donor ewes from flocks endemically infected with OPA, and mated with uninfected
rams, were transferred to 131 uninfected recipients under strict sanitary conditions,
using International Embryo Transfer Society protocols. The recipients and their
progeny were kept in a closed, isolated OPA-free flock. Thirty-eight of 51 progeny
from OPA-positive donors and 55 of 74 progeny from donors in which no lesions of
OPA were detected survived for at least five years after birth. No evidence of OPA
was found in the recipients or their progeny by embryo transfer (Parker et al., 1998).
This protection offered by embryo transfer can be due to the fact the embryos are
usually recovered 1-5 days after mating (Kiessling et al., 1986). This can be a very
short period for allowing the development of the infection in the embryo. Moreover
it has been proved that the zona pellucida appears to provide an effective physic
barrier protection to infection of embryos (Sinowatz et al., 2001). Recently, it has
been demonstrated that 8-16 cell (stage of) caprine embryos can be infected in vitro
with CAEV if the zona pellucida is removed but not if the zona pellucida is intact
(Lamara et al., 2002). The fetuses analysed in this thesis and the fetuses in the
Spanish study were collected during the late stage ofpregnancy.
Further experiments involving separation of newborn lambs from infected ewes
immediately after birth will be necessary for establishing more evidence for vertical
transmission. A certain number of the ewes involved in the epidemiological survey
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described in this chapter will be culled before May 2005 and examined for gross and
histological evidence of OPA lesions. It will be important to obtain foetuses from
positive and negative dams. The foetuses will be carefully removed from the uterus
to avoid contamination by maternal blood. PBLs from cardiac blood, lung and
thymus will be obtained and analysed for JSRV. The foetal lungs will be examined
for presence of tumour lesions by histopathology.
It is possible that both horizontal and intrauterine/transplacental can happen for
JSRV transmission; the built up of JSRV infection in the ewe and lamb population
can be due to horizontal transmission. In SRLV infection the issue of whether
intrauterine infection occurs has been addressed in several studies and is still the
most controversial route of transmission (Blacklaws et al., 2004).
In this study 8 of the 24 rams (fathers of the May 2003 offspring) were JSRV
positive. The role of JSRV infected rams for breeding to uninfected ewes requires
further investigations. Transmission of infection via semen in OPA has not been
studied yet.
Milk transmission has been well described and has a central role for small ruminant
lentivirus infection (Sihvonen, 1980). Transmission of infection from the mother to
the offspring via milk is a central point in the pathogenesis of other retroviral
infections such as MLV, MMTV and HTLV-1 (Gardner et al., 1991; Acha-Orbea &
MacDonald, 1995; Cann & Chen, 1996). Further studies are necessary to investigate
if JSRV has tropism not only for the epithelial cells of the lung but alaso for
mammary epithelial cells.
It was statistically significant in the lamb population that a prior observation of a
positive sample makes the animal more likely to be positive in subsequent samples
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(p=0.005). The estimates for the probabilities of remaining positive were consistently
lower in the lambs than in the ewes, for each of the sampling months. This situation
can be explained by the younger age of the lambs.
The JSRV U3 PCR gave consistent results along the course of the study. The
presence of JSRV provirus in PBMCs represents a crucial point in JSRV
pathogenesis. In experimentally infected lambs, JSRV proviral DNA could be
detected in lymphoid cells as early as 7 d.p.i. when no histological signs of SPA were
present (Holland et al., 1999). Palmarini et al., (1996b) found consistently JSRV
proviral DNA and RNA in the mediastinal lymph nodes of OPA affected animal. In
addition RNA was found in the spleens, in the bone marrows, in the thymuses and in
the PBMC of naturally affected animals. As for other retroviral diseases the infection
of lymphoid tissues can play a central role in the pathogenesis.
The role of macrophage and dendritic cells in the lung could be crucial for the
establishment of the persistent and latent infection in the lymphoid tissue. For
example it is now accepted that the major viral reservoir during asymptomatic HIV
infection is lymphoid tissue (Pantaleo et al., 1991; Pantaleo et al., 1993; Embretson
et al., 1993; Blacklaws, 1997).
Present OPA knowledge is unable to explain the interaction between JSRV and
immune system. JSRV provirus is present in PBMC after one week from JSRV
experimental infection and until the animal will not present clear clinical signs of
OPA. Holland et al., (1999) showed that the provirus was present in macrophages.
The interaction between the macrophages and the immune system could explain the
fact that the virus is fluctuant in the blood.
- 175 -
Macrophages are a crucial component of the innate and adaptive immune system and
control several cell-mediated immune responses (Pierson et al., 2000; Khati et al.,
2001). Macrophages are the target of HIV (Yi et al. 1998) and, since they are
resistant to the cytopathic effects ofHIV infection, they play a significant role in
spreading the virus through the body contributing to AIDS pathogenesis (Gordon et
al., 1995). Since chronically infected macrophages allow the virus to escape
detection by the immune surveillance system, they are recognised as a sanctuary of
HIV and one of the main reservoirs in HIV infection (Mazzucchelli et al., 2004).
Macrophages that are centrally involved in both the innate and adaptive arms of the
immune system are not only the main target of the human immunodeficiency virus
(HIV), but also its main reservoir and vehicle of transmission. Macrophage-tropic
(M-tropic) viruses are responsible for the initial infection, asymptomatic phase and
persistence (Verani et al., 2005). Functional impairment ofHIV-infected
macrophages plays a role in the immune dysregulation characteristic of acquired
immunodeficiency syndrome (AIDS) (Herbein et al., 2002). Efforts directed at
understanding the cellular and molecular mechanisms underlying HIV-macrophage
interactions remain the basis for devising novel and efficacious therapeutic strategies
against HIV ant the AIDS epidemic (Khati et al., 2001).
An interesting feature of OPA-affected animals is the increased numbers of
macrophages in the lungs, and it is this cell type which contains the greatest proviral
burden (Verwoerd et al., 1985; Jassim et al., 1987; Jassim, 1988). JSRV Infected
macrophages could have a functional impairment and the same time could modulate
the T cells present in their vicinity.
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The interaction between type B and type D retroviruses and lymphoid cells have
been demonstrated to be an important feature in the pathogenesis of the related
diseases. B lymphocytes have a central role in the pathogenesis ofMMTV infection
of the mammary gland. MMTV initially infects B lymphocytes and then is delivered
to the mammary gland through T cell-B cell interaction (Golovkina et al., 1992; Held
et al., 1994). SRV-1 in vivo has a broad lymphoid tropism involving lymphocytes
and mononuclear cells; infection leads to both T and B lymphocyte depletion
although monocyte and macrophage function appears to be unaffected (Maul, et al.,
1988). In lambs naturally infected with MVV, viral RNA can be detected in PBMCs
taken from animals less than one year of age. During MVV infection PCR tests in
animals less than one year old are informative about the infection status of the lamb.
In fact, during MVV infection, animals less than one year of age rarely show
seropositivity and an increased seropositivity occurs with age (Johnson et al., 1992;
Snowder at al., 1990). A number of PCR assays have been described which detect
MVV DNA in infected tissues, especially bone marrow, PBMCs and pulmonary
leukocytes (Brodie et al., 1993; Johnson et al., 1992; Celer et al., 2000). A PCR test
has been used to detect infected sheep in the Dutch National MVV/CAEV control
program (Wagter et al., 1998).
To date JSRV U3 PCR developed in this study is the only available current option
for planning OPA control strategies. Serological tools are a cheaper choice but
because the lack of antibodies in OPA they cannot be considered.
In the light of current knowledge and because co-infection of flocks with JSRV and
SRLV are very common (Dawson et al., 1990; Gonzalez et al., 1993) it would be
very interesting in selected flocks where this co-infection is present to initiate JSRV
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control programmes according to the roles already adopted in many EU Country for
SRLV. Due to the increased role of free trade of live animals, embryos and semen in
the EU, OPA should not be ignored. Control programmes for MVV have been
initiated in many countries (Rowe & East, 1999). The European pioneer in the
control of SRLVs was the Netherlands, where the eradication ofMV in breeding
flocks was initiated in the early 1980's (Houwers et al., 1987). These programmes
provided information on the routes of infection by SRLV sheep and goats.
The removal of serologically positive animals, as well as the separation of lambs and
kids of seropositive dams immediately at birth for rearing on serologically negative
or bovine colostrums, have been important features of successful MVV/CAE
eradication programs (Rowe et al., 1999). The separation of seronegative from
seropositive flocks and the strict control of live animal trade are other important
measures adopted. The prevention of contact is also necessary during transhumance.
All programmes were initiated voluntarily and highlighted the crucial role played by
motivated sheep and goat owners. (Peterhans et al., 2004).
Vaccination for JSRV as well as for MW/CAEV can be seen as a future goal.
Vaccination for retroviral infection poses several problems. In general, retroviruses
are relatively resistant to adaptive responses directed at viral antigens. This is evident
from the productive infection by HIV (60 million infected people), human T cell
leukemia virus (HTLV-1; 20 million infected people), and by many other animals
retroviruses (Coffin et al., 1997; Knipe & Howley, 2001). Most retrovirus-infected
animals mount vigorous B andT cell responses to retroviral antigens (Sellom, 1993;
Rimmelzwaan, et al., 1994; Connor et al., 1998). The ability of equine infectious
anemia virus (EIAV) to persistently infect horses in the face of a profound immune
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response by the host makes it an economically important disease for the horse
population of the United States. Its ability to evade host immune defences by lying
dormant in apparently healthy animals and by rapidly changing its antigenic
determinants is proving to be a major obstacle to vaccine development (Howe et al.,
2002).
In the case ofHIV, these responses (i) significantly reduce viral titers after the initial
burst ofviral replication early in infection (Coffin et al., 1997); (ii) generate
antibodies that can neutralize HIV in vitro (Sabin, 1992) and (iii) exert strong
selective pressures that can shape the evolution ofHIV genomes in vivo (Burns et al.,
1993; Burns. & Desrosiers, 1994; Goulder et al., 2001; Carpenter et al., 1987).
However, retroviral replication continues despite the antibody production in the vast
majority ofHIV-infected patients. This pattern is also observed in HTLV-1-infected
patients and in a variety of animals infected by their retroviruses. EIAV, FIV, CAEV,
MVV FIV ( Burkard & Dean, 2003). The importance ofhumoral response is
demonstrated by the lentiviruses that use extensive glycosylation of their envelope
proteins to shield their virions from host antibodies. Retroviral resistance to adaptive
immune responses is usually attributed to (i) the rapid and error-prone nature of
retroviral replication, which allows for antigenic drift and the subsequent
proliferation of escape mutants, and (ii) the unique problems posed by proviral
insertion in host cell chromosomes (Coffin et al., 1997).
Another complication in the complex relationship of the retrovirus with the host is
given by the presence of endogenous retroviruses. For example a strain of avian
leukosis virus (AFV) belonging to a new envelope subgroup J was isolated in the UK
in 1988 from meat-type chickens. The disease caused by the members of this
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subgroup has since spread very rapidly worldwide and has become one of the major
problems facing the broiler meat industry. Molecular characterisation of the
prototype of subgroup J, has shown that it has a structure of a typical ALV with gag,
pol and env genes. However the env gene was distinct from that of other ALVs and
was closely related to that ofnovel endogenous retroviral elements designated EAV-
HP. As other regions of the genome were closely related to ALVs, it is believed that
ALV-J has evolved by recombination with the env sequences ofEAV-HP. Recent
data show that ALV-J isolates evolve rapidly resulting in sequence changes within
the variable regions of the env gene leading to antigenic variation. Eradication
programmes established for other subgroups are proving to be effective in
eradicating ALV-J from infected flocks (Venugopal, 1999).
It is not known how the exogenous JSRV interacts with its endogenous counterpart.
enJSRVs are highly active, they are abundantly and specifically expressed in the
epithelium ofmost of the ovine female reproductive tract. The specific spatial and
temporal expression of enJSRVs supports a role in trophoblast development and
differentiation as well as conceptus implantation. In addition, enJSRVs expression
during foetal ontogeny could lead to the apparent tolerance of sheep towards the
pathogenic JSRV (Palmarini et al., 2004).
FeLV-induced lymphomas are a significant veterinary problem. Several commercial
FeLV vaccines are now available. Some of these vaccine were based on inactivated
whole virus or amix of viral proteins, predominantly Env, or recombinant SU
proteins and the overall experience for FeLV has been positive (Tartaglia et al.,
1993). Other experiences for Bovine leukaemia virus, Human T-cell leukaemia virus
and equine infectious anemia virus, were directed towards the productions of vaccine
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based on Env protein (Sugimoto et al., 1994; Leroux et al., 2004; Sundaram et al.,
2004). The first step towards vaccination for JSRV will attempt the use of
recombinant envelope proteins. A vaccine for OPA can be considered as a possible
future tool for the control of this disease. The optimisation of the challenge system to
induce OPA in older lambs (Chapter 3) represents a central point for a JSRV
vaccination project. This challenge system offers also the possibility to evaluate the
viraemia as a measure ofprotection. The fact that JSRV genome appears to be well
conserved and there is little variation in isolates from well-dispersed geographic






Chapter 5. General discussion
Studies directed at a further understanding of the biology and pathogenesis of JSRV
infection were undertaken, with an overall aim of developing techniques to support
effective control ofOPA. In addition, using the newly developed techniques, features
of JSRV infection were studied to highlight new aspects of the pathogenesis ofOPA.
Part of the work consisted of the generation of new JSRV capsid and envelope
recombinant proteins to use in immunisation experiments with viraemic and non
viraemic sheep. This to test the hypothesis that JSRV viraemic sheep are immuno¬
compromised. Production of JSRV capsid and envelope protein was achieved using a
cell-free production system. This is the first time that JSRV SU has been produced
successfully. The novel JSRV SU was used for producing rabbit antiserum for IHC
studies.
For the first time it has been shown that not only uninfected sheep respond to
immunisation with JSRV CA, but also that JSRV viraemic sheep have the ability to
develop an antibody response against JSRV CA. This result indicates that JSRV
infection does not directly render the immune system non-responsive to JSRV
antigens at the level of B cell responsiveness. However, since the immunogen used in
these studies consisted of a fusion protein, which contained non-viral protein that
could act as a hapten carrier, it is not possible to draw conclusions concerning the
responsiveness of T cells to the virus in infected animals. Further investigations will
study the immune response towards JSRV recombinant proteins that only contain
viral polypeptides.
Future research will be focused on the hypothesis that JSRV could interfere with
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Antigen presenting cells. A number of viruses including HIV, vaccinia, measles and
cytomegalovirus escape host immunity by interfering with dendritic cell (DC)
function and the generation of effector T cells. For example, vaccinia virus evades
immune responses by abortively infecting DCs, blocking their maturation and
inducing apoptosis (Engelmayer et al., 1999) while human cytomegalovirus
(Tortorella et al., 2000) and other viruses (Spriggs, 1996) can interfere with antigen
processing via the MHC pathway. Retroviruses may inhibit local immune responses
through immunosuppressive domains contained within the Env proteins (Cianciolo et
al., 1985; Manganey & Heidmann, 1998; Blaise et al., 2001). There is no evidence
to date to support the presence of immunomodulatory proteins encoded by JSRV
although the function of the product of the JSRV orf-x gene remains unknown.
Recent studies have revealed that T-regulatory cells generated from nai've precursors
can induce peripheral tolerance, have a low proliferative capacity and can suppress
both naive and memory responses (Oldenhoven et al., 2003). Examination ofDC-
lymphocyte interactions is required to identify the type of response induced by DCs
activated by JSRV, and to determine whether T cell regulation is responsible for the
loss of responses detected during vaccination and the lack of response detected in
infected sheep.
Based on the findings of the current study, future vaccination programmes will aim
to optimise further the combination of adjuvant and delivery route to produce
stronger and more sustained responses to JSRV antigens and to determine whether
these treatments can protect against JSRV infection and OPA. In particular, it will
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be important to study the immune responses to the JSRV Env glycoproteins in sheep
since these proteins are major immunogens in other retroviral infections.
Another important achievement obtained in this work was the development of an
experimental animal model for OPA in lambs up to 6 months.
In the present study clinical disease has been reproduced, pathologically confirmed
as OPA, in a high proportion of lambs inoculated intra-tracheally with infectious
lung fluid at either one, three or six months of age. The incubation periods, however,
were longer in the older age groups than in one week old lambs. The new
experimental model for OPA will permit to test protective effects of any future
vaccine to be evaluated.
JSRV experimental infection of animals at different ages confirmed that JSRV
susceptibility is higher in neonatal lambs. This increased susceptibility of the
neonatal animals to JSRV can be explained following the postnatal growth of the
lung and evolution ofmajor site of replication site of JSRV, the epithelial cells called
pneumocytes type II (ATII) and Clara cells. High level of JSRV expression is
detectable only in the transformed ATII and Clara cells ofOPA affected animals
(Palmarini et al., 1995; Piatt et al., 2002). Further, the long terminal repeats of JSRV
are specifically active in ATII and Clara cells (Palmarini et al., 2000b).
The alveolar epithelium differentiates last in utero. Type I and II pneumocytes line
the alveoli in a 1:2 ratio. In rodents and ruminants the alveoli develop for several
days after birth (Kahwa et al., 1997). In particular in ruminants, nonciliated
bronchiolar epithelial cells retained foetal characteristics of differentiation, in calves
that are 30 days old bronchiolar epithelium is well differentiated (Castleman & Lay,
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1990, Kahwa et al, 2000). During this period, the type II pneumocyte labelling index
declines from 6% at 7 days to about 1% at 3 weeks, and is 0.2% or less (Wright &
Alison, 1984). Therefore the increasing OPA incubation period in 1, 3 and 6 months
old lambs could be explained with the decline of the number of JSRV target cells.
IHC was performed using for the first time an anti-JSRV SU immune serum. JSRV
SU protein was found widespread on the surface of tumour cells of the lung of
animals infected at different ages (neonatal, 1 month, 3 months and 6 months old).
The IHC results in this study gave new insight in to the histogenesis and viral
pathogenesis ofOPA. Widespread SU Env protein on the surface of tumour cells
proves that envelope protein is consistently produced suggesting again a role in cell
proliferation.
During the development of the OPA animal model, a highly specific and sensitive
JSRV U3 PCR procedure was developed to provide high throughput assays of
clinical samples. This to support the first extensive molecular epidemiology
longitudinal survey in an OPA affected flock described in chapter 4. The one step
JSRV U3 PCR test was the key technique for undertaking the epidemiology studies.
This test was also used for monitoring the viraemia in lambs infected at different
ages and for selecting viraemic sheep to use in immunisation trials.
The longitudinal survey was performed in a large group of dams and their offspring
from a flock with natural history of OPA. The aim of this study was to investigate the
pathogenesis of JSRV infection in a flock with natural history ofOPA.
The characterisation of the behaviour of JSRV infection in natural condition gave,
for the first time, the opportunity to investigate the routes of transmission of JSRV
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and to analyse the relationship between viraemia and evolution of the disease. In
particular the study i) determined the prevalence of JSRV infection, ii) compared
prevalence in sheep of different ages and determined when infection first occurs, iii)
investigated JSRV transmission from dam to lamb.
The group of dams of different ages tested for JSRV infection in blood, using JSRV
U3 PCR, resulted heavily infected from the first test; in fact 31% of the ewes were
positive. The trend of JSRV infection in the ewes showed an increase in the number
of positive ewes until the May 2004 test. JSRV was detected more frequently in the
animals that were 4 -7 years old. The 4-7 year old ewes were consistently JSRV
positive during the survey. Despite the high number of infected ewes and lambs
followed over a period of nearly 3 years, it was remarkable that animals with clinical
signs ofOPA could not be detected. This situation shows that despite the high rate of
infection in the flock the disease develops slowly.
Post-mortem examination of these animals in the future part of the study will be very
useful to correlate viraemia and tumour development.
This study for the first time proved that JSRV infection happens very early in life. In
fact PCR results on blood samples from 117 lambs that were 20-30 days old (in May
2003) showed that 23 animals (20%) were JSRV positive. The percentage of JSRV
positive lambs increased with time but none of the lambs showed signs of disease
during the observation time. Foetuses from OPA affected mothers were found to be
JSRV infected, indicating the possibility of a transplacental/intrauterine transmission
of the virus. Further studies will be necessary to clarify the importance of each route
of transmission. Future work that will involve the separation of newborn lambs from
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infected ewes immediately after birth will be necessary for establishing more
evidence for vertical transmission. The possibility of the presence of JSRV in the
milk will be investigated.
This first extensive epidemiological survey for natural JSRV infection represents a
breakthrough for future JSRV control and management studies.
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Appendix I: Bacterial culture medium and transformation of E.coli
1.1 Transformation of competent cells JM109 (Promega)
Promega's JM109 competent cells were prepared according to a modified Hanahan
(1983), procedure. All cells were supplied were supplied in 0.2 ml aliquots and 3ng
ofpGEM-3Z plasmid DNA was provided as a test control vector. Typically, lOOpl of
competent cells are required for standard transformation. Competent cells were
stored at -70°C and they were thawed in an ice-bath. The cells were gently mixed by
flicking the tube and removed into a sterile pre-chilled (on ice) polypropylene tube
(Eppendorf).
1-50 ng of cloned DNA was added per lOOpl of competent cells, in a volume that
was never greater than lOpl. Immediately the tube was placed on ice for 10 minutes.
The cells were heat-shocked by transferring the tube in a water bath at exactly 42°C
for 45-50 seconds, without shaking the tube at all. Immediately the tube was placed
on ice for 2 minutes. 450pl of L-broth kept at room temperature was added and the
suspension was incubated for 60 minutes at 37°C with shaking at approximately 225
rpm. 100pi aliquots were spread on selective agar plates (LB/Amp or LB/Amp/X-
Gal/IPTG) agar plates which were then incubated overnight at 37°C (Hanahan,
1985).
1.2 L-Broth /Ampicillin (LB/Amp) agar plates
15 g of agarose was added per litre of L-broth. The agar was placed in a steamer until
it had dissolved then it was autoclaved. The agar was cooled to 55°C before addition
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ofAmpicillin to 150pg/ml. About 20ml of agar was used for each plate. LB/Amp
plates were stored at 4 °C for up to weeks.
1.3 LB/Amp/X-Gal/IPTG plates
Base agar was made by dissolving 15 g ofbacteriological agar per litre of L-broth.
The agar was dissolved by placing in a steamer before autoclaving. It was then
cooled to 55°C. Ampicillin was added to 150pg/ml. 80mg ofX-gal was dissolved in
lml ofDMF and 120mg of fPTG were dissolved in distilled water. X-gal and IPTG
were dissolved in 1 litre of LB/Amp agar.
1.4 Storage of bacterial stocks
An overnight culture was grown up in L-broth (plus 150pg/ml Ampicillin if
required). The bacteria were spun down by centrifugation at 6,000 rpm in a bench
centrifuge. The media was removed and the cells were resuspended in L-broth/15%
glycerol, lml aliquots were transferred to Eppendorf tubes and snap frozen on dry
ice. Stocks were stored at -70°C.
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APPENDIX II: Preparation and electrophoresis of DNA
11.1 Restriction endonuclease digestion
The optimum conditions required for digestion vary between each restriction
enzyme. The informations were supplied by the manufacturer. Generally 1 Ox
concentrated digestion buffers supplied with each enzyme were used to create
optimum buffer conditions. One tenth volume of lOx digestion buffer was added to a
DNA solution in distilled water. Restriction enzyme was then added depending on
the estimated amount ofDNA to be digested. The digestion reactions were incubated
in water bath at 37°C usually overnight.
11.2 Agarose gel electrophoresis
Solutions.
50xTAE: 242g Tris, 57.1 glacial acetic acid, 100ml 0.5 EDTA pH (8.0), and distilled
water to 1000ml.
Loading buffer: lOOnm EDTA. 30% Ficoll, 0.025 bromophenol blue, 0.025 Xylene
cyanol.
Method.
Agarose was dissolved by boiling in TAE buffer then allowed to cool a little before
that Ethidium Bromide was added to a concentration of 0.6pg/ml. The gel was
poured and left to set. TAE running buffer was made up and enough was added to the
tank to just cover the gel. 0.2 volumes of loading buffer was added to each sample.
Samples were loaded and the gel was run at 70-80Volts. Nucleic acid in the gels was
visualised on a UV transilluminator.
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11.3 Recovery of DNA from agarose
Extraction and purification ofDNA from standard or low-melting agarose gels in
TAE or TBE buffer
QIAquick gel extraction kit protocol (Qiagen).
The protocol is designed to extract and purify DNA of 70bp to lOkb from standard or
low- melt agarose gels in TAE or TBE buffer. The system combines the spin-column
technology with the selective properties of a silica-gel membrane. For processing the
spin column a bench microcentrifuge was used. Buffers are provided with each kit.
DNA adsorbs to the silica-membrane in the presence of high salt while contaminants
pass through the column. Impurities are washed away, and DNA is eluted with Tris
buffer or water. All the reagents were used according to the manufacturer 's
instructions.
For gel extraction ofDNA the QIAquick gel extraction Kit (Qiagen) protocol was
used:
1) DNA fragment was excised from the agarose gel with a clean scalpel.
2) The gel fragment was weighed and 3 volumes of Buffer QG to 1 volume of gel in
1.5 ml Eppendorf tube.
3) The gel slice was incubated at 50°C until dissolved; every 2-3 minutes the gel
slice was mixed by vortexing to help to dissolve.
4) After that the slice was dissolved completely the pH of the mixture was checked
and according to the manufacturer's protocol if the mixture was orange or violet
instead of yellow (it means pH > 7.5) 10pl of 3M sodium acetate, pH 5.0 were
added.
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5) After the slice was dissolved completely 1 volume of isopropanol was added to
the sample and mixed by vortexing. The binding and solubilization buffer QG
has been specially optimized for use with the QIAquick silica-gel membrane.
6) A QIAquick spin column was placed in a provided 2 ml collection tube.
7) To bind DNA to the silica gel membrane in the spin column, the sample was
simply applied to the spin column and it was centrifugated for 1 minute.
8) The flow-through was discarded and the spin column was placed back in the
same collection tube.
9) The spin column was washed with 0.75ml of buffer PE and it was centrifugated
for 1 minute at about 17,900x g.
10) The flow-through was completed discarded and the spin column was
centrifugated for additional 1 min at about 17,900x g. Salts are quantitatively
washed away by the ethanol-containing buffer PE. Any residual buffer PE, which
could interfere with subsequent enzymatic reactions, was removed by an
additional centrifugation step.
11) The spin column was placed into a clean 1.5 microcentrifuge tube.
For eluting DNA 50pl of Buffer EB (lOmM TrisCl, pH 8.5) were added to the
center of the spin column and the column was centrifugated for 1 minute
(Vogelstein & Gillespie, 1979; Hamaguchi & Geiduschek, 1962).
11.4 Minipreps for the isolation of plasmid DNA
For the purification of plasmid DNA was used the QIAprep Miniprep kit
(Qiagen).Trasformants grown on selective agarose plates were inoculated into L-
broth/Amp tubes and grown up overnight at 37°C with shaking. 3ml of overnight
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culture was pelletted by microcentrifugation and then the protocol by Qiagen was
followed.
The procedure is based on alkaline lysis of bacterial cells followed by adsorption of
DNA onto silica in the presence ofhigh salt (Vogelstein & Gillespie, 1979). The
purification consists of three basic steps:
1) preparation and clearing of a bacterial lysate;
2) adsorption ofDNA on to the Qiaprep membrane;
3) washing and elution of plasmid DNA.
Bacteria were lysed under alkaline conditions, and the lysate was subsequently
neutralized and adjusted to high-salt binding conditions in one step, ready for
purification on the Qiaprep silica-gel membrane (Birnboim & Doly, 1979). Qiaprep
columns use a silica-gel membrane for selective adsorption of plasmid DNA in high
salt buffer and elution in low salt buffer.
Appendix III: Quantification of DNA
Nucleid acid was quantified by the use of a spectrophotometer. DNA and RNA have
a peak of absorbance at260nm, while contaminating proteins have their peak at 280
nm (Sambrook et al., 1989). The absorbance at 260 nm reflects the amount of nucleic
acid present in the sample. An absorbance of 1 OD260 corresponds to 50pg ml"1 of
double stranded DNA and 40jag ml"1 for RNA. The ratio OD260 /OD280 should be
between 1.8 and 2.0 for a clean nucleic acid preparation. Samples were diluted to
give an OD260 between 0.1 and 0.5. An automatic spectrophotometer (Genequant,
Amersham Pharmacia) was used in this study and software automatically calculates
the concentration of nucleic acid and the OD260 /OD280 ratio.
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APPENDIX IV: SDS-PAGE and Western blotting
IV.1 SDS- Page protein gels
The Biorad Mini protean II slab gel apparatus was used. Either 10% or 5-20%
gradient separating gels were used, using a 30% acrylamide/0.8% bis stock solution
and a final concentration of 0.38M tris-Cl pH8.8, 2mM EDTA, 0.1% SDS, 0.08%
APS, 0.05% TEMED. The stacking gel was 3.48% acrylamide/0.093% bis
acrylamide,
0.145M Tris-Cl pH6.8, 0.12% SDS, 0.12% APS, 0.17% TEMED.
Running buffer contained 0.05M Tris, 0.37M glycine, 19.5pM EDTA, 0.1% SDS.
Samples were boiled for 2-3min with an equal volume of reducing buffer (0.1M Tris
pH6.8, 2% 2-mercaptoethanol, 30% glycerol, 1% SDS, 0.001% bromophenol blue)
before being loaded into the wells. Molecular weight markers were run in at least one
well of each gel. Electrophoresis was performed at 150V for approximately 45 min.
or until the dye front had reached the bottom of the gel.
IV.2 Coomassie staining
The PAGE gel was placed in a tray of 0.2% Coomassie stain (0.2% Coomassie Blue
R250 (Sigma, UK), 20% methanol, 5% acetic acid), for a minimum of 4 hours to
overnight, followed by extensive destaining with a solution of 5% acetic acid and
20% ethanol. The gel was dried under vacuum at 80°C for 1 hour.
IV.3 Western blotting
The polypeptides separated by SDS-Page were transferred from the gel onto
nitrocellulose (Hybond-C, Amersham, UK), using a blotting apparatus (Biorad), in a
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solution made with 25mM Tris, 20% methanol, 123mM glycine buffer. A current of
120mA was applied across the blotter for 1 hour.
IV.4 Developing a blot
After transfer, power supply was disconnected. The sandwich was disassembled and
the nitrocellulose membrane was marked to retain orientation. The filter was rinsed
several time with PBS. Then the primary antibody solution. Use 10 ml per 15xl5-cm
blot. All the antibody dilutions were done in PBS.The blot was incubated with
antibody for 1 hour at room temperature with agitation. The blot was washed with
four changes of PBS for 5 minutes each. Horseradish peroxidase conjugated serum
was used as secondary antibody. 3,3'- diaminobenzidine (DAB) was the substrate
used for the final stage in the blot development.
It was then incubate with suitable chemiluminescence reagents according to
manufacturers protocol (DAB, Sigma).
Appendix V: Purification of recombinant proteins
V.1 Purification of recombinant proteins under denaturing conditions
Denaturing Buffer Preparation
Stock solution A (IPX):
200 mM monobasic sodium phosphate (NaH2P04), 5M NaCl. It was prepared
dissolving 27.6 g ofmonobasic sodium phosphate and 292.9g ofNaCl in 1000 ml of
deionized water. The urea/phosphate buffers were made up to 100 ml.
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Stock solution B (IPX):
200mM dibasic sodium phosphate (NaH2P04), 5M NaCl. It was prepared by
dissolving 28.4 g of dibasic sodium phosphate and 292.9g ofNaCl in 1000 ml of
deionized water.
Mixing different predetermined amounts of stock solution A and B was the method
for making phosohate buffers of differing pH.
Denaturing binding buffer pH 7.8:
8M Urea, 20mM Sodium Phosphate, 500mM Sodium Chloride.
For 100 ml: 0.58ml of stock solution A (lOx) were combined with 9.42 ml of stock
solution B (lOx). It was added 48. lg of urea.
Denaturing wash buffer pH 6.0:
8M Urea, 20mM Sodium Phosphate, 500mM sodium Chloride.
For 100 ml: 7.38ml of stock solution A (lOx) were combined with 2.62 ml of stock
solution B (lOx). It was added 48. lg of urea.
Denaturing wash buffer pH 5.3:
8M Urea, 20mM sodium Phosphate. 500mM Sodium Chloride.
For 100 ml: 9.17ml of stock solution A (lOx) were combined with 0.83ml of stock
solution B (lOx). It was added 48. lg of urea.
Denaturing elution Buffer pH 4.00:
8M Urea, 20mM sodium Phosphate, 500mM Sodium Chloride.
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For 100 ml: 10ml of stock solution A (lOx) were combined with 48. lg of urea.
The solutions were stirred with gentle heating (50-60°C), until they were completely
dissolved. The pH was adjusted using IN NaOH or IN HC1. The solutions were
filtered using a 0.45pm filters.
V.2 Purification of recombinant proteins under native conditions
Preparation of the Native Purification Buffers
Stock solution A (10X1 (see Appendix V. 1)
Stock solution B (1 OX) (see Appendix V.l)
3M Imidazole Stock buffer IPX
500mM NaCl, 20mM NaP04 buffer, pH 6.0. For preparing 100 ml of this solution
20.6g of imidazole, 8.77 ml of Stock Solution A, 1.23 ml of Stock Solution B were
combined to 90 ml of distilled water. The pH was adjusted to 6.0 with HC1 or NaOH
as necessary.
Native Binding Buffer
20 mM Sodium Phosphate, 500 mM Sodium Chloride, pH 7.2 to 7.6.
For 50 ml: 2.9ml of lx Stock solution A was combined with 47.1 ml of lx Stock
solution B. The pH was adjusted by using lx Stock solution B to raise and lx Stock
solution A to lower the pH. This buffer was used as the binding buffer in the native
purification protocol.
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Native Wash Buffer pH 5.5
20 mM Sodium Phosphate, 500 mM Sodium Chloride, pH 5.5.
For 50 ml: 43.5 ml of lx Stock solution A was combined with 6.5 ml of lx Stock
solution B. The pH was adjusted by using lx Stock solution B to raise and lx Stock
solution A to lower the pH. This buffer was used as the high stringency wash buffer
in the native purification protocol.
Native Elution Buffer pH 4.0
20 mM Sodium Phosphate, 500 mM Sodium Chloride, pH 4.0.
For 50 ml: 50 ml of lx Stock solution A was combined with no lx Stock solution B.
The pH was adjusted by using lx Stock solution B to raise and Phosphoric Acid
(H3P04) to lower the pH. This buffer was used as the low pH wash buffer in the pH
elution protocol under native purification conditions.
Appendix VI: JSRV recombinant proteins previously produced
VI.1 Brief description of GST-CA and p-Gal-CA recombinant protein
(Palmarini ef a/., 1995)
JSRV gag gene (bases 953 to 3030 of the nucleotide sequence published by York et
al., 1992) was inserted in plasmid pBluescript-Js382. The fragment was excised by
EcoRl restriction and it was subcloned into plasmids pPSIS (supplied to Moredun by
M. Shreiber) and pGeXlA.T (Pharmacia) and expressed in E. coli host strain NM522
as P-galactosidase (Pgal-CA, plasmid pMCA) and glutanione-S- transferase (GST-
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CA, plasmid pGCA) fusion proteins respectively. Confirmation that the gag gene
was in the correct reading frame was obtained by sequencing across the vector-insert
junction, as well testing clones for production of p-galactosidase and GST fusion
proteins of the appropriate size by western blotting analysis with a goat antiserum to
Mason-Pfizer monkey virus major capsid protein (MPMV-CA) (Sharp & Herring,
1983). Transformed bacteria were grown and induced with IPTG for the expression
of recombinant proteins. Bacteria were pelleted (5000x g for 10 min) and
resuspended in 20 ml of TE (lOmM Tris pH7.5, ImM EDTA).
Phenylmethylsulphonylfluoride (2mM) was added before lysing the cell suspension
in a French press at 1500 psi (10.35 Mpa). The lysate obtained was sonicated and
clarified at 100,000 x g at 4°C for 10 min.
Pgal-CA was approximately 9mg/l of bacterial culture. Protein concentration was
estimated using BCA Protein Estimation Assay (Pierce), as recommended by the
manufacturer.
GST-CA was purified by affinity chromatography using a 4 ml column of
glutathione sepharose (Pharmacia) as recommended by the manufacturers.
GST-CA could not be eluted with free glutathione from the sepharose beads as
recommended by the manufacturers and therefore animals were immunised with the
fusion protein coupled to the beads.
VI. 2 Brief description of GST-SU
JSRV env gene (bases 5557 to 6483 of the nucleotide sequence published by York et
al. 1992) was cloned and inserted in the plasmid pGEM-T Easy (Promega,
Southampton,UK). The inserted fragment was excised and sub-cloned into plasmids:
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pGEXlXT (Pharmacia, Uppsala, Sweden) The fragment inserted in pGEXlkT was
expressed in E.coli cells as glutathione S-transferase fusion protein (GST-SU) as
described for expression and purification of recombinant JSRV-capsid protein
(Palmarini et al., 1995).
Appendix VII: Necropsy procedure for clinical OPA animal or
experimental animals
1) collect blood samples in EDTA for PCR or in tubes w/o anticoagulant for
collecting serum.
2) Euthanasia: overdose ofpentobarbitone
3) Collection of any lung fluid in a sterile jug.
4) Necropsy.
Appendix VIII : Rapid Translation System 500 (RTS-500) (Roche
Biochemicals). Procedures.
All the required reagents are supplied with the kit. The different reagent are
lyophilized in bottles with caps of different colour and they need to be reconstituted
directly prior to use with a Reconstitution Buffer. The plasmids are reconstituted
using RNase-Dnase-free water.
1. Reconstitution of lyophilized components:
Solution Component Reconstitution procedure
1 E.coli lysate ,bottle 1 (red cap) Reconstitute the lyophilizate
with 0,25 ml Reconstitution
Buffer, Bottle 5. Mix carefuly
without shaking
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2 Reaction mix , bottle 2 (green cap) Reconstitute the lyophilizate
with 0.8 ml Reconstitution
Buffer, Bottle 5.
3 Feeding mix, bottle 3, blue cap Reconstitute the lyophilizate
with 10 ml Reconstitution
Buffer, Bottle 5.
4 Energymix, Bottle 4, orange cap Reconstitute the lyophilizate
with 10 ml Reconstitution
Buffer, Bottle 5.
5 Reconstitution Buffer, Bottle 5, white
cap
Ready to use. The solution is
stable at 4°C but can also be
stored at -20°C.
2. Preparations ofworking solutions
Solution Component Preparation ofworking solution
7 Feeding solution Add o.5ml of the reconstituted
solution 4 to solution 3 to obtain
the Feeding solution
8
Reaction solution To E. coli lysate (solutionl) add
0.75 ml of solution 2,
50pl of solution 4,
5-15 pg of the DNA template
in a maximum volume of 50pl
After preparing the solutions ready the reaction compartment must be filled first with
1 ml of solution 8 and then the feeding compartment can be loaded with 10ml of
solution 7. At this point the RTS device can be inserted into the RTS Instrument. The
instrument can be set according to the instrument manual.
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Appendix IX: BCA method (Pierce)
Bovine serum albumin (BSA) was obtained from Pierce Chemical Company.
1. Make up series ofprotein standard (bovine serum albumin)
concentrations in 2 ml polypropylene tubes (do in duplicate):
Final cone Volume of albumin (2 mg/mL) Volume of
diluent (water)
200 ug/mL 5 uL 45 uL
400 ug/mL 10 uL 40 uL
600 ug/mL 15 uL 35 uL
800 ug/mL 20 uL 30 uL
1000 ug/mL 25 uL 25 uL
1200 ug/mL 30 uL 20 uL
2. Add 50 uL unknown protein samples to 2 ml polypropylene tubes.
a. Do in duplicate.
b. If protein concentration likely to be > 1 mg/mL then dilute sample
appropriately in water.
c. Suggest using serial dilution - 14: %; 1/8; 1/16.
3. Make up sufficient solution A and B.
a. Mix 1 part solution B with 50 parts solution A.
b. Count up the number of tubes (remember to count standards and
duplicates).
c. You will need at least this many rnL of solution A+B.
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d. E.g. 6x2 standards + 10 samples x 2 dilutions x 2 duplicates = 52 mLs
- suggest making up > 60 mL
4. Add 1 mL solution A/B to each tube and mix
5. Incubate at 37°C for 20-30 minutes (or can let stand at room temperature
for 2 hours)
6. Read absorbance at 562 nM in spectrophotometer using 1 mL plastic
cuvettes (only need to use 1 cuvette - wash between samples)
a. Don't allow time to elapse between readings since reaction continues
albeit slowly at room temperature.
7. Use standard curve function of spectrophotometer (linear regression) to
calculate protein concentrations (or can use raw data and Excel
spreadsheet).
Appendix X: GAPDH PCR
Primers were designed on a consensus sequence between the rat and the human
GAPDH. The sense primer (5' TCACCACCATGGAGAAGGCT 3') was based on
exon 4 of the human gene and the reverse primer was based on exon 7 (5'
TTCATTGTCATACCAGGAAA 3'). The primers were designed to amplify an 818
bp fragment The buffer employed was lOmM-Tris-HCl, 50mM-KCl, 2.5mMMgC12
(pH8.9) with 200pM each dNTP, 6,25 pmol each primer and 1.25U Taq polymerase
(Boehringer). Cycles employed were 94°C for 1 min , 35 cycles at 94°C for 45s,
52°C for 1 min and 72°C for 1 min 30s with a final extension of 72°C for 5 min.
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Appendix XI: Methods for DNA extraction from blood
XI. 1 Flexigene
Pipet 750 /x1 Buffer FG1 into a 1.5 ml centrifuge tube. Add 300 yul whole blood and
mix by inverting the tube 5 times.
2. Centrifuge for 20 s at 10,000 x g in a fixed-angle rotor.
3. Discard the supernatant and leave the tube inverted on a clean piece of absorbent
paper for 2 min, taking care that the pellet remains in the tube.
Note: In rare cases the pellet may be loose, so pour slowly. Inverting the tube onto
absorbent paper minimizes backflow of supernatant from the rim and sides of the
tube onto the pellet.
4. Add 150 /xl Buffer FG2/QIAGEN Protease, close the tube, and vortex immediately
until the pellet is completely homogenized. Inspect the
tube to check that the content is homogeneous.
Note: When processing multiple samples, vortex each tube immediately after
addition of Buffer FG2/QIAGEN Protease. Do not wait until buffer has been added
to all samples before vortexing.
Usually 3-4 pulses ofhigh-speed vortexing for 5 s each are sufficient to homogenize
the pellet. Flowever, traces ofpellet with a jelly-like consistency (often barely
visible)
may remain. If these traces are seen, add 30 /xl Buffer FG2 and vortex again.
5. Centrifuge the tube briefly (3-5 s), place it in a heating block or water bath, and
incubate at 65°C for 5 min.
Note: The sample changes color from red to olive green, indicating protein digestion.
6. Add 150 /xl isopropanol (100%) and mix thoroughly by inversion until the DNA
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precipitate becomes visible as threads or a clump.
Note: Complete mixing with isopropanol is vital to precipitate the DNA and must be
checked by inspection. For samples with very low white blood cell counts, in which
the DNA may not be visible, invert the tube at least 20 times.
7. Centrifuge for 3 min at 10,000 x g.
Note: If the resulting pellets are loose, centrifugation can be prolonged or a higher
g-force can be used.
8. Discard the supernatant and briefly invert the tube onto a clean piece of absorbent
paper, taking care that the pellet remains in the tube.
Note: In rare cases the pellet may be loose, so pour slowly.
If the white blood cell count of the sample was sufficiently high, the DNA should be
visible as a small white pellet.
9. Add 150 [i\ 70% ethanol and vortex for 5 s.
10. Centrifuge for 3 min at 10,000 x g.
Note: If the resulting pellets are loose, centrifugation can be prolonged or a higher
g-force can be used.
11. Discard the supernatant and leave the tube inverted on a clean piece of absorbent
paper for at least 5 min, taking care that the pellet remains in the tube.
Note: In rare cases the pellet may be loose, so pour slowly. Inverting the tube onto
absorbent paper minimizes backflow of ethanol from the rim and sides of the tube
onto the pellet.
12. Air-dry the DNA pellet until all the liquid has evaporated (at least 5 min).
Note: Avoid over-drying the DNA pellet, since over-dried DNA is very difficult to
dissolve.
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13. Add 150 yu.1 Buffer FG3, vortex for 5 s at low speed, and dissolve the DNA by
incubating for 10 min at 65°C in a heating block or water bath.
XI.2 Puregene
First, 600 /xl whole blood are aliquoted into a 2.0 ml microfuge tube containing 900
/xl Red blood cells lysis solution, The tube is inverted to mix and incubated for one
minute at room temperature. During the incubation the tube is inverted again gently 3
times to mix. For fresh blood collected within 1 hour, the incubation time was
increased to 3 minutes to ensure complete red blood cell lysis. The tube is
centrifuged at 13,000-16,000 x g for 20 seconds. The supernatant containing the
lysed red blood cells is removed. The tube is vortex vigorously to resuspend the
pellet; 900 yu.1 of lysis solution are added and the tube is centrifuged at 13,000-16,000
x g for 20 seconds. The supernatant is removed with a pipette, leaving behind the
visible white cell pellet and about 10-20 /xl of the residual liquid. The tube is vortex
vigorously to resuspend the white cells in the residual liquid. 600 /xl of Cell Lysis
Solution were added to the resuspended cells and pipet up and down to lyse the cells.
200 /xl Protein Precipitation Solution were added to the cell lysate. The tube is vortex
vigorously at high speed for 20 seconds to mix the Protein Precipitation Solution
uniformly with the cell lysate and then centrifuge at 13,000-16,000 x g for 1 minute.
The supernatant containing the DNA (leaving behind the precipitated protein pellet)
is poured into a clean 2.0 ml microfuge tube containing 600 /xl 100% Isopropanol (2-
propanol). The sample is then mixed by inverting the tube gently 50 times. After
centrifugation (13,000-16,000 x g for 1 minute), the DNA is visible as a white pellet.
The supernatant is poured off the supernatant and the tube drained briefly on clean,
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absorbent paper. After adding 600 jul 70% Ethanol the tube is centrifuged at 13,000-
16,000 x g for 1 minute. Carefully the ethanol is poured off and the tube inverted and
drain on clean, absorbent paper for 5 seconds. Finally add 150 /xl DNA Hydration
solution.
XI.3 Genisol
1. Dilute 2.5 ml of Lysis Buffer 10 time with distilled water to a total volume of 25
ml. Add 1 ml ofblood. Mix by inversion and leave for 2 minutes.
2. Centrifuge at about 400 g for 2 minutes.
3. Discard the supernatant taking care not to lose the soft pellet.
4. Add 5 ml of digestion buffer, vortex for 1 minute and incubate until the pellet is
not completely dissolved.
5. Add 1.6 ml ofprecipitation buffer and mix well.
6. centrifuge at 600-1000 g for 2 minutes . Remove the supernatant containg the
DNA to a new tube.
7. Add 6.6 ml of 80% (v/v) isopropanol to the supernatant and mix by inversion. The
DNA will gradually precipitate in the form ofwhite strands.
8. Pellet the DNA by centrifugation (600-1000g) for 5 minutes and discard the
supernatant. At this point the DNA can be transferred to a smaller tube.
9. Wash the DNA with 70% (v/v) ethanol; remove the excess alcohol by discarding




Precipitate DNA from the lysate/homogenate by the addition of 0.5 ml of 100%
ethanol per 1 ml ofDNAzol used for the isolation. Mix samples by inverting tubes 5-
8 times and store at room temperature for 1-3 minutes. Make sure that DNAzol and
ethanol mix well to form a homogeneous solution. DNA should quickly become
visible as a cloudy precipitate. Remove the DNA precipitate by spooling with a
pipette tip. Swirl the DNA onto the tip and attach it to the tube wall near the top of
the tube by gently sliding the DNA off the tip. Alternatively, transfer the DNA to a
clean tube. Store the tubes upright for about 1 minute and remove from the bottom of
the tubes the remaining lysate/homogenate.
2. DNA wash
Wash the DNA precipitate twice with 0.8 - 1.0 ml of 75% ethanol. At each wash,
suspend the DNA in ethanol by inverting the tubes 3-6 times. Store the tubes
vertically for 0.5 - 1 minutes to allow the DNA to settle to the bottom of the tubes
and remove ethanol by pipetting or decanting.
4. DNA solubilization
Remove any remaining alcohol from the bottom of a tube using a pipette. Next,
dissolve DNA (without drying) in 8 mM NaOH by slowly passing the pellet through
a pipette. Alternatively, dissolve DNA in water. However, the alkaline solubilization
ofDNA occurs faster and assures full solubilization of the DNA precipitate. Add an
adequate amount of 8 mM NaOH or water to approach a DNA concentration of 0.2 -
0.3 fxg/fil.
XI.5 Dneasy tissue kit method for the whole blood
Before using for the first time, add the appropriate amounts of ethanol (96-100%) to
Buffers AW1 and AW2 as indicated on the bottles. Prepare PBS, pH 7.2 (50 mM
-253 -
potassium phosphate; 150 mM NaCl), for use in step 1.Buffers AW1 and AW2 are
supplied as concentrates.
Procedure
1. Add 20 jul proteinase K and 200 /xl Buffer AL tolOO/xl ofwhole blood, mix
thoroughly by vortexing, and incubate at 70°C for 10 min. It is essential that the
sample and Buffer AL are mixed immediately and thoroughly by vortexing and
pipetting to yield a homogeneous solution.
2. Add 200 fi\ ethanol, and mix thoroughly by vortexing. It is important that the
sample and the ethanol are mixed thoroughly to yield ahomogeneous solution.
4. Pipet the mixture from step 3 (including any precipitate) into the DNeasyMini
spin column placed in a 2 ml collection tube (provided). Centrifuge at 6000 x g
for 1 min. Discard flow-through and collection tube.
5. Place the DNeasyMini spin column in a new 2 ml collection tube (provided), add
500 /xl Buffer AW1, and centrifuge for 1 min at 6000 x g. Discard flow-through and
collection tube.
6. Place the DNeasyMini spin column in a new 2 ml collection tube (provided), add
500 /x1 Buffer AW2, and centrifuge for 3 min at 20,000 x g (14,000 rpm) to dry
the DNeasy membrane. Discard flow-through and collection tube.
It is important to dry the membrane of the DNeasy Mini spin column, since residual
ethanol may interfere with subsequent reactions. This centrifugation step ensures
that no residual ethanol will be carried over during the following elution.
Following the centrifugation step, remove the DNeasyMini spin column carefully
so that the column does not come into contact with the flow-through, since this will
result in carryover of ethanol. If carryover of ethanol occurs, empty the collection
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tube, then reuse it in another centrifugation for 1 min at 20,000 x g.
7. Place the DNeasy Mini spin column in a clean 1.5 ml or 2 ml microcentrifuge tube
(not provided), and pipet 200 /fi Buffer AE directly onto the DNeasy membrane.
Incubate at room temperature for 1 min, and then centrifuge for 1 min at 6000 x g
to elute. Elution with 100 /xl (instead of 200 /xl) increases the final DNA
concentration in the eluate, but also decreases the overall DNA yield. A second
elution can be performed.
XI.6 Ultraclean
Component Amount Description
RNase A 165/il 25 mg/ml RNase A
Solution G1 99 ml Ammonium Chloride Solution
Solution G2 33 ml Detergent Solution
Solution G3 11 ml Ammonium Acetate
100 % Isopropanol 33 ml 100% Isopropanol
70% Ethanol: 30 ml 70% Ethanol in DNA Free Water
Solution G4 11ml Tris in DNA Free Water.
Protocol
1. Add 300/xl ofwhole blood to 900/xl of Solution G1.
2. Invert twice and incubate 5 minutes at room temperature.
3. Invert two times during incubation.
4. Centrifuge for 30 seconds at 13,000xg. Remove supernatant with narrow pipet tip
and discard without disturbing white pellet. (About 20/xl of supernatant will
remain.)
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5. Bump vortex to resuspend pellet completely.
6. Check Solution G2. Ifprecipitated, heat to 55° - 65°C for 5 minutes to dissolve.
Add 300/xl ofSolution G2.
7. Pipet up and down to lyse the cells (If cell clumps are still visible incubate at
37°C until no clumps are visible).
8. Add 1.5/xl ofRNase A, invert 5 times and vortex on low speed for 5 seconds.
9. Add 100/xl of Solution G3.
10. Immediately vortex for 15 seconds.
11. Centrifuge 3 minutes at 13,000xg.
12. Remove clear supernatant and transfer to a clean 2.0 ml tube.
13. Add 300/xl of 100% Isopropanol.
14. Invert 15 times and incubate at room temperature for 3 min.
15. Centrifuge 1minute at 13,000xg.
16. Pour off supernatant without disturbing pellet, and drain on a paper towel or
absorbent material.
17. Add 300/xl of 70% Ethanol.
18. Invert tube 5 times to wash.
19. Centrifuge 30 seconds at 13,000xg.
20. Carefully pour off supernatant without disturbing pellet, and drain on a paper
towel or absorbent material.
21. Centrifuge for 30 seconds, and remove residual supernatant with narrow pipet tip
without disturbing pellet.
22. Add 100/xl of Solution G4.
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23. Heat in 65°C water bath tapping tube occasionally, until pellet has resuspended
(should take no longer than 30-40min).
24. Genomic DNA in tube is now ready to use for any application.
Appendix XII: MALDI-TOF analysis of JSRV RTS SU
The band containing the supposed JSRV RTS SU protein was excised from a SDS-
PAGE gel, digested with proteolytic enzymes and then analysed by MALDI-TOF at
the Moredun Functional Genomics Unit.
The MALDI-TOF application, followed by database search, confirmed that the 43
kDa band fitted the predicted sequence of JSRV SU protein as shown in the figure
XII. 1.
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Fig.XII.l. MALDI-TOF analysis of JSRV RTS SU.
The band of about 43kDA that was supposed to be JSRVRTS SU was excised
from the SDS-PAGE and analysed by MALDI-TOF technique (A). Another






















Max. # Missed Cleavages: 1
Composition Include:
CompositionMask Type: AND
Peptide N terminus: Hydrogen
Peptide C terminus: Free Acid
CysteineModification: acrylamide
Instrument Name: MALDI-TOF
Sample ID (comment): Magic Bullet digest
Minimum Matches: 4
Sort Type: Score Sort
Considered modifications: | Peptide N-terminal Gin to pyroGlu | Oxidation ofM | Protein N-
terminus Acetylated |
Min Parent Ion Matches: 1
MOWSEOml
MOWSE P Factor 0.4
Pre Search Results
Number ofentries in the database: 576474
Molecular weight search (1000 -100000 Da) selects 548069 entries.
Full pi range: 576474 entries.
Combined molecular weight and pi searches select 548069 entries.
Pre searches select 548069 entries.
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Detailed Results
1.5/24 matches (20%).
Acc. #: Y18303 Species: SHEEP PULMONARY ADENOMATOSIS VIRUS Name: (ENV)ENV
PROTEIN.
Index: 515470 MW: 70379 Da pfc 8.6
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Click link below to search for cysteine linked fragments.
19 unmatched masses:
http://prospector.ucst.edu/ucstbm4.0u/mssearch.cgi 5/10/02
■ MS-Fit Search Results
Click link below to do a non-specific cleavage search.
19 unmatched mimy
Click link below to search for another component
19 unmatched mum'
The matched peptides cover 13% (87/622AA's) ofthe protein.
Coverage Map for This Hit (MS-Digest index #): 515470
2.5/24 matches (20%).
Acc. Y18302 Species: SHEEP PULMONARY ADENOMATOSIS VIRUS Name: (ENV)ENV
PROTEIN.
Index: 359884 MW: 70419 Dapt 8.6
Click link below to search fin cysteine linked fragments.
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Click link below to do a non-specific cleavage search.
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Click link below to search for another component
19 unmatched masses:
The matched peptides cover 13% (87/622AA's) of the protein.
Coverage Map for This Hit (MS-Digest index #): 359884
3.5/24 matches (20%).
Acc. #: AF15361S Species: OVIS ARIES Name: (env)Env.
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MS-Fit Search Results
Click link below to do a non-specific cleavage search.
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The matched peptides cover 12% (77/611AA's) ofthe protein.
Coverage Map for This Hit (MS-Digest index #): 196418
4.5/24 matches (20%).
Acc. #: P20717 Species: RATTUS NORVEGICTJS Name: (PDI2..)PROTEIN-ARGININE
DEIMINASE TYPE D (EC 3.5.3.15) (PEPTXDYLARGININEDEIMINASEII).
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The matched peptides cover 8% (55/665AA's) ofthe protein.
Coverage Map for This Hit (MS-Digest index #): 152808
5.6/24 matches (25%).
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CompositionMask Type: AND
Peptide N terminus: Hydrogen
Peptide C terminus: Free Acid
Cysteine Modification: acrylamide
InstrumentName: MALDI-TOF
Sample ID (comment): Magic Ballet digest
Minimum Matches: 4
Sort Type: Score Sort
Considered modifications: | Peptide N-terminal Gin to pyroGln | Oxidation ofM | Protein N-
terminns Acetylsted |
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Molecular weight search (1000 -100000Da) selects 548069 entries. ,
Full pi range: 576474 entries.
Combined molecularweight and pi searches select 548069 entries.
Pre searches select 548069 entries.
Data Set 1 Results




mowct #/43(%) ./ ./ Mean Data Protein . „.
ZT ™X T Spedes Proteinl
Matched ppm ppm ^ (Da)/pl
(TUFA..)








o. - trnNFI TA elongatio




























• MS-Fit Search Results
Acc. #: P21694 Species: SALMONELLA TYPH1MURIUM Name: (TUFA..)ELONGATION
FACTOR TU(EF-TU).
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Click link below to search for cysteine linked fragments.
37 unmatched masses:
Click link below to do a non-specific cleavage search.
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Click link below to search for another component
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The matched peptides cover 32% (127/393AA's) ofthe protein.
Coverage Map for This Hit (MS-Digest index #): 114536
2.11/43 matches (25%).
Acc. #: P02990 Species: ESCHERICHIA COLI Name: (TUFA..)ELONGATION FACTOR TO (EF-
TO) (P-43).
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205 223 0 HOAIDKPFLLPIEDVFSISGR fQT
Click link below to search for cysteine linked fragments.
37. unmatched mioM'
Click link below to do a non-specific cleavage search.
Click link below to search for another component
37 unmatched
The matched peptides cover 32% (127/393AA's) of the protein.
Coverage Map for This Hit (MS-Digest index #): 118450
3.11/43 matches (25%).
Acc. #: S13560 Species: SALMONELLA TYPHIMURIUM Name: translation elongation factor EF-
Tu.A - Salmonella typhimurium
Index: 92868 MW: 43252 Da pi: 5.3
Click link below to search for cysteine linked fragments.
37 unmatched mawes-
Click link below to do a non-specific cleavage search.
37 unmatchedmim-
Click link below to search for another component
32 untnhfohed masses;
The matched peptides cover 32% (127/394AA's) offoe protein












271 280 0 (R) AGENVGVLLR (G)
178 188 0 (KlALEGDAEWBAKfll
326 334 0 (KTGYRPOFYFRm
46 57 0 fRT AFDOIDNAPEEK /AT
46 59 1 HO AFDOIDNAPEEKAR (ff>
305 319 1 fKD FF.SEVYILSKDEGGR (HI
359 374 0 GOMWTLIHPIAMDDGLR (F1
359 374 0 (K)MWTLJHPIAMDDGLR(F)
60 75 0 fRT GITTNTSHVEYDTPTR (H)
189 205 0 GO IIELAGFLDSYIPEPER fAT









Acc. #: J01690 Species: ESCHERICHIA COLI Name: (tufA)Elongation factor Tu.
Index: 235212 MW: 43284 Da pi: 53
.m/* „MI* . DelUModifications Start EndSubmitted Matched ppm
Missed Database
Cleavages Sequence
1027.5918 1027.5900 1.8 271 280 0 GO AGENVGVLLR fGl
1218.5315 1218.5643 -27 178 188 0 GO ALEGDAEWEAK IT)
1233.61571233.6169 -0.98 326 334 0 GOGYRPOFYFRm
1376.61801376.6334 -11 46 57 0 (R)AFDQIDNAPEEK(A)
1603.80071603.7716 18 46 59 1 GO AFDOIDNAPEEKAR fGl
1728.8569 1728.8445 72 305 319 1 GO FESEVYILSKDEGGR GD
1780.9271 1780.9454 -10 359 374 0 GOMWTLIHPIAMDDGLR <F1
1796.9588 1796.9403 10 lMet-ox 359 374 0 (K)MWTUHPIAMDDGLR(F)
1803.9325 1803.8877 25 60 75 0 GO GITINTSHVEYDTPTR (H)
1962.0613 1962.0224 20 189 205 0 GO ILELAGFLDSY1PEPER (A1
2117.21192117.1647 22 206 224 0 GO AIDKPFLLPIEDVFSISGR (Q)
Click link below to search for cysteine linked firagments.
32 unmatched masses'
Click link below to do a non-specific cleavage search.
V ""rnatf-hf-H™fs,ys'
Click link below to search for another component
The matched peptides cover 32% (127/394AA's) ofthe protein.
CoverageMap for This Hit (MS-Digest index #): 235212
5.11/43 matches (25%).
Acc. #: AF170176 Soecies: SALMONELLA TYPHEMURIUM LT2 Name: (tufB)Salmonella
typhimurium translation elongation factors TU (EF-TU) (SW.P21694), contains similarity to PFam
domain PF00009 (GTP_EFTU, Score-541.8 E-4.6e-159,N-l.
Index: 236156 MW: 43284 Da pi: 5.3
m/z MET DeltaModifications Start End /-?®SSedSubmitted Matched ppm Cleavages Sequence
1027.59181027.5900 1.8 271 280 0 (R) AGENVGVLLR (G)
1218.53151218.5643 -27 178 188 0 GO ALEODAEWEAK IT)
1233.61571233.6169 -0.98 326 334 0 GO GYRPOFYFRffl
1376.61801376.6334 -11 46 57 0 (R) AFDOIDNAPEEK (A)
1603.80071603.7716 18 46 59 1 GO AFDOIDNAPEEKAR fGl
1728.85691728.8445 72 305 319 1 . GO FESEVYILSKDEGGR GO
1780.9271 1780.9454 -10 359 374 0 ' GOMWTLIHPIAMDDGLR GO
1796.95881796.9403 10 lMet-ox 359 374 0 (K)MVVTLIHPIAMDDGLR(F)
http://prospector.ucsf.edu/ucslbin4.0u/mssearch.cgi 5/10/02




60 75 0 Oil GmNTSHVEYDTPTR (HI
189 205 0 mi TTFT.AfiFTPSYIPEPER (A)
206 224 0 fRl AIDKPFLLPIEDVFSISGR (G)
Click link below to search for cysteine linked fragments.
37 unmatched
Click link below to do a non-specific cleavage search.
3? flnmaahBlaaaeE
Click link below to search for another component
The matched peptides cover 32% (127/394AA's) of the protein.
Coverage Map for This Hit (MS-Digest index #): 236156
MS-Fit in ProteinProspector 4.0.2u
O Copyright (1995-2002) The Regents ofthe University ofCalifornia.
http://prospector.ucst.ectu/ucstbin4.Ou/nissearcb.cgi 5/10/02
Appendix XIII: Collection of epidemiology data for statististical analysis
The PCR results regarding JSRV infection in the blood were collected in Excel
format in order to facilitate the statistical analysis (Table XIII. 1).
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Table XIII.1. Collection of epidemiological data for statistical
analysis.
The JSRV U3 PCR results for the lamb and ewe populations were tabulated
in Excel format. From the left column of the table:
Lamb Num: identification number of the lambs.
LMay 03- Lmay04: in this column the results of the PCR test for each lamb
were reported divided according to the date in which the bleed was done.
Each animal was scored with " 0 " when the PCR result was negative and
with " 1 " when the PCR test was positive. The " * " indicated a missing
value.
EweNum: identification number of the ewes.
EDec02-EDec04: in this column the results of the PCR test for each lamb
were reported divided according to the date in which the sampling was done.
Each animal was scored with " 0 " when the PCR result was negative and
with " 1 " when the PCR test was positive. The " * " indicated a missing
value.
EweAge: age of the ewes in December 2002.
Ewe/Milk: identification of the cross-breed of the ewe. IfMilksheep breed
was involved the animal was scored with " 1 " if not with " 0 ".
Ewe/Suff: identification of the cross-breed of the ewe. If Suffolk breed
was involved the animal was scored with " 1 " if not " 0 ".
Ewe/Tex: identification of the cross-breed of the ewe. If Texel breed
was involved the animal was scored with " 1 " if not with " 0 ".
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Successful induction of ovine pulmonary
adenocarcinoma in lambs of different ages and
detection of viraemia during the preclinical period
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1,2Moredun Research Institute1 and Veterinary Laboratories Agency (VLA-Lasswade)2,
Pentlands Science Park, Bush Loan, Penicuik EH26 0PZ, UK
3Universidad de Zaragoza, Facultad de Veterinaria, 50013 Zaragoza, Spain
4University of Edinburgh, Division of Veterinary Biomedical Sciences, Edinburgh EH9 1QH, UK
Ovine pulmonary adenocarcinoma (OPA) can be reproduced consistently in neonatal lambs
by intratracheal injection of inocula containing jaagsiekte sheep retrovirus (JSRV). In this study,
clinical disease, confirmed pathologically as OPA, was induced in a high proportion of lambs
that had been inoculated intratracheally with infectious lung fluid at 1, 3 and 6 months of age.
The incubation periods, however, were longer in these three age groups than in 1 -week-old
lambs that were used as controls. Viraemia was detected in all age groups before onset of
clinical signs, but occurred later in older animals. These results suggest an age-dependent
susceptibility to OPA that could be determined by the availability of JSRV target cells in the
ovine lung. The feasibility of inducing OPA in older lambs and detecting JSRV viraemia in preclinical
stages enables improved studies on the pathogenesis, assessment of vaccines, diagnosis and
control of the disease.
Ovine pulmonary adenocarcinoma (OPA) is a contagious
lung cancer that is caused by an exogenous betaretrovirus,
jaagsiekte sheep retrovirus (JSRV), which is distinct from
the transcriptionally active endogenous retroviral sequences
that are present in the ovine genome (York et al., 1992;
Palmarini et al., 2004). The mechanism by which the virus
causes oncogenic transformation of lung epithelial alveolar
type II (ATII) and Clara cells is still not understood com¬
pletely. Whilst natural OPA has a long incubation period,
with most clinical cases occurring in 2-4-year-old animals
(Sharp & DeMartini, 2003), the disease can be induced
experimentally very rapidly and efficiently by intratracheal
inoculation of newborn lambs with concentrated lung
fluid (LF) (Verwoerd et al., 1980; Sharp et al., 1983; De las
Heras et al., 2003). However, following a similar intra¬
tracheal challenge of 10-week-old lambs with tumour
extract, only 25% of them developed scattered neoplastic
nodules and none showed clinical disease after 8 months
(DeMartini et al., 1987; Rosadio et al., 1988). Similarly, in
early transmission studies that were performed in sheep
older than 1 year by parenteral inoculation or aerosol
exposure, clinical disease was seldom achieved, with incu¬
bation periods usually longer than 1 year and pathological
changes consisting of confined small tumour nodules
(Dungal, 1946; Wandera, 1968).
The neonatal lamb model has been very useful in deter¬
mining the aetiological role of JSRV in OPA and some
aspects of its pathogenesis, but is unsuitable for evaluating
the efficacy of potential vaccine preparations and studying
pathogenic mechanisms of JSRV infections that occur
later in life. These studies also have been hampered by the
absence of detectable antibodies to JSRV in affected animals
(Sharp & Herring, 1983; Ortin et al., 1998).
The aims of the present study were to investigate whether
JSRV infection, OPA lesions and clinical disease could be
induced in older lambs and to determine the dynamics of
the infection by PCR examination of peripheral blood
samples.
Four groups of Scottish Blackface lambs were inoculated
with JSRV-containing LF, as confirmed by Western blot
and RT-PCR (Palmarini et al., 1995). Ages at inoculation
were: 1 week («= 5), 1 month (n=10), 3 months (n=10)
and 6 months (n = 10). All animals were from an OPA-ffee
flock at Moredun Research Institute, UK. Six lambs from
the same source were used as unchallenged controls.
LF collected from sheep that were naturally affected with
OPA was clarified and stored at —70 °C. In order to remove
variation in JSRV titres between batches of LF and to
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ensure that each lamb received the same inoculum, several
batches of LF from different sheep were thawed, pooled
together, aliquotted and stored at — 70 °C. Immediately
before inoculation of the lambs, the appropriate number
of aliquots were thawed and concentrated to give a 12-5-
fold concentrate of the original volume (Sharp et al., 1983).
Each lamb in each age group received 5 ml of this con¬
centrated LF pool by the intratracheal route, as described
previously (Sharp et al., 1983).
Peripheral blood samples were collected into EDTA tubes
immediately before challenge and at intervals until necro¬
psy. Peripheral blood leukocytes (PBLs) were obtained
by centrifugation after lysis of erythrocytes (Garcia-Goti,
1999) and the cell pellet was stored at — 70 °C. DNA
extraction was performed by using a DNeasy Tissue kit
(Qiagen) following the manufacturer's protocol for animal
blood. Blood samples from OPA-free Icelandic sheep were
processed simultaneously as negative controls.
A single-round PCR to amplify the U3 region of JSRV was
developed, based on the previously reported primers PI and
PIII (Palmarini et al., 1996). The new PCR was validated by
using DNA from the OPA cell line JS7 (Jassim et al., 1987;
DeMartini et al., 2001), diluted in a background of 600 ng
DNA from Icelandic sheep PBLs. Optimized PCR condi¬
tions were: 5 pi 10 x PCR buffer (Qiagen), 200 pM dNTPs
(Roche Diagnostics), 200 nM each primer (MWG) and
1-25 U FIotStarTaq polymerase (Qiagen) were added to
ultra-pure water (Sigma) to a final volume of 50 pi. To this
pre-mix, 600-800 ng test DNA was added and incubated
at 94 °C for 16 min, followed by 35 cycles at 94 °C for 30 s,
59 °C for 30 s and 72 °C for 30 s, with a final extension
step of 5 min at 72 °C. This JSRV-U3-PCR successfully
amplified 10-100 copies of JSRV template that were
integrated into JS7 genomic DNA (data not shown). The
test samples were analysed in triplicate and considered to
be positive if one or more of the replicates gave a band of
the correct molecular mass. To confirm the integrity of
the DNA, samples that were negative in the JSRV-U3-PCR
were tested for the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (Palmarini et al., 1996).
Animals were monitored daily after experimental infection
for clinical signs of respiratory disease that might be sug¬
gestive of OPA. As soon as these were identified, lambs
were killed humanely. Lambs that did not show any clinical
signs were kept for a maximum of 7 months post-infection
(p.i.) and then culled. Unchallenged control animals were
culled at the end of the experiment, at the same time as the
last inoculated lambs. At necropsy, examination of the
lungs was performed to identify any gross lesions that
might be suggestive of OPA. Neoplastic-like areas or, in
their absence, a range of tissue sites from all pulmonary
lobes were taken for microscopic examination. Samples
were fixed in 10% neutral-buffered formalin, processed
routinely, sectioned at 5 pm and stained with haematoxylin
and eosin (HE). Sections from selected lung samples were
subjected to immunohistochemical examination for JSRV
capsid protein (JSRV-CA) and JSRV surface glycoprotein
(JSRV-SU) by using a newly developed antiserum, which
was prepared by immunizing rabbits with glutathione S-
transferase-SU (GST-SU) and His-tagged SU proteins in
Freund's incomplete adjuvant. Recombinant fusion pro¬
teins were made by cloning and expressing nt 5557-6483
of JSRV (GenBank accession no. M80216) following
standard molecular biology procedures (Sambrook et al.,
1989). The fragment inserted in pGEXl/.T (Pharmacia)
was expressed in Escherichia coli cells to generate GST-SU,
which was purified by using glutathione/Sepharose beads
(Invitrogen). The fragment inserted in pIVEX2.4a (Roche
Molecular Biochemicals) was expressed as a His-tagged
protein by using the cell-free translation system RTS-500
(Roche Molecular Biochemicals), purified by using ProBond
nickel resin (Invitrogen) and eluted following denaturing
conditions according to the manufacturer's protocol. Both
antibodies were used at 1/1000 dilutions as described
previously (Palmarini et al., 1995). Samples of lung and
mediastinal lymph node were taken for JSRV-U3-PCR
analysis.
None of the unchallenged control lambs developed clinical
signs of respiratory disease and their PBLs were negative
by JSRV-U3-PCR throughout the experiment. When culled
at 14 months of age, neither histopathological lesions of
OPA nor proviral DNA was detected in lung or mediastinal
lymph-node samples.
In four of five 1-week-old lambs, severe clinical signs that
were suggestive of OPA were observed at 70-74 days p.i.
(Fig. 1), whereas the other lamb (1W1; Fig. 2) died at


















1 week 1 month 3 months 6 months
Age at challenge
Fig. 1. Incubation period of experimental OPA depending on
age at challenge. Incubation period (days from experimental
infection to post-mortem) of OPA in four groups of sheep that
were challenged at different ages, all of which showed clinical
signs of the disease and histopathological confirmation of pul¬
monary neoplasia. Results are expressed as mean values; bars
indicate SEM; statistical differences between groups appear in
parentheses. NS, Not significant.
3320 Journal of Ueneral Virology 85







>• • • C
> •• ♦ r*
• *~f












































• • - «r*
O o~
O- O
O ~ O &
2 3 4 5
Time p.i. (months)
Fig. 2. Evolution of JSRV viraemia as detected by U3 PCR (O,
negative; •, positive) during the course of experimental infection
and at culling of sheep showing clinical signs of OPA (■) or not
showing such signs (□), and in which gross and/or histopatholo-
gical lesions of OPA were confirmed (+) or absent (O).
gross and microscopic lesions of OPA (Fig. 2) and were
consistendy positive after infection by JSRV-U3-PCR
(Fig. 2).
Nine out of ten 1-month-old lambs showed clinical signs
of OPA, with incubation periods ranging from 92 to
209 days (mean, 152 days; Fig. 1). The remaining lamb
(1M10; Fig. 2) was asymptomatic when culled at almost
7 months p.i. All ten lambs had macroscopic pulmonary
lesions that were confirmed histologically as OPA (Fig. 2)
and were JSRV-U3-PCR-positive throughout the incuba¬
tion period, with the exception of one (1M7; Fig. 2).
Nine out of ten 3-month-old lambs developed signs of
OPA, with incubation periods ranging from 159 to 192 days
(mean, 185 days; Fig. 1). The other animal (3M10; Fig. 2)
was asymptomatic when culled at 192 days p.i. Macroscopic
lung lesions were confirmed histologically as OPA in all ten
lambs. Whilst JSRV viraemia was detected consistently in six
lambs, including the one that remained asymptomatic, the
other four (3M2, 3M3, 3M5 and 3M8; Fig. 2) were JSRV-
U3-PCR-negative on occasions during the experiment.
Five out of ten 6-month-old lambs developed clinical OPA
with incubation periods ranging from 164 to 169 days
(mean, 182 days; Fig. 1) and, amongst the other five sheep,
three (6M8, 6M9 and 6M10) were asymptomatic when
culled at 190-192 days p.i. All five clinically affected sheep
and two asymptomatic lambs showed pathological evidence
of neoplasia, although in one of them (6M9; Fig. 2), only
microscopic lesions were detected. Two lambs (6M1 and
6M2; Fig. 2) died early from OPA-unrelated conditions; in
these and in one of the asymptomatic culls (3M10; Fig. 2),
neither gross nor microscopic lesions of OPA were found.
Within this group of 6-month-old lambs, PBLs from all
animals were JSRV-U3-PCR-negative at 3 weeks p.i. but,
with the exception of a single sheep (6M9; Fig. 2), they were
consistently positive thereafter.
Regardless of age at challenge, all sheep with histologically
confirmed OPA showed the same pattern of neoplasia,
which consisted predominandy of papillary adenocarci¬
noma of the alveoli (Fig. 3a, b). Immunohistochemical
examinations showed JSRV-CA protein in the cytoplasm
of a proportion of ATII neoplastic cells and nodules with
the features described in previous studies (Palmarini et al,
1995; Piatt et al, 2002). Detection of immunohistochemi¬
cal reactivity to JSRV-SU was consistent in epithelial cells
lining neoplastic alveoli (Fig. 3c) and in polypoid struc¬
tures in the bronchioles (Fig. 3d). Immunolabelling was
strongest at the apical surface of the cells.
JSRV was detected by U3-PCR in all mediastinal lymph-
node and lung-tissue samples that were collected from the
35 JSRV-challenged sheep.
The present study demonstrates clearly that JSRV infection
can be induced in 100 % of lambs aged 1-6 months at the
time of inoculation and that a high proportion of these
animals develop clinical signs (62-90%) and lesions (87-
100%) ofOPA. This is in contrast to a previous study on a
much smaller scale, in which only a proportion of 10-week-
old lambs developed neoplastic lesions (Rosadio et al.,
1988). One explanation for this discrepancy and for the
success of the current experiment would be a large amount
of JSRV in the inoculum, as LF contains more JSRV than
tumour extracts (Herring et al., 1983) and JSRV dose and
incubation period are correlated inversely (Verwoerd et al.,
1980). Nevertheless, some findings in the present study
support the notion of an age-related resistance to OPA.
Firstly, within those animals that developed clinical OPA,
the incubation period was significantly shorter (P<0-001)
for lambs that were inoculated at 1 week of age than for
older lambs (Fig. 1) and it was also shorter (P=0-03) for
animals that were challenged at 1 month than for those
inoculated at 3 months. Secondly, the development of
lesions was delayed in older lambs, as indicated by three
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Fig. 3. Histopathology and immunohistochemistry of experimental OPA. (a) Co-existence of papillary and acinary forms of the
tumour and presence of desquamated alveolar macrophages in the lung of a lamb inoculated at 1 month of age (HE staining).
Bar, 400 pm. (b) Papillary neoplastic proliferations involve alveoli and bronchioles, which also show hyperplasia of associated
lymphoid tissue. Para-adenomatous change is conspicuous. Lamb was inoculated at 1 month of age (HE staining). Bar,
200 pm. (c) Papillary alveolar tumour in a lamb challenged at 3 months of age, showing strong immunoreactivity for JSRV-SU
protein mainly in the apical border of transformed ATM cells. Haematoxylin counterstaining. Bar, 60 pm. (d) Proliferating cells in
a bronchiole show immunoreactivity for JSRV-SU protein (most evident in the apical cytoplasm), whereas non-transformed
cells are negative. Note some immunolabelled cells in the interstitium. Lamb was inoculated at 6 months of age. Haematoxylin
counterstaining. Bar, 60 pm.
asymptomatic lambs in the oldest age group that had no
evidence of OPA lesions and a fourth lamb with only
microscopic lesions (Fig. 2). Finally, detectable viraemia
occurred later in the group of 6-month-old lambs than in
the group of 1-week-old lambs (Fig. 2), and possibly also
later than in the 1- and 3-month-old animals, although
straight comparisons cannot be made with these two groups,
as their first PCR testing on PBLs was slightly delayed.
As the same inoculum was used for all 35 lambs, our results
suggest that age at infection has an effect on the develop¬
ment ofOPA; this is particularly noticeable between 1 week
and 1 month of life.
Other examples of age-related susceptibility to retroviral
infections include feline leukemia virus (Hoover et al., 1976;
Flynn et al., 2000), certain avian leukosis viruses (Pizer etal,
1992; Stedman et al., 2001), visna/maedi virus (Lairmore
et al., 1986; Andresson et al., 1993) and Mason-Pfizer
monkey virus (Fine et al., 1975). Whilst, for some of these
infections, differences in the ability of neonates and older
animals to mount immune responses could account for an
age-related susceptibility, this is unlikely for OPA, in view of
the lack of a specific humoral immune response to JSRV
(Sharp & Herring, 1983; Ortin et al., 1998).
A more plausible explanation for the age effect in OPA
would be that the target cells for primary JSRV infection
and oncogenesis, ATI! pneumocytes and Clara cells of the
bronchioles, are present in higher numbers in newborn
lambs than in older animals. In rodents and ruminants,
the ratio of type I pneumocytes to ATII cells at birth
is around 1:2, with ATII pneumocytes accounting for
approximately 60% of alveolar cells (Weibel & Taylor,
1996; Kahwa et al., 1997; Otto, 1997). During the first
month of life, the number of ATII cells declines progres¬
sively and dramatically, so that they represent only 6%
of alveolar cells at 7 days, 1 % at 3 weeks and 0-2% at
1 month, with no further significant changes occurring
later (Wright & Alison, 1984). Similarly, Clara cells retain
fetal characteristics in calves and goat kids that are up to
30 days old, but lose them and become fully differentiated
after this time (Castleman & Lay, 1990; Kahwa et al., 2000).
We hypothesize that following intratracheal inoculation of
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JSRV, primary virus replication would occur in the ATII
and Clara cells and that the magnitude of such replication
would depend on the availability of these target cells. Thus,
higher viral production could be expected in newborn
lambs, leading to earlier detection of viraemia and develop¬
ment of neoplastic lesions (and hence a shorter incubation
period), and vice versa in older lambs.
In conclusion, we have developed a new experimental model
to induce JSRV infection and OPA in aged lambs, which
can be monitored by an efficient PCR technique in blood
samples. Apart from providing new insights into the patho¬
genesis of the disease by confirming an age effect in the
timescale of OPA-related events, the model will be useful
to test the efficacy of potential vaccines. Finally, our PCR
results reinforce previous studies on the detection of JSRV
infection in subclinically infected sheep (Garcia-Goti, 1999;
Gonzalez et al, 2001), providing an opportunity for future
epidemiological research.
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Disease risks for the travelling pet:
Heartworm disease LUCA FERASIN
HEARTWORM disease is a parasitic infection caused by Dirofilaria immitis. This is a nematode
(roundworm) that lives primarily in the pulmonary arteries and the right heart of dogs and, less
commonly, cats and ferrets. The disease may sometimes affect other species, such as wild canids and
felids, sealions and, sporadically, humans; however, these species are generally considered dead-end
hosts as the parasite does not reach full maturity and cannot complete its biological cycle. Heartworm
disease is transmitted by mosquito bites and there are more than 70 species of mosquito that can
potentially transmit the infection. This article discusses the epidemiology and pathogenesis of
heartworm disease, as well as its diagnosis and management.
EPIDEMIOLOGY
Heartworm disease is present worldwide, but its preva¬
lence varies depending on the canine population, pres¬
ence of mosquitoes and the climate. Climatic conditions
must be sufficiently warm to allow mosquitoes to thrive
and Dirofilaria immitis larvae to develop in the insect
(see box below). For this reason, the prevalence of heart-
worm disease depends not only on geographical area, but
also on the season, and this is a key consideration when
screening for the disease or planning a chemoprophylac-
tic schedule.
Although heartworm disease has been diagnosed in
the UK in dogs imported from abroad, the disease is
unlikely to spread in this country despite the presence of
potential vectors and a large canine population, in fact,
the low average daily temperature does not allow larval
maturation within the mosquito, even in summertime.
Biological cycle of Dirofilaria immitis
D immitis adults reach sexual maturity in the pul¬
monary arteries and right ventricle of the dog. After
mating, the female nematodes release immature lar¬
vae (L1 or microfilariae) into the circulation. Micro¬
filariae are eventually ingested by mosquitoes during
a blood meal. Mosquitoes are not only a vector, but
also an obligatory intermediate host, without which
heartworm disease could not be transmitted. The
ingested microfilariae require a period of maturation
in the insect, which varies depending on environmen¬
tal conditions. This development cannot occur below
the threshold temperature of 14°C when the cycle
is temporarily suspended until warmer conditions
resume. At an average daily temperature of 30°C,
maturation can be completed in eight days; however,
maturation takes approximately one month at an
environmental temperature of 18°C. Transmission of
infective larvae is therefore limited to warm months
and varies depending on geographical location.
In the mosquito, microfilariae mature to a second
larval stage (L2) and, eventually, to the infective stage
(L3). When the L3 stage is reached, the larvae migrate
from the tubules to the insect's mouth and, during a
subsequent blood meal on an appropriate host, enter
the bite wound, colonising the local connective tissues.
After approximately one week, the larvae mature from
L3 to L4 and, following continued migration for two to
three months in the subcutaneous tissues, reach the final
stage of immature adults (L5). The L5 larvae penetrate
a systemic vein and migrate to the right heart and pul¬
monary arteries within a few days, where they mature
and mate after around three to six months, releasing
microfilariae into the circulation to complete the biologi¬
cal cycle. The average prepatent period is about six
months in dogs and eight months in cats.
Adult D immitis may survive for up to five years in
dogs; in cats, the worms develop more slowly and survive
for approximately two years. The slower development
350 In Practice • July/August 2004
PATHOGENESIS
Heartworm disease is primarily a cardiopulmonary dis¬
ease. The severity and extent of lesions depends on the
number and location of adult worms. The presence of
parasites in the pulmonary arteries causes proliferation
of the intima, resulting in narrowing and occlusion of the
vessels, which leads to pulmonary hypertension. Severe
pulmonary arterial disease may cause increased perme¬
ability of the lung vessels with periarterial oedema, and
interstitial and alveolar cellular infiltrate, which can
result in irreversible lung fibrosis. Pulmonary thrombo¬
embolism, due to platelet aggregation induced by the
parasite or in response to the death (spontaneous or
induced by adulticidal treatment) of adult worms, is
another possible sequela of heartworm disease.
In some severe cases, worms can migrate to the right
ventricle, right atrium and caudal vena cava This retro
grade migration induces incompetence of the tricuspid
valve which, in association with concurrent pulmonary
hypertension, is responsible for the clinical signs of
Adult heartworms in (left) the right ventricle of an infected dog and (right) the lung of an infected cat. Pictures, Dr Luigi Venco
and shorter survival of the parasite in cats contributes to
lower worm burdens in this species. Furthermore, micro-
filaraemia is uncommon in cats (occurring in less than
20 per cent of cases) and, when present, is only transito¬
ry. Therefore, cats are poor reservoirs of infection, as
D immitis larvae are less likely to mature to adults in this
species and, when present, are short-lived.
Dirofilaria infection without microfilaraemia is
known as occult heartworm disease.
Life cycle of Dirofilaria immitis. (A) D immitis adult worms live in the
pulmonary arteries and right ventricle of the definitive host. When
sexually mature, they mate and release immature larvae (L1 or
microfilariae) into the circulation. Microfilaraemia is rare in cats
and humans. (B) Microfilariae can be ingested by a mosquito during
a blood meal and mature in the insect to L2 and eventually the
infective stage L3. (C) L3 larvae can penetrate the local connective
tissues of the host during a subsequent blood meal. (D) The larvae
mature from L3 to L4. (E) L4 larvae mature in the subcutaneous
tissues until they reach the pre-adult stage (L5). The LS larvae migrate
to the right heart and pulmonary arteries where they mature and
mate, releasing microfilariae into the circulation to complete the
biological cycle. Modified from Ferasin and Knight (2004)
Adult heartworms (black arrows) in the pulmonary arteries with thromboembolic lesions
(white arrow). Picture, Dr Luigi Venco
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Dog with heartworm infection and ascites secondary to the development of
right-sided heart failure. Picture, Dr Luigi Venco
Postmortem findings in a dog with caval syndrome. The riqht side of the
heart (A) is dramatically distended and the liver (B) appears enlarged
(hepatomegaly) and engorged as a consequence of blood stasis occurring
secondarily to caval hypertension. Picture, Susan Shaw
right-sided heart failure (eg, jugular distension, liver
congestion, ascites). In addition, red blood cell mem¬
branes may rupture as the cells flow through the mass
of parasites, causing haemolysis and haemoglobinaemia.
The concomitant presence of acute right-sided heart fail¬
ure and intravascular haemolysis is referred to as caval
syndrome. Severe cases of caval syndrome can also be
characterised by the presence of adult worms in the cau¬
dal vena cava, thromboembolic events and disseminated
intravascular coagulation. Caval syndrome is less com¬
mon in cats due to the lighter worm burden.
Immune-mediated glomerular disease is also common¬
ly reported in dogs with heartworm disease. It is charac¬
terised by protein-losing nephropathy, which results in
proteinuria, hypoalbuminaemia and, eventually, a reduced
antithrombin III plasma concentration, which may pre¬
dispose the patient to the development of pulmonary
thromboembolism. The antigen that causes this immune-
complex disease is unknown, but could be a substance
released by circulating microfilariae.
In cats, heartworm disease generally induces a diffuse
pulmonary infiltrate and signs of eosinophilic pneumonia.
The death of adult worms may cause acute pulmonary
embolism with severe haemorrhage and oedema of the
affected lobe. Occasionally, immature nematodes can
migrate to sites other than the heart and pulmonary arter¬
ies, causing ectopic infection. Localisation of D immitis
has been reported in the eye, central nervous system, sys¬
temic arteries and subcutaneous tissues. Lctopic infec¬
tions are more commonly seen in cats than in dogs,
suggesting that the parasite is not well adapted to feline
hosts.
CLINICAL SIGNS
Heartworm disease tends to develop slowly and gradual¬
ly and clinical signs are usually only present in cases
with a high worm burden and/or when the host has a
significant allergic response to the parasite. Frequently,
clinical signs of D immitis infection only manifest during
intense exercise and, therefore, sedentary patients may
never show overt signs of heartworm disease. In dogs,
coughing is the most common clinical sign, followed by
tachypnoea and dyspnoea, exercise intolerance, chronic
352
weight loss and syncope. In severe cases, haemoptysis
can be present as a possible consequence of pulmonary
vessel rupture. Jugular distension, hepatomegaly, ascites
and marked exercise intolerance are typical signs ol
concurrent right-sided heart failure. In such patients, a
systolic heart murmur or split-second heart sound can be
heard on thoracic auscultation.
Although the majority of infected cats aire asympto¬
matic, cases of sudden death without any premonitory
clinical signs have been reported. Sometimes, the sudden
death is preceded by an acute respiratory crisis, probably
due to a parasitic embolism and obstruction of a majoi
pulmonary artery. When present, clinical signs of heart-
worm disease in cats are generally vague and non-specific.
These may include anorexia, lethargy, coughing, vomiting,
dyspnoea, syncope and collapse. In some cases, the respi¬
ratory signs are very similar to those generally observed in
feline asthma.
Caval syndrome represents a severe form of heart-
worm disease both in dogs and cats. This is characterised
by respiratory distress, intravascular haemolysis and
haemoglobinuria, signs of right-sided heart failure and.
frequently, disseminated intravascular coagulation.
DIAGNOSIS
Diagnostic investigations are justified only if there is a
previous history of exposure to mosquitoes in an area
where D immitis is likely to be present.
CLINICAL DIAGNOSIS
Cases of heartworm disease may be accompanied by
eosinophilia and basophilia, especially in the early stages
of infection. Microfilariae can also occasionally be seen
on examination of a blood smear. Serum biochemistry
may show changes related to secondary organ involve¬
ment (eg, increased urea, creatinine, liver enzymes)
However, a standard laboratory work-up is usually in¬
sufficient to make an aetiological diagnosis. A high
eosinophilic population may be found on bronchoalveo-
lar lavage, especially in cats, although differential diag¬
nosis from feline asthma is often difficult.
Survey radiographs of the thorax may show a bulge ai
the level of the main pulmonary artery, enlarged and tor-
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Echocardiogram of a dog with heartworm disease; right
parasternal short axis view at the level of the aorta (Ao).
Some adult worms are visible as hyperechoic structures
(arrows) in the main pulmonary artery (PA). RVOT Right
ventricular outflow tract. Picture, Dr Luca Benvenuti
tuous pulmonary arteries and an intersticial and/ui alveu
lar pattern. The right side of the heart may be enlarged
and the caudal vena cava, hepatomegaly and ascites
can be observed in cases of severe infection with caval
syndrome. The vascular changes are less dramatic in
cats, and radiographic abnormalities (eg, overinflation
of the lung, bronchial or alveolar pattern) resemble
those observed in cases of feline asthma or Aeluro-
strongylus abstrusus infection. Occasionally, adult heart-
worms can be visualised on echocardiography at the
level of the main pulmonary artery, right ventricle
and right atrium. The echogenicity of the body wall of
the parasite gives rise to a double-lined hyperechoic
appearance. In severe cases, echocardiography may also
reveal signs of pulmonary hypertension (eg, right ven¬




If present, microfilariae can be easily identified on direct
microscopic examination of a drop of fresh blood
because they can vigorously move the surrounding red
blood cells. However, although this method offers an
easy and inexpensive diagnosis, it is not sufficiently sen¬
sitive, especially when there is a low concentration of
microfilariae in the bloodstream. Filtration methods (eg,
Difil-test; EVSCO Pharmaceuticals, Buena, New Jersey,
Thoracic radiograph of a dog with heartworm disease. The
presence of adult heartworms in the pulmonary arterial
circulation causes enlarged and tortuous pulmonary
arteries (arrows) and a mixed interstitial/alveolar pattern
(arrowheads) affecting, in particular, the caudal lung fields.
Picture, Susan Shaw
USA) and the modified Knott's test (haemolysis, cen-
trifugation and staining with methylene blue) are more
sensitive and allow morphological examination of the
microfilariae. In cats, given the absence or short-term
presence of circulating microfilariae, these tests have
little practical value.
Antigen tests
ELISA antigen tests detect specific circulating proteins
released by the reproductive tract of mature female
worms. These are available as either in-house or labora¬
tory tests and their sensitivity and specificity approach
100 per cent (see top table on page 354). The antigen
levels become undetectable eight to 12 weeks after adul-
ticidal therapy and this should be taken into account
when re-screening for heartworm disease or evaluating
the response to treatment. Small worm burdens, the
presence of immature females or male-only infections
are common causes of low antigen titres and false
negative results, especially in cats, where these circum¬
stances occur more frequently. In dogs, specific aggluti-
•Vn LI larva (microfilaria) identified using the modified Knott's test. The
arva is surrounded by red blood cells and its dark colour is due to the






Some in-house antigen diagnostic kits available for canine
Dirofilaria infection. (A) SNAP Canine HW; IDEXX Laboratories;
(B) SoloStep CH; Heska; (C) Witness HW; Synbiotics
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SEROLOGICAL TESTS FOR THE DETECTION OF HEARTWORM ANTIGENS IN DOGS AND CATS




(%) (range) Species Type of sample
PetChek IDEXX Laboratories ELISA
(microwell
SNAP Canine HW IDEXX Laboratories ELISA
(membrane)
SNAP Feline HW IDEXX Laboratories ELISA
(membrane)
SoloStep CH Heska Lateral flow
immunochromatography
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nation and immunochromatography techniques are also
available. An antigen test performed too soon after infec¬
tion (first six to seven months) may yield false negative




Antibody tests are currently available for routine screen¬
ing of feline heartworm infection, either as in-house or
laboratory tests (see table below). The presence of anti¬
bodies provides information about previous exposure,
but not necessarily current infection. Consequently, anti¬
body tests are more useful to help rule out infection
rather than confirm it. These tests are no longer used in
dogs given their low specificity and the availability of
highly reliable antigen tests.
PCR-based tests
Polymerase chain reaction (PCR)-based tests offer a very
sensitive and specific diagnostic tool for routine identifi¬
cation of mature and immature adult worms, especially
in unconventional hosts. However, at present, these tests
are not widely available.
ADULTICIDAL TREATMENT
The decision as to whether or not to treat a dog with
heartworm disease and the relative prognosis depend on
the severity of the infection. In an attempt to assess this,
animals may be classified as:
■ Class l. Patients with subclinical or no clinical signs;
■ Class 2. Patients with mild to moderate clinical signs
and mild to moderate radiographic changes;
■ Class 3. Patients with severe clinical signs (eg, per¬
sistent cough, haemoptysis, dyspnoea, right-sided heart
failure) and severe radiographic changes.
The prognosis for dogs in class 1 following adulti-
cidal treatment is generally very good. Dogs in class 2
may have a positive outcome. Animals in class 3 have a
guarded prognosis due to the high risk of pulmonary
thromboembolism; in these cases, the potential compli¬
cations of adulticidal treatment should be thoroughly
discussed with the owners.
In cats, adulticidal treatment may be dangerous even
in patients with low grade infection, and pulmonary
thromboembolism due to premature death of parasites
1 SEROLOGICAL TESTS FOR THE DETECTION OF HEARTWORM ANTIBODIES IN CATS





















84 (60-97) 85 (81-89) Serum, plasma,
whole blood
Assure FH Synbiotics ELISA
(wand)
68 (43-87) 93 (89-95) Serum, plasma
Witness HW Synbiotics Lateral flow
immunochromatography
? ? Serum, plasma,
whole blood
? Published data not available
From Ferasin and Knight (2004)
354 In Practice • July/August 2004
administration of melarsomine, the likelihood of pul¬
monary thromboembolism can be minimised with cage
rest and corticosteroids at anti-inflammatory doses.
If adulticidal treatment is declined by the owner,
monthly administration of prophylactic doses of ivermectin
may represent a reasonable option because it will prevent
further infection and may kill some adult nematodes.
Patients with severe caval syndrome may benefit from
physical removal of worms from the right side of the
heart and the main pulmonary artery using flexible croco¬
dile or basket-type retrieval forceps. This procedure is
complex, requires general anaesthesia and fluoroscopic
imaging, but may reduce the risk of thromboembolism
following subsequent adulticidal treatment.
MICROFILARICIDAL TREATMENT
Circulating microfilariae should be eliminated four to six
weeks after successful adulticidal treatment. There are
no approved drugs for microfilaricidal treatment. How¬
ever, a single administration of ivermectin (50 ftg/kg)
or milbemycin oxime (500 pg/kg) has been shown to be
highly effective in eliminating microfilariae from the cir¬
culation within a few hours. Moxidectin and selamectin
are also known to be potent microfilaricides but, at pre¬
sent, there is little experience of their use in the clinical
setting. Oral prednisolone (1 to 2 mg/kg) administered
with microfilaricidal drugs may control anaphylactic
reactions which may occur secondarily to the sudden
death of a large number of microfilariae.
PREVENTION
Prophylaxis of heartworm disease should be considered
for all dogs and cats living in endemic areas during the
transmission period. For example, in northern Italy,
where a high prevalence of heartworm disease has been
reported, mosquitoes are only present during the summer
and, therefore, prophylaxis is recommended from May to
October.
The currently approved prophylactic drugs are listed
in the table below. However, only milbemycin oxime
(Program Plus; Novartis) and selamectin (Stronghold;
1 CHEMOPROPHYLACTIC DRUGS AVAILABLE FOR THE PREVENTION OF HEARTWORM DISEASE I





























Fort Dodge Moxidectin Dog Monthly Oral
Proheart 6
(Guardian 6)
Fort Dodge Moxidectin microspheres Dog Six-monthly Injectable
Stronghold*
(Revolution)
Pfizer Selamectin Dog, cat Monthly Topical
('spot on')
Filaribits Plus Pfizer Diethylcarbamazine Dog Daily Oral
citrate (+oxibendazole)
♦Licensed in the UK for the prevention of heartworm
From Ferasin and Knight (2004)
J
Adult heartworms can be removed from the right side of the
heart and pulmonary artery using flexible crocodile retrieval
forceps inserted through a jugular vein. Picture, Dr Luigi Venco
is a common complication. Considering that some cats
may undergo spontaneous clinical remission if parasites
die naturally, periodic monitoring of the patient is more
appropriate than adulticidal treatment. Cats with respirato¬
ry signs can be treated symptomatically in the same way
as patients with feline asthma. Cage rest, oxygen supple¬
mentation, fluid therapy, bronchodilators and injectable
steroids (eg, dexamethasone) can be used to stabilise
acutely ill cats. Adulticidal treatment should only be con¬
sidered for cats in a stable condition that fail to respond to
supportive treatments.
Adulticidal treatment involves the administration of
a new generation arsenical compound, melarsomine di-
hydrochloride (Immiticide, Merial; this product is not
licensed for use in the UK). Melarsomine is less nephro¬
toxic and hepatotoxic than its predecessor thiacetars-
amide, and has a higher efficacy. Melarsomine is injected
intramuscularly into the lumbar muscles at a recommend¬
ed dose of 2-5 mg/kg, repeated after 24 hours. However,
only a single dose should be administered to class 3 dogs,
to kill just a proportion of worms and hence minimise
the risk of pulmonary thromboembolism. If the patient
remains stable, the standard adulticidal protocol can be
administered one month later. In the week following the
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Of the delegates who attended The European
Parasitology Tour 2004:
agreed that modern topical adulticides often do NOT kill fleas fast enough to prevent egg
production in the 3rd and 4th week.
agreed that topical adulticides encourage clients to take a "flreflghting" approach to flea control.
agreed that PROGRAM encourages a preventative approach.
said that given the choice, their clients would generally prefer to use flea control that cannot
rub oft on them or their children.
agreed that an IGR (like PROGRAM) should be used in nearly all cases.
Who are we to argue? To find out more contact us on 0800 854 100
„, 1,% I
iOVARTIS
PROGRAM and PROGRAM b Month Intertable tor Cats contain lutenuron. PROGRAM Plus contains lutenuron and
milbemycin oxime I RUM !. tor further information Olease contact the Practice Supoort Line on (J8UU 8b4 iuu or write tO;
Novartffltnimai Health UK ltd., New Cambridge House, Litlington, Nr Royston, Herts, SG8 USS.






n Parasitology Tour 20
Pets travelling from the UK Subcutaneous dirofilariasis
When pets travel from the UK to areas where heart-
worm disease has been reported, prophylactic inter¬
vention should be considered. If a dog or cat has
been exposed to mosquitoes in an endemic area for
less than one month, a single administration of a
prophylactic agent immediately after its return to
the UK should be sufficient to prevent the disease.
Conversely, for longer stays in endemic areas, own¬
ers should administer the drug on a monthly basis,
starting within a month of their departure.
Pfizer) are licensed in the UK for the prevention
of heartworm disease. Preventive drugs kill migrating
larvae of D immitis up to the sixth week of infection.
Therefore, they all provide a high degree of protection
when administered on a monthly basis. If a patient miss¬
es one or more doses in the prophylactic schedule, it
should be tested for heartworm disease after six months.
The risk of incomplete protection due to owner non¬
compliance can be eliminated with a recently introduced
sustained-release injectable formulation of moxidectin
(Proheart 6; Fort Dodge).
High doses of ivermectin and milbemycin oxime are
potentially toxic in approximately one-third of collies.
However, side effects are not observed in these breeds
when prophylactic drugs are administered at the recom¬
mended doses.
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Subcutaneous dirofilariasis is primarily caused by Dirofilaria (Nochtiella) repens,
which parasitises domestic dogs in Europe (especially Italy, Spain, Greece, the for¬
mer Yugoslavia and France), Africa and Asia, and bears in the USA and Canada.
D repens is also transmitted by a variety of mosquito species and its biological
cycle is very similar to that of D immitis except that adult worms live in subcuta¬
neous tissues. The clinical significance of adult worms in dogs and cats has not
been clearly defined, but nodular skin lesions, abscesses and immunological reac¬
tions have been described. Treatment is achieved by surgical removal of adult
worms from the skin lesions. Although there are no drugs currently licensed for
the prevention of D repens infection, prophylaxis can be achieved using the
same chemoprophylactic regimen used for D immitis.
Human dirofilariasis
Although humans are considered incidental hosts, D immitis and D repens infec¬
tions have been reported in people and represent an important zoonotic risk,
especially in endemic areas. In recent studies conducted in southern Europe, a
high prevalence (26 to 37 per cent) of clinically healthy people were found to be
positive for antibodies against D immitis. D immitis may cause pulmonary injuries
in humans when an immature parasite dies after having entered the right ventri¬
cle, causing embolisation and small lung infarctions, which may appear as soli¬
tary nodules on thoracic radiography. D repens is occasionally found in people in
various body locations including the conjunctiva, eyelids, scrotum, inguinal area,
breasts, arms and legs. The diagnosis of human dirofilariasis depends mainly on
microscopic evaluation of the morphological characteristics of the nematode in
histopathological specimens.
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in dogs and cats YVONNE McGROTTY and ROSS DOUST
Collection of purulent fluid
within the abdominal cavity
due to ruptured pyometra.
Turbid fluid is suggestive
of bacterial peritonitis
Management of peritonitis
PERITONITIS is localised or diffuse inflammation of the peritoneal cavity and is most commonly associated
with bacterial contamination from the gastrointestinal tract. Mortality associated with this condition
is high, and rapid diagnosis and early surgical and/or medical intervention is essential to optimise the
outcome. This article describes the diagnostic tests, and various medical and surgical options available
for the treatment of peritonitis in small animals, with emphasis on the management of bacterial (septic)
peritonitis and uroperitoneum (urine peritonitis). In addition, it discusses the factors that influence
the prognosis and outcome of affected cases.
CLASSIFICATION OF PERITONITIS
Peritonitis is the severe and often fatal inflammation of
the peritoneal lining and abdominal viscera and can be
classified as either primary or secondary. Primary gener¬
alised peritonitis occurs as a result of haematogenous
spread ot an infectious agent to the peritoneum. Sec¬
ondary generalised peritonitis results from direct bacteri¬
al or chemical contamination of the abdominal cavity
and is a more common presentation in dogs (see box
below). Frequent causes of secondary peritonitis include
Causes of secondary peritonitis
Aseptic






■ Sclerosing encapsulating peritonitis
Septic
■ Leakage of gastrointestinal tract contents
(rupture, dehiscence)
■ Urinary tract rupture (with bacterial infection)
■ Reproductive tract rupture (pyometra)
■ Biliary tract rupture (with bacterial infection)
■ Penetrating abdominal wounds
■ Iatrogenic (bacteria introduced during surgery)
penetrating abdominal wounds, rupture of a hollow vis-
cus or surgical contamination. Secondary peritonitis can
be further classified as either septic or aseptic. Septic
causes are often associated with rupture or dehiscence of
surgical wounds of the gastrointestinal tract and, as a
result. Gram-negative bacteria are commonly isolated
from the peritoneal cavity in such cases. Aseptic causes
include pancreatitis, neoplasia and sterile foreign bodies
(eg, surgical swabs).
Chemical peritonitis results from leakage of bile, urine
or pancreatic secretions into the abdominal cavity. Ab¬
dominal trauma or necrotising cholecystitis can lead to
rupture of the biliary system and subsequent leakage of
toxic bile salts into the peritoneal cavity. Uroperitoneum
is usually mild, unless bacterial contamination is present;
however, electrolyte abnormalities (hyperkalaemia) asso¬
ciated with uroperitoneum can cause severe clinical signs.
Release of pancreatic enzymes causes severe peritonitis
and initiates a systemic inflammatory response.
DIAGNOSIS
Clinical signs associated with peritonitis can be vague
and non-specific. Haematology results can be variable.
However, in some cases, serum biochemistry may help
to identify the type of peritonitis present. Bile peritonitis
results in increased concentrations of total bilirubin and
liver enzymes, while uroperitoneum is associated with
increased urea, creatinine and potassium concentrations.
Serum protein concentrations are often decreased in cases
of bacterial peritonitis and also in cases of aseptic peri¬
tonitis as a result of protein exuding into abdominal fluid.
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Lateral abdominal radiograph demonstrating loss of contrast due to free
abdominal fluid
Lateral radiograph showing increased abdominal contrast due to free
abdominal air
Abdominal radiographs may demonstrate a loss of
contrast due to the presence of an effusion. Free abdomi¬
nal gas is suggestive of gastrointestinal tract rupture or
penetrating abdominal injury and is always an abnormal
finding unless the animal has had recent abdominal
surgery or abdominocentesis using an open needle. Free
abdominal air can be identified on radiographs for 14
days or occasionally longer following abdominal surgery.
Abdominocentesis is a very useful tool for the diagno¬
sis of peritonitis (see box on the right), but can produce
negative results in early cases or in those with localised
peritonitis. Approximately 5 to 6 ml/kg of abdominal fluid
is required to produce a positive abdominal tap. The peri¬
toneal cavity of healthy animals contains <1 ml/kg of
clear yellow transudate which reduces friction between
the abdominal organs. Abdominal ultrasound is a more
sensitive means of detecting smaller volumes of peritoneal
fluid and is used to identify an appropriate site for
abdominocentesis in cases with localised peritonitis.
Alternatively, diagnostic peritoneal lavage can be per¬
formed if abdominocentesis is negative, but there is a high
index of suspicion for peritonitis (see box on the right).
Turbid fluid is suggestive of septic peritonitis. Green
fluid suggests bile peritonitis and a significant volume of
clear yellow fluid may indicate urine leakage. The fluid can
be classified as transudate, modified transudate or exudate
using the criteria outlined in the table on the right. Total
solids can be measured using a refractometer and give an
estimate of the protein content of the fluid. All fluid sam¬
ples require further cytological and bacteriological analysis.
Abdominocentesis
■ Clip and surgically prepare the skin around the umbilicus over the ventral
midline of the abdomen
■ Insert an 18 to 20 gauge needle or intravenous catheter just caudal and later¬
al to the umbilicus at a 30° to 40° angle
■ A four-quadrant tap is recommended (cranial and caudal sites on both the left
and right sides of the midline). Care should be taken to avoid the spleen and
bladder
■ Allow fluid to drain freely from the needle into a sterile container (EDTA
tubes for cytology and cell counts, fluoride oxalate tubes for glucose, and plain
tubes for biochemistry and bacteriology)
Diagnostic peritoneal lavage
If no fluid is obtained using the above technique, diagnostic peritoneal
lavage is carried out as follows:
■ Infuse 22 ml/kg of lactated Ringer's solution (warmed to body tempera¬
ture) into the abdomen via the needle/catheter
■ Gently rock the animal to encourage distribution of the fluid within the
abdominal cavity





(x109/litre) Cell types Possible cause(s)
True transudate <25 <1 Mononuclear Hypoproteinaemia











Septic abdominal exudate demonstrating toxic neutrophils
with intracellular bacteria
Bacterial peritonitis may be diagnosed by demonstrat¬
ing the presence of degenerate or toxic neutrophils with
intracellular bacteria in the peritoneal fluid and this find¬
ing warrants surgical exploration of the abdomen. An
abdominal fluid glucose concentration of <2-80 mmol/
litre is consistent with a septic effusion. However, a dif¬
ference of >112 mmol/litre between the concentration of
glucose in the blood and abdominal fluid is considered a
more reliable indicator of a septic effusion than abdomi¬
nal fluid glucose alone (Boncynski and others 2003).
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Indications for exploratory abdominal surgery
■ Intracellular bacteria identified in peritoneal fluid
■ Penetrating abdominal injury
■ Vegetable fibres in peritoneal fluid
■ Peritoneal fluid creatinine concentration >serum creatinine concentration
■ Peritoneal fluid potassium concentration >serum potassium concentration
■ Peritoneal fluid bilirubin concentration >serum bilirubin concentration
■ Free air in abdominal cavity (normal for up to 14 days following abdominal
surgery)
■ Haemoabdomen unresponsive to medical management (ie, continued bleed¬
ing despite medical intervention and exclusion of coagulopathies)
Uroperitoneum can be confirmed by demonstrating
higher concentrations of creatinine and potassium in the
effusion than serum concentrations obtained at the same
time. If urinary tract rupture is suspected, contrast stud¬
ies should be performed to identify the site of the rupture
prior to surgical correction. Measures to reduce serum
potassium levels should be implemented before anaes¬
thesia and surgery are considered (see later), as hyper¬
kalemia has dramatic cardiovascular effects.
bile peritonitis is confirmed by demonstrating higher
concentrations of bilirubin in the abdominal fluid than in
the serum. Increased amylase and lipase concentrations
in abdominal fluid compared to serum are suggestive of
pancreatitis, but pancreatitis often occurs in conjunction
with other types of peritonitis.
Surgical exploration of the abdominal cavity is war¬
ranted in many cases of peritonitis in order to identify and
correct the underlying cause (see box above).
MANAGEMENT OF UROPERITONEUM
Uroperitoneum occurs following rupture of the urinary
tract (eg, trauma, bladder obstruction) and often results in
severe electrolyte abnormalities. Hyperkalemia associat¬
ed with uroperitoneum can have profound cardiovascular
consequences and must be resolved prior to anaesthesia
and surgical intervention. Treatment of severe, life-threat¬
ening hyperkalaemia is outlined in the box below.
Rupture occurs more frequently in the lower urinary
tract (bladder and urethra). A positive contrast retrograde
urethrogram (vaginourethrogram) is obtained to identify
a rupture in this area (see page 365). A non-ionic, water
soluble contrast agent should be used to minimise exac¬
erbation of the chemical peritonitis. In cases where the
Management of hyperkalaemia
■ Sodium chloride 0-9 per cent (up to 40 to 60 ml/kg, rapid intravenous infusion)
■ Calcium gluconate 10 per cent (0-5 to TO ml/kg, slow intravenous infusion)
■ Glucose 50 per cent (1 to 2 ml/kg intravenously)
■ Regular insulin (1 unit/kg intravenously) and glucose (2 g/unit of insulin intra¬
venously)
■ Sodium bicarbonate 8-4 per cent (0-5 to 1 ml/kg, slow intravenous infusion)
Note that not all of the above measures will be required. Most cases respond to
a combination of intravenous fluids and glucose. Calcium gluconate reduces the
effects of hyperkalaemia on the myocardium while other methods aimed at
reducing potassium take effect.
retrograde study is inconclusive, an intravenous urogram
can be performed to identify upper urinary tract (kidney
or ureter) rupture. If no site of rupture can be identified
with these studies and a diagnosis of uroabdomen has
been confirmed, it may be that a small rupture has
occurred, and has already healed. In these cases,
exploratory surgery may not be necessary and treatment
with urinary diversion and intravenous fluid therapy for
five to seven days may be more appropriate.
Surgical technique
For lower urinary tract rupture, an indwelling urinary
catheter is placed to remove urine and bypass the area
of leakage. Urethral leaks, for example, are first treated
with urinary diversion for seven to 10 days. If the urine
is leaking from the upper urinary tract (ie, the kidneys
or ureters), it should be removed from the abdomen by
abdominocentesis three to four times a day, depending
on the rate of accumulation. With effective urine diver¬
sion. hyperkalaemia should resolve within 12 to 24 hours
with aggressive fluid therapy alone.
Once the site of leakage has been confirmed, a mid¬
line coeliotomy is performed to repair the bladder, ure¬
thra or ureter. In cases where a ruptured ureter cannot
be repaired, the options are either to re-implant the ureter
in the bladder wall or, as a last resort, to perform a
ureteronephrectomy. If healing of a urethral leak does
not occur following urinary diversion, repair of the ure¬
thra may be attempted or. if the damage is too severe, a
urethrostomy may be performed (perineal or prepubic,
depending on the length of viable urethra proximally).
Bladder wall ruptures are repaired by routine debride¬
ment of any tissue of questionable viability and closure
of the resultant cystotomy incision in a single or double
layer with simple interrupted or continuous appositional
suture patterns. Care must be taken around the dorsal-
caudal aspect and at the site of insertion of the ureters,
but otherwise debridement should be aggressive. The




Almost all patients presenting with bacterial peritonitis
will be hypovolaemic as a result of fluid and protein
exudation into the abdomen. As a result, most patients
are poor candidates for anaesthesia and surgery and
require aggressive fluid therapy to restore cardiovascular
stability prior to definitive surgical treatment.
Fluid therapy
Shock rates of crystalloids (up to 90 ml/kg/hour in the
dog and 60 ml/kg/hour in the cat) are often required ini¬
tially; care should be taken in cases with haemoabdomen
as the increase in blood pressure may result in further
haemorrhage (hypotensive resuscitation to a mean arteri¬
al pressure of around 60 mmHg is less likely to cause
bleeding). Bolus crystalloid therapy (10 to 20 ml/kg over
20 minutes) may also be used and may be safer as it
is less likely to result in volume overload. Additional
boluses can be administered depending on the clinical
response. The use of natural or synthetic colloids (eg.
hydroxyethyl starches) may be beneficial. Most patients
with a septic effusion will be hypoproteinaemic as a
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result of protein loss into the abdominal fluid. High fluid
rates and volumes in hypoproteinaemic patients can lead
to oedema as a result of decreased oncotic pressure and
so synthetic or natural colloids are often indicated.
Excessive volumes of colloids can lead to volume over¬
load, coagulopathies and haemodilution.
Antimicrobials
An empirical choice of broad-spectrum antimicrobials
should be administered systemically once a diagnosis of
bacterial peritonitis is confirmed. A combination of anti¬
microbials with activity against Gram-negative, Gram-
positive and anaerobic bacteria should be administered
intravenously while awaiting the results of culture and
sensitivity testing of the peritoneal fluid (see box, above
right). The most common isolates from cases of bacterial
peritonitis are Escherichia coli, and Clostridium species
which reflect the high incidence of gastrointestinal rup¬
ture. E coli is the most common isolate in cases with bile
peritonitis.
Heparin therapy
The use of heparin therapy to reduce fibrin formation is
controversial. Heparin was shown to improve survival in
dogs with experimental peritonitis (Gupta and Jain 1985).
SURGICAL TREATMENT
Aims
The main aims of surgical treatment of bacterial peri¬
tonitis are to:
■ Remove the underlying source of infection:
■ Reduce the bacterial population within the peritoneal
cavity;
■ Remove foreign material, and the cells and mediators
of inflammation;
■ Prevent recurrence.
Surgical exploration of the abdomen is required to
identify and remove the source of infection in all cases
of bacterial peritonitis.
Surgical technique
Delayed wound healing and an increased incidence of
suture line disruption may occur in cases of septic peri¬
tonitis and, hence, surgical techniques and material selec¬
tion may need to be modified. Suture materials that
provide prolonged support are recommended, and non¬
absorbable materials may be considered. Monofilament
suture materials are preferred as bacteria may colonise
Antimicrobial combinations
■ Amoxycillin/clavulanic acid (20 mg/kg intravenously every eight hours) +
metronidazole (10 mg/kg intravenously every 12 hours)
■ Cefuroxime (20 mg/kg intravenously every eight hours) + metronidazole
(10 mg/kg intravenously every 12 hours)
■ Ampicillin (22 mg/kg intravenously every eight hours) + fluoroquinolone
(5 mg/kg intravenously every 24 hours). This combination is not licensed for
intravenous use
the interstices of braided materials and form colonies that
are protected from the immune system. Catgut is definite¬
ly contraindicated in cases of septic inflammation as it
degrades more rapidly than normal. Simple interrupted
appositional suture patterns should be used. Serosal
patching may be considered to prevent potential leakage
from a hollow viscus in areas where an omental patch
would be appropriate in the non-inflamed abdomen.
A midline coeliotomy from the xiphoid to the pubis
is mandatory in all cases to allow for a complete exami¬
nation of the abdomen. Effusion is removed by suction
and the abdomen is explored thoroughly to identify the
site(s) of contamination. Exploration may be performed
by dividing the abdomen into specific regions (quad¬
rants) or, more commonly, by examination of the indi¬
vidual organs, including the diaphragm and body wall.
The examination is completed even if a lesion is identi¬
fied and then the underlying cause is corrected.
Necrotic and fibrinous areas are debrided and the
abdomen thoroughly lavaged with copious volumes of
warm, sterile isotonic fluid prior to closure. Initially, a
volume of 200 to 300 ml/kg is recommended, but lavage
should continue until the return fluid is clear. As much
fluid as possible should be removed before closure.
Debridement and lavage decreases the levels of intra¬
abdominal bacteria, foreign material contaminants, inflam¬
matory mediators and peritoneal fibrin. Lavage fluid left
in the abdomen impairs immune function
by reducing chemotaxis of inflammatory
cells and also prevents antibiotics reaching
effective concentrations.
A number of approaches have been
described for the management of bacterial
peritonitis in small animals following
surgical correction of the underlying
cause (see box on the riuht).
Methods used to manage
peritonitis
■ Open peritoneal drainage
■ Sump-Penrose drainage
■ Closed suction drainage
■ Peritoneal lavage
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OPEN PERITONEAL DRAINAGE
Open peritoneal drainage treats the abdomen as an
abscess and helps to remove bacteria, foreign material,
and inflammatory cells and mediators. The procedure is
indicated where there is severe systemic illness, ineffec¬
tive drainage with conventional techniques or extensive
suppuration or necrosis of the deep layers of the abdomi¬
nal incision. Although in many cases, open peritoneal
drainage is considered to be a superior form of treatment
for severe peritonitis, it should only be attempted where
adequate 24-hour monitoring and intensive care facilities
are available. In addition, due to the high incidence of
complications associated with the technique (see box
below) there should be provision for synthetic and natur¬
al colloid administration.
cular fascia, subcutaneous fat and skin. The cranial half
to two-thirds of the wound is loosely sutured with a sim¬
ple continuous or simple interrupted suture pattern, leav¬
ing a gap between the wound edges. The gap between
the sutures should be sufficient to allow a finger to be
inserted into the abdomen.
The open wound is covered with sterile gauze followed
by a sterile disposable nappy, which is secured in place
with gauze bandages. Male dogs are catheterised to pre¬
vent urinary contamination of the open wound. Sterile
dressings are changed at least every four to six hours ini¬
tially or as soon as there is fluid strikethrough. Further
dressing changes are performed once daily as a minimum,
or more frequently if the dressing becomes saturated.
Soiled dressings are weighed to monitor fluid loss from
Criteria for secondary closure
■ Decreased volume of fluid draining from the abdominal wound
■ Absence of intracellular bacteria in the abdominal fluid
■ Reduced cellularity of the abdominal fluid
Drainage may continue for one to 14 days (average four days). If intra¬






■ Fluid losses via the wound




The abdomen is surgically explored and the cause of
the peritonitis surgically corrected. Copious amounts of
warmed saline should be used to lavage the abdominal
cavity and then removed by suction. The midline abdom¬
inal incision is divided into cranial and caudal segments.
The falciform fat is removed to allow for more effective
drainage. Closure of the caudal segment of the wound is
routine, with apposition of the external abdominal mus-
Gaps are left between sutures to allow a finger to be
inserted into the abdomen to aid adhesion break down
The wound for open peritoneal drainage is covered with sterile gauze
(above) and then by a sterile nappy (right)
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the open wound. The animal is encouraged to stand during
dressing changes and a sterile drape is placed underneath
in case herniation of abdominal contents should occur.
Herniated guts are gently pushed back into the abdomen.
Repeated extensive herniations may indicate that a repeat
operation is required and that the size of the opening
should be reduced. Adhesions are broken down once daily
by inserting a sterile gloved hand between the sutures.
Opioid analgesics (eg, pethidine, morphine) are adminis¬
tered before adhesion break down is attempted.
An alternative technique is to place suture loops in the
cranial muscular fascia so that a single length of umbilical
tape can be threaded through the loops for loose closure,
in a bootlace pattern with the incision edges separated for
drainage. The animal is anaesthetised once or twice daily
for dressing changes; the tape is removed, the abdomen
thoroughly lavaged (as above) and a fresh tape replaced.
POSTOPERATIVE MONITORING
All animals undergoing open peritoneal drainage require
24-hour monitoring and intensive nursing. Monitoring
of patients with bacterial peritonitis managed using open
peritoneal drainage should include paying close attention
to the following parameters:
■ Vital signs (temperature, pulse, respiration, mucous
membrane colour, capillary refill time);
■ Urine output;
■ Packed cell volume/total solids;
■ Electrolytes;
■ Albumin;
■ Arterial blood pressure;
■ Bodyweight and nutritional status;
■ +/- Central venous pressure.
In addition, adequate analgesia should be provided
using systemic opioid analgesics or epidural anaesthesia.
ABPOMIRIAL PRAIIMAGE
A variety of different drain materials and designs have
been used in veterinary and human medicine. Drains are
used in humans to maintain drainage of intra-abdominal
abscesses, to control a fistula that cannot be exteriorised
or for continuous postoperative lavage. Most drains do
not effectively drain the entire cavity and are susceptible
to blockage of the lumen or exit site by omentum;
furthermore, nosocomial infection is a significant risk in
affected animals.
The two drains used most successfully in small
animals are the triple lumen sump drain and the Parker
peritoneal dialysis catheter, both of which are available
commerically. Alternatively, triple lumen sump drains
may be constructed from a Penrose drain and a Foley
catheter. The tip of the Foley catheter, including the bal¬
loon, is cut off and the tube fenestrated. Fenestrations are
made along the length of the Penrose drain, which is
placed over the Foley catheter and secured with an encir¬
cling suture at the external end.
Drains are placed along the ventral abdominal wall,
and sutured to the abdominal wall using a Chinese finger
trap pattern. Triple sump drains are attached to a closed
suction system that allows continuous suction of the
cavity. Air is allowed into the abdominal cavity, via the
former balloon lumen, to facilitate drainage. Indwelling
drains allow the infusion of lavage fluid on a regular
basis, although in an abdominal cavity with fibrinous
adhesions the lavage fluid may not be distributed
throughout the entire cavity. Omentectomy may reduce
problems with drain obstruction, but may potentiate
infection. An alternative is to surgically secure the omen¬
tum onto areas of potential leakage away from the drain.
There is no evidence that the postoperative complica¬
tions associated with open peritoneal drainage (with the
exception of herniation) are reduced by the use of drains.
IMUTRITIOIMAL SUPPORT
Nutritional support is essential in all cases of peritonitis
as these animals are usually catabolic as a result of sep¬
sis, hypoproteinaemia and a reduced nutritional intake.
The use of naso-oesophageal, oesophagostomy, gastros¬
tomy or jejunostomy tubes is encouraged. Enteral feed¬
ing stimulates the gut and can help prevent paralytic
ileus associated with abdominal surgery and infection.
Parenteral nutrition can be used in cases where enteral
nutrition is not possible, although this approach is asso¬
ciated with higher complication rates.
SUMMARY
Peritonitis, regardless of the underlying cause, is associat¬
ed with a high mortality rate. Irrespective of whether
patients are managed medically or surgically, a high stan¬
dard of perioperative care is vital to optimise the outcome.
In most cases, 24-hour monitoring is essential along with
access to natural and synthetic colloids for cases of septic
peritonitis. If open peritoneal drainage is considered an
appropriate therapeutic option, the clinician is encouraged
to refer the patient to a hospital that has adequate facilities
for perioperative monitoring and intensive care.
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Healthcare in the modern dairy herd
AS the UK dairy industry continues to change, the role of the veterinary surgeon on the modern dairy
farm has evolved and is increasingly that of an adviser, encompassing all aspects of health, productivity
and welfare. Together with other specialists, such as nutritionists, housing consultants and breeding
companies, the practitioner's involvement spans all areas of farm management. Undoubtedly, veterinary
intervention in key areas such as farm assurance, fertility, nutrition, and disease monitoring and
prevention can have a significant impact on the productivity of a unit. This article reviews these areas,
providing examples of where veterinary effort may best be directed. Future articles in In Practice will
elaborate on specific elements of veterinary input into the dairy enterprise.
IMPLICATIONS OF THE DRIVE FOR
PROFITABLE MILK PRODUCTION
The UK dairy industry is going through a period of major
restructuring, with many producers giving up farming
altogether. Since 1996. 25 per cent of dairy producers
have left the industry. 7 per cent of which gave up during
2002 mostly because of low milk prices and the 2001
outbreak of foot-and-mouth disease (FMD). The remain¬
ing producers have tended to expand herd size in order to
reduce overheads and remain profitable. One survey of
costs conducted last year (HSBC/ADAS 2003) showed
the gap between the top and bottom 25 per cent of farms
to be widening. Total costs per litre of milk produced
were 16-9 pence per litre (ppl) for the top 25 per cent
compared with 21-9 ppl for the bottom 25 per cent. The
top 25 per cent remained in profit (+3-1 ppl) while the
middle 50 per cent broke even (+0-1 ppl) and the bottom
25 per cent lost money (-3-2 ppl).
It may therefore be concluded that, for dairy farming
to remain viable in the UK, production costs must be
kept under control, especially as milk prices are predict¬
ed to fall to 15 ppl by 2007 (Colman and Harvey 2004).
The veterinary surgeon looking after the modern dairy
herd plays a key role in this as both clinical and subclini¬
cal disease will have a major impact on production costs.
The costs of the major diseases in dairy animals have
been well quantified and targets are available (Esslemont
and Kossaibati 2002) which, if achieved, should ensure
profitable milk production.
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Many cows are housed in buildings best described as 'slums'
Cow comfort may be dramatically improved by simple
alterations to cubicles such as replacing the lower rail
with rope
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A full clinical examination should be carried out on
all sick cows
Animal welfare is central to profitable milk produc-
tion. Neglect of welfare in terms of housing and feeding
will inevitably lead to falling profitability which invari¬
ably results in a further decline in welfare standards
until, finally, the business becomes non-viable and shuts
down, to the detriment of both animals and producers.
The health of the modern dairy cow is largely a reflec¬
tion of her environment and management in relation
to the physiological demands placed on her with regard
to lactation and reproduction. Consequently, effective
healthcare should revolve around providing an environ¬
ment and management system that satisfies the basic
requirements of the cow. A herd that truly enjoys
the 'five freedoms' (Webster 1994) is unlikely to have
major health problems and. furthermore, is likely to be
profitable.
However, many cows are housed in cubicle buildings
erected 25 to 30 years ago when cattle were considerably
smaller. The result is poor cubicle acceptance and signif¬
icantly reduced lying times. This is associated, all too
often, with unacceptably high levels of lameness which
have adverse effects on production and profitability.
Current farm profitability is such that it is usually impos¬
sible to invest in major rebuilding projects, thereby
condemning those cows to life in buildings that if they
were used for people would be referred to as 'slums'
(J. Hughes, personal communication).
Digital dermatitis was first reported in the UK in 1985
and is now a major cause of lameness in dairy herds
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THE SICK COW: THE TIP OF THE ICEBERG
The nature of veterinary work within the cattle industry
has changed immensely over the past 40 years, with
increased emphasis being placed on the whole herd and
less on the individual sick cow, which is also worth less
in monetary terms. This regrettable trend means that the
individual sick cow invariably represents just the 'tip of
the iceberg', with subclinical or inapparent losses dwarf¬
ing those due to actual clinical disease. Studies in the
USA have suggested that, in many herds, the economic
losses associated with Johne's disease are mainly due to
poor production und premature culling of unproductive
animals, rather than culling of clinical cases (Chiodini
and others 1984). A similar situation applies to many
other diseases, including mastitis, bovine virus diarrhoea
(BVD) and so on.
While, in general, the veterinary knowledge of farm
staff has increased with expanding herd size, this may not
always be the case. Farmers and stockpersons have an
ethical and moral obligation to ensure that any animal
showing ill health is examined properly by a veterinary
surgeon. Indeed, a full veterinary examination should be
performed on all clinical cases seen and samples taken, as
required. It is interesting to note, for example, that while
traumatic reticulitis is now a relatively uncommon diag¬
nosis in dairy cattle practice, it has been reported as a fre¬
quent postmortem finding (Grohn and Bruss 1990). This
may be due to the reluctance of farmers to present cases
early or of some veterinary surgeons to carry out a full
clinical examination, including an assessment of ruminal
and reticular motility (Williams 1955).
Lameness is a major problem on almost all dairy
units although its prevalence is often underestimated
by farmers. Treatment is usually provided by the farmer
or a lay foot trimmer. In such cases, the attending veteri¬
nary surgeon may have little information about the
lameness situation, as treatment records only give an
indication of the prevalence of severely lame animals.
Ideally, lameness scoring of the entire herd should be
carried out by the veterinary surgeon in conjunction with
the herdsman at least twice a year to assess true preva¬
lence (Manson and Leaver 1988). This offers a valuable
training opportunity, allowing herdsmen to learn how to
recognise lameness.
Automatic scrapers are a well recognised risk factor for
digital dermatitis
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WORKING TO ENSURE THE CREDIBILITY
OF FARM ASSURANCE AND HERD HEALTH
PLANS
A major development in all sectors of UK agriculture
over the past decade has been the concept of farm assur¬
ance. This has been driven by buyers and fuelled by con¬
sumer concerns following the BSE epidemic, with the
major buyers, food processors and supermarkets having
taken leading roles. Initially, there was a multiplicity of
dairy schemes with varying standards, but these have
now been unified under the banner of the National Dairy
Farm Assurance Scheme (NDFAS). Since January 2003,
all producers supplying the major dairies and super¬
markets have had to belong to a recognised scheme.
Such schemes have a broad remit to ensure the safety of
produce, traceability of the retail product back to the
farm of origin, and high standards of animal health and
welfare. However, there is evidence to suggest that
membership of a farm assurance scheme per se has no
significant effect on lameness prevalence compared with
farms that are not assured, suggesting that membership
in itself may have little effect on pre-existing welfare
problems (Main and others 20021. This issue needs to be
addressed urgently if farm assurance is to retain credibil¬
ity in the eyes of both the producer and the consumer.
A central plank of livestock farm assurance is the
construction of a herd health plan for all classes of stock
on the farm. The British Cattle Veterinary Association
(BCVA) has played a major role in developing the con¬
cept of herd health plans and has put together protocols
and training courses for veterinary surgeons wishing to
develop herd health plans for clients. The BCVA herd
health plan is increasingly recognised as the industry
standard. Essentially, a herd health plan states the agreed
actions that a farmer will take with regard to identifica¬
tion, recording, treatment and prevention of disease on
a particular farm. To be credible, a herd health plan
must be tailor-made for each farm, taking into account
the specific circumstances pertaining to a unit. All farm¬
ers are required by law to record all veterinary drug
usage, but there is no legal obligation to record the rea¬
sons why a drug is administered. The construction of a
herd health plan provides the clinician with a useful
opportunity to review husbandry and disease on a farm
and is usually educational for both the farmer and the
veterinary surgeon.
A herd health plan in itself is. however, of little value
unless it is implemented correctly. It should therefore be
reviewed periodically and altered, as required. It must be
stressed that recording of disease events is essential to an
effective herd health plan and offers the veterinary sur¬
geon a real opportunity to identify disease trends and act
accordingly. The BCVA herd plan is evolving rapidly
(Orpin and Sibley 2002) and now includes farm risk
assessment for the major infectious diseases and a
'disease cost calculator' which allows both the cost of
disease and the financial benefits of veterinary interven¬
tion to be estimated.
ROUTINE FERTILITY WORK: A GOOD
STARTING POINT
Dairy cow fertility is an area where regular veterinary
intervention can pay dividends. In an attempt to maintain
income, milk yields and herd size have both increased
while labour has been shed on many farms. These trends
have conspired to produce a marked decline in fertility
over the past 15 years, which has been estimated to be in
the region of 1 per cent per annum (Royal and others
2000, Washburn and others 2002, McGuirk 2004). The
financial losses associated with fertility are well quanti¬
fied (Esslemont and Kossaibati 2002). In most herds,
optimal financial benefits are associated with a calving
index of about 370 days and an overall culling rate of
18 per cent, with a failure to conceive culling rate
(FTC-CR) of around 7 per cent. Based on data from the
National Milk Records, the average UK calving index is
406 days and the overall culling rate is about 30 per cent,
with an FTC-CR of about 17 per cent.
The genetic base of the UK dairy herd has changed
markedly over the past 20 years with the importation of
Holstein genetics from North America and this has
driven milk yield up while lactation curves have tended
to flatten. There is evidence that, in high yielding herds
with flat lactations, it may be advantageous to extend the
calving index (Arbel and others 2001). This extension
has certainly occurred in many UK herds. However, the
question of whether it is the farmer or the cows that dic¬
tate fertility policy and the length of the calving index
Farmer education
As herd size increases and the value of the individ¬
ual animal decreases, there is more piessuie on
farmeis to peifuim many veterinary tasks them¬
selves (eg, diagnosis and treatment of toxic mastitis
with intravenous infusions, and treatment of lame
cows). It is therefore essential that, in such cases,
the attending veterinary surgeon ensures that ani¬
mal welfare does not suffer. This involves training
and educating farmers; clinicians can either under¬
take this themselves, or suggest that farmers attend
a recognised training course on, for example, foot
care or ultrasound examination. In the USA, veteri¬
nary surgeons are closely involved with training
farm staff in specified tasks and it is likely that this
trend will cross the Atlantic. This aspect of the prac¬
titioner's workload is expected to increase due to
the difficulty in recruiting skilled dairy staff.
Training of farm staff is likely to become a key role for the modern veterinary surgeon
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should always be asked; all too often, it is the latter.
While the direct losses due to culling may easily be cal¬
culated. involuntary high culling rates due to infertility
or disease mean that there is less scope for genetic
improvement in the herd through voluntary culling on
the basis of production or type indices.
Fertility work involving the recording of calving and
other fertility-associated events, and subsequent analysis
using specialist computer software (eg, Daisy, Interherd),
has increasingly become the backbone of dairy practice.
However, far too often, fertility is taken in isolation (the
'PD and go' approach) whereas in reality it is usually a
sensitive indicator of underlying deficits in the manage¬
ment, nutrition or housing of the herd; for example, lame¬
ness has a profound effect on fertility indices (Collick
and others 1989) while the value of condition scoring as a
monitor of nutritional status and its effects on fertility are
well recognised (Biggadike and Drew 2001).
The routine fertility visit is an established aspect of
veterinary work in a dairy herd and can serve as the
starting point from which elements relating to other
areas of the enterprise can be built up. Such a visit
should extend beyond merely examining cows per rec¬
tum to include regular inspection of the herd in order to
assess condition scores and husbandry practices (Bors-
berry 2002). Recording of condition scores and rumen
fill scores of animals presented at routine fertility visits
is desirable. Simple observation of cows in their environ¬
ment (for example, noting whether animals are cudding
or lying down, and also the consistency of their faeces)




Monitoring of disease on a farm is essential if effective
control is to be achieved. This is done primarily by accu¬
rate record keeping of all disease events and their regular
review by a veterinary surgeon, which, as mentioned
earlier, is an integral part of a successful herd health
plan. Such an approach should alert the farmer and his
professional advisers that a problem may be developing
and trigger a focused investigation of the problem. This
constitutes passive surveillance. Active surveillance,
meanwhile, involves regular collection and laboratory
testing of samples, thus allowing trends in subclinical
disease to be identified.
Routine fertility visits should not be based on the 'PD and
go' approach
Bulk milk serological analysis
Bulk milk serology is increasingly being used for the
diagnosis and monitoring of the infectious disease status
of the dairy herd (Pritchard 2001). At present, bulk milk
ELISA testing for BVD. leptospirosis and infectious
bovine rhinotracheitis (1BR) is available, and it is likely
that, in the future, testing will include other diseases such
as Johne's disease and neosporosis. Such testing offers
cost-effective monitoring of disease status if performed at
regular intervals (eg, every three months). Results are usu¬
ally interpreted quantitatively to estimate the proportion
of seropositive cows. However, caution must be exercised
when interpreting results as the bulk milk ELISA reading
is a reflection of the immune status of the animals current¬
ly being milked and this is continually changing as ani¬
mals enter or leave (ie, at drying off) the lactating herd.
It should be borne in mind that high seropositivity does
not necessarily indicate active infection as antibodies may
persist for life in animals with BVD and IBR.
Cohort sampling (eg, of first lactation heifers) may
be useful in the interpretation of whole herd bulk milk
results as it allows conclusions to be drawn about
whether antibodies are historic or whether the infection is
active in the herd. Similarly, testing a cohort of unvacci-
nated animals in a herd previously vaccinated can help to
establish whether the infection is still present and whether
vaccination should be resumed. Bulk milk testing allows
a farmer to ascertain the disease status of potential herd
replacements cheaply before purchasing animals by
requesting bulk milk serology results from the vendor.
Milk quality analysis
Milk quality analysis is carried out regularly by milk pur¬
chasing companies and offers an insight into the nutri¬
tional status of the herd. Milk protein is considered to be
a useful indicator of long-term dietary energy supply
while butterfat is an indicator of dietary fibre. Care is
required when interpreting results as a number of factors
(eg, stage of lactation, herd yield) may influence both
milk protein and butterfat content. Some dairies routinely
use bulk milk urea measurements as an aid to assessing
dietary protein and energy content. These must be inter¬
preted with extreme caution because, as with bulk milk
ELISAs, they primarily reflect the make-up of the herd at
the time of sampling, rather than the adequacy of the diet.
Bulk milk somatic cell counts (BMSCC) and Bacto-
scan readings provide valuable information regarding
mastitis and dairy hygiene. In fact, a rising cell count will
often alert the farmer to a developing problem of subclin-
Good record keeping is essential on the modern dairy farm






ical mastitis without a marked change in the incidence
of clinical cases being observed. However, BMSCC are
not a reliable indicator of infection by Gram-negative
coliforms and there is some debate about whether low
cell counts may in fact be a significant risk factor
for Escherichia coli mastitis (Green 1998). Somatic cell
counts reflect the incidence of mastitis in a herd, whether
it be clinical or subclinical, and also provide a direct mea¬
sure of milk quality. It is for this reason that dairy compa¬
nies pay a bonus for low cell counts (rather than for any
welfare considerations as is usually assumed). It is ironic
that mastitis control was only taken seriously by many
farmers when dairies started to first pay them a premium
on the basis of cell counts and then introduced penalties if
these counts were not low enough.
The majority of dairy farmers receive monthly indi¬
vidual cow somatic cell counts (ICSCC) and these, if
used correctly, offer an invaluable tool for monitoring the
acquisition of new intramammary infections and the
effect of therapeutic intervention, as well as for identify¬
ing problem cows for intensive therapy or culling. An
ICSCC of over 200,000 cells/ml indicates an intramam¬
mary infection. If this threshold is exceeded on three con¬
secutive recordings before cows are dried off, the count
has a sensitivity of 80 per cent and a specificity of 62 per
cent for detecting Gram-positive intramammary infec¬
tions (Bradley 2002). Routine bacteriology of clinical
cases is useful for monitoring and investigating mastitis
and may provide helpful information about the selection
of intramammary antibiotics. As a matter of course, many
farmers now collect pre-treatment milk samples from
clinical cases and store them deep frozen. It is recom¬
mended that 25 per cent of such samples are cultured to
enable trends in infection to be detected. In the event of
a mastitis problem requiring an in-depth investigation,
frozen samples provide a useful source of historical data.
Blood sampling
Blood sampling in cattle is conducted on either an indi¬
vidual animal or group basis for the diagnosis or moni¬
toring of infectious disease, or as an aid to assessing
nutritional adequacy.
While bulk milk serology is relatively inexpensive,
the interpretation of results is often difficult because, as
discussed, titres may reflect past events and have little
bearing on the current health status of a herd. Selected
cohort blood sampling can often clarify whether milk
titres for, say, BVD or leptospirosis reflect historic
events only or whether infection remains active in the
herd (Houe 1995).
Blood sampling may also reveal the existence of sub¬
clinical disease within a herd, but caution must be exer¬
cised with regard to sample size selection. The minimum
sample size required to establish the presence or absence
of a disease in a population depends on the sensitivity
and specificity of the test being performed as well as the
likely within-herd prevalence of the disease in question.
In many cases, whole herd testing is required (eg, for
Johne's disease where the ELISA has a low sensitivity,
ranging from 10 to 50 per cent depending on the stage of
infection in the individual animal tested).
Samples may be taken to assist in the diagnosis of
clinical disease (eg, abortion, milk drop syndrome and
pneumonia) where affected animals may be tested for
antibodies to selected disease agents. Paired serology
is useful in assessing the contribution of a particular
pathogen to the current disease situation; for instance, in
the case of a pneumonia outbreak, a rising titre to a viral
pathogen suggests the involvement of that particular
pathogen, while a static or falling titre suggests previous
exposure which is possibly unrelated to the incident
under investigation.
Failure of passive transfer of colostral antibodies is
well recognised as being a key factor in incidents of
disease in young calves. Investigation of any disease
outbreak in neonatal calves should always include blood
sampling of a number of healthy and diseased calves for
immunoglobulin estimation. The most widely used test
is the zinc sulphate turbidity test, but others include the
sodium sulphite turbidity test and estimation of total pro¬
tein concentration using a refractometer.
Faeces
Examination of faecal samples is not usually carried out
routinely in dairy cattle. However, regular faecal egg
counting is being increasingly advocated in sheep as
an aid to effective parasite control and this might be of
value for the control of parasitic gastroenteritis in calves,
especially on organic enterprises where routine anthel¬
mintic administration is prohibited.
Faecal sampling of diarrhoeic calves is frequently
undertaken to identify the likely pathogens involved.
However, single samples from diarrhoeic animals are of
little diagnostic value, and samples should be taken from
both diarrhoeic and healthy calves in the affected group.
An organism is only implicated in a disease outbreak if it
is isolated at a higher frequency from diarrhoeic calves
compared with healthy ones (Reynolds and others 1986).
Faecal culture remains the gold standard for the iden¬
tification of animals infected with Mycobacterium avium
subspecies paratuberculosis (Johne's disease), but the
cost is prohibitive. Workers in Holland have suggested
that culture of pooled faecal samples, taken from 10 ani¬
mals, may offer a cost-effective alternative to using the




The lactating dairy cow is under considerable nutritional
stress, especially in early lactation when dry matter
intake is not yet maximal. Negative energy balance, a
common finding in cows at this stage of the production
cycle, is a major factor in the poor reproductive perfor-
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performance when the actual problem relates to gross
nutritional deficiency (ie, negative energy balance) or
poor heat detection.
'Sorting' of a total mixed ration diet by cows may result in
severe nutritional problems
mance seen in many herds. Nutritional status may be
easily monitored by regular inspection and condition
scoring of animals. The aim is to limit the loss of condi¬
tion during early lactation so that a condition score of
only 0-5 is lost between calving and peak lactation. Any
greater loss may indicate a nutritional problem.
Assessment of faecal score, rumen fill and cleanliness
score offers a valuable insight into rumen function and
housing (Hughes 2001). Metabolic profiles are useful for
monitoring nutritional status and in the investigation of
nutritional problems (Ward and others 1995).
Subacute ruminal acidosis is a widespread and often
undiagnosed nutritional disorder which appears to be
increasing with the large-scale adoption of feeding maize
silage and total mixed rations (TMRs). This syndrome is
characterised by poor production, reduced butterfat, poor
fertility and increased lameness (Grove-White 2004).
The importance of long fibre in the diet of cattle is
well recognised. Particle size may be assessed using a
Penn State Particle Forage Separator (Lammers and oth¬
ers 1996), although diets containing large amounts of
grass silage may need to be air-dried before testing. It
may be useful to carry out an estimation of long fibre
content at intervals over a 24-hour period to assess
whether cows are 'sorting' the ration (ie, picking out and
eating small high energy particles and avoiding the long
fibre). Sorting is particularly important in situations
where there is competition at the feed barrier.
Attention must be paid not only to diet composition,
but also the manner of feeding with regard to feed barri¬
ers, and so on. TMRs are designed to be available 24
hours a day. At least 5 per cent of the ration should
remain at the barrier before more food is provided. This
'stale food' should be removed and discarded; it should
not be fed to young replacement stock as this represents
a breach of biosecurity, particularly with regard to
Johne's disease. Common problems are that not enough
food is placed in front of the cows or that it is not pushed
up to the barrier so that cows can actually eat it. Such
simple errors may be miosod unless the veterinary sur¬
geon visits the farm before feeding commences (or even
in the middle of the night!).
Trace element deficiencies are encountered relatively
frequently, especially in growing animals where they
may be associated with poor growth rates. There are
likely to be associations between trace element deficien¬
cies and reproductive performance although there are
few reports in the peer-reviewed literature demonstrating
this. Conversely, it is likely that trace element deficien¬
cies are often wrongly blamed for poor reproductive
BIOSECURITY: COMING OUT OF
THE DARK AGES
The 2001 FMD epidemic in the UK highlighted the
importance of biosecurity in modern livestock agricul¬
ture. Compared with the pig and poultry industries,
which have long recognised the importance of biosecuri¬
ty. the dairy sector remains in the 'dark ages' although
awareness is increasing to some extent with the advent
of herd health plans. While a full review of biosecurity
measures is beyond the remit of this article, there are
some basic principles which need to be considered:
■ Biosecurity may operate at a national, regional, local
or farm level. Diseases of interest may be infectious or
non-infectious (eg, foodborne toxicosis);
■ Biocontainment refers to the control of disease agents
already on the farm (eg, prevention of calfhood infection
with M avium subspecies paratuberculosis via adult fae¬
ces, colostrum or 'waste milk');
■ Risk analysis (hazard analysis and critical control
points - HACCP) should be performed before designing
a biosecurity plan. This should include an assessment of:
- Which diseases are of interest/relevance;
- The likelihood of the disease entering the unit;
- The consequences of disease entry. This may depend
on the existing disease status of the unit;
- Which biosecurity measures can be instituted;
- The likely efficacy of the biosecurity measures put in
place;
- Cost;
■ The disease status of the herd should be established
prior to setting up the biosecurity plan. There may be
little point in disease prevention if infection is already
present in the herd;
■ Disease monitoring should be carried out at regular
intervals in order to detect disease early on.
Biosecurity plans should encompass some or all of
the following components:
■ Purchase policies of livestock, foods, and so on;
■ Physical or chemical barriers:
- Siting of farm buildings and routing of farm traffic;
- Disinfection and hygiene measures;
- Quarantine;
- Fomites (eg, farm staff, visitors, lorries);
- Role of vectors (eg, birds, insects);
Wild animals and birds may represent risks to biosecurity
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■ Testing of animals prior to entry onto the premises or
into the herd. It is essential that the limitations of any
test performed are recognised and understood. For exam¬
ple, there is little point in performing an EL1SA for
Johne's disease on a young hull before purehase as the
sensitivity of the test is likely to be between 10 and 20
per cent. In such cases, assurance regarding the Johne's
disease status of the bull can only be obtained by testing
the herd of origin or purchasing from a recognised
Johne's disease-free herd;
■ Vaccination prior to entry into the herd (eg, against
BVD, I BR) where the home herd is endemically
infected;
■ Treatment prior to entry. For example, the adminis¬
tration of suitable anthelmintics to minimise the intro¬
duction of resistant nematodes and footbathing cattle for
digital dermatitis.
VETERINARY FEES; A WAY FORWARD?
The current fee structure of veterinary practice is usually
based on either charging a set fee for work carried out
or an hourly rate for time spent on the farm. Neither of
these fee structures encourage the involvement of the
practitioner in advisory work - the farmer often feels
reluctant to pay for advice received and the clinician is
unlikely to carry out work for which there will be little
remuneration. One possible solution is to negotiate an
annual contract for all work (exclusive of drugs) based
on a set charge per litre of milk produced, taking milk
quality into account (eg, 0-5 ppl). This provides an
incentive for the practitioner as his/her income rises as
production improves alongside improved health status.
Conversely, income declines if production declines. The
veterinary surgeon therefore becomes a stakeholder in
the business, to the advantage of all concerned.
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of the colicky horse DEBRA ARCHER
A number of factors
influence whether
a horse with colic is
a medical or potential
surgical case























COLIC is one of the most commonly encountered emergency conditions of the horse seen in practice.
Many owners are aware of the potentially life-threatening consequences of colic and such cases can be
stressful to deal with, particularly for inexperienced practitioners or those who deal infrequently with
horses. Decisions about which diagnostic tests to perform and the most suitable treatment options are
important in ensuring that appropriate action is taken. Although many cases of colic seen in first opinion
practice are mild and recover spontaneously or following medical treatment, it is vital to identify those
animals that may require surgery, if this is an option for the owner. For such patients, early referral is
essential as this will maximise the chance of a successful outcome. This article discusses the factors which
should be considered in this decision-making process.
Is it colic?
A variety of conditions may
mimic the signs of gastrointestinal-
associated pain (so-called 'false
colic', see box on the right). It is
important to differentiate between
colic and false colic in order to
ensure that appropriate treatment
is administered. In some cases, this
can be a challenge but valuable
information can be obtained from
the history and by observing the
horse before starting a clinical
examination.
Causes of 'false' colic
■ Laminitis
■ Rhabdomyolysis






■ Central nervous system disease
(eg, tetanus)
■ Ovulation/granulosa cell tumour Telltale signs of colic that has been present for severalhours include disturbed bedding and abrasions, particularly
around the head and over the tuber coxae
IVIAIMIFESTATIOIM OF ABDOWUMAL PAIBI
Colic is the behavioural manifestation of pain that is
localised in the abdomen and is most often related to the
gastrointestinal tract. In most cases, pain results from
a disturbance in normal gut motility. Horses suffering
from colic may exhibit varying degrees of pain, ranging
from mild to severe, or depression. Pain may arise from
one or a combination of intestinal spasm, mucosal irrita¬
tion, distension of the bowel wall by gas or ingesta,
tension on the mesentery or ischaemia of the intestinal
wall. Such pain is termed visceral. Obstruction of the
gastrointestinal tract is broadly divided into simple and
strangulating obstructions. Many textbooks describe the
pathogenesis of these types of obstruction and the course
of time over which they manifest. It is important to note
that strangulating obstructions develop rapidly and can
result in death within 24 to 36 hours.
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HISTORY TAKING
A good history provides valuable information and helps
to determine the possible cause of colic. Certain risk fac¬
tors (eg. age. recent box rest) are associated with particu¬
lar types of colic. The duration and severity of colic may
be difficult to establish when an affected horse has been
found in the morning. Where a strangulating lesion has
been present for several hours, acute signs of pain may
become less obvious and the horse may appear quiet
and dull due to the progressively worsening bowel wall
necrosis and endotoxaemia.
Where bouts of colic are recurrent in nature, it is
important to determine whether the episodes are changing
in frequency, duration or severity. Initially, the priority
is to assess whether the current episode is potentially
life-threatening. If medical therapy is successful, further
investigations should then be undertaken.
CLINICAL EXAMINATION
The severity of the clinical signs and possible cause of
colic should be determined before making a decision on
how to manage an affected case. The initial clinical exam¬
ination should be quick but thorough and systematic, and
should include an assessment of heart and respiratory
rates, mucous membrane colour, hydration status, rectal
temperature and abdominal distension, and auscultation
for abdominal borborygmi (intestinal sounds). For safety
reasons, if the horse is in extreme pain and likely to make
violent movements, sedation may be justified before start¬
ing an examination. It is useful to assess the horse's heart
rate before the administration of any sedatives or butyl-
scopolamine (Buscopan Compositum; Boehringer Ingel-
heim) due to their transient effects on the resting heart
rate, which make further comparisons more difficult.
Such information provides a picture of the systemic
status of the horse and also a baseline against which
the results of a repeat examination can be compared.
In many cases, a specific diagnosis cannot be made.
Regardless of the diagnosis, continued deterioration of
the horse's parameters despite medical therapy indicates
the need for potential surgical intervention.
Specific information that should be obtained
■ Signalment
■ When the colic was first observed
■ Signs of colic observed
■ When the horse was last seen to be normal
■ Any recent episodes of colic
■ Recent changes in management or exercise
■ Worming history (including prophylaxis against tapeworms)
■ Recent dental examination
■ Current medications (eg, non-steroidal anti-inflammatory drugs [NSAIDs])
■ Whether the mare is pregnant and the stage of gestation (or recent foaling)
RECTAL EXAMINATION
Rectal examination should always be performed in any
horse exhibiting moderate to severe, or persistent, pain
despite analgesia. In mild cases of colic seen for the first
time, rectal examination may be omitted, particularly if
the horse is fractious or strains relentlessly. Rectal exam¬
ination will not be possible in foals or very small ponies.
Fractious horses should be sedated; xylazine is useful
for its short-term sedative and analgesic effects. Spasmo-
Colic in the pregnant mare
It is important to establish whether colic in the preg¬
nant mare is related to the gastrointestinal tract
or directly to the uterus and fetus (eg, impending
abortion or parturition). Most analgesic drugs are
not specifically licensed for use in the pregnant
mare and the lack of such data relating to the mare
can make it difficult to decide on the most appropri¬
ate drugs to use. Most data have been extrapolated
from other species and the effects of many drugs
on the fetus are inconclusive. In general terms,
sufficient analgesia should be administered to con¬
trol the signs of pain. In a mare with a surgical
lesion, the priority is to provide analgesia and anti-
endotoxic therapy and to get the patient to a refer¬
ral centre as soon as possible.
Colic in the foal
Diagnosis of colic in the foal can be challenging and
it can be difficult to determine the need for surgical
intervention. Common conditions in the neonatal foal
include meconium impaction and gastric ulceration.
In addition, other conditions, such as ruptured blad¬
der, can be confused with signs of true colic in the
neonatal animal. Imaging modalities, such as ultra¬
sonography and radiography, can be useful in the
evaluation of these cases. Neonatal foals can deterio¬
rate quickly so they should be monitored carefully
if medical therapy is undertaken; they should be
referred immediately if there is no response to treat¬
ment or if the foal's condition continues to deterio¬
rate. No NSAIDs are licensed for use in foals less than
six weeks of age, but they can be used at lower dose
rates. Care should be taken to ensure the foal is
adequately hydrated before NSAIDs are administered.
Suitable NSAIDs include flunixin and carprofen.
Stress in conjunction with the use of NSAIDs can
result in gastroduodenal ulceration; therefore, anti¬
ulcer therapy should be administered concurrently
using a proton pump inhibitor (omeprazole) or one
of the H2-antagonists (eg, cimetidine or ranitidine).





lytics or instillation of a local anaesthetic into the rectal
lunten can aid rectal examination in a horse that persis¬
tently strains, thereby reducing the risks of causing a
rectal tear.
Rectal examination may be conclusive (eg, pelvic
flexure impaction, small intestinal distension, tight taenial
bands or gas-distended large colon) but. in many cases
of mild colic, no abnormalities will be found. In horses
showing more severe signs of colic, failure to identify an
abnormality does not rule out a surgical lesion (for exam¬
ple, the lesion may be out of reach). In any case of colic
that is non-responsive to analgesia, repeat rectal examina¬
tion can be helpful to detect any changes and the results
of this examination should be considered together with
the results of other clinical tests.
NASOGASTRIC INTUBATION
Nasogastric intubation should always be carried out
in a horse with moderate to severe, or persistent, colic
despite analgesia. This may not be warranted on the first
visit to a case exhibiting mild signs of colic. In most hors¬
es, only a small amount of fluid can normally be retrieved
(usually <500 ml). A net reflux of 2 litres or more is often
significant and indicates the potential need for surgery.
Reflux is usually caused by physical (eg, pedunculated
lipoma) or functional (eg, dysautonomia or ileus) obstruc¬
tion of the small intestine or, sometimes, by large colon
displacement resulting in duodenal compression. Horses
cannot vomit, so nasogastric intubation is important in
the diagnosis of gastric distension as it allows the stom¬
ach to be decompressed. Decompression also provides
pain relief and prevents rupture of the stomach, which is
invariably fatal.
ABDOMINOCENTESIS
Abdominocentesis can be performed relatively easily with
minimal equipment (see box, below left) and can provide
vital information about acute and recurrent cases of colic.
Rectal examination should be performed initially to iden¬
tify gross distension of a viseus. Abdominocentesis in
such cases (eg, a heavily pregnant mare or gross small
intestinal or large colon distension) can cause laceration of
a viscus if a needle is used; the use of a teat cannula can
reduce this risk. Where rectal findings are indicative of
severe intestinal disease, the results of abdominocentesis
may not alter the decision to send a horse to a referral
facility. In such cases, referral should not be delayed until
obvious changes in peritoneal fluid occur (by which time
the disease process is usually advanced). In foals, the thin
intestinal walls may be easily lacerated with a needle;
therefore, if a sample of peritoneal fluid is required, ultra¬
sonography of the abdomen is preferable in the first
instance before a teat cannula is employed.
The use of peritoneal taps for distinguishing between
cases of medical and surgical colic will be discussed in a
forthcoming article in In Practice.
HAEMATOLOGY AND BIOCHEMISTRY
In practical terms, haematological and biochemical eval¬
uation is unnecessary in cases that obviously require
surgery and the priority is to get the horse to the referral
facility as soon as possible. However, packed cell vol¬
ume, systemic total protein and peripheral white blood
cell count are basic parameters that should be measured
in less critical cases and serial measurements can help in
the assessment of a response to therapy. More extensive
biochemical and haematological profiles are justified in
the investigation of recurrent colic.
REPEAT EXAMINATION
Repeat examination is essential in cases of colic that
do not respond to analgesia, particularly if moderate to
potent analgesics have been given and the cause of colic
cannot be determined. A full re-evaluation of the patient
should be performed. Changes in a horse's haematologi¬
cal and biochemical parameters, or findings on rectal
examination, nasogastric intubation and abdominocente¬
sis can help to determine whether continued medical
therapy is justified or if potential surgical intervention
is required. Some owners do not appreciate the signifi¬
cance of recurrent, albeit sometimes less severe, signs of
pain once the effects of analgesia wear off. It is therefore
useful to arrange a repeat examination one to two hours
later, or sooner, if signs of pain recur; at the very least,
the veterinary surgeon should telephone the owner to get
an update on the horse's progress to decide if a re-evalu-
ation is necessary.
ADVICE TO THE OWNER
The cause of one-off episodes of colic may be clear from
the history and appropriate advice should be given
regarding the prevention of further episodes. In horses
that are not regularly wormed, it is worth submitting
samples for faecal worm egg and larval counts and an
analysis of tapeworm burden (serum HL1SA) to rule out
these potential causes of colic. Teeth should be checked.
Abdominocentesis
Site
■ Midline or to the right of midline
■ Most dependent portion of the abdomen
Preparation




■ EDTA and plain blood tubes
■ 18 gauge, 3-75 cm needle or teat cannula (local
anaesthetic and No 15 scalpel blade is required if






<20 to 25 g/litre
■ White blood cell
count. <5 x 109/litre
(above) Equipment needed for abdominocentesis
and (right) collection of peritoneal fluid
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particularly where regular dental care is not undertaken.
Further investigations are not usually necessary in most
one-off episodes unless the signs of colic recur.
AIMALCESIA
The choice of analgesic is one of the most important deci¬
sions that need to be made regarding the management of a
colicky horse. Analgesia should be sufficient to relieve the
signs of visceral pain, but should not alter the ability to
detect persistent or increasing pain. Drugs such as flunixin
and dctomidine piovide potent relief of visceral pain, but
can mask signs of continued pain if the animal is not mon¬
itored carefully. Failure to respond to these more potent
analgesics can indicate the need for surgery or euthanasia.
Where potent analgesia has been given, the results of a
rectal examination, nasogastric intubation and abdomino-
centesis will usually indicate the need for surgery, hence
highlighting the importance of a thorough repeat examina¬
tion in such cases.
non-steroidal anti-inflammatory drugs
Flunixin meglumine
Flunixin meglumine provides good to excellent analge¬
sia. Its anti-endotoxic effects will reduce the degree of
pain and lessen alterations in mucous membrane colour
and heart rate in strangulating lesions. Hence, this drug
should be used with caution where signs of mild pain are
evident or if no definitive diagnosis has been reached on
the initial examination.
Ketoprofen
Ketoprofen provides good visceral analgesia and has
anti-endotoxic properties. It is not as potent an analgesic
as flunixin, but may still mask the signs of mild to mod¬
erate visceral pain.
A variety of drugs are
licensed for use in horses
with colic, but they vary in
potency and the duration
of analgesia they provide
Phenylbutazone
Phenylbutazone provides mild visceral analgesia, similar
to the effects of metamizole. It is therefore useful for
colic cases exhibiting mild signs of pain.
Other NSAIDs
Other NSAIDs, such as carprofen, vedaprofen and
eltenac, are licensed for use in horses with musculo¬
skeletal pain and soft tissue inflammation. However,
their use in cases of visceral pain has not been fully eval¬
uated (ie, their potency is unknown).
alpha2-agonists
Xylazine provides good to excellent visceral analgesia,
but is relatively short acting. Therefore, it is useful for
horses with painful colic because it allows sufficient
time to perform a full clinical examination safely, with¬
out masking the effects of pain for prolonged periods of
time. Detoniidine has more potent sedative and analgesic
effects and should be used with caution; a failure to
respond to detomidine, or a recurrence of signs within
an hour, indicates the potential need for surgery. Romi-
fidine provides good, but less potent visceral analgesia.
I ANALGESIC DRUGS LICENSED FOR USE IN HORSES WITH COLIC 9






0-25-1 -1 mg/kg every 12 hours
iv or po
One to 24 hours, depending on
the cause and severity of the pain
Anti-endotoxic dose 0-25 mg/kg every six to eight hours
Ketoprofen
Ketofen (Merial)
2-2 mg/kg every 24 hours iv Similar to flunixin
Phenylbutazone
Equipalazone (Arnolds)
Up to 4-4 mg/kg iv or po Up to 14 hours Many potential side effects, but rarely seen in practice;




5 ml/100 kg iv Combined NSAID and spasmolytic; transient increase in








0-2-10 mg/kg iv 10 to 40 minutes depending
on the dose used
Contraindicated in the first and last month of




0-01-0-02 mg/kg iv or im One to three hours Do not use in the last month of pregnancy
Romifidine
Sedivet (Boehringer Ingelheim)
0-04-0-08 mg/kg iv 0-5 to three hours Do not use in the last month of pregnancy
Butorphanol
Torbugesic (Fort Dodge)
0 1 mg/kg iv 0-5 to three hours Often combined with alpha2-agonists at lower dose
rates
Pethidine 2-0 mg/kg im 20 to 60 minutes Only licensed for use in spasmodic colic
Pethidine Injection (Arnolds)
po Orally, iv Intravenously, im Intramuscularly
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All of these drugs may be combined at lower dosages
with butorphanol, which provides useful sedation in the
field and allows a rectal examination to be performed
safely. However, not all of these combinations are
licensed for use in horses with colic.
opiates
Butorphanol provides good visceral analgesia and will
not mask the signs of severe pain for long periods of
time. Excitatory effects can be seen, but tend to be less
evident in horses exhibiting signs of pain. Pethidine is
licensed for use in cases of spasmodic colic and provides
short-term analgesia.
spasmolytics
Butylscopolamine is a spasmolytic and mild analgesic
that acts mainly on the smooth muscle of the gastro¬
intestinal and urinary tracts. It is combined with the
NSAID metamizole, a weak visceral analgesic. It is use¬
ful in horses with mild, spasmodic colic and the degree
of analgesia will not mask signs of more severe pain.
OTHER MEDICAL THERAPIES
laxatives
Laxatives are most commonly indicated in the manage¬
ment of large colon impactions. They help to increase
the softness of ingesta and may be combined with fluid
therapy in more severe cases. Laxatives include mineral
oil (liquid paraffin), osmotic laxatives (magnesium sul¬
phate and sodium chloride), dioctyl sodium sulphosucci-
nate and psyllium hydrophilic mucilloid.
fluid therapy
Oral fluids
Administration of oral fluids via a nasogastric tube can
be useful in any horse with colic, although mild cases
that respond to analgesia will rapidly correct any fluid
deficits without intervention. Oral fluids should never be
administered in any case in which reflux occurs.
Intravenous fluids
Intravenous fluid therapy can be useful in the medical
management of some cases of colic, particularly large
colon impactions that do not respond to laxatives or oral
fluid therapy. Ideally, intravenous therapy should be
undertaken in facilities where the catheter site and fluid
rate can be monitored closely by veterinary staff. Intra¬
venous fluid therapy is critical in the management of sur¬
gical colic cases, but generally it is far better to get the
horse to a referral facility quickly rather than waste time
placing an intravenous catheter or collecting the neces¬
sary equipment to do so. Large volumes of fluid need to
be administered to have a significant effect, which is
impractical in many cases. If there is a delay in obtaining
transport, particularly if the referral facility involves a
journey of several hours or more, fluid therapy may be
administered during this time.
KEY DECISIONS
is surgical intervention required?
The question of whether surgical intervention is required
is one of the key decisions which need to be made in the
management of the colicky horse. Although most horses
seen in first opinion practice will have mild colic of
unknown origin that responds to medical therapy alone,
approximately 7 per cent of cases will have a surgical
lesion. A number of factors will help to determine
whether the horse should be treated medically or referred
for potential surgery. In many cases, the lack of response
to medical therapies will help to decide this. Some cases
will fall into the 'in-between' category. Where referral is
an option, it is better to refer cases early rather than delay
further by which time the decision regarding the need for
surgery may be easy, but valuable hours may then be lost
during transport.
Improvements in anaesthetic and surgical techniques
have ccwlilljiileil In im|iiuued success rates for the
surgical treatment of colic over the past ?n years
MM
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Large colon torsion showing severe infarction of the colon wall and tears
in the serosa. In this case, surgical correction was not possible due to the
degree of strangulation and the location of the torsion
Large colon torsion of shorter duration than that pictured on the left,
exhibiting less severe compromise of the bowel wall. Resection was




■ Mild to moderate pain
■ Good response to mild analgesics
■ Heart rate <50 beats per minute
■ Normal packed cell volume and total protein
■ Negative findings on rectal examination
■ Continuous or improving intestinal motility
■ No nasogastric reflux
■ Resolving or no abdominal distension
■ Grossly normal peritoneal fluid with normal total
protein and white blood cell count
Indications for referral
■ Severe, unrelenting pain despite the use of
analgesia
■ Recurrence of pain following the administration
of moderate to potent analgesia
■ Heart rate persistently >60 beats per minute
■ Net gastric reflux of >2 litres
■ Positive findings on rectal examination
■ Alterations in peritoneal fluid
■ Progressive deterioration in mucous membrane
colour
■ Progressive reduction in intestinal motility
■ Progressive abdominal distension
DECISION TO CONTINUE MEDICAL THERAPY
Large colon impactions are often encountered in practice
and most will respond to treatment with analgesics, oral
fluids and laxatives. Those that show no sign of
improvement over 24 to 48 hours may require more
aggressive medical therapy (eg, intravenous fluid thera¬
py). Practitioners should be aware that this condition
may occasionally occur secondarily to another lesion,
such as concurrent large colon displacement or im¬
paction of the right dorsal colon. These cases can often
only be resolved by surgical intervention.
Strangulation of a short
portion of small intestine
by a pedunculated lipoma.
REFERRAL This type of lesion is most
commonly seen in older
ponies
REFERRAL FACILITIES
A large number of equine clinics in universities and pri¬
vate practices provide facilities for surgical and intensive
medical treatment of colic. The decision to refer can
sometimes be difficult to make, but advice can always
be sought from these clinics. In some horses, the need
for surgery is obvious, but this should not deter the refer¬
ral of animals that show equivocal signs. The facilities in
the stable yard or in the field may preclude a full clinical
examination and referral clinics may have other more
sophisticated diagnostic or imaging equipment that can
be of great help in deciding whether or not to operate.
Even if initial medical treatment is instituted, the horse
can be monitored intensively and surgery can be under¬
taken quickly if the patient's condition deteriorates
suddenly. Although the horse's clinical signs may have
improved dramatically on arrival at a referral facility
(the 'therapeutic box ride'), most owners are usually
delighted that their horse does not need (expensive)
surgery and this situation is preferable to the surgical
case in which referral is delayed, which may make the
prognosis hopeless, despite surgery.
In Practice • July/August 2004 383










* Contain clindamycin hydrochloride, an essential antibiotic particularly for
anaerobic and dental infections
Vetoquinol
★ Splittable tablets offering increased dose accuracy and cost effectiveness
★ Three familiar strengths: 25mg, 75mg & 150mg
★ Cost effective - with the added value of the Vetoquinol antibiotic range JWwe,
For further information please call 01280 825475 or 01280 825476. Vetoquinol UK Limited, Vetoquinol House, Great Slade, Buckingham, MK18 1PA.
Tel: 01280 814500 Fax: 01280 825460 email: office@vetoquinol.co.uk website: www.vetoquinol.co.uk
A case for euthanasia?
Surgery may be ruled out by the owner for financial
or personal reasons. The priority in such cases is to
provide sufficient analgesia if a definitive diagnosis
cannot be made. Failure to respond to potent
analgesia and a continued deterioration in the
horse's condition indicates progressive endotoxic
shock and the need for euthanasia. Rupture of a
viscus may result in a dramatic decrease in the
degree of abdominal pain. Such cases rapidly suc¬
cumb to severe endotoxic shock, showing marked
tachycardia, cyanosis of the mucous membranes
and profuse sweating. The patient will often exhib¬
it 'boarding' of the abdomen due to peritonitis
and peritoneal fluid contaminated with green
ingesta will be obtained. These animals should be
euthanased immediately.
CONTACT WITH THE REFERRAL FACILITY
The facility to which a horse is to be referred should
always be contacted before a case is sent and referral
costs and medical therapy discussed. Cases of colic with
pyrexia and/or diarrhoea may indicate impending colitis.
Salmonellosis is always a potential consideration in
these horses and, consequently, some clinics may prefer
such animals to be treated on their own premises or will
admit them into isolation.
ing at the long-term survival of these cases and the
problems encountered following discharge. It is hoped
that information from such studies will provide owners
and practitioners with a better understanding of what to
expect in the long term in horses that have been treated
surgically for colic.
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OWNER INFORMATION
In cases of severe, unrelenting colic, referral should be
discussed at an early stage and transport arrangements
made (to avoid any unnecessary and frustrating delays
in getting a horse to a suitable facility). Costs should
always be discussed with the owner first and the insur¬
ance company should be notified at the earliest opportu¬
nity where applicable. The owner or transporter should
be given contact telephone numbers and clear directions
to the facility. Updates are usually appreciated by the
referral facility if any unforeseen delays occur.
PROGNOSIS FOLLOWING SURGERY
The management of the surgical colic patient has
improved significantly over the past 20 years. Early
referral, improved management of the patient under
anaesthesia and postoperatively, as well as advances in
surgical techniques have all contributed to improved sur¬
gical success rates. The practitioner is essential in identi¬
fying the need for surgery and referring the horse at an
early stage before the effects of endotoxaemia worsen.
The horse's chances of survival postoperatively are also
dictated by a number of other, often interrelated, factors
including the duration of the colic, the duration of
surgery and the need fm inirsiinal iHsenion. Certain
types of surgical colic (eg, large colon torsion and epi¬
ploic foramen entrapment) may have an inherently worse
prognosis. A precise diagnosis can be difficult to make
preoperatively; therefore, it can be difficult to offer the
owner a prognosis until exploratory laparotomy has been
undertaken. While most studies have concentrated on
horse survival until discharge from the hospital (ic,
short-term survival), several studies are currently lnok-
NOW THAT IS SOMETHING
TO SING A DANCE ABOUT
Fortiflex is a tasty one a day supplement for the maintenance
of healthy joints in dogs. Fortiflex is available in 3 pack sizes,
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Typical gross pathology of ovine
pulmonary adenocarcinoma (OPA).
Currently, the only means of controlling
OPA is by regular inspection of affected
flocks, with culling of suspected cases.
However, work is underway to develop
improved diagnostic procedures and it is
hoped that this will change the overall
approach to disease control
Owine pulmonary adenocarcinoma:
the story to date
DANIELA SALVATORI, MARCELO DE LAS HERAS and MIKE SHARP
(above and right) Frothy seromucoid fluid is discharged
from the nostrils of sheep with OPA when the hindquarters
are raised and the head lowered








TUMOURS are generally uncommon in domestic livestock, but small ruminants are unusual because
two neoplastic diseases - ovine pulmonary adenocarcinoma (OPA) and enzootic nasal adenocarcinoma
of sheep and goats - can affect many animals in countries and flocks where they are endemic. These
diseases can be transmitted experimentally, but do not seem to affect cattle or other animals. They are
contagious and caused by two distinct but closely related betaretroviruses. Both types of tumour arise
from secretory epithelial cells that retain their secretory function after transformation. OPA is produced
by a tumour in the lungs of sheep; the tumour has also been seen in goats and wild moufflon, but more
rarely. The disease has been recognised in over 20 countries spanning Europe, Africa, the Americas and
Asia, and in a wide variety of breeds. Studies in Britain and South Africa show that OPA accounts for
almost 70 per cent of all sheep tumours. As discussed in this article, recent studies have thrown light on
the aetiology, pathogenesis and epidemiology of OPA and this, in turn, has led to current research efforts
to develop preclinical diagnostic tests for the disease.
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OPA is generally accepted to have a long incubation
period in naturally infected sheep because the disease is
not obvious clinically until animals are about two to four
years old. However, tumours have been seen exception¬
ally in lambs as young as a few weeks and in sheep as
old as 11 years of age.
Clinical signs are those of an afebrile, progressive
respiratory illness associated with loss of weight. The
severity of the tachypnoea and dyspnoea, which is often
associated with noticeable movement of the abdominal
wall (abdominal lift), depends on the extent of the
tumour and the loss of normal functional lung. A patho¬
gnomonic feature of OPA is the accumulation of fluid
(lung fluid) within the respiratory tract, which may flow
from the nostrils when the hindquarters are raised
(wheelbarrow test). In advanced cases, high-pitched and
moist sounds may be heard on auscultation or even by
the unaided ear.
Appetite is maintained in affected animals, although
loss of weight is obvious. Death inevitably occurs, often
suddenly, from a complicating Mannheimia haemolytica
(formerly Pasteurella haemolytica) pneumonia.
Heras is chair of
veterinary pathology





of sheep and goats.
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History and geographical distribution of OPA
OPA was first recognised in South Africa in the 19th century as a cause of respi¬
ratory distress in sheep. The Afrikaans name 'jaagsiekte', derived from 'driving'
(jaag) and 'sickness' (ziekte), reflected the tendency of diseased sheep to lag
behind the flock during herding. Since then, OPA has been identified in a wide
variety of breeds worldwide. A number of other names have been used to
describe the disease, including sheep pulmonary adenomatosis and ovine pul¬
monary carcinoma, but at a workshop in Missilac, France, in 2001 it was agreed
that the term OPA would be used to describe the disease in future.
To date, OPA has been identified in over 20 countries on the continents of
Europe, Africa, the Americas and Asia; it appears to be absent from Australia and
New Zealand. The disease occurred in Iceland (see below) but, following a suc¬
cessful eradication programme, no cases of OPA have been recorded since 1952.
OPA in Iceland
OPA was introduced into Iceland in the 1930s, along with scrapie, maedi-visna
and paratuberculosis, by a small number of Karakul rams imported from
Germany but originating from Bukhara in Russia. A year after their arrival,
the first case of what was later identified as OPA appeared in one- to three-
year-old sheep; during the next two to three years about 60 per cent of the
breeding stock in affected flocks died of the disease. Subsequently, mortality
due to OPA dropped to under 10 per cent in three years and, during this
period, another respiratory disease, 'maedi' (Icelandic for dyspnoea),
emerged. Maedi is caused by the lentivirus maedi-visna virus (MVV). It was
later established that two of the imported Karakul rams were infected with
MVV and one of them was carrying the jaagsiekte agent. Sigurdsson (1954)
used the adjective 'slow' to describe the peculiar clinical evolution of this
group of diseases.
In some countries, another form of the tumour (atypi¬
cal OPA) has been reported, which is not associated with
excess accumulation of fluid in the lung (as discussed
below) and. therefore, generally presents as an incidental
finding at necropsy or in the abattoir.
PATHOLOGY
OPA lesions are confined to the lungs, although occa¬
sionally the associated lymph nodes are involved.
Commonly, OPA presents as extensive tumours involv¬
ing the entire ventral half of the diaphragmatic and other
lobes. Affected lungs are enlarged and heavier than
normal.
Tumours are solid and grey-pink in colour, with a
shiny translucent sheen; often they are separated from
adjacent normal lung tissue by a narrow emphysematous
zone. The presence of frothy white fluid exuding from
cut surfaces or in the respiratory passages is a prominent
feature and is obvious even with very small lesions.
Histological examination of OPA lesions reveals the
characteristic proliferation of cuboidal or columnar cells
that replace the normal thin alveolar cells. Often these
tumour cells form papilliform growths that project into
the alveoli. Intrabronchiolar proliferation may also be
present. Electron microscopy has revealed that the cells
forming alveolar lesions are type II pneumocytes, while
those forming bronchiolar tumours are Clara cells. Thus,
OPA is a tumour of secretory epithelial cells in the lung,
type II pneumocytes secreting lung surfactant and Clara
cells secreting other proteins for the distal airways.
Large macrophages frequently accumulate in the alveoli
surrounding the tumours. A small proportion of tumours
contain nodules of loose connective tissue in a muco¬
polysaccharide substance.
In contrast to this pathological picture for classical
OPA, tumours in the atypical form of OPA comprise
solitary or coalesced hard white nodules, which have a
dry cut surface and show clear demarcation from sur¬
rounding tissues (see right); the presence of excess fluid
is not a prominent feature. The histological appearance
of these tumours is essentially the same as for classical
OPA but with fibrosis and an exaggerated inflammatory
response, mostly involving lymphocytes and plasma
cells.
Secondary infections, particularly pneumonic pas-
teurellosis, are common in sheep with OPA, leading to
pleurisy and abscessation. Flocks that experience recur¬
ring problems with pasteurellosis should consider OPA
as an underlying factor, as lesions of OPA may be
masked by the acute reaction to the bacteria.
EVIDENCE THAT OPA IS CAUSED
BY A RETROVIRUS
Transmission of OPA through inter-flock and interna¬
tional trade of live animals has clearly demonstrated that
the disease is contagious and stimulated the search for
the causal agent. A number of studies have consistently
shown lung fluid and tumours from OPA-affected sheep
to contain a retrovirus, known as jaagsiekte sheep retro-
' \
A
Pathology findings in classical OPA. (left) Tumour appears as purple-
coloured areas in the cranioventral part of the lung, (above) Section
of the diaphragmatic lODe of a lung sliuwing tumour. Affected areas have
a 'meaty' appearance and frothy fluid is exuding from the bronchioles




Atypical OPA. (top) Well-demarcated, white, solitary
tumour nodule in the dorsocaudal area of the right lung,
(bottom) Section of a lung from a severe case, showing
numerous disseminated dry confluent nodules
virus (JSRV). Although it was unclear at first that this
virus had anything to do with the aetiology of OPA, it
was found that successful transmission of OPA could
be achieved only with inocula that contained JSRV.
These observations made JSRV the best candidate for
the aetiological agent of OPA.
However, confirmation of the pathogenic role of
JSRV in OPA was complicated by the presence of 15
to 20 copies per sheep genome of JSRV-related endoge¬
nous sequences (see box on the right). These sequences
increased the difficulty of detecting integrated exoge¬
nous JSRV. and raised the possibility that the expression
of JSRV in OPA may represent the activation of endoge¬
nous virus(es) in the host cells as a consequence of
carcinogenesis. The development of reagents and tech¬
niques to distinguish between exogenous and endoge¬
nous ovine retroviruses was, therefore, a critical step.
Specifically, the availability of a genomic sequence for
JSRV facilitated the development of recombinant JSRV
capsid antigens (JSRV-CA). These were used to produce
specific antisera and a blocking ELISA to detect JSRV
and to determine the anatomical distribution of JSRV in
sheep.
JSRV was detected only in lung fluid and tumours
from affected animals and not in any other tissue from
affected or unaffected sheep. Immunohistochemical
examination of tumour tissues, using the same antiserum
to JSRV-CA, detected JSRV protein in the cytoplasm of
the transformed epithelial cells in the pulmonary alveoli
of both naturally and experimentally OPA-affected
sheep. Although JSRV-CA was observed in all OPA
tumours, not all tumour cells were positive, even in the
same nodule. There was no staining of non-transformed
epithelial cells, nor of stromal cells, and specific staining
was observed only rarely in the extracellular alveolar
spaces. Specific staining was not demonstrated in any
other tissue, with the exception of a few large lympho-
blastoid cells in the paracortical zones and medullary
sinuses of the tracheobronchial and mediastinal lymph
nodes and some macrophages within the pulmonary
alveoli. These observations demonstrated that JSRV
appears to replicate principally in the transformed
epithelial cells in OPA tumours as well as a minor subset
of lymphoid cells.
These results supported the notion that JSRV causes
OPA, but did not rule out other possibilities. JSRV might
be acting as a helper virus for some other replication
defective, acutely transforming retrovirus; alternatively,
it may represent an endogenous virus, reactivated as a
consequence of neoplasia or, indeed, as a result of
recombination with endogenous sequences, as has been
reported in other species.
To investigate this relationship further, the distribu¬
tion of JSRV transcripts was examined in various tissues
from OPA-affected and unaffected animals. Transcripts
were demonstrated in both OPA-affected and unaffected
animals, providing clear evidence for transcription
of JSRV-related endogenous retroviruses (enJSRVs).
However, RNA transcripts in lung fluid (exogenous
JSRV) were shown by molecular analysis to differ from
the enJSRV transcripts obtained from non-tumour tis¬
sues. Furthermore, the exogenous form of JSRV was
exclusively and consistently present in tumour tissues,
draining lymph nodes and lung secretions of OPA-
affected sheep. To rule out the possibility that the exoge¬
nous form of JSRV may have represented enJSRV that
normally was transcriptionally silent but had reactivated
as a downstream event of neoplasia, it was necessary to
Betaretroviruses: biology and clinical implications
Betaretrovirus is a genus of the family Retroviridae and consists of:
■ Exogenous viruses:
- Jaagsiekte sheep retrovirus (JSRV)
- Enzootic nasal tumour virus (ENTV-1) associated with enzootic nasal adenocar¬
cinoma of sheep
- Enzootic nasal tumour virus (ENTV-2) associated with enzootic nasal adenocar¬
cinoma of goats
■ Endogenous viruses known as enJSRVs: this group of viruses is closely related
to JSRV and ENTV; 15 to 20 copies of enJSRVs are present in the genome of
sheep and goats
Features of endogenous retroviruses (enJSRVs)
■ enJSRVs are integrated in the germ line of their host species and thus can be
transmitted vertically
■ Within the family Retroviridae, several exogenous retroviruses have endoge¬
nous counterparts (feline leukaemia virus, mouse mammary tumour virus,
murine leukaemia virus and avian leukaemia virus)
■ enJSRVs are highly expressed along the epithelium of the genital tract of the
ewe and in the thymus of ovine fetuses
Biological significance of enJSRVs
■ enJSRVs and the exogenous and pathogenic JSRV use the same receptors
for entering into cells; thus enJSRVs can compete with JSRV at the level of
receptor usage and interfere with JSRV at the level of virus entry (receptor
interference)
■ The expression of endogenous elements during fetal development can lead
the immune system to recognise the viral elements as 'self' (tolerance phenome¬
non); this could explain why there is no antibody response to JSRV
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Resemblance between OPA and
human bronchoalveolar carcinoma
IMMUNE AND INFLAMMATORY
RESPONSES TO JSRV IN SHEEP
The histology and ultrastructure of human broncho¬
alveolar carcinoma (BAC) closely resembles OPA.
BAC is a subset of pulmonary adenocarcinoma aris¬
ing from type II pneumocytes or Clara cells. It is
now defined as a type of adenocarcinoma with a
pure bronchoalveolar carcinoma growth pattern
and no evidence of stromal, vascular or pleural
invasion; the neoplastic cells grow as a single
layer along the walls of the terminal airways and
alveoli.
Recently, evidence of a protein related immuno¬
logically to JSRV in some human lung tumours sug¬
gested a possible correlation between BAC and an
endogenous retrovirus. Two hundred and seventy-
four samples from patients with BAC, other pul¬
monary malignancies, non-malignant pulmonary
lesions and normal lung were examined by
immunohistochemistry using a rabbit antiserum
towards the major capsid protein of JSRV. The
tumours included 129 BACs, 65 adenocarcinomas
and 41 squamous cell carcinomas. Thirty-nine of the
129 BAC samples (30-2 per cent) and 17 of the 65
adenocarcinoma samples (26-2 per cent) were posi¬
tive (de las Heras and others 2000). No positive
staining was observed in non-tumour lesions or
normal lung tissues.
These results support the view that the antigen
in the human tumours may be a retrovirus protein,
although no other virological or molecular data
was obtained to support these observations.
demonstrate exogenous JSRV proviral DNA only in
OPA-affected sheep and not unaffected animals.
Using a PCR specific for exogenous JSRV. this virus
was demonstrated in 100 per cent of tumours and drain¬
ing lymph nodes, as well as in a high proportion of other
lymphoreticular tissues and peripheral blood mono¬
nuclear cells of OPA-affected sheep, but not in unaffect¬
ed sheep. More recently, in situ PCR was employed
to demonstrate JSRV proviral DNA in transformed and
a few untransformed type II pneumocytes, alveolar
macrophages and cortical follicles and paracortex of the
draining lymph nodes. The results showed that JSRV
was expressed at much higher levels in the transformed
epithelial cells than in the lymphoid tissues, particularly
those at non-local sites.
These experiments confirmed that the exogenous
form of JSRV was associated exclusively with OPA and
that it could play a major role the aetiology of the dis¬
ease. However, final confirmation that exogenous JSRV
was the cause of OPA required the isolation of patho¬
genic molecular clones of JSRV. This has since been
achieved. Full-length proviral clones of JSRV were
obtained from an OPA tumour and an OPA cell line,
and JSRV virions produced in vitro by transient
transfection of a cell line with the JSRV plasmid. The
JSRV virus particles induced OPA in experimentally
inoculated lambs, some within four months, providing
definitive evidence that JSRV is the aetiological agent of
OPA.
A unique feature of OPA is the absence of a specific
antibody response to JSRV, despite the highly produc¬
tive infection in the lungs and the disseminated lym¬
phoid infection. The reactivity to recombinant JSRV-CA
in sera from affected sheep, described in some accounts,
was not specific and reflected the presence of antibodies
to the fusion partner of the recombinant antigen used in
the assays. However, serum antibodies can be induced
readily in sheep by immunisation with recombinant
JSRV protein in adjuvant. These results indicate that
sheep are not inherently unresponsive to JSRV antigens.
It is possible that the expression of endogenous JSRV
during ontogeny or in neonatal life may interfere with
the exogenous JSRV infection and disease outcome via
the induction of immunological tolerance. To date,
specific cellular immune responses have not been
demonstrated.
Another prominent feature of naturally OPA-affected
sheep is marked peripheral neutrophilia and lympho¬
penia, specifically affecting CD4+ T lymphocytes (other
subsets remain unaffected).
The persistent and disseminated infection of the lym¬
phoreticular system by JSRV and dysregulation of the
immune and inflammatory responses of infected sheep
suggest that JSRV may interfere with the host immune
responses. This theory is supported by studies demon¬
strating JSRV infection of a wide range of lymphoid
cells. Holland and others (1999) showed that, in natural¬
ly infected sheep. JSRV proviral burden was greatest in
the macrophage/monocyte cell population (1/2500 cells),
followed by B cells (1/3800 cells), CD4+ T lymphocytes
(1/6800 cells) and CD8+ T lymphocytes (1/16,700 cells).
Furthermore, dissemination of JSRV was an early event
following experimental infection of young lambs. The
virus was present in CD4+ and CD8+ T lymphocytes, B
lymphocytes and adherent mononuclear cells in the pul¬
monary lymph nodes as early as seven days post-inocu¬
lation, and was detected in peripheral blood leucocytes
(PBLs) by 14 days post-inoculation. These observations
are particularly significant as they indicate that dissemi¬
nation of JSRV precedes transformation and. for the first
time, that infected animals might be detected in OPA-
affected flocks before the appearance of clinical signs.
In contrast to the haematological changes observed in
naturally occurring OPA. no significant alterations were
identified in the peripheral blood during the first 20
weeks after experimental inoculation of young lambs
with JSRV. compared to age- and breed-matched con¬
trols (Summers and others 2002). These observations
indicate that the alterations in peripheral blood lymphoid
cell subsets are not an early event and probably do not
occur in direct response to JSRV infection, but are a
consequence of the superimposed bacterial infections
that are common in natural cases of OPA.
Functional defects were also demonstrated in the
immune responses of .ISRV-infected sheep (Summers
and others 2002). Lymphocytes from both natural cases
of OPA and lambs inoculated experimentally with JSRV
showed a significantly reduced proliferative response to
concanavalin-A, a cell mitogen. The reduced response
was detected in the lambs as early as eight weeks after
inoculation and prior to clinical disease, when the
response was only 33 per cent that of the control lambs.
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These observations have provided the first indications
that JSRV may alter the functional activity of immune
cells in infected animals, although the virus apparently
does not alter the phenotypic profile of the peripheral
blood.
EPIDEMIOLOGY
The prevalence of OPA appears to vary between coun¬
tries. For example, the disease is endemic in Peru,
Scotland and South Africa and, in these countries, it can
cause between 2 and 10 per cent annual mortality in
adult sheep in affected flocks. A five-year longitudinal
survey of two OPA-affected flocks in Scotland revealed
that about 30 per cent of the sheep had histologically
confirmed lesions in their lungs, and between 12 and 21
per cent had subclinical tumours (Sharp and DeMartini
2003). In contrast, OPA is infrequently diagnosed in the
USA or Canada, where only a few cases have been
reported. These differences in prevalence and incidence
of the disease may reflect variations in viral strains, host
susceptibility or animal management systems.
Most estimations of the prevalence of OPA have been
based on clinical observations and histopathological
diagnosis. Information on the true prevalence of JSRV
infection in OPA-affected flocks is currently not avail¬
able and this represents a major gap in veterinary knowl¬
edge. The detection of JSRV in the peripheral blood of
experimentally infected lambs, before the development
of tumour or onset of clinical disease, was therefore an
important finding that offers a means to investigate the
extent of JSRV infection in OPA-affected flocks
(Gonzalez and others 2001).
These findings have been applied in studies involving
sheep from OPA-affected commercial flocks in Spain
(Garcia-Goti 1999). PBLs and tissue samples from sheep
were examined for JSRV using PCR techniques. Overall,
JSRV was detected in all sheep with either the classical
or atypical form of OPA, as well as in 80 per cent of
in-contact sheep. None of 71 samples from control sheep
were positive. Although an earlier report had indicated
that as few as 1/250,000 PBLs might be positive for
JSRV (Holland and others 1999), in this study JSRV was
detected in PBLs of all sheep with classical OPA, 83 per
cent of sheep with atypical OPA, as well as 40 per cent
of lesion-free in-contact sheep. These results clearly
demonstrated, for the first time, that JSRV can be detect¬
ed in naturally infected live sheep before the onset of
clinical disease and even in the absence of discernible
lung tumours. Although only a small number of in-
contact sheep were examined, it would appear that
subclinical JSRV infection can reach a high level in
OPA-affected flocks.
To investigate further the dynamics of JSRV infection
in flocks with OPA, Garcia-Goti and others (2000)
conducted a small prospective longitudinal survey in
an affected flock. Using PCR techniques, JSRV was
detected in PBLs of 28 per cent of the sheep.
Subsequently, PBLs of 15 animals testing positively and
five testing negatively were examined by PCR at monthly
intervals for four months. JSRV was detected in only nine
Enzootic nasal adenocarcinoma of sheep and goats
Clinical signs
Clinical signs of enzootic nasal adenocarcinoma
include seromucous nasal discharge, stertorous
breathing, coughing and dyspnoea. The continuous
flow of nasal secretions causes a characteristic discol¬
oration and hair loss around the nostrils. The growth
of the tumour mass ran cause skull deformation, soft¬
ening of the cranial bones and exophthalmos.
The disease is afebrile. After several months the
affected animal loses weight and dies as a result of
complications.
Gross pathology of enzootic nasal adenocarcinoma.
The tumour is grey in colour with a nodular surface and a
scanty mucous secretion. The tumour can fill the ethmoidal
area and may occlude nasal passages
Depilation around the nostrils is caused by the
continuous flow of seromucous fluid produced by the
tumour. Exophthalmos and tumefaction of the frontal
areas of the skull are also typical signs of enzootic nasal
adenocarcinoma
Pathology
Tumours arise uni- or bilaterally from the ethmoid
turbinates. These masses are soft, grey or reddish-
white with a granular surface covered by mucus.
Sometimes they can fully occupy the nasal chambers
and invade maxillary or frontal areas; this can cause
compression of the surrounding structures. Histo¬
logically, these tumours are classified as low-grade
adenocarcinomas. The transformed cells originate
from the nasal mucosal glands. No metastases to
regional lymph nodes or other organs have been
found.
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Future research priorities
Questions that need to be answered
■ What is the prevalence of OPA?
■ What proportion of sheep develop OPA?
■ When does infection occur?




■ Familial susceptibility? High/low incidence line?
How information will be used
■ To identify management approaches to reduce the
risks of on-farm transmission of JSRV
■ To identify familial trends and high/low incidence
lines
■ To identify a resistance gene that will allow:
- Screening for resistant sheep
- Breeding for resistant sheep
■ Possible vaccination?
of the original 15 positive sheep during this period and
in four of those that were negative. These results demon¬
strated the fluctuation in detection of JSRV in blood and,
more importantly, confirmed the high prevalence of
JSRV infection in OPA-affected flocks.
In the mid-1980s, a severe outbreak of a disease resem¬
bling OPA was described in a flock of captive moufflon
(Ovis musimon), a species of wild sheep phylogenetically
related to the domestic sheep, Ovis aries. The flock com¬
prised over 60 moufflon which were kept on a game farm
in Sardinia, Italy, with the aim of producing animals to be
released later into their natural habitats. The moufflon and
a flock of sheep in which OPA was endemic had repeated
contacts (Ceretto and Deiana 1967). Studies on DNA from
archival materials concluded that JSRV was the cause of
OPA in the moufflon (Sanna and others 2001).
APPROACH TO DISEASE CONTROL
At present, the only means of control of OPA is regular
inspection of adult sheep in affected flocks. Prompt
culling of any suspicious animal, as well as the offspring
of affected ewes (which frequently develop OPA), is
advisable. These methods have not been shown to eradi¬
cate OPA from a flock in which the disease is endemic,
but may bring about a reduction in the prevalence of
infection. PCR techniques able to detect JSRV in the
blood before the onset of clinical signs offer new oppor¬
tunities that may lead to effective control. Currently, a
large EU collaboration involving Scotland, Spain and
Italy is undertaking research to improve diagnostic tests
to detect JSRV during the preclinical stages of infection.
Meanwhile epidemiological studies are currently in
progress in Scotland and Spain that will report the preva¬
lence of JSRV infection in flocks with history of OPA
(D. Salvatori, C. Cousens, L. Gonzalez, P. Dewar and J.
M. Sharp, unpublished data). Further aims of these stud¬
ies are to understand what proportion of infected sheep
will develop OPA, when the infection is acquired and the
routes of transmission (eg, vertical transmission, in utero,
via milk). Investigations using PCR techniques have
provided some preliminary evidence of the presence of
JSRV in fetuses (D. Salvatori and M. de las Heras,
unpublished data). This finding apparently conflicts with
the findings of an earlier study by Parker and others
(1998) which showed that embryo transfer can be used to
obtain animals free of OPA. In that experiment, 215
embryos recovered from 76 donor ewes from flocks with
endemic OPA and mated with rams that did not have any
sign of OPA were transferred to 131 recipients. Thirty-
eight of 51 progeny from OPA-positive donors and 55 of
74 progeny from donors in which no lesions of OPA
were detected survived for at least five years. During this
time, there was no evidence of OPA in the recipients or
their progeny on the basis of clinical and pathological
criteria. Further investigations are necessary to clarify
whether vertical transmission of infection occurs.
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Did you know that over half of aM cases
of endometritis are probably missed'2? And
that those missed eases are costing-yayr.jaAl?
clients hundreds of pounds in
Well now there's a new way to pick tip far more
of those cases - as well as a new treatment
designed specifically to resolve them.
The new product is Metricure, an advanced
intra-uterine antibiotic. And new research
will help you identify those cows that wouldl
most benefit from its use, simply by inspecting
herd records4.
For your copy of this ground-breaking work, calU
0800 169 5351 free and ask for 'The At-Risk Cow.J
A New Perspective on the Identification ana
Treatment of Endometritis'. I
Because suddenly it really has got that easy.
1. Dohmen, M J Wet al (1995) Theriogenology 43, 1379-1388. 2. LeBlanc, S (2003) Cattle Practice 11, 255-261.
3. Esslemont R J and Kossaibati, M (2002) DAISY Research Report No 5. 4. McDougall, S (2003) Cattle Practice 11, 271-283.
Metricure is indicated for the treatment of subacute and chronic endometritis in cows. Each 19g syringe contains 500mg
icephapirin (as cephapirin b /ithdrawal periods: Meat - 48 hours; Milk - Zero hours. For contra-indications and







Trading structures for veterinary
practices 1. The options
TRADITIONALLY, the options for structuring a veterinary practice
were restricted to the sole principal set-up or the partnership and,
although the RCVS relaxed the rules governing trading structures for
practices some years ago, these remain the most common trading
vehicles in the profession. In the first of two articles, Andy Moore
looks at the different trading structures that are available for
veterinary businesses and, in the light of changes in the tax
treatment for some of these structures, outlines the various
opportunities and drawbacks that come with each one.
ANDY MOORE
Andy Moore is a









THERE have been various develop¬
ments over recent years regarding
the available trading structures, and
the taxation thereof, not only for vet¬
erinary practices but for businesses
generally. This, combined with chan¬
ges in the tax treatment for some of
those structures, means that there is a
need for businesses to review their
position to establish whether there
are potential benefits (or pitfalls) of a
change in trading structure.
in order to consider the position
fully, we need to look at three areas:
■ The different trading structures
that arc currently available within
the UK and the benefits and dis¬
advantages of each of them.
■ The potential tax savings of incor¬
poration - if incorporation is the
route selected, what are the potential
financial benefits for the practice?
This will be discussed in detail in a
second article, to be published in the
September issue of In Practice.
■ The potential opportunities and




Broadly speaking, there are four
potential structures: the sole princi¬
pal set-up. the partnership, the limit¬
ed company (that is, incorporation)
and the limited liability partnership.
A fifth, 'halfway house' option, that
of the service company, is also brief¬
ly reviewed.
This article does not consider joint
venture arrangements, nor the possi¬
bility of limited company partners,
which has come back into fashion
and is being suggested by some ad¬
visers at present. The former are rela¬
tively well developed arrangements
evolved by specific corporate enti¬
ties. Suffice to say, they are not per¬
fect for everyone but, for some, they
present the ideal route into veteri¬
nary practice. In the case of limited
company partners, a limited company
is formed and becomes a partner
in an existing partnership. Funds are
then diverted through to the com¬
pany as profit share which, in turn, is
drawn as dividends from the limited
company. While this arrangement
can produce some tax savings, these




Until relatively recently, the RCVS
would not permit a veterinary prac¬
tice to trade in any vehicle other
than a sole principal or partnership
structure. These are, therefore, by
far the most common trading struc¬
tures within the profession. In the
late 1990s, it became permissible for
veterinary practices to trade through
a limited company; the rules regard¬
ing non-veterinary ownership of vet¬
erinary practices were also relaxed.
Up to now, there has not been
a great uptake by practices wishing
to transfer ownership to a different
structure. However, with effect from
April 1, 2002, a change in the way
in which limited companies are
taxed has increased the attractive¬
ness of incorporation. Specifically,
the rates at which they pay tax were
altered, allowing a company to earn
up to £10,000 in a year and pay 0
per cent tax. At about the same time,
the pensions legislation was reform¬
ed, with the result that it was no
longer necessary to have earnings
every year in order to be able to
fund a pension contribution. This
has allowed profits to be extracted
by way of dividends as opposed to
salary, and that has brought with it
a National Insurance (Nl) saving
which grows as NI rates increase.
The latest Budget countered this use
of the rules but, in short, the changes
only reduce the savings where total
profits are under £50.000 per year.
The following sections will con¬
sider each of the potential trading
structures in more detail.
SOLE PRINCIPAL AND
PARTNERSHIP
These two trading structures can be
considered together due to their very
similar treatment as far as tax and
legalities are concerned. As men¬
tioned above, they are the most
common structures that exist within
the veterinary profession.
The structures of sole principal
and partnership are the most flexi-
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ble. and both are very easily formed.
They are also the cheapest in terms
of professional fees to set up and to
run. In addition, one of the major
attractions of these structures is the
complete privacy of the individual's,
or partners', financial affairs.
Most veterinary surgeons will be
familiar with the overall financial
workings of the sole principal/
partnership structure in that the prin¬
cipal or partners take drawings from
the practice. Hopefully, these draw¬
ings are less than the profits generat¬
ed. The tax paid by the principal or
partners is calculated on the profits
generated by the practice, rather
than the amounts withdrawn or
introduced into the practice, and the
tax liability is paid in three instal¬
ments during the course of the year,
in January, July and a balancing
payment in the next January. Tax
returns have to be completed for the
partnership and partners or for the
sole principal.
Normal business regulations
apply to these business structures.
There are, of course, additional re¬
quirements for veterinary practices,
such as those relating to the COSHH
regulations and the Medicines Act,
the need for professional indemnity
insurance, and so on.
Legal aspects
If the practice trades as a partnership
then it is normal (though not obliga¬
tory) to have a partnership agree¬
ment. If there is no partnership
agreement then, in the event of
a dispute or any decisions being
required, one would revert to the
Partnership Act 1890. although this
is obviously not ideal and should be
considered the last resort.
Finally, there is joint and several
unlimited liability in both of these
structures. If something happens to
affect the financial affairs of the
partnership adversely then the part¬
ners' or sole principal's personal
financial position is also affected.
LIMITED COMPAIMY
The major difference between limit¬
ed companies and any other struc¬
ture is that there are completely
separate legal identities for those
owning the business (shareholders)
and those running the business
(directors). Directors and sharehold¬
ers do not necessarily need to be the
same individuals, although for many
small privately owned companies
this is often the case.
The roles of director and share¬
holder have distinct responsibilities,
which will not be considered in
depth in this article. Suffice to say, it
is important not to lose sight of the
distinction.
If we first consider the drawbacks
to trading through a limited company
we can then go on to consider the
distinctions and the benefits.
Drawbacks
The main drawbacks to trading
through a limited company can be
summarised as follows:
■ The accounts have to be filed
with the Registrar of Companies and
are available for inspection by the
public. For small and medium-sized
companies these can be lodged in
abbreviated form and. therefore, the
amount of financial information
available to the public will be
reduced. The Companies Act is
currently in the process of being
reviewed. One proposal contained
within the revised Companies Act is
that there is full financial disclosure
of the profit and loss account for the
limited company. However, even if
this is applied, it is likely that the
figures disclosed will be in a
reduced format when compared with
normal partnership accounts.
■ Following on from the above,
accounts have to be prepared in a for¬
mat specified by the Companies Act
1985. Additionally, if the turnover of
the practice is in excess of £5-6 mil¬
lion (from March 30, 2004), there is
a requirement to undergo an audit.
This means an increase in the profes¬
sional fees payable by the company.
Where the shareholders and directors
are the same individuals, some
believe there is little added value.
■ There are additional deadlines
relating to filing of the accounts and
the annual return at Companies
House. Failure to meet these dead¬
lines results in an automatic fine. It
is therefore a regulated environment,
and one in which good business
organisation is essential.
■ Corporation tax, which is based
on profits retained (before divi¬
dends) by the company, is usually
paid in one instalment, nine months
after the company's year end. This
can have an impact on cash flow.
■ The directors of the limited com¬
pany. who are equivalent to the part¬
ners in a partnership, are employees
of the company and. as such, are
Forming a limited company
Limited companies are very straightforward to set up in that
they can be purchased 'off the shelf' for approximately £100.
If the word 'veterinary' is used within the name of the com¬
pany then approval has to be sought from the RCVS before
incorporation; indeed, the Registrar of Companies will not
permit the use of the word without this approval. To an
extent, the simplicity ends there.
Limited companies are governed and subject to additional
regulatory requirements over and above those applied to a
normal trading business. The Registrar of Companies is con¬
cerned with the filing of various documents, such as accounts
and annual returns. The company must have a Memorandum
and Articles of Association, which are its 'rule book'; these
documents set out what the company can and cannot do (as
it has no mind of its own). The directors must run the compa¬
ny in accordance with this rule book. In addition, they have
to produce financial statements in a format laid down by the
Companies Act 1985 and in accordance with financial report¬
ing standards currently in force. On top of this, there is a
considerable amount of additional regulation involved.
subject to the employment tax
regime; for example, if they are pro¬
vided with a car by the company
then that is treated as a company car
and taxed as a benefit in kind.
■ There will be larger professional
fees incurred in running a company,
mainly due to the increased work
required on the annual accounts.
Distinctions
The main distinctions between a
limited company and other struc¬
tures can be summarised as follows:
■ As mentioned above, the compa¬
ny and the individuals involved with
the company have separate legal
identities. The shareholders own the
company and the directors run it.
For veterinary practices, the clinical
directors of the company, who
control the clinical decision-making,
must all be members of the RCVS;
care needs to be taken in this area to
ensure control procedures are in
place to avoid any (say financial or
income-generating) decisions by a
non-MRCVS impacting on the clini¬
cal decision-making.
■ The profits (which, in a partner¬
ship, are taken as drawings by the
partners) are taken by way of salary
for the directors, in respect of the
work that they undertake; and as
dividends by the shareholders, in
respect of the return on the capital
they have invested.
Benefits of incorporation
So, having considered the draw¬
backs and differences, why might
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Service company
The final option to consider - the service company - is really a 'halfway house' between a partner¬
ship and a limited company. In this structure, in outline, a limited company is set up to run along¬
side the partnership. The limited company employs all the members of staff and buys in the
supplies. The company then sells those supplies and staff to the partnership at a mark-up. The level
of mark-up is quite closely regulated, as there is scope to manipulate the figures - which the Inland
Revenue is keen to stamp out.
The effect of this arrangement is that profits are held within the limited company, where they
are taxed at a lower rate than would apply within the partnership - where profits would be taxed
at the highest rate of tax, currently 41 per cent. This vehicle therefore provides potential
savings, albeit less than full incorporation of the entire practice, but still an improvement on the
position as compared with a partnership.
This does necessitate running a second business, with a second VAT registration, a second bank
account - and incurring a second set of accountancy fees! However, the transactions are limited and
costs should not be that great.
The savings across the practice are potentially 41 per cent on the first £10,000 of profits if
retained (15 per cent if paid out), and then roughly 20 per cent on the next £40,000 of profits if
retained (or 1-75 per cent if paid out), and approximately 20 per cent on the balance of profits
included within the limited company. This is a saving across the entire practice, rather than per
partner. Therefore, practices with more partners will make a smaller saving per partner.
Reference
GUNN, D. (2004) Budget 2004-
implications for veterinary
practice. In Practice 26, 282-283
practices consider incorporation?
Some reasons are outlined below,
and there will be further discussion
on this in the next article.
■ A starting corporation tax rate
of 0 per cent, rising to 19 per cent
for profits up to £300,000, and com¬
bined with the reform of the pensions
legislation, has increased the incen¬
tive for practices to look at this alter¬
native. Even after the latest Budget
changes (Gunn 2004). savings could
be made by many practices.
■ The potential tax and N1 savings
are at a reasonable level and warrant
practices giving further considera¬
tion to incorporation.
■ The main reason for limited com¬
panies being developed, many years
ago, was to limit the liability of
those starting in business or going
into business. This benefit still at¬
taches to the limited company struc¬
ture, but many are unaware of it. The
limitation of liability applies assum¬
ing the governing regulations and
legislation have been compiled with.
■ A corporate structure can help
with succession planning and in




Limited liability partnerships were
created to a large extent by the big
accountancy practices, prompted by
concern at the increase in litigation,
in terms of both the frequency
and the size of claims. Professional
partnerships were keen to find ways
in which they might be able to pro¬
tect the family assets. The result was
a hybrid arrangement, a limited lia¬
bility partnership. This is formed,
regulated and governed in a very
similar manner to a limited compa¬
ny. The liabilities of individual part¬
ners are restricted to an extent,
although there is not a complete lim¬
itation of liability.
Limited liability partnerships are
very similar to a partnership as far as
tax and internal running are con¬
cerned. The partners within a limi¬
ted liability partnership are called
members: rather than having a part¬
nership agreement, they have a
members' agreement.
This structure has been in force
for a relatively short period of time
and, initially, commentators felt it
would be the vehicle of choice.
However, there has been very little
take-up of trading through this struc¬
ture. Essentially, limited liability
partnerships appear to suffer the
heavier regulation of a limited com¬
pany without any of the associated
tax benefits. The tax is calculated
as though for a partnership and,
therefore, unlike a limited com¬
pany, there is no tax advantage
to changing to a limited liability
partnership.
In general, this structure should
probably be avoided by veterinary
practices unless a real and substan¬
tial uninsured risk may exist and
a limited company arrangement is
not appropriate. At the end of the
day, this structure was designed by
accountants for accountants, audi¬
tors and lawyers; in general, any¬
thing designed for those sectors
should be avoided, due to complexi¬
ty and expense.
TIME TO TAKE STOCK
As discussed above, recent changes
in legislation have forced businesses
generally to consider incorporation.
Within the professions there has
generally been a very slow uptake of
incorporation. Taking the account¬
ancy profession as an example, it
has been possible to trade through
a limited company since 1989 but,
until recently, there had been rela¬
tively few incorporations. Within the
past year, however, there has been
a rush of incorporations, driven by
businesses looking to maximise their
tax benefits.
Historically, one of the reserva¬
tions held by the professions with
regard to incorporation was the lack
of financial privacy. However, given
the limited nature of the information
held on public record regarding
finances, an individual would need a
certain degree of financial knowl¬
edge and ability to be able to inter¬
pret the figures and ascertain likely
earnings in a year. Of course, they
would also have to have the desire to
do so. We always remind practices
of the fact that if clients are happy
with the service they have been pro¬
vided with, and they feel they have
received value for money, then they
will have no desire to search out
how much money the local vet has
made but. rather, will sing the vet's
praises to their acquaintances. The
situation may be different with
regard to competitors, but this type
of information is available in the
general commercial world for many
other types of business.
There is always a concern that
the Government may change the leg¬
islation so that the position becomes
less advantageous. If that is the case,
it is possible under the current legis¬
lation to transfer back to a partner¬
ship relatively easily, but it does
require the practice to be 'on the
ball' in order to react to changes.
Incorporation may not be the
right move for every practice, but I
would certainly advocate that prac¬
tices review their own position to
decide one way or another, rather
than simply continue as they are
through apathy or inertia.
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Practice microscope - toy or tool?
IN this article, Donald Mactaggart argues that the microscope is
possibly the most important tool in a veterinary practice. If used
to its full potential it is also one of the most cost-efficient. Treat





The minimum requirements for the
practice setting are a binocular
microscope with four objective
lenses - x4, xlO, x40 and xlOO (oil
immersion). The eyepieces contain
xlO lenses, thus giving final mag¬
nifications of x40, xlOO. x400 and
xlOOO. Older, monocular micro¬
scopes without an integral light
source are not adequate for use in
the practice.
The choice of magnification
depends on the specimen to be
examined: X40 (ie, using the x4
objective) is mainly used for exami¬
nation of large ectoparasites such
as fleas, ticks, lice and Trombicula
species mites; xlOO is more useful
for identifying smaller mites, such
as Demodex and Sarcoptes species.
or for examination of samples of
urine for crystals or faeces for worm
eggs; X400 is mainly used for high-
power scanning cytology of tissue
aspirates and blood smears; and
xlOOO (oil immersion) is used for
detailed cytology and microbiology
(eg, examination of bacteria or
yeasts).
The microscope settings will
need to be adjusted depending on
the material being examined. It
is these movable parts that are the
most likely to wear out or be dam¬
aged in old or cheaper instruments.
The quality of these movable parts
should be checked before purchase.
The controls for the diaphragm, con¬
denser. stage and focus should be
smooth to use and hard-wearing.
The iris diaphragm and condenser
knob are adjusted to vary the
amount of light and contrast within
(left) A good quality binocular microscope, suitable for practice use. An old,
monocular microscope with no integral light source (pictured right) would not
be adequate in the practice setting
the sample. When performing cy¬
tology, the condenser and diaphragm
should be opened up, allowing
maximum light onto the slide. When
examining skin scrapings or urine
crystals, the condenser and dia¬
phragm should be turned down to
reduce the intensity of light. This
will increase the contrast, making
the sample less transparent and
easier to see.
CARE OF THE MICROSCOPE
A microscope is a precision instru¬
ment and should be treated with
respect. It should be kept in a
convenient area, away from vibra¬
tion, with a comfortable seat provid¬
ed to avoid operator discomfort
after frequent use. The microscope
should not be moved unnecessarily.
The lenses should be cleaned on
a daily basis, using lens tissue
wipes to avoid scratching them. The
oil immersion lens should be
wiped with spirit and dried after
each use. The microscope should
be protected with a dust cover when
not in use.
It may be useful to have a full
service carried out every five to 10
years, but with good routine main¬
tenance this may not be necessary.
PRACTICAL MICROSCOPY
A microscope will be principally
















and has been close to
his microscope ever
since.




upon good sample collection,
a good quality microscope and
good interpretation/diagnostic
skills.
One of the main advantages
of examining samples micro¬
scopically yourself is the rapid
result. Another advantage is
that one knows if the sample
collected is of good quality
straight away and, if it is
not, it is simple to collect an¬
other one. The main limiting
factor is your own diagnos¬
tic skills, but these will im¬
prove with experience. If in
doubt, send the sample off to
a more experienced clinician
for assessment.
of skin scrapings, for cytology, and
for examining samples of urine,
faeces and blood.
Skin scrapings
Skin scrapings are indicated in any
animal with skin disease. Taking
them involves minimal time and cost
and can give that rare thing in
dermatology, an instant diagnosis!
If you are struggling to differentiate
Demodex mites from hair, it is
probably time to buy a new micro¬
scope.
Cytology
Cytology has many and varied appli¬
cations (see box below), yet is
underused in practice. Again, it can
provide rapid results at minimal
cost.
The most common indications
for cytology in small animal practice
are microbial examination of the
General indications for the use of
cytology
Examination/assessment of:
■ Thoracic or abdominal effusions
■ Respiratory aspirates/washes
■ Organomegaly - liver, kidney, prostate, spleen
■ Unidentified abdominal masses
■ Lymphadenopathy
■ Urine sediment
■ Cutaneous masses/ulcerative lesions
■ Disease of the gastrointestinal tract
■ Reproductive system
An adult Demodex canis mite
(original magnification xlOO).
Skin scrapings should be
taken and examined
microscopically in any case




ears or skin, and examination of
cutaneous 'lumps'. Cytology can
guide us on what therapy to use for
the infection or what action should
be taken with the 'lump'.
With experience, the veterinary
practitioner can soon become famil¬
iar with basic cytology, for example,
differentiating inflammation from
neoplasia or bacterial from yeast
infection. However, detailed cyto-
logical interpretation, such as the
classification of neoplasia, requires
the experience of a trained cyto-
pathologist.
When evaluating cytological
samples, it is a good idea to take
two samples, examine one yourself
and send the other to a trained
cytologist. This allows you to assess
whether your sample collection
technique is good before sending the
sample off to the lab; in addition,
your learning curve will increase
dramatically if you can compare
your interpretation with that of the
expert.
Urine samples
Urine samples are examined micro¬
scopically mainly for the presence of
crystals. Cytological examination is
also useful in checking for infection
and neoplasia in the urinary tract.
Faecal examination
With faecal samples, microscopy
is mainly carried out to assess the
presence of endoparasites and their
ova, but special stains can also be
used in investigating malabsorption/
maldigestion.
Blood smears
A blood smear should always be
examined microscopically when a
blood sample is taken for haema-
tology.
Cytological examination
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Making the microscope work for you: costs and fees relating to microscopy
1. Cost of consumables required for microscopy (based on 2004 list price, excluding VAT)
Cost per pack (£) Number in pack/quantity Cost per preparation (£)
Skin scrapes
Microscope slides 5.36 50 0.11
Coverslips 2.25 100 0.02
Scalpels 12.00 100 0.12
Liquid paraffin 5.17 2000 ml 0.005*
Total per preparation 0.25
Cytology
5 ml syringes 4.19 100 0.04
23 G needles 4.25 100 0.04
Microscope slides 5.36 50 0.11
RapiDiff stain (Triangle Biomedical Sciences) 40.00 500 ml 0.08*
Coverslips 2.25 100 0.02
Microscope oil 7.45 100 ml 0.01*
Lens tissue wipes 2.73 25 0.11
Total per preparation 0.41
Examination of urine samples for crystals/faecal samples for eggs
Centrifuge tubes Free from laboratory 0.00
Disposable pipettes 2.85 50 0.06
Microscope slides 5.36 50 0.11
Coverslips 2.25 100 0.02
Total per preparation 0.19
*Approximate costs, based on the estimated volume used per slide
2. Fees generated by microscopy
The following costings are based on the work carried out in a three-man small animal practice over one month (February 2004).
No referral work has been included; haematology is outsourced, so no blood smears are examined. All prices are exclusive of VAT
Fees charged Consumable costs Fees - costs Samples examined Income generated Approximate income
per sample (£) per sample (£) (£) during the month during the month (£) per year (£)+
Cytology 11.70 0.41 11.29 23 259.67 3277
Skin scrapes 16.25 0.25 16.00 17 272.00 3433
Urine analysis 16.25 0.19 16.06 6 96.36 1216
Faecal analysis 16.25 0.19 16.06 1 16.06 203
Total 8129
^Calculated for a leap year as (monthly income e 29) x 366 and rounded to the nearest £
Predicted fees generated minus consumable costs, per full-time veterinary surgeon, per year £2710
FINANCIAL AND OTHER
BENEFITS
A good basic microscope can be
bought for under £500 but, as with
most equipment, you get what you
pay for. If you have a particular
interest in microscopy then the extra
investment in a superior instrument
is well worthwhile. Even if you
choose a top quality microscope,
costing £1500, your costs should
soon be recovered.
The analysis presented in the box
above suggests that a full-time veteri¬
nary surgeon should be able to gener¬
ate approximately £2700 per annum
through microscopy work. This
could easily triple if there was some¬
one in the practice with a specific
interest in dermatology or cytology.
Non-financial benefits
In addition to the large amount
of revenue generated for a relatively
small outlay, microscopy can pro¬
vide other, non-financial benefits
to the practice. Most of all, the
clinical interest of the veterinary
surgeon is maintained; veterinary
nurses, too, are often interested
in laboratory work and. by exten¬
sion, may also enjoy microscopy. It
is very satisfying to be able to
collect a sample, analyse it and
give your client the result within
minutes. Clients appreciate this
rapid turnaround, and the micro¬
scope is also useful for client
edu-cation: it is always easier to
convince clients that their pet has




A microscope should last at least 10
years; a good quality one should last
twice this if it is well looked after.
I cannot think of another piece of
equipment in veterinary practice that
costs so little, generates so much
income and has such a long lifespan.
Take care of your microscope
and it will take care of you - as well
as your patients.
Further reading
HILL, P. B. (2002) Performing and
interpreting diagnostic tests. In Small
Animal Dermatology. Oxford,
Butterworth-Heinemann. pp 148-230
RASKIN, R. E. & MEYER, D. J. (2001)
Atlas of Canine and Feline Cytology.
Philadelphia, W. B. Saunders
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in the art of veterinary practice
AS the veterinary curriculum gets increasingly crowded, opportunities
for general practitioners to show students something of the art of
the profession are becoming fewer and need to be grasped. For
Alan Leyland, an invitation to talk to third-year veterinary students
about practical aspects of antibiotic use proved a good way for him to
share his knowledge and give something back to his profession. There
were other benefits, too. The experience provided an interesting




Liverpool in 1968 and
works in small animal
practice in Wallasey,
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the University of
Liverpool between
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OVER a period of four years, I was
asked to spend an afternoon each
year with the third-year veterinary
students at the University of Liver¬
pool, talking about 'the use of
antibiotics in practice' as part of
their infectious diseases course.
The invitation originally came
out of the blue from the lecturer who
was in charge of the course at the
time. Not being a veterinary surgeon
herself, she saw the benefit of invit¬
ing an ordinary general practitioner
to talk about practical aspects of the
topic. Although in former days 1 had
lectured at the university in clinical
pathology, I am fairly sure that the
invitation was extended to me as a
local vet in practice rather than as a
former lecturer.
I had no specialised knowledge
of the pharmacology or esoterics
of antibiotics. So, could 1 provide
something of benefit to the students
and, in so doing, enhance my own
interest in the subject?
PREPARING FOR THE
TASK
As I was not expected to do much
more than tickle the students' inter¬
est and make the academic studies
they had been doing relevant to
life in practice, you might think that
the necessary preparation was
minimal, but 1 did spend a fair
amount of time considering my
approach and then checking many
of the points I wished to make in
textbooks and journals. The only
guidance I had been given when I
was invited to contribute was 'tell
the students how you make an
informed choice of antibiotics for
particular cases' - which was, of
course, a deceptively simple sound¬
ing request!
I believe that the best possible
way to undertake personal CPD is
through preparing a presentation,
and. even though I had no intention
of lecturing on the scientific minu¬
tiae, I was certainly stimulated to
improve my own knowledge of the
subject.
Bridging the gap between
academia and practice
The concept was to stimulate the
interest of the students, at a time
when the enthusiasm with which
they had ventured into the veterinary
faculty in their first year was waning
to a low point before commencment
of their clinical studies, as well as to
make the course content relevant to
the job for which they were all, in
the main, aiming.
Pressures on university lecturers
to gain academic experience, and
discouragement from undertaking
locums, as had been more common
in former times, means that there is
an increasing dearth of staff with
real practice experience. 1 therefore
viewed becoming involved with lec¬
turing the students as a very small
campaign on my part to redress the
balance, and to give them the benefit
of a little bit of practical know-how.
AN INTERACTIVE
APPROACH
My approach was to pose a series
of questions and statements to the
students and encourage them to
respond and interact. This worked
well, with the students entering into
the spirit of a very 'knockabout' ses¬
sion. My first assertion was that
'antibiotics are the most abused and
overused drugs in our armamentari¬
um'; secondly, I made the cynical,
but true, observation that 'therapy
works best where there is a natural
A job for everyone?
Many vets might be daunted by
the prospect of speaking to a
group of students for an after¬
noon, but if they were pre¬
pared to have a go many would
enjoy it.
The students relate very well
to anyone in practice. Clearly
they see themselves as being
there soon and realise they
might not be ready, having
concentrated on academic and
practical knowledge. I recently
spent a full day taking part in a
communication training day for
fourth-year students. The day
involved having to play out sce¬
narios with trained actors. I
found the students' reaction to
me, as one at the 'coal face', to
be very positive.
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A cartoon used by the author to encourage students to think about the
importance of making the correct choice of antibiotic drug
tendency for resolution' and that,
therefore, it is important to 'do no
harm'.
I chose not to include anything
about, for example, 'macrolide'
antibiotics or bactericidal versus
bacteriostatic modes of action, as I
presumed the students had already
learned those sorts of things as
part of the formal lecturing they had
received. Rather, I asked, in a given
situation, 'should an antibiotic be
used at all?'
Practical emphasis
To make the point that I was
giving an essentially practical dis¬
course, I started by asking the
students to compare the costs of
a 10-day course of four different
antibiotics for a 20 kg collie: oxy-
tetracycline, combined trimethoprim
and sulphadiazine, potentiated
amoxycillin and enrofloxacin. To
encourage them to think about the
impact of these costs on the client, I
also asked them what the current old
age pension was worth, which most
students knew!
Next, consideration was given to
the activity of antibiotics against
specific organisms, and when it was
appropriate to carry out sensitivity
and resistance testing. A discussion
of routes of administration raised
many interesting concerns regard¬
ing, for example, client compliance,
and achieving suitable blood levels
in some compromised animals with
poor ability to absorb drugs from the
alimentary tract.
Making the correct choice of
antibiotics for various sites in the
body was discussed in respect of
issues such as the acid pH of the
prostate affecting the in vivo activity
compared to in vitro activity, and
efficacy in the presence of pus or
fibrosis, or at a site in bone. Adverse
reactions and their reporting, com¬
patibility with other medications,
legislation, particularly the 'cas¬
cade', and suitability for age and
species were all of great interest to
the students.
Encouraging debate
Finally, by working through a series
of hypothetical cases, I attempted
to persuade my audience that
although antibiotics are essential for
some conditions and surgery, their
use should be unnecessary for cases
such as lump removals, spaying and
neutering, or, for example, in the
mildly ill dog with 'gastritis', unless
there is blood or pyrexia. This
caused some disquiet and debate
among the students about sterile
technique, and so on, as many of
them had seen antibiotics used in
these situations in practice.
POSITIVE REACTIONS
The first year I spoke to the students
I was one of three vets who had
been invited, but in following years I
was invited to lead the discussions
for the whole afternoon - so I sup¬
pose I must have been OK at it!
Each year, I would change my
presentation to make it 'fresher',
both for the benefit of the students
and for myself. I always had a great
reaction from the students, who
would queue up after the session to
ask further questions or arrange
EMS at my practice.
On a nostalgic note, returning
to the same lecture theatre where,
more than 30 years ago, I sat with
40 of my peers, now stuffed with
100 students, was a strange experi¬
ence.
OTHER OPPORTUNITIES
Over time there were changes to
the personnel at the university and, 1
believe, it was an oversight one year
for me not to be asked to speak
again. Although there was some
sympathy for my lecture to continue,
I think pressures on the syllabus
overrode this.
However, since then, I have been
given other opportunities to speak to
groups of students and vets in prac¬
tice. I used the same material on the
use of antibiotics when sent by the
Society of Practising Veterinary
Surgeons (SPVS) to speak to the
Bristol students' clinical club. I also
get to make presentations to other
groups - twice so far at BSAVA
satellite management days, last year
and this, and the occasional clinical
seminar.
1 am not sure you can go looking
for these opportunities so much as
accept them if they come along, but,
as some vets would run a mile if
invited to make this kind of presen¬
tation, perhaps it helps to be known
as someone who is keen to become
involved. Many of my opportunities
to speak have sprung from being an
ex-president of SPVS, as well as
being known to have strong views
on some issues!
TIME WELL SPENT
I enjoyed the experience of speaking
to the students immensely. At the
time I was invited to speak I had
not thought about remuneration, and
was surprised to receive a modest
fee - although the amount would
certainly not count as a 'practice
builder' and would not in itself be a
reason for doing the sessions.
Overall, would I recommend
being a visiting lecturer as a way of
adding interest to a regular job in
practice? Most definitely: it was a
good way to do my own learning
and, of course, provided an opportu¬
nity to give something back to the
profession from which I have profit¬
ed. In addition, once you have been
in practice for many years, anything
which breaks up the week is a good
thing!
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A partner ponders
ALMOST daily, the cheerful, cheru¬
bic figure of Declan Curry waxes
lyrical on breakfast TV about the
financial markets here and abroad.
Apparently innocently, he prefaces
his prediction for the opening moves
of the London financial market with
the depressing phrase 'and the book¬
ies predict'. His clear declaration that
the performance of my hard-earned
pension pot is part dependent on
professional gamblers does not
inspire confidence. Nor does the
performance of my managed pension
funds inspire me, as it seems that
without inside information, luck or
exceptional expertise it is impossible
for fund managers to consistently
outperform the indices. The old
axiom 'You can't beat the market'
appears a truism.
These financially morbid thoughts
were well implanted in my psyche
when, three years ago, Her Majesty's
Government launched the 'stake¬
holder pension' scheme. As a non-
intervener in the financial affairs of
others, I was obligated to select a
stakeholder scheme for our staff.
Conscious then of the pensions mis-
selling scandal of a previous genera¬
tion, I elected to adopt safety first
mode and go with a major pensions
company then confidently described
as the largest mutually owned insur
anre company in Luropo and with
multibillion pound reserves.
Thankfully, my negative expecta¬
tions of the stakeholder scheme seem
to have been continuous and none of
our staff has taken out such a scheme
through the practice. In the interven¬
ing period, the index of top 100 UK
companies has declined by 25 per
cent (from 6000 to 4500 as I write),
the insurance company then defiantly
mutual is in the throes of demutuali-
sation and the multibillion pound
reserves, yes you've guessed it, all
but gone as a result of the company's
decision to retain high exposure to
equities when others moved into
bonds. Our stakeholder scheme has
been a compliance paper exercise,
apparently like 80 per cent of all
such schemes set up by employers;
it is an empty shell with no members
and seems destined to remain so
unless, or rather until, employer con¬
tributions become mandatory.
Only recently did 1 realise that
our staff had launched their own
investment scheme which involved
weekly contributions to a mutually
owned, low-cost fund with the poten¬
tial for almost unlimited returns.
Investing in the National Lottery via
a practice syndicate is admittedly a
high-risk investment strategy but
does benefit from transparently -
most weeks you are almost guaran¬
teed to lose, but the adrenaline rush
more than compensates for this when
one or two numbers come up.
Most financial articles conclude
with a confident tip, and this is no
exception. I suggest that all partners
participate in practice lottery syndi
cates - for when such a syndicate
enjoys a multimillion pound win, the
beneficiaries may opt to desert the
practice 'en maooo' and, by charing
in the win, you will have the option
of doing likewise!
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The monthly CPD guide
IN each issue. In Practice publishes information for veterinary surgeons about courses and meetings
in the months ahead. Details of forthcoming events which might be included in this CPD guide should
be sent to 'Coming Up', In Practice, 7 Mansfield Street, London W1G 9NQ, fax 020 7637 0620, at least
two months before the event is due to take place. A more extensive listing of courses and events,
which is updated weekly, appears in the CPD calendar on The Veterinary Record/In Practice website
at www.vetrecord.co.uk



































2: the vomiting cat
and dog





















be held at the veterinary
school. Details from
the CPD Unit,
telephone 0141 330 4995,
fax 0141 330 2256,
e-mail: cpd@vet.gla.ac. uk
13 TO 14















Conference, to be held
in New Orleans. USA.



















•Orthopaedics level 1 -
beginners










be held at the veterinary
school. Details from
the CPD Unit,
telephone 0141 330 4995,


















to be held in
Huntingdon. Details

























telephone 00 43 1 531 1671,







by the British Equine
Veterinary Association,











by the British Cattle
Veterinary Association
and Nottingham University,
to be held at Sutton
Bonington. Details











telephone 0151 328 0444,
fax 0151 328 0555
e-mail: info@
cpd-solutions. com
Advanced equine dental technicians course, August 27 to 28
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World Association for
the History of Veterinary
Medicine congress,




can we learn from
each other?
Workshop, part of the
Association for Medical
Education in Europe
Conference, to he held
in Edinburgh. Details





Course, organised by the
Royal (Dick) School of
Veterinary Studies, to
be held at Easter Bush.
Details from the CPD Unit.




Workshop, to be held
in Cheltenham. Details
from CPD Solutions,
telephone 0151 328 0444.






Course, organised by the
Royal (Dick) School of
Veterinary Studies, to be
held at Easter Bush. Details
from the CPD Unit,
telephone 0131 651 1180.
7 TO 9
OVS welfare training
(red and white meat)
Course, organised by
Bristol University, to
be held at Langford.
Details from Dr L. Hewitt.
telephone 0117 928 9295.






BCF Technology, to be
held in Leominster. Details





























Course, organised by Bristol













to be held at Torrington
Orthopaedic Referrals,
Brighouse, West Yorkshire.









Course, organised by the
Royal (Dick) School of
Veterinary Studies, to be
held at Easter Bush. Details
from the CPD Unit.
telephone 0131 651 1180.
8 to 9
Pharmacy








8 TO 1 1
World Association
for the History of
Veterinary Medicine
Congress, to be held in
Turin, Italy. Details from
Professor M. Galloni,








by BCF Technology, to be
held in Cheshire. Details









the BSAVA, to be held
at the Bellhouse De Vere
Hotel, Beaconsfield.

















e-mail: cpdvets@ liv.ac. uk




organised by the Royal
Veterinary College, to be










Liverpool University, to be
held at Leahurst. Details
from the DBR Coordinator,
telephone 0151 794 6081,




Module 1 of a three-part
course, organised by the
Royal Veterinary College,
to be held at the Hawkshead
campus. Details







Course, to be held at




telephone 0151 328 0444,







Part 5 of a modular course,
organised by Bristol






















to be held at Leahurst.











telephone 0151 328 0444,






Course, organised by the
Royal Veterinary College,




















College, to be held at
the Hawkshead campus.







Module 1 of a three-part
course, to be held in
Cheltenham. Details
from CPD Solutions,
telephone 0151 328 0444,





Workshop, to be held in
Milton Keynes. Details
from CPD Solutions,
telephone 0151 328 0444,




Course, organised by BCF









Course, to be held in
Milton Keynes. Details
from CPD Solutions,
telephone 0151 328 0444,






Module I of a five-part
course, to be held at
Eastwood Park, Falfield,
Gloucester. Details




telephone 0117 946 6087,








College, to be held at
the Hawkshead campus.








Congress of the European
Society of Feline Medicine,
to be held at the Burlington
Hotel, Dublin, Ireland.
Details from the ESFM.









to be held at Leahurst.















Mastitis - a business
opportunity?
Meeting, organised
by the British Cattle
Veterinary Association
and Intervet, to be held












to be held at the Faculty
of Veterinary Science
Building, Liverpool.







Module 1 of a three-part
course, to be held in
Milton Keynes. Details
from CPD Solutions,
telephone 0151 328 0444,








to be held at the Faculty
of Veterinary Science
Building. Liverpool.






Workshop, organised by the
British Equine Veterinary
Association, to be held in








Course, organised by the
BSAVA Practice Support
Group, to be held at the
Nottingham Gateway
Hotel, Nottingham. Details










to be held at the Faculty
of Veterinary Science
Building. Liverpool.










be held at the veterinary
school. Details from
the CPD Unit,
telephone 0141 330 4995,






Module 1 of a four-part
course, to be held in




telephone 0151 328 0444,





To be held at the
Cavendish Conference
Centre, London.
Details from the BVA,
telephone 020 7636 6541,




of the Gl tract
Course, organised by
the BSAVA, to be held
at the Hilton Leeds
Garforth Hotel, Leeds.








Course, organised by the
British Equine Veterinary
Association Trust, to










Workshop, to be held




telephone 0151 328 0444.





Course, to be held in
Milton Keynes. Details






telephone 0151 328 0444,

















day, sponsored by lutervet,
to be held at the Scottish
Exhibition and Conference
Centre, Glasgow, as part
of the 10th International
Conference on Human-
Animal Interactions.








Course, to be held at
Chester Zoo. Details
from CPD Solutions.
telephone 0151 328 0444,



















Module 1 of a three-part
course, to be held in
Ellesmere Port. Details
from CPD Solutions.
telephone 0151 328 0444,





the Blue Cross, to be held












the BSAVA. to be held












and critical care cases
Course, organised by the
Royal Veterinary College,












to be held at Leahurst.







Course, to be held in
Milton Keynes. Details
from CPD Solutions.
telephone 0151 328 0444.





Workshop, to be held in
Milton Keynes. Details
from CPD Solutions,
telephone 0151 328 0444,




Fix that itch: Tim and
Peter's top tips
Course, organised by the
BSAVA. to be held at the
Hilton Manchester Airport
Hotel. Manchester.






















Course, organised by BCF
























Module l of a four-part
course, to be held in




telephone 0151 328 0444,








to be held at the veterinary
school. Details from
the CPD Unit.
telephone 0141 330 4995,
fax 0141 330 2256,
e-mail: cpd@vet.gla.ac.uk
16, 23 and 30
• Recent graduate
reunion seminars
Organised by the Veterinary
Defence Society, to be held
at Langford, October 16:
Garscube. October 23;
and the Royal Veterinary
College, October 30.






Course, organised by the
Royal Veterinary College,









Module 2 of a three-part
course, organised by the
Royal Veterinary College,









Course, to be held in
Milton Keynes. Details
from CPD Solutions,
telephone 0151 328 0444,






by the Cambridge Pet
Crematorium and the Pet
Bereavement Support
Service,to be held in





Workshop, to be held in
Milton Keynes. Details
from CPD Solutions,
telephone 0151 328 0444,






Course, to be held
at the Vetdent Training
Centre. Studley. Details
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from Ms J. Lindsay,
telephone 01527 853022
23
















to be held at the veterinary
school. Details from
the CPD Unit.
telephone 0141 330 4995,


















Basic course, organised by
the Animal Health Trust, to
be held at Lanwades Park.
Kentford, Newmarket.








Course, organised by the
British Equine Veterinary
Association, to be held in







• The cat's third life
Course, organised hy
Glasgow University, to
be held at the veterinary
school. Details from
the CPD Unit.
telephone 0141 330 4995,




To be held at the Hilton
Hotel. Blackpool. Details









Organised by the British
Equine Veterinary
Association, to be held in












Course, organised by the
British Equine Veterinary





















Workshop, to be held in
Ellesmere Port. Details
from CPD Solutions.
telephone 0151 328 0444,







how we do it
Course, organised
by the BSAVA.















be held at the veterinary
school. Details from
the CPD Unit,
telephone 0141 330 4995,
fax 0141 330 2256.
e-mail: cpd@vet.gla.ac.uk

















Course, organised by the
Royal Veterinary College,









Meeting, organised by the
Association of Veterinary
Soft Tissue Surgeons and
the British Association of
Veterinary Emergency
Care, to be held at Burleigh
Court, Loughborough.




OVS red and poultry
meat hygiene




wishing to apply for
Official Veterinary Surgeon
designation, to be held
at Langford. Details from
the Langford Continuing
Education Unit.






Workshop, to be held in
Milton Keynes. Details
from CPD Solutions,
telephone 0151 328 0444,
fax 0151 328 0555,
e-mail: info@
cpd-solutions.com
i 0 to 1 1
Cattle fertility
Meeting, organised by the
British Cattle Veterinary
Association and Intervet, to









Workshop, to be held in
Milton Keynes. Details
from CPD Solutions,
telephone 0151 328 0444,






a medical crisis and
veterinary perspective
Conference, organised
by the Royal College
of Pathologists, to be
held in London. Details
from Miss M. Casey,





Course, organised by the
Blue Cross, to be held












BCF Technology, to be
held in Cheshire. Details
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12 to 13
Spinal surgery
Course, to be held in




telephone 0151 328 0444,





zoo and wild animal
medicine
Meeting, to be held at
the Zoological Society
of London. Details from
Mr A. Sainsbury,






Conference, to be held at
the School of Chemistry,
Bristol University. Details







Course, organised by the
Royal Veterinary College,











Part 6 of a modular course,
organised by Bristol




telephone 0117 928 9502,






To be held in Milton
Keynes. Details
from CPD Solutions,
telephone 0151 328 0444,






Course, to be held at
Chester Zoo. Details
from CPD Solutions,
telephone 0151 328 0444,






Module 2 of a three-part
course, to be held in
Cheltenham. Details
from CPD Solutions,
telephone 0151 328 0444,

















by the Society of
Practising Veterinary
Surgeons, to be held









Course, part of the Glasgow
Alumni Homecoming
Weekend from November
19 to 21, organised by
Glasgow University,
to be held at the veterinary
school. Details from
the CPD Unit,
telephone 0141 330 4995,
fax 0141 330 2256,
e-mail: cpd@vet.gla.ac.uk
1 9 TO 21
Challenges in internal
medicine: how to solve
those tricky cases
Course, organised by the
BSAVA, to be held at the
Palace Hotel, Buxton.








Course, organised by the
Royal Veterinary College,









Symposium, to be held
at the University of
Georgia, Athens, USA
Details from Ms S. Kilgo.




•OVS red and poultry
meat hygiene




wishing to apply for
Official Veterinary Surgeon
designation, to be held at
Langford. Details from the
Langford Continuing
Education Unit.






Course, organised by the
British Cattle Veterinary
Association, to be held











be held at the veterinary
school. Details from
the CPD Unit,
telephone 0141 330 4995,





Course, organised by BCF











Module 1 of a five-part
course, organised by the
International Institute of
Veterinary Chiropractic,
to be held in East Leake,
Loughborough. Details
from the IIVC,
telephone 00 49 4282
590099,





To be held in Ellesmere
Port. Details from
CPD Solutions,







Module 2 of a four-part





telephone 0151 328 0444,





to be held at the veterinary
school. Details from
the CPD Unit,
telephone 0141 330 4995,
fax 0141 330 2256,
e-mail: cpd@ vet.gla. ac. uk
27 to 28
• Basic echocardiography
of the dog and cat
Course, organised by the
Royal Veterinary College,
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